Novel substituted isoindolinone skeleton-based compounds, bifunctional protein degraders containing same, and uses thereof

Abstract

The present disclosure relates to compounds of formula (I) and formula (II), or salts, enantiomers, stereoisomers, solvates, isotopically enriched analogs, prodrugs, or polymorphs thereof, and the use thereof. The present disclosure also relates to a pharmaceutical composition comprising a compound of formula (I) or a compound of formula (II), or a salt, enantiomer, stereoisomer, solvate, isotopically enriched analog, prodrug, or polymorph thereof as an active ingredient, and uses thereof.

Description

Novel substituted isoindolinone-based skeleton compounds, bifunctional protein degraders containing the same, and their applications Technical Field The present disclosure relates to compounds of formula (I), novel substituted isoindolinone-based backbone compounds of formula (II), and their uses. The novel substituted isoindolinone-based backbone compounds of formula (II) disclosed herein can bind to Cereblon (CRBN) E3 ubiquitin ligase and are used to prepare compounds of formula (I). Compounds of formula (I) disclosed herein, designed based on compounds of formula (II) and various target protein ligands, can exhibit a wide range of pharmacological activities by degrading / inhibiting various pathogenic protein classes or families. Background Art Bifunctional protein degradation targeted drugs consist of three parts: a ligand warhead that can bind to a specific target protein at one end and a small molecule ligand for the E3 ubiquitin ligase at the other end. These two parts are connected by a linker unit of different lengths and types in the middle. Bifunctional protein degradation small molecule compounds can use the binding effect of the ligands at both ends to simultaneously bind to specific target proteins and E3 ubiquitin ligases, thereby recruiting the E3 ubiquitin ligase to the vicinity of the specific target protein and allowing the E3 ubiquitin ligase to ubiquitinate the target protein. Target proteins marked with multiple ubiquitination will be recognized and degraded by the proteasome in the body. This bifunctional protein degrader can fundamentally eliminate disease progression caused by abnormal expression of driver genes and drug resistance caused by acquired mutations in driver genes. The E3 ubiquitin ligases implicated in the design of targeted protein degradation drugs include over 600 different proteins, each with distinct cellular expression profiles. They can be divided into multiple classes based on the structural elements underlying their E3 functional activity. Currently, only a few ligases have been successfully employed in preclinical and clinical degrader studies, with CRBN E3 ubiquitin ligase being one of the most widely used. Currently known CRBN-type E3 ubiquitin ligase ligands (CRBN ligands) include thalidomide and its analogs, pomalidomide and lenalidomide, all of which possess a phthalimide backbone. CRBN-type E3 ubiquitin ligase ligands can also act as molecular glues to induce degradation of specific proteins. CRBN forms a functional E3 ubiquitin ligase complex with damaged DNA binding protein 1 (DDB1) and Cullin 4A, where CRBN acts as a substrate receptor. Binding of molecular glue degraders such as thalidomide to CRBN induces CRBN to recognize new substrate proteins, leading to their ubiquitination and subsequent degradation by the proteasome. CRBN ligands can act as molecular glue degraders to induce the degradation of various substrate proteins, and can also serve as part of bifunctional protein degraders to effectively degrade specific pathogenic proteins. Currently discovered candidate CRBN ligands exhibit limited structural novelty, leading to the development of diverse scaffolds and a broader range of CRBN ligands, which are key research and development areas. Therefore, there is an urgent need for a series of novel CRBN E3 ubiquitin ligase ligands that can serve as effective molecular glue degraders, and the corresponding bifunctional protein degraders can be further synthesized for the treatment and / or prevention of diseases or conditions mediated by or associated with the target protein. SUMMARY OF THE INVENTION In view of the above, the present disclosure aims to provide novel E3 ubiquitin ligase small molecule ligands, bifunctional protein degradation molecules designed based on novel E3 ubiquitin ligase small molecule ligands and various target protein ligands, their uses, and methods of use. The advantages of the compounds provided herein are that they can have a wide range of pharmacological activities by degrading / inhibiting various pathogenic protein classes or families. To achieve the above-mentioned and other related objectives, the present disclosure provides, in one aspect, compounds based on a novel substituted isoindolinone backbone that can act as molecular glues to bind to the CRBN E3 ubiquitin ligase. The compounds designed in the present invention, based on a novel substituted isoindolinone backbone, exhibit CRBN binding and anti-tumor activity, and can be applied to bifunctional protein-degrading small molecule drugs. In some embodiments, the novel substituted isoindolinone-based scaffold compounds disclosed herein may be compounds of formula (II) or salts, stereoisomers (including enantiomers), solvates, isotopically enriched analogs, prodrugs, or polymorphs thereof: in Z represents C(O) or CH2; R a1 、R a2 、R a3 and R a4 The same or different and each independently represents hydrogen, deuterium, halogen, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy or halogenated C 1-6 alkoxy; (R a5 ) mm represents that the isoindoline ring connected thereto is optionally replaced by m R a5 Replace, each R a5 The same or different and each independently represents deuterium, Halogen, hydroxyl, thiol, nitro, amino, cyano, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy or halogenated C 1-6 alkoxy; m represents an integer 0, 1, 2 or 3; R E express: Among them, ring Y 1 represents a heterocyclic group containing at least 2 nitrogen atoms, (R d1 ) n1 Represents ring Y 1 Optionally n1 R d1 Group Generation, each R d1 Each independently represents deuterium, halogen, hydroxyl, mercapto, nitro, amino, cyano, oxo, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy or C 1-6 alkoxy, and n1 represents an integer of 0-20: and R1 represents N(R w ), where R w Represents hydrogen or C 1-3 Alkyl, and R E1 represents hydrogen; or R1 represents a bond, and R E1represents NH2; or R E express: Among them, ring Y 3 represents a heterocyclic group containing one nitrogen atom, (R d3 ) n3 Represents ring Y 3 Optionally n3 R d3 Group substitution, Each R d3 Each independently represents deuterium, halogen, hydroxyl, mercapto, nitro, amino, cyano, oxo, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy or C 1-6 alkoxy, and n3 represents an integer of 0-20; and where R s1 express Symbol **** indicates the ring Y 3 The connection point of R E2 represents NH2; Provided that the following compounds are not included: 3-(1-oxo-5-(piperazin-1-ylamino)isoindolin-2-yl)piperidine-2,6-dione. On the other hand, the bifunctional protein degradation molecules designed based on novel E3 ubiquitin ligase small molecule ligands and various target protein ligands disclosed herein can be compounds of formula (I) or salts, stereoisomers (including enantiomers), solvates, isotopically enriched analogs, prodrugs or polymorphs thereof: PBM-LIN-ULM (I) Wherein PBM represents a targeting moiety capable of binding to a protein, and PBM is covalently linked to ULM via the group LIN; ULM represents a ligand moiety capable of binding to an E3 ubiquitin ligase and represents a structure of the following formula (ULM): in Z represents C(O) or CH2; R a1 、R a2 、R a3 and R a4 The same or different and each independently represents hydrogen, deuterium, halogen, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6Alkoxy, deuterated C 1-6 Alkoxy or halogenated C 1-6 alkoxy; (R a5 ) m represents that the isoindoline ring connected thereto is optionally replaced by m R a5 Replace, each R a5 The same or different and each independently represents deuterium, Halogen, hydroxyl, thiol, nitro, amino, cyano, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy or halogenated C 1-6 alkoxy; m represents an integer 0, 1, 2 or 3; R a6 express: Among them, ring Y 1 represents a heterocyclic group containing at least 2 nitrogen atoms, (R d1 ) n1 Represents ring Y 1 Optionally n1 R d1 Group Generation, each R d1 Each independently represents deuterium, halogen, hydroxyl, mercapto, nitro, amino, cyano, oxo, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy or C 1-6 alkoxy, and n1 represents an integer of 0-20: and R1 represents N(R w ), where R w Represents hydrogen or C 1-3 Alkyl, and R2 represents a bond, or R2 represents CH2, C(O), **- NHC(O)- or **-N(CH3)C(O)-, or R2 represents the structure of the following formula: Among them, ring Y 2 represents a cycloalkylene group or a heterocyclic group containing at least one nitrogen atom, (R d2 ) n2 Represents ring Y 2 Optionally n2 R d2 Group substitution, each R d2 are independently deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano, oxo, C 1-6Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy or C 1-6 alkoxy, and n2 represents an integer of 0-20; or R1 represents a bond, and R2 represents N(R w ), where R w Represents hydrogen or C 1-3 Alkyl, or R2 represents **C(O)N(R w ), where R w Represents hydrogen or C 1-3 Alkyl, or R2 represents **-CH=N-; or R a6 express: where R x represents NH or **-CH=N-; or R a6 express: Among them, ring Y 3 represents a heterocyclic group containing one nitrogen atom, (R d3 ) n3 Represents ring Y 3 Optionally n3 R d3 Group substitution, Each R d3 Each independently represents deuterium, halogen, hydroxyl, mercapto, nitro, amino, cyano, oxo, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy or C 1-6 alkoxy, and n3 represents an integer of 0-20; and where R s1 express Symbol **** indicates the ring Y 3 The connection point of R s2 N(R w )or **C(O)N(R w ), where R w Represents hydrogen or C 1-3 an alkyl group (e.g., methyl, ethyl, or propyl); The symbols ** in the above formulas indicate the connection point with LIN; and LIN represents a bond or a structure of the following formula: where R w2Connect PBM, R w1 Connect R a6 ; R w2 represents a bond, C(O), C(O)NH, or NHC(O); Each ring A 1 are the same or different and each independently represent a heterocyclylene group, a cycloalkylene group, an arylene group or a heteroarylene group, and y1 represents an integer of 0, 1, 2 or 3, (R y1 ) a1 Represents each ring A 1 independently optionally be a1 R y1 Group substitution, each R y1 Deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, carboxyl, C 2-6 Alkynyl or C 2-6 alkenyl, and a1 represents an integer of 0-10; Each ring A 2 are the same or different and each independently represent a heterocyclylene group, a cycloalkylene group, an arylene group or a heteroarylene group, and y2 represents an integer of 0, 1, 2 or 3, (R y2 ) a2 Represents each ring A 2 Each independently optionally represented by a2 R y2 Group substitution, each R y2 Deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, carboxyl, C 2-6 Alkynyl or C 2-6 alkenyl, and a2 represents an integer of 0-10; Each ring A 3 are the same or different and each independently represent a heterocyclylene group, a cycloalkylene group, an arylene group or a heteroarylene group, and y3 represents an integer of 0, 1, 2 or 3, (R y3 ) a3 Represents each ring A 3 Independently optionally a3 R y3 Group substitution, each R y3 Deuterium, C 1-6 Alkyl, deuterated C 1-6Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, carboxyl, C 2-6 Alkynyl or C 2-6 alkenyl, and a3 represents an integer of 0-10; R w1 represents a bond, or represents an optionally substituted straight or branched C 1-20 Alkylene, wherein the linear or branched C 1-20 Alkylene Any one or more methylene groups of the main carbon chain skeleton may be optionally replaced by one or more groups selected from the following: a 、R b and any combination thereof, each group R a Each independently selected from O, C(O), OC(O), S, S(O), S(O)2, S(O)2N(R a7 )、N(R a7 )S(O)2、C(O)N(R a7 )、N(R a7 )C(O), N(R a7 ) and N(R a7 )C(O)N(R a7 ), where each R a7 Each independently represents H or C 1-3 Alkyl, and when the linear or branched C 1-20 Any two or more methylene groups of the main carbon chain skeleton of the alkylene group are replaced by two or more groups R a When substituted, each group R a Not directly connected to each other; each group R b Each is independently selected from optionally substituted cycloalkylene, optionally substituted arylene, optionally substituted heterocyclylene, optionally substituted heteroarylene, alkynylene, alkenylene, and any combination thereof. In another aspect, the present disclosure provides a pharmaceutical composition comprising a compound of formula (I) or a salt, stereoisomer (including enantiomer), solvate, isotopically enriched analog, prodrug or polymorph thereof, and at least one pharmaceutically acceptable carrier. In another aspect, the present disclosure also provides a pharmaceutical kit or a test kit comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising the same. In another aspect, the present disclosure provides a compound of formula (I) or a salt, stereoisomer (including enantiomer), solvate, isotopically enriched analog, prodrug or polymorph thereof, or a pharmaceutical composition comprising the same as an active ingredient, for use as a medicament. On the other hand, the compound of formula (I) provided by the present disclosure or its salt (e.g., pharmaceutically acceptable salt), stereoisomer (including enantiomers, diastereomers), solvate, isotopically enriched analog, prodrug or polymorph or pharmaceutical composition comprising the same as an active ingredient can be used to treat and / or prevent the following diseases or conditions: tumors, infectious diseases, autoinflammatory diseases, inflammatory diseases, autoimmune diseases, neurological diseases, respiratory diseases, hemorrhagic shock, transplant rejection, multiple organ dysfunction syndrome (MODS), sarcoidosis, adult respiratory distress syndrome, cardiovascular disease, Richter syndrome (RS), acute liver failure, diabetes, Kennedy disease, seborrheic alopecia, hirsutism, skin diseases, functional uterine bleeding, anemia, pediatric aplastic anemia, endometriosis, polycystic ovary syndrome and thyroid disease. On the other hand, the present disclosure also provides the use of the compound of formula (I) or its pharmaceutically acceptable salt, stereoisomer (including enantiomers, diastereomers), solvate, isotopically enriched analog, prodrug or polymorph, or the pharmaceutical composition of the present disclosure, wherein the use is for preparing a medicament for treating and / or preventing the following diseases or conditions: tumors, infectious diseases, autoinflammatory diseases, inflammatory diseases, autoimmune diseases, neurological diseases, respiratory diseases, hemorrhagic shock, transplant rejection, multiple organ dysfunction syndrome (MODS), sarcoidosis, adult respiratory distress syndrome, cardiovascular disease, Richter syndrome (RS), acute liver failure, diabetes, Kennedy disease, seborrheic alopecia, hirsutism, skin diseases, functional uterine bleeding, anemia, aplastic anemia in children, endometriosis, polycystic ovary syndrome and thyroid disease. In another aspect, the present disclosure also provides a method for treating or preventing a disease or condition in a subject, comprising administering to the subject a therapeutically effective amount of a compound of formula (I) or a salt, enantiomer, stereoisomer, solvate, isotopically enriched analog, prodrug or polymorph thereof, or a pharmaceutical composition comprising the same, wherein the disease or condition comprises: tumors, infectious diseases, autoinflammatory diseases, inflammatory diseases, autoimmune diseases, neurological diseases, respiratory diseases, hemorrhagic shock, transplant rejection, multiple organ dysfunction syndrome (MODS), sarcoidosis, adult respiratory distress syndrome, cardiovascular disease, Richter syndrome (RS), acute liver failure, diabetes, Kennedy disease, seborrheic alopecia, hirsutism, skin diseases, functional uterine bleeding, anemia, aplastic anemia in children, endometriosis, polycystic ovary syndrome and thyroid disease. In another aspect, the present disclosure provides the use of a compound of formula (II) or a salt, stereoisomer (including enantiomer), solvate, isotopically enriched analog, prodrug or polymorph thereof for preparing a compound of formula (I) or a salt, enantiomer, stereoisomer, solvate, isotopically enriched analog, prodrug or polymorph thereof of the present disclosure. In another aspect, the present disclosure also provides a method for preparing a compound of formula (I) of the present disclosure or a salt, enantiomer, stereoisomer, solvate, isotopically enriched analog, prodrug or polymorph thereof using a compound of formula (II) or a salt, stereoisomer (including enantiomer), solvate, isotopically enriched analog, prodrug or polymorph thereof. In another aspect, the present disclosure provides the use of 3-(1-oxo-5-(piperazin-1-ylamino)isoindolin-2-yl)piperidine-2,6-dione or a salt, stereoisomer (including enantiomer), solvate, isotopically enriched analog, prodrug or polymorph thereof for preparing a compound of formula (I) of the present disclosure or a salt, enantiomer, stereoisomer, solvate, isotopically enriched analog, prodrug or polymorph thereof. In another aspect, the present disclosure also provides a method for preparing a compound of formula (I) of the present disclosure, or a salt, enantiomer, stereoisomer, solvate, isotopically enriched analog, prodrug or polymorph thereof, using 3-(1-oxo-5-(piperazin-1-ylamino)isoindolin-2-yl)piperidine-2,6-dione or a salt, stereoisomer (including enantiomer), solvate, isotopically enriched analog, prodrug or polymorph thereof. In another aspect, the present disclosure provides a pharmaceutical composition comprising a compound of formula (II) or a salt, stereoisomer (including enantiomer), solvate, isotopically enriched analog, prodrug or polymorph thereof, and at least one pharmaceutically acceptable carrier. In another aspect, the present disclosure also provides a pharmaceutical kit or a test kit comprising a compound of formula (II) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising the same. In another aspect, the present disclosure provides a compound of formula (II) or a salt, stereoisomer (including enantiomer), solvate, isotopically enriched analog, prodrug or polymorph thereof, or a pharmaceutical composition comprising the same as an active ingredient, for use as a medicament. In another aspect, the present disclosure provides a compound of formula (II) or a salt, stereoisomer (including enantiomer), solvate, isotopically enriched analog, prodrug or polymorph thereof, or a pharmaceutical composition comprising the same as an active ingredient, which can be used to treat and / or prevent diseases or conditions associated with cereblon protein. Diseases or conditions associated with cereblon protein include tumors, cancer, and autoimmune diseases. In another aspect, the present disclosure further provides the use of the compound of formula (II) or its pharmaceutically acceptable salts, stereoisomers (including enantiomers, diastereomers), solvates, isotopically enriched analogs, prodrugs or polymorphs, or the pharmaceutical compositions of the present disclosure, for preparing a medicament for treating or preventing diseases or conditions associated with cereblon protein. In some embodiments, diseases or conditions associated with cereblon protein include tumors, cancer, and autoimmune diseases. In another aspect, the present disclosure also provides a method for treating or preventing a disease or condition associated with cereblon protein in a subject, the method comprising administering to the subject a therapeutically effective amount of a compound of formula (II) or a salt, enantiomer, stereoisomer, solvate, isotopically enriched analog, prodrug or polymorph thereof, or a pharmaceutical composition comprising the same. In some embodiments, the disease or condition associated with cereblon protein includes tumors, cancer, and autoimmune diseases. In another aspect, the present disclosure also provides the use of the compound of formula (II) or its pharmaceutically acceptable salt, stereoisomer (including enantiomers, diastereomers), solvate, isotopically enriched analog, prodrug or polymorph for preparing a Cereblon protein (CRBN) binder. In another aspect, the present disclosure provides 3-(1-oxo-5-(piperazin-1-ylamino)isoindolin-2-yl)piperidine-2,6-dione, or a salt, stereoisomer (including enantiomer), solvate, isotopically enriched analog, prodrug, or polymorph thereof, or a pharmaceutical composition comprising the same as an active ingredient, for use in treating and / or preventing diseases or conditions associated with cereblon protein. In some embodiments, diseases or conditions associated with cereblon protein include tumors, cancer, and autoimmune diseases. In another aspect, the present disclosure further provides the use of the 3-(1-oxo-5-(piperazin-1-ylamino)isoindolin-2-yl)piperidine-2,6-dione or a pharmaceutically acceptable salt, stereoisomer (including enantiomers, diastereomers), solvate, isotopically enriched analog, prodrug, or polymorph thereof for the preparation of a medicament for treating or preventing a disease or condition associated with the cereblon protein. In some embodiments, the disease or condition associated with the cereblon protein includes tumors, cancer, and autoimmune diseases. In another aspect, the present disclosure also provides a method for treating or preventing a disease or condition associated with cereblon protein in a subject, the method comprising administering to the subject a therapeutically effective amount of 3-(1-oxo-5-(piperazin-1-ylamino)isoindolin-2-yl)piperidine-2,6-dione or a salt, enantiomer, stereoisomer, solvate, isotopically enriched analog, prodrug, or polymorph thereof, or a pharmaceutical composition comprising the same. In some embodiments, the disease or condition associated with cereblon protein includes tumors, cancer, and autoimmune diseases. On the other hand, the present disclosure also provides the use of the 3-(1-oxo-5-(piperazin-1-ylamino)isoindolin-2-yl)piperidine-2,6-dione or its pharmaceutically acceptable salt, stereoisomer (including enantiomers, diastereomers), solvate, isotopically enriched analogue, prodrug or polymorph for the preparation of a Cereblon protein (CRBN) binder. In another aspect, the present disclosure also provides a method for preparing a compound of formula (I), comprising using a compound of formula (M1) and a compound of formula (M2) as starting materials to prepare a compound of formula (I): Among them, PBM, R a1 、R a2 、R a3 、R a4 、(R a5 ) m , Z, R w2 , Ring A 1 Ring A 2Ring A 3 ,y1,y2,y3,(R y1 ) a1 、 (R y2 ) a2 and (R y3 ) a3 As defined in the compounds of formula (I) and its various sub-embodiments disclosed herein; R w3 represents a bond, or represents an optionally substituted straight or branched C 1-19 Alkylene, wherein the linear or branched C 1-19 Alkylene Any one or more methylene groups of the main carbon chain skeleton may be optionally replaced by one or more groups selected from the following: R a 、R b and any combination thereof, each group R a Each independently selected from O, C(O), OC(O), S, S(O), S(O)2, S(O)2N(R a7 )、N(R a7 )S(O)2、C(O)N(R a7 )、N(R a7 )C(O), N(R a7 ) and N(R a7 )C(O)N(R a7 ), where each R a7 Each independently represents H or C 1-3 Alkyl, and when the linear or branched C 1-19 Any two or more methylene groups of the main carbon chain skeleton of the alkylene group are replaced by two or more groups R a When substituted, each group R a Not directly connected to each other; each group R b Each independently selected from optionally substituted cycloalkylene, optionally substituted arylene, optionally substituted heterocyclylene, optionally substituted heteroarylene, alkynylene, alkenylene and any combination thereof; and wherein the linear or branched C 1-19 One or more hydrogen atoms of the alkylene group may be selected from deuterium, hydroxyl, amino, mercapto, nitro, halogen, cyano, haloC 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 3-6 Cycloalkyl, halogenated C 3-6 Cycloalkyl, deuterated C 3-6 cycloalkyl, 4- to 10-membered heterocyclyl, and any combination thereof; and R w4Indicates CHO, COOH or Among them, ring Y 2 and (R d2 ) n2 As disclosed herein, the compound of formula (I) and its various sub-embodiments As defined in the case; Where (1) when R w4 When it represents CHO or COOH, (a1)R L1 N(R w ), R L2 and R L3 Together with the N atoms to which they are attached, they form or (a2)R L1 and R L2 Together And R L3 Indicates H or C 1-3 alkyl; or (a3)R L1 Indicates NH, R L2 Indicates a key, R L3 means H; or (a4)R L1 express The symbol **** indicates that L2 The connection point, R L2 express The symbol ### indicates the connection point with N, and the ring Y 3 and (R d3 ) n3 As defined in the compounds of formula (I) and its various sub-embodiments disclosed herein, and R L3 Indicates H or C 1-3 alkyl; or Where (2) when R w4 express When R L1 N(R w ), R L2 and R L3 Together with the N atoms to which they are attached, they form as well as Among them, the above R w 、Ring Y 1 and (R d1 ) n1 As defined in the compounds of formula (I) and various subembodiments thereof of the present disclosure. In another aspect, the present disclosure also provides a method for preparing a compound of formula (II), comprising using a compound of formula (M3) and a compound of formula (M4) as starting materials to prepare a compound of formula (II): where R a1 、R a2 、R a3 、R a4 、(R a5 ) m , Z, Ring Y 1 、R w and (R d1 ) n1 As disclosed herein, the compound of formula (II) and its various sub-embodiments As defined in the case; Y represents F or Br; W1 represents H, and W2 represents an amino protecting group; or W1 represents an amino protecting group, and W2 represents H; and R E express: Among them, ring Y 1 represents a heterocyclic group containing at least 2 nitrogen atoms, (R d1 ) n1 Represents ring Y 1 Optionally n1 R d1 Group Generation, each R d1 Each independently represents deuterium, halogen, hydroxyl, mercapto, nitro, amino, cyano, oxo, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy or C 1-6 alkoxy, and n1 represents an integer of 0-20; and R1 represents N(R w ), where R w Represents hydrogen or C 1-3 Alkyl, and R E1 represents hydrogen; or R1 represents a bond, and R E1 Indicates NH2. Detailed Description of the Invention The following detailed description is provided as an exemplary embodiment to help those skilled in the art understand and implement the present disclosure. However, it should be understood that such description is not intended to limit the scope of the present disclosure. Without departing from the spirit and scope of the present disclosure, the specific embodiments described in the present disclosure may be subjected to various modifications and changes, and these changes and improvements all fall within the scope of the present disclosure as claimed. I. Compounds of formula (I) The compounds of formula (I) disclosed herein, or their salts (including pharmaceutically acceptable salts), stereoisomers (including enantiomers), solvates, isotopically enriched analogs, prodrugs, or polymorphs, can bind to target proteins, recruiting them to E3 ubiquitin ligases for ubiquitination and degradation. The compounds of formula (I) disclosed herein can specifically target specific target protein classes or families, exhibiting a wide range of pharmacological activities by degrading / inhibiting a variety of target protein classes or families. PBM-LIN-ULM (I) wherein PBM, LIN and ULM are as defined above in the compound of formula (I). In some embodiments, the PBM can be a small molecule ligand that binds to a specific target protein, including but not limited to epidermal growth factor receptor (EGFR), cyclin-dependent kinase 4 / 6 (CDK4 / 6), breakpoint cluster region (BCR)-Abelson leukemia virus (ABL) (BCR-ABL) tyrosine kinase, androgen receptor (AR), or interleukin-1 receptor-associated kinase 1 / 2 / 3 / 4 (IRAK1 / 2 / 3 / 4). In some embodiments, the PBM in the compound of formula (I) comprises a structure selected from the group consisting of: in (R 1a ) p1a Indicates that the benzene ring to which it is connected can be optionally replaced by p1a R 1a Replace, each R 1a Same or different and independent The ground represents deuterium, halogen, hydroxyl, NH2, NO2, cyano, C 1-6Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy or halogenated C 1-6 alkoxy; p1a represents an integer 0, 1, 2, 3, 4, or 5; R 1b represents a bond or optionally selected from C 1-3 Alkyl, deuterated C 1-3 Alkyl, halogenated C 1-3 Alkyl and halogen substituted C 1-2 Asia alkyl; (R 1c ) p1b The quinazoline ring in formula (PBM-1) is optionally replaced by p1b R 1c Replace, each R 1c The same or different and each independently represents Deuterium, halogen, NO2, cyano, halogenated C 1-6 Alkyl, C 1-10 Alkyl, deuterated C 1-10 Alkyl, C 1-10 Alkoxy, halogenated C 1-10 Alkoxy, -O-optionally substituted heterocyclyl, or -NHC(O)R 1e , where R 1e Indicates C 1-10 Alkyl, deuterated C 1-10 Alkyl or C 2-10 Alkenyl, such as R 1c Represents methyl, methoxy, For example p1b represents an integer 1, 2, or 3; R 1d Represents hydrogen, deuterium or C 1-3 alkyl; R in formula (PBM-2) 2a represents -NHC(O)- or -C(O)NH-; R 2b Indicates -NH-, -N(C 1-6 alkyl)- or ethynylene; Ring A in formula (PBM-2) represents a 5- to 20-membered monocyclic, bicyclic or polycyclic heteroaromatic ring containing 1 to 4 heteroatoms selected from N, O and S. Base, (R 2c ) p2a Indicates that the ring A is optionally replaced by p2a R 2c Replace, and each R 2cThe same or different and each independently represent an optionally substituted 5- to 15-membered heteroaryl, deuterium, halogen, hydroxyl, cyano, amino, NO2, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy or halogenated C 1-6 alkoxy; p2a represents an integer 0, 1, 2, or 3; Each (R 2d ) p2b Each independently represents that the benzene ring connected thereto is each independently optionally replaced by p2b R 2d Replace, each R 2d The same or different and each independently represents deuterium, halogen, hydroxyl, cyano, amino, NO2, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Alkyl, deuterated C 1-6 Alkyl or halogenated C 1-6 alkyl; Each p2b is the same or different and independently represents an integer of 0, 1, 2, 3 or 4; (R 3a ) p3a Indicates that the benzene ring connected to it is p3a R 3a Replace, each R 3a Same or different and independent of each other Deuterium, halogen, hydroxyl, cyano, amino, NO2, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Alkyl, deuterated C 1-6 Alkyl or halogenated C 1-6 alkyl; p3a represents an integer 1, 2, 3, 4, or 5; R 3b Halogen, C 1-6 Alkyl, deuterated C 1-6 Alkyl or halogenated C 1-6 alkyl; X1 in the formula (PBM-4) represents CR 4e or fragment The symbol # represents the connection point of N adjacent to X1, and the symbol ## represents Shows the connection point with X2, and each R 4e Each independently represents deuterium, hydrogen, halogen, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C1-6 Alkyl, -C(O)-C 1-6 Alkyl, -C(O)-deuterated C 1-6 Alkyl or -C(O)NR 4f R 4g , where R 4f 、R 4g are the same or different and each independently represent hydrogen, C 1-6 Alkyl or deuterated C 1-6 Alkyl, and R 4f 、R 4g Not simultaneously hydrogen; X2 in formula (PBM-4) represents N or CR 4h , where R 4h Represents hydrogen, deuterium, halogen, C 1-6 Alkyl, deuterated C 1-6 Alkyl or halogenated C 1-6 alkyl; X3 and X4 each independently represent CH or N; R 4a represents a bond or an optionally substituted heteroarylene (e.g., a halogen- or deuterium-substituted heteroarylene); R 4b Represents hydrogen, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, or optionally substituted C 3-12 Cycloalkyl; (R 4c ) p4a The pyridine ring connected thereto is optionally replaced by p4a R 4c Replace, each R 4c Same or different and each unique Deuterium, halogen, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy or halogenated C 1-6 Alkoxy, p4a represents an integer of 0, 1, 2 or 3; (R 4d ) p4b represents a nitrogen-containing bicyclic heteroaromatic ring connected thereto which is optionally replaced by p4b R 4d Replace, each R 4d Same or different and independently represent deuterium, halogen, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6Alkoxy or halogenated C 1-6 Alkoxy, p4b represents an integer of 0 or 1; Ring B in formula (PBM-5) represents a 5- to 20-membered monocyclic or bicyclic or polycyclic heterocyclic ring containing 1 to 4 heteroatoms selected from N, O and S. aryl; R 5b represents an optionally substituted 5- to 15-membered heteroaryl, an optionally substituted 5- to 15-membered heterocyclic group, deuterium, halogen, hydroxyl, cyano, amino Base, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy or halogenated C 1-6 alkoxy; R 5a Represents hydrogen, halogen, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy or halogenated C 1-6 alkoxy; R in formula (PBM-6) x1 Indicates a bond or C(O), or R x1 Represents -C(O)NH-R x2 -C(O)-***, where the symbol *** represents the c of Connect the points, and R x2 represents an optionally substituted C 3-15 Cycloalkyl; (R 6a ) p6a Indicates that the 1H-pyrrolo[2,3-b]pyridine ring connected thereto is optionally replaced by p6a R 6a Replace, and each R 6a Independent surface Indicates cyano, halogen, hydroxyl, amino, nitro, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy or halogenated C 1- 6 alkoxy, and p6a represents an integer of 0, 1, 2, 3, 4 or 5; (R 6b ) p6b Indicates that the pyridine ring connected thereto is optionally replaced by p6b R 6b Replace, and each R 6b Each independently represents a cyano group, a halogen group, Hydroxyl, nitro, C 1-6Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy or halogenated C 1-6 Alkoxy or NR 6c R 6d , where R 6c 、R 6d are the same or different and each independently represent hydrogen, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, optionally substituted C 3-15 cycloalkyl or an optionally substituted 4- to 15-membered heterocyclyl, and p6b represents an integer of 0, 1, 2 or 3; Ring C in formula (PBM-7) represents C 6-10 Aryl or 5- to 20-membered heteroaryl (e.g., containing 1 or 2 5- to 7-membered rings and 1 to 4 selected 5- to 20-membered heteroaryl) containing a heteroatom selected from N, O and S, said ring C being optionally substituted with one or more R 7a Replace, and each R 7a The same or different and each independently is deuterium, halogen, hydroxyl, cyano, amino, nitro, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkenyl, or C 2-6 Alkynyl; Ring D in formula (PBM-7) represents C 3-15 Cycloalkyl or 4- to 20-membered heterocyclic group (e.g., containing 1 to 4 heteroatoms selected from N, O and S) wherein the ring D is optionally substituted by one or more R 7b Replace, and each R 7b The same or different and each independently is deuterium, halogen, hydroxyl, cyano, amino, nitro, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy or halogenated C 1-6 alkoxy; Ring E in formula (PBM-7) represents a 5- to 20-membered heteroaryl group (e.g., a 5- to 20-membered heteroaryl group containing 1 to 4 heteroatoms selected from N, O and S). monocyclic or bicyclic heteroaryl), said ring E is optionally substituted by one or more R 7c Replace, and each R 7cThe same or different and each independently is deuterium, halogen, hydroxyl, cyano, amino, nitro, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy or halogenated C 1-6 alkoxy; R in formula (PBM-8) 8a Indicates N or CH; R 8b represents NHC(O), C(O)NH, NHS(O)2 or S(O)2NH; (R 8c ) p8a Indicates R-containing 8a The six-membered ring is p8a R 8c Replace, each R 8c The same or different and each independently represents halogen, Hydroxyl, thiol, cyano, amino, nitro, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy or halogenated C 1-6 alkoxy, and p8a represents an integer of 0, 1, 2, 3 or 4; Ring F represents a 5- to 15-membered heteroarylene group, (R 8d ) p8b Indicates that the ring F connected to it is optionally replaced by p8b R 8d Replace, each R 8d Same or Different and each independently represents halogen, hydroxyl, mercapto, cyano, amino, nitro, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, hydroxy substituted C 1-6 Alkyl, amino substituted C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy or optionally substituted C 3-15 cycloalkyl, and p8b represents an integer of 0, 1, 2 or 3; and R in each general formula c Each independently represents a bond, -O-, -N(R d )-, -NHC(O)-*, -C(O)NH-*, -N(R d )-R f -N(R e )-*、- R f -C(O)NH-*、-Rf -NHC(O)-*、-R f -C(O)O-*、-R f -OC(O)-*, -C(O)O-*, -OC(O)-*, -R f -、-R f -N(R d )-*、-OR f -N(R d )-*、 Among them, each ring W 1 are the same or different and each independently represent a nitrogen-containing heterocyclylene group, a cycloalkylene group, an arylene group or a heteroarylene group, t1 represents an integer 0, 1, or 2, (R c1 ) m2 Indicates each ring W 1 Each independently optionally represented by m1 R c1 Group substitution, each R c1 Deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, carboxyl, C 2-6 Alkynyl, C 2-6 Alkenyl, optionally deuterated C 3-6 Cycloalkyl, or R c4 -R c3 -, where R c3 is an optional substituted C 1-6 Alkylene or optionally substituted C 2-6 Alkenylene, R c4 Represents halogen, R c5 R c6 N-, hydroxy, carboxyl, ethynyl, or vinyl, where R c5 and R c6 The same or different and each independently represents hydrogen or C 1-3 alkyl, and m1 represents an integer of 0-20; Each ring W 2 The same or different and each independently represents a nitrogen-containing heterocyclylene group, a cycloalkylene group, an arylene group or a heteroarylene group, t2 represents Integer 0 or 1, (R c2 ) m3 Indicates each ring W 2 Independently optionally m2 Rc2 Group substitution, each R c2 Deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, carboxyl, C 2-6 Alkynyl, C 2-6 Alkenyl, optionally deuterated C 3-6 Cycloalkyl, or R c8 -R c7 -, where R c7 is an optional substituted C 1-6 Alkylene or optionally substituted C 2-6 Alkenylene, R c8 Represents halogen, R c9 R c10 N-, hydroxy, carboxyl, ethynyl, or vinyl, where R c9 and R c10 The same or different and each independently represents hydrogen or C 1-3 alkyl, and m2 represents an integer of 0-20; and R d and R e Each independently represents hydrogen or C 1-6 Alkyl, R f and R g Each independently represents an optionally substituted C 1-6 Alkylene or optional Substituted C 2-6 alkenylene, and the symbol * indicates the point of attachment to LIN. In various embodiments of the present disclosure, the number of substituents is in principle not subject to any limitation, either automatically limited by the size of the building block (ie, the total number of replaceable hydrogen atoms of the building block), or as explicitly defined herein. In various embodiments of the present disclosure, each R c As defined herein. In some embodiments, the PBM represents a small molecule ligand for EGFR. In some embodiments, PBM represents the structure of the following formula (PBM-1): in (R 1a ) p1a Indicates that the benzene ring to which it is connected can be optionally replaced by p1a R 1a Replace, each R 1a Same or different and independent deuterium, halogen (such as fluorine, chlorine, bromine or iodine), hydroxyl, NH2, NO2, cyano, C 1-6 Alkyl (e.g. C 1-4 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halo-C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 Alkoxy (e.g. C 1-4 Alkoxy, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), or halo-C 1-6 Alkoxy (e.g., halo-C 1-4 Alkoxy, for example F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-); p1a represents an integer 0, 1, 2, 3, 4, or 5; R 1b represents a bond or optionally selected from C 1-3 Alkyl, deuterated C 1-3 Alkyl, halogenated C 1-3 Alkyl and halogen substituted C 1-2 Asia an alkyl group (e.g., methylene or ethylene); (R 1c ) p1b The quinazoline ring in formula (PBM-1) is optionally replaced by p1b R 1c Replace, each R 1c The same or different and each independently represents Deuterium, halogen, NO2, cyano, halogenated C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl groups, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), C 1-10Alkyl (e.g. C 1-6 Alkyl or C 1-4 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), deuterated C 1- 10 Alkyl (e.g. deuterated C 1-6 Alkyl or deuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-10 Alkoxy (e.g. C 1-6 Alkoxy or C 1-4 Alkoxy, for example methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), halo C 1-10 Alkoxy (e.g., halo-C 1-6 Alkoxy or halogenated C 1-4 alkoxy, such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O-, or CH2ClCH2-O-), -O-optionally substituted heterocyclyl (e.g., -O-optionally substituted 4- to 20-membered heterocyclyl), or -NHC(O)R 1e , where R 1e Indicates C 1-10 Alkyl (e.g. C 1-8 Alkyl, C 1-6 Alkyl or C 1-4 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl, hexyl, heptyl or octyl), deuterated C 1-10 Alkyl (e.g., perdeuterated C 1-8 Alkyl, fully deuterated C 1-6 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.) or C 2-10 Alkenyl (e.g. C 2-6 Alkenyl or C 2-4 alkenyl, such as ethenyl, propenyl, butenyl or pentenyl), such as R 1c Represents methyl, methoxy, For example p1b represents the integer 1, 2, or 3; and R 1d Represents hydrogen, deuterium or C 1-3 Alkyl (eg, methyl, ethyl, or propyl). In some embodiments, PBM represents the non-limiting example of the following structure of Formula (PBM-1), i.e., the structure of Formula (PBM-1-1A), Formula (PBM-1-1B), Formula (PBM-1-1C), or Formula (PBM-1-1D): Among them (R 1a ) p1a 、R 1b 、(R 1c ) p1b 、R 1d and R c As defined herein in each embodiment of Formula (PBM-1) and each subembodiment thereof. In some embodiments, (R 1c ) p1b In Formula (PBM-1), Formula (PBM-1-1A), Formula (PBM-1-1B), Formula (PBM-1-1C) or Formula (PBM-1-1D), each quinazoline ring is independently replaced by p1b R 1c substituted, wherein p1b represents an integer of 1, 2, or 3, R 1c represents an optionally substituted -O- heterocyclic group, wherein the heterocyclic group is a 4- to 20-membered (e.g., 4- to 15-membered, 4- to 12-membered, 4- to 10-membered, 4- to 7-membered, or 4- to 6-membered) monocyclic or bicyclic or polycyclic heterocyclic group containing one or more (e.g., 1-4 or 1, 2, 3, or 4) heteroatoms selected from nitrogen, oxygen, and sulfur, including but not limited to azetidinyl, oxetanyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, oxazolidinyl, thiazolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, dioxanyl, azepanyl, diazepanyl, 1,4-diazacycloheptane-1-yl), azacyclooctane, diazacyclooctane, azabicyclo[3.1.1]heptane, azabicyclo[2.2.1]heptane, azabicyclo[3.2.1]octane, azabicyclo[2.2.2]octane, diazabicyclo[3.1.1]heptane, diazabicyclo[2.2.1]heptane, diazabicyclo[3.2.1]octane (e.g. 3,8-diazabicyclo[3.2.1]octane-3-yl), diazabicyclo[2.2.2]octane (e.g. 2,5-diazabicyclo[2.2.2]octane-2-yl). In some embodiments, the heterocyclic group is optionally selected from deuterium, hydroxyl, amino, thiol, nitro, halogen, cyano, optionally deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, optionally deuterated C 3-6 Cycloalkyl, optionally deuterated C 1-6 Alkoxy, optionally deuterated C 1-6 Alkyl-NH-, NH2-C1-6 Alkylene, optionally deuterated C 1-6 Alkyl-NHC(O)-, optionally deuterated C 1-6 In some embodiments, p1b represents an integer of 1. In some embodiments, R described herein 1c express: fluorine, chlorine, bromine or iodine; methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl, hexyl, heptyl or octyl; methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy; -NHC(O)-C 2-10 Alkenyl, such as -NHC(O)-vinyl (i.e. ), -NHC(O)-propenyl or -NHC(O)-butenyl; or In some embodiments, R described herein 1b represents a bond or optionally selected from C 1-3 Alkyl, deuterated C 1-3 Alkyl, halogenated C 1-3 Alkyl and halogen substituted C 1-2 In some embodiments, R 1b represents a bond or optionally selected from C 1-3 Alkyl, deuterated C 1-3 Alkyl, halogenated C 1-3 In some embodiments, R 1b Indicates a key. In some embodiments, PBM represents the structure of Formula (PBM-1-1), Formula (PBM-1-2), Formula (PBM-1-3), Formula (PBM-1-4), or Formula (PBM-1-5): In some embodiments, the PBM represents a small molecule ligand for BCR-ABL. In some embodiments, the PBM represents the structure of formula (PBM-2): in R 2a represents -NHC(O)- or -C(O)NH-; R 2b Indicates -NH-, -N(C 1-6 alkyl)- or ethynylene; Ring A in formula (PBM-2) represents a 5- to 20-membered monocyclic, bicyclic or polycyclic heteroaromatic ring containing 1 to 4 heteroatoms selected from N, O and S. Base, (R 2c ) p2a Indicates that the ring A is optionally replaced by p2a R 2c Replace, and each R 2c The same or different and each independently represent an optionally substituted 5- to 15-membered heteroaryl, deuterium, halogen (such as fluorine, chlorine, bromine or iodine), hydroxyl, cyano, amino, NO2, C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halo-C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 Alkoxy (e.g. C 1-4 Alkoxy, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), or halo-C 1-6 Alkoxy (e.g., halo-C 1-4 Alkoxy, for example F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-); p2a represents an integer 0, 1, 2, or 3; Each (R 2d ) p2b Each independently represents that the benzene ring connected thereto is each independently optionally replaced by p2b R 2d Replace, each R 2d The same or different and each independently represents deuterium, halogen (such as fluorine, chlorine, bromine or iodine), hydroxyl, cyano, amino, NO2, C 1-6 Alkoxy (e.g. C 1-4Alkoxy, for example methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), halo C 1-6 Alkoxy (e.g., halo-C 1-4 Alkoxy, for example F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-), C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.) or halogenated C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl groups, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2-, or CH2ClCH2-); and Each p2b is the same or different and independently represents an integer of 0, 1, 2, 3 or 4. In some embodiments, Ring A in Formula (PBM-2) represents a 5- to 20-membered monocyclic or bicyclic or polycyclic heteroaryl group containing 1-4 heteroatoms selected from N, O, and S. In one subembodiment, examples of 5- to 20-membered monocyclic or bicyclic or polycyclic heteroaryl groups include, but are not limited to, furyl, oxazolyl, isoxazolyl, oxadiazolyl, thienyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, indolyl, isoindolyl, benzofuranyl, isobenzofuranyl, benzothienyl, indazolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzotriazolyl, benzo[2,1,3 ]oxadiazolyl, benzo[2,1,3]thiadiazolyl, benzo[1,2,3]thiadiazolyl, quinolyl, isoquinolyl, naphthyridinyl, cinnolinyl, quinazolinyl, quinoxalinyl, phthalazinyl, pyrazolo[1,5-a]pyridinyl, pyrazolo[1,5-a]pyrimidinyl, imidazo[1,2-a]pyridinyl, 1H-pyrrolo[3,2-b]pyridinyl, 1H-pyrrolo[2,3-b]pyridinyl, pyrrolo[2,1-b]thiazolyl, imidazo[2,1-b]thiazolyl or imidazo[1,2-b]pyridazinyl. Heteroaryl is optionally replaced by p2a R 2c substituted, p2a represents an integer of 0, 1, 2, or 3, and each R 2c The same or different and each independently represent: optionally substituted 5- to 15-membered heteroaryl, deuterium, halogen (such as fluorine, chlorine, bromine or iodine), hydroxyl, cyano, amino, NO2, C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halo-C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 Alkoxy (e.g. C 1-4 Alkoxy, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), or halo-C 1-6 Alkoxy (e.g., halo-C 1-4Alkoxy groups, such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-). In some embodiments, R in formula (PBM-2) 2c represents an optionally substituted 5- to 15-membered heteroaryl. In some embodiments, the 5- to 15-membered heteroaryl is a 5- to 15-membered monocyclic or bicyclic aromatic ring group containing 1 or more (e.g., 1 to 6, or 1 to 5, or 1 to 4, or 1 to 3) heteroatoms independently selected from oxygen, nitrogen, and sulfur. In some subembodiments, examples of heteroaryl include, but are not limited to, furanyl, oxazolyl, isoxazolyl, oxadiazolyl, thienyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, indolyl, isoindolyl, benzofuranyl, isobenzofuranyl, benzothienyl, indazolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzotriazolyl, benzo[2,1,3]oxadiazolyl, benzo or imidazo[1,2-b]pyridazinyl. The heteroaryl group is optionally substituted with one or more (e.g., 1-6, e.g., 1, 2, 3, 4, 5, or 6) substituents, wherein the substituents are optionally selected from: halogen (e.g., fluorine, chlorine, bromine, or iodine), hydroxyl, cyano, amino, C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halo-C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 Alkoxy (e.g. C 1-4 Alkoxy, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), or halo-C 1-6 Alkoxy (e.g., halo-C 1-4 Alkoxy groups, such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-). In some embodiments, R in formula (PBM-2) 2b It represents -NH-. In some embodiments, PBM represents the following non-limiting example of a structure of Formula (PBM-2), ie, a structure of Formula (PBM-2-1A): in R 2a represents -NHC(O)- or -C(O)NH-; (R 2c ) p2a represents that the pyrimidine group connected thereto is optionally replaced by p2a R 2c Replace, and each R 2c The same or different and each independently represents Optionally substituted 5- to 15-membered heteroaryl, deuterium, halogen (eg, fluorine, chlorine, bromine or iodine), hydroxy, cyano, amino, NO2, C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halo-C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 Alkoxy (e.g. C 1-4Alkoxy, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), or halo-C 1-6 Alkoxy (e.g., halo-C 1-4 Alkoxy, for example F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-); p2a represents an integer 0, 1, 2, or 3; Each (R 2d ) p2b Each independently represents that the benzene ring connected thereto is each independently optionally replaced by p2b R 2d replace, Each R 2d The same or different and each independently represents deuterium, halogen (such as fluorine, chlorine, bromine or iodine), hydroxyl, cyano, amino, NO2, C 1- 6 alkoxy (e.g. C 1-4 Alkoxy, for example methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), halo C 1-6 Alkoxy (e.g., halo-C 1-4 Alkoxy, for example F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-), C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.) or halogenated C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl groups, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2-, or CH2ClCH2-); and Each p2b is the same or different and independently represents an integer of 0, 1, 2, 3 or 4. In some embodiments, R in formula (PBM-2-1A) 2c represents an optionally substituted 5- to 15-membered heteroaryl. In some embodiments, the 5- to 15-membered heteroaryl is a 5- to 15-membered monocyclic or bicyclic aromatic ring group containing 1 or more (e.g., 1 to 6, or 1 to 5, or 1 to 4, or 1 to 3) heteroatoms independently selected from oxygen, nitrogen, and sulfur. In some subembodiments, examples of heteroaryl include, but are not limited to, furanyl, oxazolyl, isoxazolyl, oxadiazolyl, thienyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, indolyl, isoindolyl, benzofuranyl, isobenzofuranyl, benzothienyl, indazolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzotriazolyl, benzo[2,1,3]oxadiazolyl, benzo or imidazo[1,2-b]pyridazinyl. The heteroaryl group is optionally substituted with one or more (e.g., 1-6, e.g., 1, 2, 3, 4, 5, or 6) substituents, wherein the substituents are optionally selected from: halogen (e.g., fluorine, chlorine, bromine, or iodine), hydroxyl, cyano, amino, C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halo-C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 Alkoxy (e.g. C 1-4 Alkoxy, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), or halo-C1-6 Alkoxy (e.g., halo-C 1-4 Alkoxy groups, such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-). In some embodiments, PBM represents the structure of the following formula (PBM-2-1): In some embodiments, the PBM represents the structure of formula (PBM-3): in (R 3a ) p3a Indicates that the benzene ring connected to it is p3a R 3a Replace, each R 3a Same or different and independent of each other Deuterium, halogen, hydroxyl, cyano, amino, NO2, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Alkyl, deuterated C 1-6 Alkyl or halogenated C 1-6 alkyl; p3a represents an integer 1, 2, 3, 4, or 5; R 3b Halogen, C 1-6 Alkyl, deuterated C 1-6 Alkyl or halogenated C 1-6 alkyl. In some embodiments, each R 3a Each independently represents deuterium, halogen (such as fluorine, chlorine, bromine or iodine), hydroxyl, cyano, amino, NO2, C 1-6 Alkoxy (e.g. C 1-4 Alkoxy, for example methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), halo C 1-6 Alkoxy (e.g., halo-C 1-4 Alkoxy, for example F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-), C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halo-C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-) or deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.). In some embodiments, R 3b represents halogen (e.g., fluorine, chlorine, bromine or iodine), C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halo-C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-) or deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.). In some embodiments, PBM represents the structure of the following formula (PBM-3-1): In some embodiments, the PBM represents a small molecule ligand for CDK4 / 6. In some embodiments, the PBM represents the structure of formula (PBM-4): in X1 in the formula (PBM-4) represents CR 4e or fragment The symbol # represents the connection point of N adjacent to X1, and the symbol ## represents Shows the connection point with X2, and each R 4e Each independently represents deuterium, hydrogen, halogen, C 1-6 Alkyl, deuterated C 1-6Alkyl, halogenated C 1-6 Alkyl, -C(O)-C 1-6 Alkyl, -C(O)-deuterated C 1-6 Alkyl or -C(O)NR 4f R 4g , where R 4f 、R 4g are the same or different and each independently represent hydrogen, C 1-6 Alkyl or deuterated C 1-6 Alkyl, and R 4f 、R 4g Not simultaneously hydrogen; X2 in formula (PBM-4) represents N or CR 4h , where R 4h represents hydrogen, deuterium, halogen (such as fluorine, chlorine, bromine or iodine), C 1-6 alkyl (For example, C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 Alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), (such as perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.) or halogenated C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl or halogenated C 1-3 Alkyl, for example F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-); X3 and X4 each independently represent CH or N; R 4a represents a bond or an optionally substituted heteroarylene group (e.g., an optionally substituted group containing one or more (e.g., 1 to 6, or 1 to 5 a 5- to 20-membered monocyclic, bicyclic or polycyclic aromatic ring group containing 1, 2, 3, 4, or 1 to 3 heteroatoms independently selected from oxygen, nitrogen and sulfur); R 4b Represents hydrogen, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, or optionally substituted C 3-12 Cycloalkyl; (R 4c ) p4a The pyridine ring connected thereto is optionally replaced by p4a R4c Replace, each R 4c Same or different and each unique deuterium, halogen (such as fluorine, chlorine, bromine or iodine), C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), halogenated C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl groups, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), C 1-6 Alkoxy (e.g. C 1-4 Alkoxy, for example methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy) or halogenated C 1-6 Alkoxy (e.g., halo-C 1-4 Alkoxy, such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-), p4a represents an integer 0, 1, 2 or 3; and (R 4d ) p4b represents a nitrogen-containing bicyclic heteroaromatic ring connected thereto which is optionally replaced by p4b R 4d Replace, each R 4d Same or different and independently represent deuterium, halogen (such as fluorine, chlorine, bromine or iodine), C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), halogenated C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl groups, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), C 1-6 Alkoxy (e.g. C 1-4 Alkoxy, for example methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy) or halogenated C 1-6 Alkoxy (e.g., halo-C 1-4 alkoxy, such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-), p4b represents an integer 0 or 1. In some embodiments, X1 represents CR 4e , where R 4e represents deuterium, hydrogen, halogen (such as fluorine, chlorine, bromine or iodine), C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halo-C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), -C(O)-C 1-6 Alkyl (e.g. -C(O)-C 1-5 Alkyl or -C(O)-C 1-3 Alkyl, such as -C(O)-CH3, -C(O)-CH2CH3), -C(O)-deuterated C 1-6 Alkyl (e.g. -C(O)-deuterated C 1-5 Alkyl or -C(O)-deuterated C 1-3 Alkyl, such as -C(O)-CD3) or -C(O)NR4f R 4g , where R 4f 、R 4g are the same or different and each independently represent hydrogen, C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl) or deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), and R 4f 、R 4g Not hydrogen at the same time. In some embodiments, X1 represents a fragment The symbol # represents the connection point of N adjacent to X1, the symbol ## represents the connection point with X2, and R 4e represents deuterium, hydrogen, halogen (such as fluorine, chlorine, bromine or iodine), C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halo-C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), -C(O)-C 1-6 Alkyl, -C(O)-deuterated C 1-6 Alkyl or -C(O)NR 4f R 4g , where R 4f 、R 4g are the same or different and each independently represent hydrogen, C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl) or deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.). In some embodiments, R 4a represents a bond or an optionally substituted heteroarylene group (e.g., an optionally substituted 5- to 20-membered monocyclic or bicyclic or polycyclic aromatic ring group containing 1 or more (e.g., 1 to 6, or 1 to 5, or 1 to 4, or 1 to 3) heteroatoms independently selected from oxygen, nitrogen and sulfur), wherein the heteroarylene group is optionally substituted by one or more (e.g., 1-4, such as 1, 2, 3, or 4) groups each independently selected from halogen (e.g., fluorine, chlorine, bromine or iodine), hydroxyl, cyano, amino, C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halo-C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 Alkoxy (e.g. C 1-4 Alkoxy, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), or halo-C 1-6 Alkoxy (e.g., halo-C 1-4 The alkoxy group is substituted with a substituent such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-). In some embodiments, R 4arepresents an optionally substituted heteroarylene, for example an optionally substituted 5- to 14-membered monocyclic or bicyclic or polycyclic heteroarylene containing 1 or more (e.g. 1 to 6, or 1 to 5, or 1 to 4, or 1 to 3) heteroatoms independently selected from oxygen, nitrogen and sulfur. Examples of heteroarylene groups include, but are not limited to, furanylene, oxazolylene, isoxazolylene, oxadiazolylene, thienylene, thiazolylene, isothiazolylene, thiadiazolylene, pyrrolylene, imidazolylene, pyrazolylene, triazolylene, pyridinylene, pyrimidinylene, pyridazinylene, pyrazinylene, indolylene, isoindolylene, benzofuranylene, isobenzofuranylene, benzothienylene, indazolylene, benzimidazolylene, benzoxazolylene, benzisoxazolylene, benzothiazolylene, benzisothiazolylene, benzotriazolylene, benzo[2,1,3]oxadiazolylene, Benzo[2,1,3]thiadiazolylene, benzo[1,2,3]thiadiazolylene, quinolinylene, isoquinolinylene, naphthyridinylene, cinnolinylene, quinazolinylene, quinoxalinylene, phthalazinylene, pyrazolo[1,5-a]pyridinylene, pyrazolo[1,5-a]pyrimidinylene, imidazo[1,2-a]pyridinylene, 1H-pyrrolo[3,2-b]pyridinylene, 1H-pyrrolo[2,3-b]pyridinylene, 4H-fluoro[3,2-b]pyrroleylene, pyrrolo[2,1-b]thiazolylene and imidazo[2,1-b]thiazolylene. The heteroarylene group is optionally substituted with one or more (e.g., 1-4, such as 1, 2, 3, or 4) substituents selected from halogen (e.g., fluorine, chlorine, bromine, or iodine), hydroxy, cyano, amino, C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halo-C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 Alkoxy (e.g. C 1-4 Alkoxy, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), or halo-C 1-6 Alkoxy (e.g., halo-C 1-4Alkoxy groups, such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-). In some embodiments, R 4b Represents hydrogen, C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halo-C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), or optionally substituted C 3-12 Cycloalkyl (e.g. cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl or cycloheptyl, which may be optionally substituted, for example, with halogen, C 1-6 Alkyl, halogenated C 1-6 Alkyl or deuterated C 1-6 substituted with a substituent on the alkyl group). In some embodiments, PBM represents the following non-limiting example of a structure of Formula (PBM-4), i.e., a structure of Formula (PBM-4-1A), Formula (PBM-4-1B), Formula (PBM-4-1C), or Formula (PBM-4-1D): in Each R 4e Each independently represents deuterium, hydrogen, halogen (such as fluorine, chlorine, bromine or iodine), C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halo-C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl or halogenated C 1-3Alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), -C(O)-C 1-6 Alkyl (e.g. -C(O)-C 1-5 Alkyl or -C(O)-C 1-3 Alkyl, such as -C(O)-CH3, -C(O)-CH2CH3), -C(O)-deuterated C 1-6 Alkyl (e.g. -C(O)-deuterated C 1-5 Alkyl or -C(O)-deuterated C 1-3 Alkyl, such as -C(O)-CD3) or -C(O)NR 4f R 4g , where R 4f 、R 4g are the same or different and each independently represent hydrogen, C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl) or deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), and R 4f 、R 4g Not simultaneously hydrogen; Each X2 independently represents N or CR 4h , where R 4h represents hydrogen, deuterium, halogen (such as fluorine, chlorine, bromine or iodine), C 1-6 alkyl (For example, C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.) or halogenated C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl or halogenated C 1-3 Alkyl, for example F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-); X3 and X4 each independently represent CH or N; R in formula (PBM-4-1B) and formula (PBM-4-1D) 4a Each independently represents an optionally substituted heteroarylene group (for example, an optionally substituted 1 or more (e.g. 1 to 6, or 1 to 5, or 1 to 4, or 1 to 3) 5- to 20-membered monocyclic or bicyclic or polycyclic aromatic ring groups independently selected from oxygen, nitrogen and sulfur heteroatoms), wherein the heteroarylene group is optionally substituted by one or more (e.g. 1-4, such as 1, 2, 3, or 4) independently selected from halogen (e.g. fluorine, chlorine, bromine or iodine), hydroxyl, cyano, amino, C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halo-C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 Alkoxy (e.g. C 1-4 Alkoxy, for example methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), halo C 1-6 Alkoxy (e.g., halo-C 1-4Alkoxy, such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-) or any combination thereof; Each R 4b Each independently represents hydrogen, C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 Alkyl groups such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halogenated C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), or optionally substituted C 3-12 Cycloalkyl (e.g. cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl or cycloheptyl, which may be optionally substituted, for example, with halogen, C 1-6 Alkyl, halogenated C 1-6 Alkyl or deuterated C 1-6 substituted with a substituent on the alkyl group); Each (R 4c ) p4a Each independently represents the pyridine ring connected thereto which is optionally replaced by p4a R 4c Replace, each R 4c Same or different and each unique deuterium, halogen (such as fluorine, chlorine, bromine or iodine), C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), C 1-6 Alkoxy (e.g. C 1-4 Alkoxy, for example methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), halo C 1-6 Alkoxy (e.g., halo-C 1-4Alkoxy, such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.) or halogenated C 1-6 Alkyl (e.g. halo-C 1-4 alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), p4a represents an integer 0, 1, 2 or 3; and Each (R 4d ) p4b Each independently represents a bicyclic nitrogen-containing heteroaromatic ring connected thereto, optionally replaced by p4b R 4d Replace, each R 4d Same or different and each independently represents deuterium, halogen (such as fluorine, chlorine, bromine or iodine), C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), C 1-6 Alkoxy (e.g. C 1-4 Alkoxy, for example methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), halo C 1-6 Alkoxy (e.g., halo-C 1-4 Alkoxy, such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.) or halogenated C 1-6 Alkyl (e.g. halo-C 1-4alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), p4b represents an integer of 0 or 1. In some embodiments, R in Formula (PBM-4-1B) and Formula (PBM-4-1D) 4a Each independently represents an optionally substituted heteroarylene, such as an optionally substituted 5- to 14-membered monocyclic or bicyclic or polycyclic heteroarylene containing 1 or more (e.g. 1 to 6, or 1 to 5, or 1 to 4, or 1 to 3) heteroatoms independently selected from oxygen, nitrogen and sulfur. Examples of heteroarylene groups include, but are not limited to, furanylene, oxazolylene, isoxazolylene, oxadiazolylene, thienylene, thiazolylene, isothiazolylene, thiadiazolylene, pyrrolylene, imidazolylene, pyrazolylene, triazolylene, pyridinylene, pyrimidinylene, pyridazinylene, pyrazinylene, indolylene, isoindolylene, benzofuranylene, isobenzofuranylene, benzothienylene, indazolylene, benzimidazolylene, benzoxazolylene, benzisoxazolylene, benzothiazolylene, benzisothiazolylene, benzotriazolylene, benzo[2,1,3]oxadiazolylene, Benzo[2,1,3]thiadiazolylene, benzo[1,2,3]thiadiazolylene, quinolinylene, isoquinolinylene, naphthyridinylene, cinnolinylene, quinazolinylene, quinoxalinylene, phthalazinylene, pyrazolo[1,5-a]pyridinylene, pyrazolo[1,5-a]pyrimidinylene, imidazo[1,2-a]pyridinylene, 1H-pyrrolo[3,2-b]pyridinylene, 1H-pyrrolo[2,3-b]pyridinylene, 4H-fluoro[3,2-b]pyrroleylene, pyrrolo[2,1-b]thiazolylene and imidazo[2,1-b]thiazolylene. The heteroarylene group is optionally substituted with one or more (e.g., 1-4, such as 1, 2, 3, or 4) substituents selected from halogen (e.g., fluorine, chlorine, bromine, or iodine), hydroxy, cyano, amino, C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halo-C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 Alkoxy (e.g. C 1-4 Alkoxy, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), or halo-C 1-6 Alkoxy (e.g., halo-C 1-4 Alkoxy groups, such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-). In some embodiments, PBM represents the structure of the following Formula (PBM-4-1) or Formula (PBM-4-2): In some embodiments, the PBM represents a small molecule ligand of the interleukin-1 receptor-associated kinases IRAK (IRAK1, IRAK2, IRAK-3, and IRAK4). In some embodiments, the PBM represents the structure of formula (PBM-5): in Ring B in formula (PBM-5) represents a 5- to 20-membered monocyclic or bicyclic or polycyclic heterocyclic ring containing 1 to 4 heteroatoms selected from N, O and S. aryl; R 5b represents an optionally substituted 5- to 15-membered heteroaryl, an optionally substituted 5- to 15-membered heterocyclyl, deuterium, halogen (e.g., fluorine, chlorine, bromine) or iodine), hydroxyl, cyano, amino, C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), halogenated C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl groups, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), C1-6 Alkoxy (e.g. C 1-4 Alkoxy, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), or halo-C 1-6 Alkoxy (e.g., halo-C 1-4 Alkoxy groups, such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O-, or CH2ClCH2-O-); and R 5a represents hydrogen, halogen (such as fluorine, chlorine, bromine or iodine), C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 Alkyl groups, e.g. methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), halogenated C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl groups, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), C 1-6 Alkoxy (e.g. C 1-4 Alkoxy, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), or halo-C 1-6 Alkoxy (e.g., halo-C 1-4 Alkoxy groups, such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-). In some embodiments, Ring B in Formula (PBM-5) represents a 5- to 20-membered monocyclic, bicyclic, or polycyclic heteroarylene group containing 1 to 4 heteroatoms selected from N, O, and S. In some embodiments, the 5- to 20-membered monocyclic, bicyclic, or polycyclic heteroarylene group is a 5- to 20-membered monocyclic, bicyclic, or polycyclic divalent aromatic ring group containing 1 to 4 (e.g., 1 to 4, 1 to 3, 1 to 2, or 1) heteroatoms independently selected from oxygen, nitrogen, and sulfur. In some subembodiments, examples of 5- to 20-membered monocyclic or bicyclic or polycyclic heteroarylene groups include, but are not limited to, furanylene, oxazolylene, isoxazolylene, oxadiazolylene, thienylene, thiazolylene, isothiazolylene, thiadiazolylene, pyrrolylene, imidazolylene, pyrazolylene, triazolylene, pyridinylene, pyrimidinylene, pyridazinylene, pyrazinylene, indolylene, isoindolylene, benzofuranylene, isobenzofuranylene, benzothienylene, indazolylene, benzimidazolylene, benzoxazolylene, benzisoxazolylene, benzothiazolylene, benzisothiazolylene, benzotriazolylene, benzo [2,1,3]oxadiazole group, benzo[2,1,3]thiadiazolylidene, benzo[1,2,3]thiadiazolylidene, quinolinylene, isoquinolinylene, naphthyridinylene, cinnolinylene, quinazolinylene, quinoxalinylene, phthalazinylene, pyrazolo[1,5-a]pyridinylene, pyrazolo[1,5-a]pyrimidinylene, imidazo[1,2-a]pyridinylene, 1H-pyrrolo[3,2-b]pyridinylene, 1H-pyrrolo[2,3-b]pyridinylene, pyrrolo[2,1-b]thiazolylidene, imidazo[2,1-b]thiazolylidene or imidazo[1,2-b]pyridazinylene. The 5- to 20-membered monocyclic or bicyclic or polycyclic heteroarylene group is optionally further substituted by one or more (e.g., 1-3, such as 1, 2, or 3) substituents, each of which independently represents deuterium, halogen (e.g., fluorine, chlorine, bromine or iodine), hydroxyl, cyano, amino, C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halo-C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C1-6 Alkoxy (e.g. C 1-4 Alkoxy, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), or halo-C 1-6 Alkoxy (e.g., halo-C 1-4 Alkoxy groups, such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-). In some embodiments, R in formula (PBM-5) 5b represents an optionally substituted 5- to 15-membered heteroaryl. In some embodiments, the 5- to 15-membered heteroaryl is a 5- to 15-membered monocyclic, bicyclic, or polycyclic aromatic ring group containing 1-4 (e.g., 1 to 4, 1 to 3, 1 to 2, or 1) heteroatoms independently selected from oxygen, nitrogen, and sulfur. In some subembodiments, examples of heteroaryl include, but are not limited to, furanyl, oxazolyl, isoxazolyl, oxadiazolyl, thienyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, indolyl, isoindolyl, benzofuranyl, isobenzofuranyl, benzothienyl, indazolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzotriazolyl, benzo[2,1,3]oxadiazolyl, benzo R is 1H-pyrrolo[3,2-b]pyridinyl, 1H-pyrrolo[2,3-b]pyridinyl, 1H-pyrrolo[2,1-b]thiazolyl, 1H-pyrrolo[2,1-b]thiazolyl, 1H-pyrrolo[2,3-b]pyridinyl, 1H-pyrrolo[2,1-b]thiazolyl, 1H-imidazo[2,1-b]thiazolyl, 1H-imidazo[2,1-b]thiazolyl or 1H-imidazo[1,2-b]pyridazinyl. 5b The heteroaryl represented by is optionally further substituted by one or more (eg, 1-3, such as 1, 2, or 3) substituents, wherein the substituents are optionally selected from: -N(R 5c )-C 1-6 Alkylene-optionally substituted C 3-8 Cycloalkyl, -N(R 5c )-optionally halogenated C 1-6 Alkyl, halogen (such as fluorine, chlorine, bromine or iodine), hydroxy, cyano, amino, C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halo-C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 Alkoxy (e.g. C 1-4 Alkoxy, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), or halo-C 1-6 Alkoxy (e.g., halo-C 1-4 Alkoxy, such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-), wherein each R 5c independently represents hydrogen or C 1-3 In some embodiments, R 5b The substituent of the heteroaryl represented by 5c )-C 1-6 Alkylene-optionally substituted C 3-8 Cycloalkyl, where R 5c Represents hydrogen or C 1-3 In some embodiments, C 1-6 Examples of alkylene groups include, but are not limited to, C 1-3 In some embodiments, C 3-8 Examples of cycloalkyl groups include, but are not limited to, C 3-6 In some embodiments, C 3-8 Representative examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, and cyclooctyl. 3-8 The cycloalkyl group may be further substituted by one or more (eg 1-3, such as 1, 2, or 3) groups each independently selected from C1-C3 alkyl, C 3-6 Cycloalkyl, hydroxyl, amino, mercapto, halogen, C1-C3 alkoxy, C1-C3 alkylamino, halogenated C1-C3 alkyl, amino-substituted C 1-3In some embodiments, R 5b The substituent of the heteroaryl represented by 5c )-optionally halogenated C 1-6 Alkyl, where R 5c Represents hydrogen or C 1-3 In some embodiments, the alkyl group is optionally halogenated. 1-6 Examples of alkyl groups include, but are not limited to, optionally halogenated C 1-4 Alkyl, optionally halogenated C 1-3 Alkyl and optionally halogenated C 1-2 In some embodiments, the alkyl group may be optionally halogenated. 1-6 Representative examples of alkyl groups include, but are not limited to, -CH2-CF3. In some embodiments, R in formula (PBM-5) 5b Represents an optionally substituted 5- to 15-membered heterocyclyl. In some subembodiments, "5- to 15-membered heterocyclyl" refers to a 5- to 15-membered monocyclic, bicyclic, tricyclic or polycyclic saturated or partially unsaturated (i.e., having one or more double bonds, but not fully conjugated) cycloalkyl containing one or more (e.g., 1 to 5, 1 to 4, 1 to 3, 1 to 2, or 1) heteroatoms independently selected from sulfur, oxygen, and nitrogen. In some subembodiments, examples of heterocyclic groups include, but are not limited to, azetidinyl, oxetanyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, oxazolidinyl, thiazolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, dioxane, azepanyl, azocanyl, diazepanyl (e.g., 1,4-diazepan-1-yl), and diazepanyl. The heterocyclic group is optionally substituted with one or more (e.g., 1 to 5, 1 to 4, 1 to 3, 1 to 2, or 1) groups each independently selected from deuterium, hydroxyl, amino, sulfhydryl, nitro, halogen (e.g., fluorine, chlorine, bromine, or iodine), cyano, C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halo-C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C 3-6 Cycloalkyl, C 1-6 Alkoxy (e.g. C 1-4 Alkoxy, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), or halo-C 1-6 Alkoxy (e.g., halo-C 1-4 The alkoxy group is substituted with a substituent such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-). In some embodiments, PBM represents the structure of Formula (PBM-5-1), Formula (PBM-5-2), Formula (PBM-5-3), or Formula (PBM-5-4): In some embodiments, the PBM represents the structure of formula (PBM-6): in R in formula (PBM-6) x1 Indicates a bond or C(O), or R x1 Represents -C(O)NH-R x2 -C(O)-***, where the symbol *** represents the c of Connect the points, and R x2 represents an optionally substituted C 3-15 Cycloalkyl; (R 6a ) p6a Indicates that the 1H-pyrrolo[2,3-b]pyridine ring connected thereto is optionally replaced by p6a R 6a Replace, and each R 6a Independent surface represents cyano, halogen (such as fluorine, chlorine, bromine or iodine), hydroxy, amino, nitro, C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1- 3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), halogenated C1-6 Alkyl (e.g. halo-C 1-4 Alkyl groups, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), C 1-6 Alkoxy (e.g. C 1-4 Alkoxy, such as methoxy, CD3-O-, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), or halo 1-6 Alkoxy (e.g., halo-C 1-4 alkoxy, such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, F2ClC-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-), and p6a represents an integer 0, 1, 2, 3, 4 or 5; (R 6b ) p6b Indicates that the pyridine ring connected thereto is optionally replaced by p6b R 6b Replace, and each R 6b Each independently represents a cyano group, a halogen (e.g. fluorine, chlorine, bromine or iodine), hydroxyl, nitro, C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halo-C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 Alkoxy (e.g. C 1-4 Alkoxy, for example methoxy, CD3-O-, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), halo 1-6 Alkoxy (e.g., halo-C 1-4Alkoxy, such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, F2ClC-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-) or NR 6c R 6d , where R 6c 、R 6d are the same or different and each independently represent hydrogen, C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), halogenated C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), optionally substituted C 3-15 p6b represents an integer of 0, 1, 2 or 3; p6b represents an optionally substituted 4- to 15-membered heterocyclic group; and p6b represents an integer of 0, 1, 2 or 3. In some embodiments, R in formula (PBM-6) x1 Indicates a key. In some embodiments, R in formula (PBM-6) x1 Represents C(O). In some embodiments, R in formula (PBM-6) x1 Represents -C(O)NH-R x2 -C(O)-***, where the symbol *** represents the c The connection point, and R x2 represents an optionally substituted C 3-15 In some subembodiments, the optionally substituted C 3-15 Examples of cycloalkyl groups include, but are not limited to, optionally substituted C 3-11 Cycloalkyl and optionally substituted C 3-8 Cycloalkyl, such as optionally substituted cyclopropyl, optionally substituted cyclobutyl, optionally substituted cyclopentyl, optionally substituted cyclohexyl, optionally substituted cycloheptyl, or optionally substituted cyclooctyl.3-15 The cycloalkyl group is optionally substituted with one or more (e.g., 1-3, 1, 2, or 3) substituents each independently selected from the group consisting of deuterium, hydroxy, amino, mercapto, nitro, halogen (e.g., fluorine, chlorine, bromine, or iodine), cyano, C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halo-C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 Alkoxy (e.g. C 1-4 Alkoxy, such as methoxy, CD3-O-, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), or halo 1-6 Alkoxy (e.g., halo-C 1-4 Alkoxy groups, such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, F2ClC-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-). In some embodiments, (R 6a ) p6a In formula (PBM-6), the 1H-pyrrolo[2,3-b]pyridine ring connected thereto may be optionally replaced by p6a R 6a Replace, and each R 6a are each independently cyano, halogen (such as fluorine, chlorine, bromine or iodine), hydroxy, amino, nitro, C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halo-C 1-6 Alkyl (e.g. halo-C 1-4Alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 Alkoxy (e.g. C 1-4 Alkoxy, such as methoxy, CD3-O-, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), or halo 1-6 Alkoxy (e.g., halo-C 1-4 alkoxy, such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, F2ClC-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-), and p6a represents an integer 0, 1, 2, 3, 4 or 5. In some embodiments, (R 6a ) p6a In the formula (PBM-6), the 1H-pyrrolo[2,3-b]pyridine ring connected thereto is replaced by p6a R 6a substituted, wherein p6a represents the integer 1, and R 6a It's cyano. In some embodiments, (R 6b ) p6b Indicates that the pyridine ring connected thereto is optionally replaced by p6b R 6b Replace, and each R 6b are each independently cyano, halogen (such as fluorine, chlorine, bromine or iodine), hydroxyl, nitro, C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halo-C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 Alkoxy (e.g. C 1-4 Alkoxy, for example methoxy, CD3-O-, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), halo 1-6 Alkoxy (e.g., halo-C 1-4 Alkoxy, such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, F2ClC-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-) or NR 6c R 6d , where R 6c 、R 6d are the same or different and each independently represent hydrogen, C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), halogenated C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), optionally substituted C 3-15 Cycloalkyl (eg, optionally substituted C 3-12 Cycloalkyl and optionally substituted C 3-8 cycloalkyl) or an optionally substituted 4- to 15-membered heterocyclyl (e.g., an optionally substituted 4- to 12-membered heterocyclyl or an optionally substituted 4- to 10-membered heterocyclyl), and p6b represents an integer 0, 1, 2, or 3. In some subembodiments, the optionally substituted C 3-15Examples of cycloalkyl include, but are not limited to, optionally substituted cyclopropyl, optionally substituted cyclobutyl, optionally substituted cyclopentyl, optionally substituted cyclohexyl, optionally substituted cycloheptyl, or optionally substituted cyclooctyl. In some subembodiments, examples of optionally substituted 4- to 15-membered heterocyclyl include, but are not limited to, azetidinyl, oxetanyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, oxazolidinyl, thiazolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, dioxane, azepanyl, diazepanyl, azooctanyl, or diazaoctanyl. In some subembodiments, optionally substituted C 3-15 The substituents of the cycloalkyl and optionally substituted 4- to 15-membered heterocyclyl are each independently optionally selected from the group consisting of: deuterium, hydroxy, amino, mercapto, nitro, halogen (e.g., fluorine, chlorine, bromine or iodine), cyano, C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halo-C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 Alkoxy (e.g. C 1-4 Alkoxy, such as methoxy, CD3-O-, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), or halo 1-6 Alkoxy (e.g., halo-C 1-4 Alkoxy groups, such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, F2ClC-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-). In some embodiments, (R 6b ) p6b Indicates that the pyridine ring connected to it is p6b R 6b Substitution, wherein p6b represents the integer 1, and R6b It is NR 6c R 6d , where R 6c represents hydrogen, and R 6d Indicates C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl). In some embodiments, PBM represents the structure of Formula (PBM-6-1), Formula (PBM-6-2), Formula (PBM-6-3), or Formula (PBM-6-4): In some embodiments, the PBM represents the structure of formula (PBM-8): in R in formula (PBM-8) 8a Indicates N or CH; R 8b represents NHC(O), C(O)NH, NHS(O)2 or S(O)2NH; (R 8c ) p8a Indicates R-containing 8a The six-membered ring is p8a R 8c Replace, each R 8c The same or different and each independently represents a halogen (e.g., fluorine, chlorine, bromine or iodine), hydroxyl, mercapto, cyano, amino, nitro, C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1- 3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halogenated C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 Alkoxy (e.g. C 1-4Alkoxy, for example methoxy, CD3-O-, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), halo 1-6 Alkoxy (e.g., halo-C 1-4 an alkoxy group, such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, F2ClC-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O-, or CH2ClCH2-O-), and p 8a represents an integer 0, 1, 2, 3, or 4; and Ring F represents a 5- to 15-membered heteroarylene group, (R 8d ) p8b Indicates that the ring F connected to it is optionally replaced by p8b R 8d Replace, each R 8d Same or Different and each independently represents halogen (such as fluorine, chlorine, bromine or iodine), hydroxyl, mercapto, cyano, amino, nitro, C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halo-C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), hydroxyl-substituted C 1-6 Alkyl, amino substituted C 1-6 Alkyl, C 1-6 Alkoxy (e.g. C 1-4 Alkoxy, for example methoxy, CD3-O-, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), halo 1-6 Alkoxy (e.g., halo-C 1-4Alkoxy, such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, F2ClC-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-) or an optionally substituted C 3-15 cycloalkyl, and p8b represents an integer of 0, 1, 2 or 3. In some embodiments, R 8a represents N. In some embodiments, R 8a Indicates CH. In some embodiments, (R 8c ) p8a Indicates R-containing 8a The six-membered ring is optionally replaced by p8a R 8c Replace, each R 8c The same or different and each independently represents halogen (such as fluorine, chlorine, bromine, iodine), hydroxyl, mercapto, cyano, amino, nitro, C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halo-C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 Alkoxy (e.g. C 1-4 Alkoxy, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), or halo-C 1-6 Alkoxy (e.g., halo-C 1-4 Alkoxy, such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, F2ClC-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2C1CH2-O-), p8a represents an integer of 0, 1, 2, 3 or 4, and contains R 8aThe aromatic ring is a pyridine ring or a benzene ring. 8a The aromatic ring is a pyridine ring, R 8c represents F3C-, and p8a represents the integer 1. In some embodiments, ring F represents a 5- to 15-membered heteroarylene group, such as a 5- to 12-membered heteroarylene group, or a 5- to 10-membered heteroarylene group. In some embodiments, examples of ring F include, but are not limited to, benzimidazolylene, benzothiazolylene, 2H-indazoleylidene, benzoxazolylene, isoindolylene, benzofurylene, isobenzofurylene, benzothiophenylene, benzisoxazolylene, benzisothiazolylene, benzotriazolylene, benzo[2,1,3]oxadiazolylene, benzo[2,1,3]thiadiazolylene, benzo[1,2,3]thiadiazolylene, quinolinylene, isoquinolinylene, naphthyridinylene, cinnolin ...1,2,3]thiadiazolylene, quinolinylene, benzo[2,1,3]thiadiazolylene, benzo[1,2,3]thiadiazolylene, quinolinylene, benzo[2,1,3]thiadiazolylene, benzo[1,2,3]thia Quinazolinyl, quinoxalinyl, phthalazinyl, pyrazolo[1,5-a]pyridinyl, pyrazolo[1,5-a]pyrimidinyl, imidazo[1,2-a]pyridinyl, 1H-pyrrolo[3,2-b]pyridinyl, 1H-pyrrolo[2,3-b]pyridinyl, pyrrolo[2,1-b]thiazolyl, imidazo[2,1-b]thiazolyl, imidazo[1,2-b]pyridazinyl or 6,7-dihydro-5H-pyrrolo[1,2-c]imidazolyl. Ring F is optionally substituted with p8b R 8d Replace, each R 8d The same or different and each independently represents halogen (such as fluorine, chlorine, bromine, iodine), hydroxyl, mercapto, cyano, amino, nitro, C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halo-C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), hydroxyl-substituted C 1-6 Alkyl (e.g. hydroxy substituted C 1-4 Alkyl, such as hydroxypropyl, hydroxyisopropyl), amino-substituted C 1-6 Alkyl (e.g. amino substituted C 1-4Alkyl, such as aminopropyl, aminoisopropyl), C 1-6 Alkoxy (e.g. C 1-4 Alkoxy, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), or halo-C 1-6 Alkoxy (e.g., halo-C 1-4 Alkoxy, such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, F2ClC-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-) or an optionally substituted C 3-15 cycloalkyl, and p8b represents an integer of 0, 1, 2 or 3. In some embodiments, R 8d represents hydroxypropyl or hydroxyisopropyl, and p8b represents an integer of 1. In some embodiments, R 8d represents an optionally substituted C 3-15 Cycloalkyl. C 3-15 Examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, cyclooctyl, decahydronaphthyl, octahydropentalenyl, octahydro-1H-indenyl, 2,3-dihydro-1H-indenyl, spirocyclyl (e.g., C 5-15 Spirocyclyl), adamantyl, noradamantyl and norbornyl. C 3-15 Optional substituents of the cycloalkyl group are optionally selected from halogen (eg, fluorine, chlorine, bromine or iodine), hydroxy, mercapto, cyano, amino, nitro, C 1-6 Alkyl (e.g. C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halo-C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl or halogenated C 1-3 Alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 Alkoxy (e.g. C 1-4Alkoxy, such as methoxy, CD3-O-, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), and halo 1-6 Alkoxy (e.g., halo-C 1-4 Alkoxy groups, such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-). In some embodiments, PBM represents the structure of Formula (PBM-8-1), Formula (PBM-8-2), Formula (PBM-8-3), Formula (PBM-8-4), Formula (PBM-8-5), Formula (PBM-8-6), Formula (PBM-8-7), Formula (PBM-8-8), Formula (PBM-8-9), Formula (PBM-8-10), Formula (PBM-8-11), Formula (PBM-8-12), or Formula (PBM-8-13): In some embodiments, PBM represents a small molecule ligand for AR. In some embodiments, the PBM represents the structure of formula (PBM-7): in Ring C represents C 6-10 aryl or 5- to 20-membered heteroaryl (e.g., containing 1 or 2 5- to 7-membered rings and 1-4 selected from N, O and S) heteroatom), ring C is optionally substituted by one or more (e.g., 1-10, 1-8, or 1-6, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) R 7a Replace, and each R 7a are the same or different and are each independently deuterium, halogen (such as fluorine, chlorine, bromine or iodine), hydroxyl, cyano, amino, nitro, C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halo-C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 Alkoxy (e.g. C 1-4 Alkoxy, for example methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), halo C 1-6 Alkoxy (e.g., halo-C 1-4 Alkoxy, for example F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-), C 2-6 alkenyl (e.g., ethenyl, propenyl, or butenyl), or C 2-6 Alkynyl (e.g., ethynyl, propynyl, or butynyl); Ring D represents C 3-15 Cycloalkyl or 4- to 20-membered heterocyclic group (e.g., 4- to 20-membered heterocyclic group containing 1 to 4 heteroatoms selected from N, O and S) heterocyclyl), wherein ring D is optionally substituted by one or more (e.g., 1-10, 1-8, or 1-6, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) R 7b Replace, and each R 7b are the same or different and are each independently deuterium, halogen (such as fluorine, chlorine, bromine or iodine), hydroxyl, cyano, amino, nitro, C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halo-C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 Alkoxy (e.g. C 1-4 Alkoxy, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), or halo-C 1-6Alkoxy (e.g., halo-C 1-4 Alkoxy groups, such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O-, or CH2ClCH2-O-); and Ring E represents a 5- to 20-membered heteroaryl group (e.g., a 5- to 20-membered monocyclic or bicyclic heteroaryl group containing 1 to 4 heteroatoms selected from N, O and S). aryl), wherein ring E is optionally substituted by one or more (e.g., 1-10, 1-8, or 1-6, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) R 7c Replace, and each R 7c are the same or different and are each independently deuterium, halogen (such as fluorine, chlorine, bromine or iodine), hydroxyl, cyano, amino, nitro, C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halo-C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 Alkoxy (e.g. C 1-4 Alkoxy, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), or halo-C 1-6 Alkoxy (e.g., halo-C 1-4 Alkoxy groups, such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-). In some embodiments, PBM represents the structure of the following formula (PBM-7-1A): in The benzene ring in formula (PBM-7-1A) may be replaced by one or more (e.g., 1-10, 1-8, or 1-6, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10)R 7a Replace, and each R 7a are the same or different and are each independently deuterium, halogen (such as fluorine, chlorine, bromine or iodine), hydroxyl, cyano, amino, nitro, C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halo-C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 Alkoxy (e.g. C 1-4 Alkoxy, for example methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), halo C 1-6 Alkoxy (e.g., halo-C 1-4 Alkoxy, for example F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-), C 2-6 alkenyl (e.g., ethenyl, propenyl, or butenyl), or C 2-6 Alkynyl (e.g., ethynyl, propynyl, or butynyl); Ring D represents C 3-15 Cycloalkyl or 4- to 20-membered heterocyclic group (e.g., 4- to 20-membered heterocyclic group containing 1 to 4 heteroatoms selected from N, O and S) heterocyclyl), wherein ring D is optionally substituted by one or more (e.g., 1-10, 1-8, or 1-6, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) R 7b Replace, and each R 7b are the same or different and are each independently deuterium, halogen (such as fluorine, chlorine, bromine or iodine), hydroxyl, cyano, amino, nitro, C1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halo-C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 Alkoxy (e.g. C 1-4 Alkoxy, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), or halo-C 1-6 Alkoxy (e.g., halo-C 1-4 Alkoxy, for example F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-); Q1 represents N or CH; and The heteroaryl group containing Q1 and a nitrogen atom in formula (PBM-7-1A) may be optionally replaced by one or more (eg, 1-3, such as 1, 2 or 3) R 7c substituted, and each R7c is the same or different and is independently deuterium, halogen (eg, fluorine, chlorine, bromine or iodine), hydroxyl, cyano, amino, nitro, C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halo-C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 Alkoxy (e.g. C 1-4 Alkoxy, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), or halo-C 1-6 Alkoxy (e.g., halo-C 1-4 Alkoxy groups, such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-). In some embodiments, Ring D in Formula (PBM-7) and Formula (PBM-7-1A) each independently represents C 3-15 Cycloalkyl or 4- to 20-membered heterocyclic group (eg, 4- to 20-membered heterocyclic group containing 1 to 4 heteroatoms selected from N, O and S). 3-15 Examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, cyclooctyl, decahydronaphthyl, octahydropentalenyl, octahydro-1H-indenyl, 2,3-dihydro-1H-indenyl, spirocyclyl (e.g., C 5-15 Spirocyclyl), adamantyl, noradamantyl and norbornyl. C 3-15 Optional substituents of the cycloalkyl group are optionally selected from deuterium, halogen (eg, fluorine, chlorine, bromine, or iodine), hydroxy, cyano, amino, nitro, C 1-6 Alkyl (e.g. C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halo-C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl or halogenated C 1-3 Alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 Alkoxy (e.g. C 1-4Alkoxy, such as methoxy, CD3-O-, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), and halo 1-6 Alkoxy (e.g., halo-C 1-4 alkyl, such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O-, or CH2ClCH2-O-). Examples of the 4- to 20-membered heterocyclic radical include, but are not limited to, azetidinyl, oxetanyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, oxazolidinyl, thiazolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, dioxanyl, azepanyl, diazepanyl (e.g., 1,4-diazepan-1-yl), azocanyl, diazacanyl, azabicyclo[3.1.1]heptane alkyl, azabicyclo[2.2.1]heptyl, azabicyclo[3.2.1]octyl, azabicyclo[2.2.2]octyl, diazabicyclo[3.1.1]heptyl, diazabicyclo[2.2.1]heptyl, diazabicyclo[3.2.1]octyl (e.g. 3,8-diazabicyclo[3.2.1]octane-3-yl), diazabicyclo[2.2.2]octane (e.g. 2,5-diazabicyclo[2.2.2]octane-2-yl). Optional substituents for the 4- to 20-membered heterocyclyl are optionally selected from deuterium, halogen (e.g. fluorine, chlorine, bromine or iodine), hydroxy, cyano, amino, nitro, C 1-6 Alkyl (e.g. C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halo-C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl or halogenated C 1-3 Alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 Alkoxy (e.g. C 1-4 Alkoxy, such as methoxy, CD3-O-, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), and halo1-6 Alkoxy (e.g., halo-C 1-4 Alkoxy groups, such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-). In some embodiments, PBM represents the structure of Formula (PBM-7-1), Formula (PBM-7-2), Formula (PBM-7-3), Formula (PBM-7-4), Formula (PBM-7-5), Formula (PBM-7-6), Formula (PBM-7-7), or Formula (PBM-7-8): In some embodiments, in each of the general formulas (PBM-1), (PBM-1-1A), (PBM-1-1B), (PBM-1-1C), (PBM-1-1D), (PBM-1-1), (PBM-1-2), (PBM-1-3), (PBM-1-4), (PBM-1-5), (PBM-2), (PBM-2-1A), (PBM-2-1 ), Formula (PBM-3), Formula (PBM-3-1), Formula (PBM-4), Formula (PBM-4-1A), Formula (PBM-4-1B), Formula (PBM-4-1C), Formula (PBM-4-1D), Formula (PBM-4-1), Formula (PBM-4-2), Formula (PBM-5), Formula (PBM-5-1), Formula (PBM-5-2), Formula (PBM-5-3), Formula (PBM-5-4), Formula (PBM-5-5 M-6), formula (PBM-6-1), formula (PBM-6-2), formula (PBM-6-3), formula (PBM-6-4), formula (PBM-7), formula (PBM-7-1A), formula (PBM-7-1), formula (PBM-7-2), formula (PBM-7-3), formula (PBM-7-4), formula (PBM-7-5), formula (PBM-7-6), formula (PBM-7-7), formula (PBM-7-8), Each R in formula (PBM-8), formula (PBM-8-1), formula (PBM-8-2), formula (PBM-8-3), formula (PBM-8-4), formula (PBM-8-5), formula (PBM-8-6), formula (PBM-8-7), formula (PBM-8-8), formula (PBM-8-9), formula (PBM-8-10), formula (PBM-8-11), formula (PBM-8-12), and formula (PBM-8-13) c Each independently represents a bond, -O-, -NHC(O)-*, -C(O)NH-*, -C(O)O-*, -OC(O)-*, or -NH-. In some embodiments, in each of the general formulas (PBM-1), (PBM-1-1A), (PBM-1-1B), (PBM-1-1C), (PBM-1-1D), (PBM-1-1), (PBM-1-2), (PBM-1-3), (PBM-1-4), (PBM-1-5), (PBM-2), (PBM-2-1A), (PBM-2-1 ), Formula (PBM-3), Formula (PBM-3-1), Formula (PBM-4), Formula (PBM-4-1A), Formula (PBM-4-1B), Formula (PBM-4-1C), Formula (PBM-4-1D), Formula (PBM-4-1), Formula (PBM-4-2), Formula (PBM-5), Formula (PBM-5-1), Formula (PBM-5-2), Formula (PBM-5-3), Formula (PBM-5-4), Formula (PBM-5-5 M-6), formula (PBM-6-1), formula (PBM-6-2), formula (PBM-6-3), formula (PBM-6-4), formula (PBM-7), formula (PBM-7-1A), formula (PBM-7-1), formula (PBM-7-2), formula (PBM-7-3), formula (PBM-7-4), formula (PBM-7-5), formula (PBM-7-6), formula (PBM-7-7), formula (PBM-7-8), Each R in formula (PBM-8), formula (PBM-8-1), formula (PBM-8-2), formula (PBM-8-3), formula (PBM-8-4), formula (PBM-8-5), formula (PBM-8-6), formula (PBM-8-7), formula (PBM-8-8), formula (PBM-8-9), formula (PBM-8-10), formula (PBM-8-11), formula (PBM-8-12), and formula (PBM-8-13) c Each independently represents the structure of the following formula: -N(R d )-、-N(R d )-R f -N(R e )-*、-R f -C(O)NH-*、-R f -NHC(O)-*、-R f -C(O)O-*、-R f -OC(O)-*、-R f -、-R f - N(R d )-*、-OR f -N(R d )-*、 Among them, each ring W 1 are the same or different and each independently represent a 4- to 20-membered nitrogen-containing heterocyclic group, C 3-20 Cycloalkylene, C 5-20 Arylene, or a 5- to 20-membered heteroarylene group, t1 represents an integer of 0, 1 or 2, (R c1 ) m2 Indicates each ring W 1 Each independently optionally represented by m1 R c1 Group substitution, each R c1 Deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, carboxyl, C 2-6 Alkynyl, C 2-6 Alkenyl, optionally deuterated C 3-6 Cycloalkyl, or R c4 -R c3 -, where R c3 is an optional substituted C 1-6 Alkylene or optionally substituted C 2-6 Alkenylene, R c4 Represents halogen, R c5 R c6 N-, hydroxy, carboxyl, ethynyl, or vinyl, where R c5 and R c6 The same or different and each independently represents hydrogen or C 1-3 alkyl, and m1 represents an integer of 0-20; Each ring W 2 are the same or different and each independently represent a 4- to 20-membered nitrogen-containing heterocyclic group, C 3-20 Cycloalkylene, C 5-20 Arylene, or 5- to 20-membered heteroarylene, t2 represents an integer of 0 or 1, (R c2 ) m3 Indicates each ring W 2 Independently optionally m2 R c2 Group substitution, each R c2 Deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, deuterated C 1-6Alkoxy, halogen, amino, hydroxy, mercapto, cyano, carboxyl, C 2-6 Alkynyl, C 2-6 Alkenyl, optionally deuterated C 3-6 Cycloalkyl, or R c8 -R c7 -, where R c7 is an optional substituted C 1-6 Alkylene or optionally substituted C 2-6 Alkenylene, R c8 Represents halogen, R c9 R c10 N-, hydroxy, carboxyl, ethynyl, or vinyl, where R c9 and R c10 The same or different and each independently represents hydrogen or C 1-3 alkyl, and m2 represents an integer of 0-20; and R d and R e Each independently represents hydrogen or C 1-6 Alkyl, R f and R g Each independently represents an optionally substituted C 1-6 Alkylene or optionally substituted C 2-6 alkenylene; The C 1-6 Alkylene and C 2-6 Each alkenylene group is independently optionally substituted with one or more radicals selected from deuterium, halogen, hydroxyl, mercapto, cyano, amino Base, nitro, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy or halogenated C 1-6 Substitution of the alkoxy group by a substituent; and The symbol * indicates the connection point to LIN. In some embodiments, R d and R e Each independently represents hydrogen or C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl). In some embodiments, R f and R g Each independently represents C 1-6 Alkylene (e.g. C 1-5 Alkylene, C 1-4 Alkylene, C 1-3Alkylene or C 1-2 Alkylene, for example methylene, ethylene, propylene, isopropylene, butylene, sec-butylene, tert-butylene, pentylene or hexylene) and C 2-6 Alkenylene (e.g. C 2-4 Alkenylene or C 2-3 C 1-6 Alkylene and C 2-6 The alkenylene group may be optionally substituted by one or more (eg, 1-5, such as 1, 2, 3, 4, or 5) groups each independently selected from deuterium, halogen, hydroxyl, mercapto, cyano, amino, nitro, C 1-6 Alkyl, halogenated C 1-3 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy or halogenated C 1-6 The substituents of the alkoxy group are substituted. In some embodiments, t1 represents the integer 0. In some embodiments, t1 represents the integer 1. In some embodiments, t1 represents the integer 2. In some embodiments, each ring W 1 the same or different and each independently represents a 4- to 20-membered (e.g., 4- to 15-membered, 4- to 12-membered, 4- to 11-membered, 4- to 10-membered, 4- to 9-membered, 4- to 8-membered, 4- to 7-membered, 4- to 6-membered, 5- to 15-membered, or 5- to 9-membered) nitrogen-containing heterocyclic group, C 3-20 Cycloalkylene (e.g. C 3-15 Cycloalkylene or C 3-11 Cycloalkylene), C 5-20 Arylene (e.g. C 6-20 Arylene, C 5-15 Arylene or C 6-15In some embodiments, the 4- to 20-membered nitrogen-containing heterocyclylene group is a 4- to 20-membered (e.g., 4- to 15-membered, 4- to 12-membered, 4-11-membered, 4- to 10-membered, 4- to 9-membered, 5- to 8-membered, 5- to 7-membered, or 5- to 6-membered) heterocyclylene group containing one nitrogen atom and optionally containing a heteroatom selected from nitrogen, oxygen, and sulfur. Examples of nitrogen-containing heterocyclic groups include, but are not limited to, piperidinylene, piperazinylene, morpholinylene, azetidinylene, pyrrolidinylene, imidazolidinylene, pyrazolidinylene, oxazolidinylene, thiazolidinylene, thiomorpholinylene, azepanylene, diazepanylene, azaoctanylene, diazaoctanylene, azabicyclo[3.1.1]heptanylene, azabicyclo[2.2.1]heptanylene, azabicyclo[3.2.1]octanylene, azabicyclo[3.2.1]octanylene, In some embodiments, C 3-20 Cycloalkylene (e.g. C 3-15 Examples of cycloalkylene groups include, but are not limited to, cyclopropylene, cyclobutylene, cyclopentylene, cyclopentenylene, cyclohexylene, cyclohexenylene, cycloheptylene, cyclooctylene, decahydronaphthylene, octahydropentalenylene, octahydro-1H-indenylene, 2,3-dihydro-1H-indenylene, spirocyclylene (e.g., C 5-15In some embodiments, 5- to 20-membered arylene groups include, but are not limited to, phenylene or naphthylene. In some embodiments, 5- to 20-membered heteroarylene groups are 5- to 20-membered (e.g., 5- to 15-membered, 5- to 12-membered, 5- to 9-membered, 5- to 8-membered, 5- to 7-membered, or 5- to 6-membered) heteroarylene groups containing one nitrogen atom and optionally containing a heteroatom selected from nitrogen, oxygen, and sulfur. In some embodiments, examples of 5- to 20-membered heteroarylene groups include, but are not limited to, for example, oxazolylene, isoxazolylene, oxadiazolylene, thienylene, thiazolylene, isothiazolylene, thiadiazolylene, pyrrolylene, imidazolylene, pyrazolylene, triazolylene, pyridinylene, pyrimidinylene, pyridazinylene, pyrazinylene, indolylene, isoindolylene, benzofuranylene, isobenzofuranylene, benzothienylene, indazolylene, benzimidazolylene, benzoxazolylene, benzisoxazolylene, benzothiazolylene, benzisothiazolylene, benzotriazolylene, Benzo[2,1,3]oxadiazole group, benzo[2,1,3]thiadiazolylidene, benzo[1,2,3]thiadiazolylidene, quinolinylene, isoquinolinylene, naphthyridinylene, cinnolinylene, quinazolinylene, quinoxalinylene, phthalazinylene, pyrazolo[1,5-a]pyridinylene, pyrazolo[1,5-a]pyrimidinylene, imidazo[1,2-a]pyridinylene, 1H-pyrrolo[3,2-b]pyridinylene, 1H-pyrrolo[2,3-b]pyridinylene, pyrrolo[2,1-b]thiazolylidene, or imidazo[2,1-b]thiazolylidene. Each ring W 1 Each independently optionally represented by m1 R c1 Group substitution, each R c1 Deuterium, C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), halogenated C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl groups, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), C 1-6 Alkoxy (e.g. C 1-4Alkoxy, for example methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), halo C 1-6 Alkoxy (e.g., halo-C 1-4 Alkoxy, such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-), deuterated C 1-6 Alkoxy, halogen (such as fluorine, chlorine, bromine or iodine), amino, hydroxy, mercapto, cyano, carboxyl, C 2-6 Alkynyl (e.g. C 2-4 Alkynyl, such as ethynyl, propynyl, or butynyl), C 2-6 Alkenyl (e.g. C 2-4 alkenyl, such as vinyl, propenyl, or butenyl), optionally deuterated C 3-6 Cycloalkyl (eg, optionally perdeuterated cyclopropyl, optionally perdeuterated cyclobutyl, optionally perdeuterated cyclopentyl, or optionally perdeuterated cyclohexyl), or R c4 -R c3 -, where R c3 is an optional substituted C 1-6 Alkylene (e.g., optionally substituted C 1-4 alkylene, such as optionally substituted methylene, ethylene or propylene) or optionally substituted C 2-6 Alkenylene (eg, optionally substituted C 2-4 alkenylene, such as optionally substituted vinylene, propenylene, butenylene), R c4 represents halogen (e.g., fluorine, chlorine, bromine or iodine), R c5 R c6 N-, hydroxy, carboxyl, ethynyl, or vinyl, where R c5 and R c6 The same or different and each independently represents hydrogen or C 1-3 Alkyl (such as methyl, ethyl or propyl), and the C 1-6 The alkylene group and the C 2-6 The alkenylene group may be optionally substituted by one or more (e.g. 1-5, e.g. 1, 2, 3, 4 or 5) groups each independently selected from deuterium, halogen (e.g. fluorine, chlorine, bromine or iodine), hydroxyl, mercapto, cyano, amino, nitro, C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halo-C 1-3 Alkyl (e.g. halo-C 1-2Alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-3 Alkoxy (such as methoxy, ethoxy, propoxy, or isopropoxy), or halogenated C 1-3 Alkoxy (e.g., halo-C 1-2 m1 represents an integer from 0 to 20, for example, an integer of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 20. The number of substituents is in principle not subject to any restrictions or automatically limited by the size of the building block. In some embodiments, each ring W 1 The same or different and each independently represent the following optionally substituted groups: Each ring W 1 Each independently optionally represented by m1 R c1 Group substitution, each R c1 Deuterium, C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), halogenated C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl groups, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), C 1-6Alkoxy (e.g. C 1-4 Alkoxy, for example methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), halo C 1-6 Alkoxy (e.g., halo-C 1-4 Alkoxy, such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-), deuterated C 1-6 Alkoxy, halogen (such as fluorine, chlorine, bromine or iodine), amino, hydroxy, mercapto, cyano, carboxyl, C 2-6 Alkynyl (e.g. C 2-4 Alkynyl, such as ethynyl, propynyl, or butynyl), C 2-6 Alkenyl (e.g. C 2-4 alkenyl, such as vinyl, propenyl, or butenyl), optionally deuterated C 3-6 Cycloalkyl (eg, optionally perdeuterated cyclopropyl, optionally perdeuterated cyclobutyl, optionally perdeuterated cyclopentyl, or optionally perdeuterated cyclohexyl), or R c4 -R c3 -, where R c3 is an optional substituted C 1-6 Alkylene (e.g., optionally substituted C 1-4 alkylene, such as optionally substituted methylene, ethylene or propylene) or optionally substituted C 2-6 Alkenylene (eg, optionally substituted C 2-4 alkenylene, such as optionally substituted vinylene, propenylene, butenylene), R c4 represents halogen (e.g., fluorine, chlorine, bromine or iodine), R c5 R c6 N-, hydroxy, carboxyl, ethynyl, or vinyl, where R c5 and R c6 The same or different and each independently represents hydrogen or C 1-3 Alkyl (such as methyl, ethyl or propyl), and the C 1-6 The alkylene group and the C 2-6 The alkenylene group may be substituted with one or more radicals selected from deuterium, halogen (e.g., fluorine, chlorine, bromine or iodine), hydroxyl, mercapto, cyano, amino, nitro, C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halo-C 1-3 Alkyl (e.g. halo-C 1-2Alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-3 Alkoxy (such as methoxy, ethoxy, propoxy, or isopropoxy), or halogenated C 1-3 Alkoxy (e.g., halo-C 1-2 m1 represents an integer from 0 to 20, for example, an integer of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 20. The number of substituents is in principle not subject to any restrictions or automatically limited by the size of the building block. In some embodiments, each ring W 2 the same or different and each independently represents a 4- to 20-membered (e.g., 4- to 15-membered, 4- to 12-membered, 4- to 11-membered, 4- to 10-membered, 4- to 9-membered, 4- to 8-membered, 4- to 7-membered, 4- to 6-membered, 5- to 15-membered, or 5- to 9-membered) nitrogen-containing heterocyclic group, C 3-20 Cycloalkylene (e.g. C 3-15 Cycloalkylene or C 3-11 Cycloalkylene), C 5-20 Arylene (e.g. C 6-20 Arylene, C 5-15 Arylene or C 6-15In some embodiments, the 4- to 20-membered nitrogen-containing heterocyclylene group is a 4- to 20-membered (e.g., 4- to 15-membered, 4- to 12-membered, 4- to 11-membered, 4- to 10-membered, 4- to 9-membered, 4- to 8-membered, 4- to 7-membered, or 5- to 6-membered) heterocyclylene group containing one nitrogen atom and optionally containing a heteroatom selected from nitrogen, oxygen, and sulfur. Examples of 4- to 20-membered nitrogen-containing heterocyclylene groups include, but are not limited to, piperidinylene, piperazinylene, morpholinylene, azetidinylene, pyrrolidinylene, imidazolidinylene, pyrazolidinylene, oxazolidinylene, thiazolidinylene, thiomorpholinylene, azepanylene, diazepanylene, azaoctanylene, diazaoctanylene, azabicyclo[3.1.1]heptanylene, azabicyclo[2.2.1]heptanylene, azabicyclo[3.2.1]octanylene In some embodiments, C 3-20 Cycloalkylene (e.g. C 3-15 Examples of cycloalkylene groups include, but are not limited to, cyclopropylene, cyclobutylene, cyclopentylene, cyclopentenylene, cyclohexylene, cyclohexenylene, cycloheptylene, cyclooctylene, decahydronaphthylene, octahydropentalenylene, octahydro-1H-indenylene, 2,3-dihydro-1H-indenylene, spirocyclylene (e.g., C 5-15In some embodiments, 5- to 20-membered arylene groups include, but are not limited to, phenylene or naphthylene. In some embodiments, 5- to 20-membered heteroarylene groups are 5- to 20-membered (e.g., 5- to 15-membered, 5- to 12-membered, 5- to 9-membered, 5- to 8-membered, 5- to 7-membered, or 5- to 6-membered) heteroarylene groups containing one nitrogen atom and optionally containing a heteroatom selected from nitrogen, oxygen, and sulfur. In some embodiments, examples of 5- to 20-membered heteroarylene groups include, but are not limited to, for example, oxazolylene, isoxazolylene, oxadiazolylene, thienylene, thiazolylene, isothiazolylene, thiadiazolylene, pyrrolylene, imidazolylene, pyrazolylene, triazolylene, pyridinylene, pyrimidinylene, pyridazinylene, pyrazinylene, indolylene, isoindolylene, benzofuranylene, isobenzofuranylene, benzothienylene, indazolylene, benzimidazolylene, benzoxazolylene, benzisoxazolylene, benzothiazolylene, benzisothiazolylene, benzotriazolylene, Benzo[2,1,3]oxadiazole group, benzo[2,1,3]thiadiazolylidene, benzo[1,2,3]thiadiazolylidene, quinolinylene, isoquinolinylene, naphthyridinylene, cinnolinylene, quinazolinylene, quinoxalinylene, phthalazinylene, pyrazolo[1,5-a]pyridinylene, pyrazolo[1,5-a]pyrimidinylene, imidazo[1,2-a]pyridinylene, 1H-pyrrolo[3,2-b]pyridinylene, 1H-pyrrolo[2,3-b]pyridinylene, pyrrolo[2,1-b]thiazolylidene, or imidazo[2,1-b]thiazolylidene. Each ring W 2 Independently optionally m2 R c2 Group substitution, each R c2 Deuterium, C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), halogenated C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl groups, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), C 1-6 Alkoxy (e.g. C 1-4Alkoxy, for example methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), halo C 1-6 Alkoxy (e.g., halo-C 1-4 Alkoxy, such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-), deuterated C 1-6 Alkoxy, halogen (such as fluorine, chlorine, bromine or iodine), amino, hydroxy, mercapto, cyano, carboxyl, C 2-6 Alkynyl (e.g. C 2-4 Alkynyl, such as ethynyl, propynyl, or butynyl), C 2-6 Alkenyl (e.g. C 2-4 alkenyl, such as vinyl, propenyl, or butenyl), optionally deuterated C 3-6 Cycloalkyl (eg, optionally perdeuterated cyclopropyl, optionally perdeuterated cyclobutyl, optionally perdeuterated cyclopentyl, or optionally perdeuterated cyclohexyl), or R c8 -R c7 -, where R c7 is an optional substituted C 1-6 Alkylene (e.g., optionally substituted C 1-4 alkylene, such as optionally substituted methylene, ethylene or propylene) or optionally substituted C 2-6 Alkenylene (eg, optionally substituted C 2-4 alkenylene, such as optionally substituted vinylene, propenylene, butenylene), R c8 represents halogen (e.g., fluorine, chlorine, bromine or iodine), R c9 R c10 N-, hydroxy, carboxyl, ethynyl, or vinyl, where R c9 and R c10 The same or different and each independently represents hydrogen or C 1-3 Alkyl (eg, methyl, ethyl, or propyl); and the C 1-6 The alkylene group and the C 2-6 Each alkenylene group is independently optionally substituted with one or more (e.g., 1-5, such as 1, 2, 3, 4, or 5) deuterium, halogen, hydroxyl, mercapto, cyano, amino, nitro, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy or halogenated C 1-6m2 represents an integer from 0 to 20, for example, an integer of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 20. The number of substituents is not subject to any restrictions in principle or automatically limited by the size of the building block. In some embodiments, each ring W 2 The same or different and each independently means: Each ring W 2 Independently optionally m2 R c2 Group substitution, each R c2 Deuterium, C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), halogenated C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl groups, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), C 1-6 Alkoxy (e.g. C 1-4 Alkoxy, for example methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), halo C 1-6 Alkoxy (e.g., halo-C 1-4 Alkoxy, such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-), deuterated C 1-6 Alkoxy, halogen (such as fluorine, chlorine, bromine or iodine), amino, hydroxy, mercapto, cyano, carboxyl, C 2-6 Alkynyl (e.g. C 2-4 Alkynyl, such as ethynyl, propynyl, or butynyl), C 2-6 Alkenyl (e.g. C 2-4 alkenyl, such as vinyl, propenyl, or butenyl), optionally deuterated C 3-6Cycloalkyl (eg, optionally perdeuterated cyclopropyl, optionally perdeuterated cyclobutyl, optionally perdeuterated cyclopentyl, or optionally perdeuterated cyclohexyl), or R c8 -R c7 -, where R c7 is an optional substituted C 1-6 Alkylene (e.g., optionally substituted C 1-4 alkylene, such as optionally substituted methylene, ethylene or propylene) or optionally substituted C 2-6 Alkenylene (eg, optionally substituted C 2-4 alkenylene, such as optionally substituted vinylene, propenylene, butenylene), R c8 represents halogen (e.g., fluorine, chlorine, bromine or iodine), R c9 R c10 N-, hydroxy, carboxyl, ethynyl, or vinyl, where R c9 and R c10 The same or different and each independently represents hydrogen or C 1-3 Alkyl (eg, methyl, ethyl, or propyl); and the C 1-6 The alkylene group and the C 2-6 Each alkenylene group is independently optionally substituted with one or more (e.g., 1-5, such as 1, 2, 3, 4, or 5) deuterium, halogen, hydroxyl, mercapto, cyano, amino, nitro, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy or halogenated C 1-6 m2 represents an integer from 0 to 20, for example, an integer of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 20. The number of substituents is not subject to any restrictions in principle or automatically limited by the size of the building block. In some embodiments, t2 represents the integer 0. In some embodiments, t2 represents the integer 1. In some embodiments, in R c In the general formulas of Represents the following groups: wherein said groups are each independently optionally further substituted with one or more (eg 1-5, such as 1, 2, 3, 4 or 5) selected from deuterium, C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), halogenated C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl groups, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), C 1-6 Alkoxy (e.g. C 1-4 Alkoxy, for example methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), halo C 1-6 Alkoxy (e.g., halo-C 1-4 Alkoxy, such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-), deuterated C 1-6 Alkoxy (e.g., perdeuterated C 1-4 Alkoxy, such as CD3-O-, CD3CD2-O-, or CD3CD2CD2-O-), halogen (such as fluorine, chlorine, bromine or iodine), amino, hydroxy, mercapto, cyano, carboxyl, C 2-6 Alkynyl (e.g. C 2-4 Alkynyl, such as ethynyl, propynyl, or butynyl), C 2-6 Alkenyl (e.g. C 2-4 alkenyl, such as vinyl, propenyl, or butenyl), optionally deuterated C 3-6 Cycloalkyl (eg, optionally perdeuterated cyclopropyl, optionally perdeuterated cyclobutyl, optionally perdeuterated cyclopentyl, or optionally perdeuterated cyclohexyl), R c12 -R c11 , or any combination thereof, wherein R c11 is an optional substituted C 1-6 Alkylene (e.g., optionally substituted C 1-4 alkylene, such as optionally substituted methylene, ethylene or propylene) or optionally substituted C 2-6 Alkenylene (eg, optionally substituted C 2-4 alkenylene, such as optionally substituted vinylene, propenylene, butenylene), R c12represents halogen (e.g., fluorine, chlorine, bromine or iodine), R c13 R c14 N-, hydroxy, carboxyl, ethynyl, or vinyl, where R c13 and R c14 The same or different and each independently represents hydrogen or C 1-3 Alkyl (such as methyl, ethyl or propyl), the C 1-6 Alkylene and C 2-6 Each alkenylene group is independently optionally substituted with one or more radicals selected from deuterium, halogen, hydroxyl, mercapto, cyano, amino, nitro, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy or halogenated C 1-6 The substituents of the alkoxy group are substituted. In some embodiments, R of the compound of formula (I) c Represents the following groups: Bond, -O-, -NHC(O)-*, -C(O)NH-*, -C(O)O-*, -OC(O)-*, -CH2C(O)O-*, -CH2OC(O)-*, -NH-, - N(CH3)-, -NH-CH2-*, -N(CH3)-CH2-*, -N(CH3)-(CH2)2-N(CH3)-*, -N(CH3)-(CH2)3-N(CH3)-*, -NH-(CH2)2-N(CH3)-*, -N(C or wherein said groups are each independently optionally further substituted with one or more (eg 1-5, such as 1, 2, 3, 4 or 5) selected from deuterium, C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), halogenated C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl groups, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), C 1-6 Alkoxy (e.g. C 1-4 Alkoxy, for example methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), halo C 1-6 Alkoxy (e.g., halo-C 1-4 alkoxy, such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-), halogen (such as fluorine, chlorine, bromine or iodine), amino, hydroxy, mercapto, cyano, C 2-6 Alkynyl (e.g. C 2-4 Alkynyl, such as ethynyl, propynyl, or butynyl), C 2-6 Alkenyl (e.g. C 2-4 alkenyl, such as vinyl, propenyl, or butenyl), optionally deuterated C 3-6 Cycloalkyl (eg, optionally perdeuterated cyclopropyl, optionally perdeuterated cyclobutyl, optionally perdeuterated cyclopentyl, or optionally perdeuterated cyclohexyl), R c12 -R c11 -, or any combination thereof, wherein R c11 is an optional substituted C 1-6 Alkylene (e.g., optionally substituted C 1-4 alkylene, such as optionally substituted methylene, ethylene or propylene) or optionally substituted C 2-6 Alkenylene (eg, optionally substituted C 2-4 alkenylene, such as optionally substituted vinylene, propenylene, butenylene), R c12 represents halogen (e.g., fluorine, chlorine, bromine or iodine), R c13 R c14 N-, hydroxy, carboxyl, ethynyl, or vinyl, where R c13 and R c14 The same or different and each independently represents hydrogen or C 1-3 Alkyl (such as methyl, ethyl or propyl), and the C 1-6 The alkylene group and the C 2-6Each alkenylene group is independently optionally substituted with one or more deuterium, halogen, hydroxyl, mercapto, cyano, amino, nitro, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy or halogenated C 1-6 Substitution of the alkoxy group by a substituent; and The symbol * indicates the connection point to LIN. In some embodiments, examples of PBMs of compounds of Formula (I) include, but are not limited to, structures of the following formula: In some embodiments, the ULM of the compound of Formula (I) represents a ligand portion capable of binding to an E3 ubiquitin ligase and represents the structure of the following Formula (ULM): in Z represents C(O) or CH2; R a1 、R a2 、R a3 and R a4 are the same or different and each independently represent hydrogen, deuterium, halogen (such as fluorine, chlorine, bromine or iodine), C 1-6 alkyl Base (such as C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halo-C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 Alkoxy (e.g. C 1-4 Alkoxy, for example methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), halo C 1-6 Alkoxy (e.g., halo-C 1-4Alkoxy, such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-) or deuterated C 1-6 alkoxy; (R a5 ) m represents that the isoindoline ring connected thereto is optionally replaced by m R a5 Replace, each R a5 The same or different and each independently represents deuterium, Halogen (e.g., fluorine, chlorine, bromine or iodine), hydroxy, mercapto, nitro, amino, cyano, C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halo-C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 Alkoxy (e.g. C 1-4 Alkoxy, for example methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), halo C 1-6 Alkoxy (e.g., halo-C 1-4 Alkoxy, such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-) or deuterated C 1-6 alkoxy; m represents an integer 0, 1, 2 or 3; R a6 express: Among them, ring Y 1 represents a heterocyclic group containing at least 2 nitrogen atoms, (R d1 )n1 Represents ring Y 1 Optionally n1 R d1 Group Generation, each R d1 Each independently represents deuterium, halogen (such as fluorine, chlorine, bromine or iodine), hydroxyl, mercapto, nitro, amino, cyano, oxo, C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halo-C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1- 6 alkoxy (e.g. C 1-4 Alkoxy, for example methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy) or halogenated C 1-6 Alkoxy (e.g., halo-C 1-4 an alkoxy group such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-), and n1 represents an integer from 0 to 20; and R1 represents N(R w ), where R w Represents hydrogen or C 1-3 alkyl (e.g., methyl, ethyl, or propyl), and R2 represents a bond, or R2 represents CH2, C(O), **-NHC(O)- or **-N(CH3)C(O)-, or R2 represents the structure of the following formula: Among them, ring Y 2 represents a cycloalkylene group or a heterocyclic group containing at least one nitrogen atom, (R d2 ) n2 Represents ring Y 2 Optionally n2 R d2Group substitution, each R d2 are each independently deuterium, halogen (such as fluorine, chlorine, bromine or iodine), hydroxyl, mercapto, nitro, amino, cyano, oxo, C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halo-C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 Alkoxy (e.g. C 1-4 Alkoxy, for example methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy) or halogenated C 1-6 Alkoxy (e.g., halo-C 1-4 an alkoxy group such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-), and n2 represents an integer from 0 to 20; or R1 represents a bond, and R2 represents N(R w ), where R w Represents hydrogen or C 1-3 Alkyl, or R2 represents **C(O)N(R w ), where R w Represents hydrogen or C 1-3 Alkyl, or R2 represents **-CH=N-; or R a6 express: where R x represents NH or **-CH=N-; or R a6 express: Among them, ring Y 3 represents a heterocyclic group containing one nitrogen atom, (Rd3 ) n3 Represents ring Y 3 Optionally n3 R d3 Group substitution, Each R d3 Each independently represents deuterium, halogen (such as fluorine, chlorine, bromine or iodine), hydroxyl, mercapto, nitro, amino, cyano, oxo, C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halo-C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 Alkoxy (e.g. C 1-4 Alkoxy, for example methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy) or halogenated C 1-6 Alkoxy (e.g., halo-C 1-4 an alkoxy group such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-), and n3 represents an integer from 0 to 20; and where R s1 express Symbol **** indicates the ring Y 3 The connection point of R s2 N(R w )or **C(O)N(R w ), where R w Represents hydrogen or C 1-3 alkyl; and The symbols ** in the above formulas indicate the connection points with LIN. In some embodiments, Z of the structure of formula (ULM) represents C(O). In some embodiments, Z of the structure of formula (ULM) represents CH2. In some embodiments, R of the structure of formula (ULM) a1 、R a2 、R a3 and R a4 Represents hydrogen. In some embodiments, m of the structure of formula (ULM) represents the integer 0. In some embodiments, m of the structure of Formula (ULM) represents an integer of 1, 2, or 3. In some embodiments, each R of the structure of Formula (ULM) a5 The same or different and each independently represent a halogen (eg, fluorine, chlorine, bromine or iodine). In some embodiments, R of the structure of formula (ULM) a6 express: Among them, ring Y 1 represents a heterocyclic group containing at least 2 nitrogen atoms, (R d1 ) n1 Represents ring Y 1 Optionally n1 R d1 Group substitution, each R d1 Each independently represents deuterium, halogen (such as fluorine, chlorine, bromine or iodine), hydroxyl, mercapto, nitro, amino, cyano, oxo, C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halo-C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 Alkoxy (e.g. C 1-4 Alkoxy, for example methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy) or halogenated C 1-6 Alkoxy (e.g., halo-C 1-4an alkoxy group such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-), and n1 represents an integer from 0 to 20; and (i) R1 represents N(R w ), where R w Represents hydrogen or C 1-3 alkyl, and R2 represents a bond, or R2 represents CH2, C(O), **-NHC(O)- or **-N(CH3)C(O)-, or R2 represents the structure of the following formula: Among them, ring Y 2 represents a cycloalkylene group or a heterocyclic group containing at least one nitrogen atom, (R d2 ) n2 Represents ring Y 2 Optionally n2 R d2 base Group replacement, each R d2 are each independently deuterium, halogen (such as fluorine, chlorine, bromine or iodine), hydroxyl, mercapto, nitro, amino, cyano, oxo, C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halo-C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 Alkoxy (e.g. C 1-4 Alkoxy, for example methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy) or halogenated C 1-6 Alkoxy (e.g., halo-C 1-4an alkoxy group such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-), and n2 represents an integer from 0 to 20; or (ii) R1 represents a bond, and R2 represents N(R w ), where R w Represents hydrogen or C 1-3 Alkyl, or R2 represents **C(O)N(R w ), where R w surface Shows hydrogen or C 1-3 Alkyl, or R2 represents **-CH=N-; and The symbols ** in the above formulas indicate the connection points with LIN. In some embodiments, R a6 Ring Y in 1 represents a 4- to 20-membered heterocyclylene group containing at least 2 nitrogen atoms. Examples of 4- to 20-membered heterocyclylene groups containing at least 2 nitrogen atoms include, but are not limited to, 4- to 20-membered heterocyclylene groups containing 2-4 nitrogen atoms. Representative examples include: diazetidinylene, imidazolidinylene, pyrazolidinylene, piperazinylene, 1,2,3,4-tetrahydropyrazinylene, hexahydropyrimidinylene, hexahydropyridazinylene, diazaheptanylene, diazaoctanylene, diazabicyclo[3.1.1]heptanylene, diazabicyclo[2.2.1]heptanylene, diazabicyclo[3.2.1]octanylene, diazabicyclo[2.2.2] octanylidene, diazaspiro[2.3]hexaneylidene, diazaspiro[3.3]heptaneylidene, diazaspiro[2.4]heptaneylidene, diazaspiro[3.4]octanylidene, diazaspiro[3.5]nonaneylidene, diazaspiro[4.4]nonaneylidene, diazaspiro[4.5]decaneylidene, diazaspiro[5.5]undecaneylidene, octahydropyrrolo[3,4-c]pyrroleylidene or decahydronaphthyridinylidene, or Among them, ring Y 1 Optionally n1 R d1 Group substitution, each R d1 are independently deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano Group, oxo group, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy or C 1-6 alkoxy; and n1 represents an integer from 0 to 20. The (R d1 ) n1 Represents ring Y 1 Optionally n1 R d1 Group substitution, each R d1 are each independently deuterium, halogen (such as fluorine, chlorine, bromine or iodine), hydroxyl, mercapto, nitro, amino, cyano, oxo, C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halo-C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 Alkoxy (e.g. C 1-4 Alkoxy, for example methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy) or halogenated C 1-6 Alkoxy (e.g., halo-C 1-4 alkoxy, for example F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-), and n1 represents an integer from 0 to 20, for example an integer of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 20. The number of substituents is in principle not subject to any restrictions or automatically limited by the size of the building block. In some embodiments, R a6 R1 in represents N(R w ), where R w Represents hydrogen or C 1-3 alkyl, and R2 represents a bond. In some embodiments, R a6 R1 in represents N(R w ), where R w Represents hydrogen or C1-3 alkyl, and R2 represents CH2, C(O), **-NHC(O)- or **-N(CH3)C(O)-, and the symbol ** indicates the point of attachment to LIN. In some embodiments, R a6 R1 in represents N(R w ), where R w Represents hydrogen or C 1-3 alkyl, and R2 represents the structure of the following formula: Among them, ring Y 2 Indicates C 3-20 Cycloalkylene or a 4- to 20-membered heterocyclylene containing at least one nitrogen atom, (R d2 ) n2 Represents ring Y 2 Optionally n2 R d2 Group substitution, each R d2 are each independently deuterium, halogen (such as fluorine, chlorine, bromine or iodine), hydroxyl, mercapto, nitro, amino, cyano, oxo, C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halo-C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 Alkoxy (e.g. C 1-4 Alkoxy, for example methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy) or halogenated C 1-6 Alkoxy (e.g., halo-C 1-4 an alkoxy group such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-), and n2 represents an integer from 0 to 20; and The symbol ** indicates the connection point to LIN. In some embodiments, R a6 Ring Y in 2 Indicates C 3-20 Cycloalkylene (e.g. C 3-15 Cycloalkylene or C 3-11 In some embodiments, C 3-20 Cycloalkylene (e.g. C 3-15 Examples of cycloalkylene groups include, but are not limited to, cyclopropylene, cyclobutylene, cyclopentylene, cyclopentenylene, cyclohexylene, cyclohexenylene, cycloheptylene, cyclooctylene, decahydronaphthylene, octahydropentalenylene, octahydro-1H-indenylene, 2,3-dihydro-1H-indenylene, C 5-15 Spirocyclylene, C 5-15 A bridged cyclic group (e.g., adamantylene, noradamantylene, norbornylene). Ring Y 2 Optionally n2 R d2 Group substitution, each R d2 are independently deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano, oxo, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy or C 1-6 alkoxy; n2 represents an integer from 0 to 20, for example an integer of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 20. The number of substituents is in principle not subject to any restrictions or automatically limited by the size of the building block. In some embodiments, R a6 Ring Y in 2represents a 4- to 20-membered heterocyclylene group containing 1 to 4 nitrogen atoms (e.g., a 4- to 15-membered, 4- to 12-membered, 4- to 11-membered, 4- to 10-membered, 4- to 9-membered, 4- to 8-membered, 4- to 7-membered, 4- to 6-membered, 5- to 15-membered, or 5- to 9-membered heterocyclylene group). A 4- to 20-membered heterocyclylene group containing 1 to 4 nitrogen atoms is a 4- to 20-membered (e.g., a 4- to 15-membered, 4- to 12-membered, 4- to 11-membered, 4- to 10-membered, 4- to 9-membered, 4- to 8-membered, 4- to 7-membered, 4- to 6-membered, 5- to 15-membered, or 5- to 9-membered) heterocyclylene group containing 1 to 4 nitrogen atoms and optionally containing a heteroatom selected from nitrogen, oxygen, and sulfur. Examples of 4- to 20-membered heterocyclylene groups containing 1-4 nitrogen atoms include, but are not limited to, azetidinylene, diazetidinylene, pyrrolidinylene, imidazolidinylene, pyrazolidinylene, piperidinylene, tetrahydropyridinylene, piperazinylene, 1,2,3,4-tetrahydropyrazinylene, hexahydropyrimidinylene, hexahydropyridazinylene, azepanylene, diazepanylene, azacycloheptanylene, azepan ... Octanediyl, diazacyclooctandiyl, azabicyclo[3.1.1]alkanediyl, azabicyclo[2.2.1]heptanediyl, azabicyclo[3.2.1]octandiyl, azabicyclo[2.2.2]octandiyl, diazabicyclo[3.1.1]heptanediyl, diazabicyclo[2.2.1]heptanediyl, diazabicyclo[3.2.1]octandiyl, diazabicyclo[2 .2.2]octanylidene, azaspiro[2.3]hexaneylidene, azaspiro[3.3]heptaneylidene, azaspiro[2.4]heptaneylidene, azaspiro[3.4]octanylidene, azaspiro[3.5]nonaneylidene, azaspiro[4.4]nonaneylidene, azaspiro[4.5]decaneylidene, azaspiro[5.5]undecaneylidene, diazaspiro[2.3]hexaneylidene, diazaspiro [3.3]heptanediyl, diazaspiro[2.4]heptanediyl, diazaspiro[3.4]octanylidene, diazaspiro[3.5]nonanediyl, diazaspiro[4.4]nonanediyl, diazaspiro[4.5]decanediyl, diazaspiro[5.5]undecanediyl, octahydrocyclopenta[c]pyrrolediyl, octahydropyrrolo[3,4-c]pyrrolediyl or decahydronaphthyridinylidene, or The symbol ** indicates the connection point to LIN; and The ring Y 2 Optionally n2 R d2 Group substitution, each R d2 are independently deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano Group, oxo group, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6Alkyl, halogenated C 1-6 Alkoxy or C 1-6 alkoxy; and n2 represents an integer of 0-20, for example, an integer of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 20. In some embodiments, R of the structure of formula (ULM) a6 express: where R x represents NH or **-CH=N-, and the symbol ** indicates the connection point with LIN. In some embodiments, R of the structure of formula (ULM) a6 express: Among them, ring Y 3 represents a heterocyclic group containing one nitrogen atom (e.g., a 4- to 20-membered heterocyclic group containing one nitrogen atom), (R d3 ) n3 express Ring Y 3 Optionally n3 R d3 Group substitution, each R d3 Each independently represents deuterium, halogen (such as fluorine, chlorine, bromine or iodine), hydroxyl, mercapto, nitro, amino, cyano, oxo, C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halo-C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 Alkoxy (e.g. C 1-4 Alkoxy, for example methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy) or halogenated C 1-6 Alkoxy (e.g., halo-C 1-4alkoxy, such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-), and n3 represents an integer from 0 to 20 (e.g., an integer of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 20); and where R s1 express Symbol **** indicates the ring Y 3 connection points; R s2 N(R w ) or **C(O)N(R w ), where R w Represents hydrogen or C 1-3 Alkyl (eg, methyl, ethyl, or propyl); and The symbol ** indicates the connection point to LIN. In some embodiments, R a6 Ring Y in 3 represents a 4- to 20-membered heterocyclylene group containing one nitrogen atom (e.g., a 4- to 15-membered, 4- to 12-membered, 4- to 11-membered, 4- to 10-membered, 4- to 9-membered, 4- to 8-membered, 4- to 7-membered, 4- to 6-membered, 5- to 15-membered, or 5- to 9-membered heterocyclylene group). A 4- to 20-membered heterocyclylene group containing one nitrogen atom is a 4- to 20-membered (e.g., a 4- to 15-membered, 4- to 12-membered, 4- to 11-membered, 4- to 10-membered, 4- to 9-membered, 4- to 8-membered, 4- to 7-membered, 4- to 6-membered, 5- to 15-membered, or 5- to 9-membered) heterocyclylene group containing one nitrogen atom and optionally containing a heteroatom selected from oxygen and sulfur. Examples of 4- to 20-membered heterocyclylene groups containing one nitrogen atom include, but are not limited to, azetidinylene, pyrrolidinylene, piperidinylene, tetrahydropyridinylene, azepanylene, azaoctanylene, azabicyclo[3.1.1]alkaneylene, azabicyclo[2.2.1]heptaneylene, azabicyclo[3.2.1]octanylene, azabicyclo[2.2.2] ... azaspiro[2.3]hexanediyl, azaspiro[3.3]heptandiyl, azaspiro[2.4]heptandiyl, azaspiro[3.4]octandiyl, azaspiro[3.5]nonanediyl, azaspiro[4.4]nonanediyl, azaspiro[4.5]decanediyl, azaspiro[5.5]undecanediyl, octahydrocyclopenta[c]pyrrolidyl or octahydropyrrolo[3,4-c]pyrrolidyl, or The ring Y 3Optionally n3 R d3 Group substitution, each R d3 are independently deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano Group, oxo group, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy or C 1-6 alkoxy; and n3 represents an integer from 0 to 20. In some embodiments, R a6 R in s1 Indicates S. In some embodiments, R a6 Rs1 in the formula represents ****-CH2-S-, or ****-CH2CH2-S-, and the symbol **** indicates that the ring Y 3 connection point. In some embodiments, R of the compound of formula (I) a6 express: -NH-NH- or **-CH=N-NH-; The symbol ** indicates the connection point to LIN. In some embodiments, the ULM of the compound of Formula (I) represents the following structure of Formula (ULM-1-1), Formula (ULM-1-2), Formula (ULM-1-3), or Formula (ULM-1-4): in Z represents C(O) or CH2; R a1 、R a2 、R a3 and R a4 are the same or different and each independently represent hydrogen, deuterium, halogen (such as fluorine, chlorine, bromine or iodine), C 1-6 alkyl Base (such as C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halo-C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 Alkoxy (e.g. C 1-4 Alkoxy, for example methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), halo C 1-6 Alkoxy (e.g., halo-C 1-4 Alkoxy, such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-) or deuterated C 1-6 alkoxy; (R a5 ) m represents that the isoindoline ring connected thereto is optionally replaced by m R a5 Replace, each R a5 The same or different and each independently represents deuterium, Halogen (e.g., fluorine, chlorine, bromine or iodine), hydroxy, mercapto, nitro, amino, cyano, C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halo-C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 Alkoxy (e.g. C 1-4 Alkoxy, for example methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), halo C 1-6 Alkoxy (e.g., halo-C 1-4Alkoxy, such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-) or deuterated C 1-6 alkoxy; m represents an integer 0, 1, 2 or 3; R a6 express: Among them, ring Y 1 represents a heterocyclic group containing at least 2 nitrogen atoms, (R d1 ) n1 Represents ring Y 1 Optionally n1 R d1 Group Generation, each R d1 Each independently represents deuterium, halogen (such as fluorine, chlorine, bromine or iodine), hydroxyl, mercapto, nitro, amino, cyano, oxo, C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halo-C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1- 6 alkoxy (e.g. C 1-4 Alkoxy, for example methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy) or halogenated C 1-6 Alkoxy (e.g., halo-C 1-4an alkoxy group, for example F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-), and n1 represents an integer from 0 to 20 (for example an integer of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 20. The number of substituents is in principle not subject to any restrictions or automatically limited by the size of the building block); and R1 represents N(R w ), where R w Represents hydrogen or C 1-3 Alkyl, and R2 represents a bond, or R2 represents CH2, C(O), **- NHC(O)- or **-N(CH3)C(O)-, or R2 represents the structure of the following formula: Among them, ring Y 2 represents a cycloalkylene group or a heterocyclic group containing at least one nitrogen atom, (R d2 ) n2 Represents ring Y 2 Optionally n2 R d2 Group substitution, each R d2 are each independently deuterium, halogen (such as fluorine, chlorine, bromine or iodine), hydroxyl, mercapto, nitro, amino, cyano, oxo, C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halo-C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 Alkoxy (e.g. C 1-4 Alkoxy, for example methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy) or halogenated C 1-6 Alkoxy (e.g., halo-C 1-4an alkoxy group, for example F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-), and n2 represents an integer from 0 to 20 (for example an integer of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 20. The number of substituents is in principle not subject to any restrictions or automatically limited by the size of the building block); or R1 represents a bond, and R2 represents N(R w ), where R w Represents hydrogen or C 1-3 Alkyl, or R2 represents **C(O)N(R w ), where R w Represents hydrogen or C 1-3 Alkyl, or R2 represents **-CH=N-; or R a6 express: where R x represents NH or **-CH=N-; or R a6 express: Among them, ring Y 3 represents a heterocyclic group containing one nitrogen atom, (R d3 ) n3 Represents ring Y 3 Optionally n3 R d3 Group substitution, Each R d3 Each independently represents deuterium, halogen (such as fluorine, chlorine, bromine or iodine), hydroxyl, mercapto, nitro, amino, cyano, oxo, C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halo-C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 Alkoxy (e.g. C 1-4 Alkoxy, for example methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy) or halogenated C 1-6 Alkoxy (e.g., halo-C 1-4 an alkoxy group, for example F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-), and n3 represents an integer from 0 to 20 (for example an integer of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 20. The number of substituents is in principle not subject to any restrictions or automatically limited by the size of the building block); and where R s1 express Symbol **** indicates the ring Y 3 The connection point of R s2 N(R w )or **C(O)N(R w ), where R w Represents hydrogen or C 1-3 alkyl; and The symbols ** in the above formulas indicate the connection points with LIN. In some embodiments, the ULM of the compound of formula (I) represents a structure of the formula: Among them, Z, (R a5 ) m and R a6 As defined herein. In some embodiments, LIN of the compound of formula (I) represents: where R w2 Connect PBM, R w1 Connect R a6 ; R w2 represents a bond, C(O), C(O)NH, or NHC(O); Each ring A 1 The same or different and each independently represents a heterocyclylene group (e.g., a 4- to 20-membered heterocyclylene group), a cycloalkylene group (e.g., C 3- 20 Cycloalkylene), arylene (e.g. C 5-20arylene), or heteroarylene (e.g., 5- to 20-membered heteroarylene), y1 represents an integer of 0, 1, 2 or 3, (R y1 ) a1 Represents each ring A 1 independently optionally be a1 R y1 Group substitution, each R y1 Deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, carboxyl, C 2-6 Alkynyl or C 2-6 alkenyl, and a1 represents an integer of 0-10; Each ring A 2 The same or different and each independently represents a heterocyclylene group (e.g., a 4- to 20-membered heterocyclylene group), a cycloalkylene group (e.g., C 3- 20 Cycloalkylene), arylene (e.g. C 5-20 arylene), or heteroarylene (e.g., 5- to 20-membered heteroarylene), y2 represents an integer of 0, 1, 2 or 3, (R y2 ) a2 Represents each ring A 2 independently optionally by a2 R y2 Group substitution, each R y2 Deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, carboxyl, C 2-6 Alkynyl or C 2-6 alkenyl, and a2 represents an integer of 0-10; Each ring A 3 The same or different and each independently represents a heterocyclylene group (e.g., a 4- to 20-membered heterocyclylene group), a cycloalkylene group (e.g., C 3- 20 Cycloalkylene), arylene (e.g. C 5-20 arylene), or heteroarylene (e.g., 5- to 20-membered heteroarylene), y3 represents an integer of 0, 1, 2 or 3, (R y3 ) a3 Represents each ring A 3 Independently optionally a3 R y3 Group substitution, each R y3 Deuterium, C 1-6 Alkyl, deuterated C1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, carboxyl, C 2-6 Alkynyl or C 2-6 alkenyl, and a3 represents an integer of 0-10; R w1 represents a bond, or represents an optionally substituted straight or branched C 1-20 Alkylene, wherein the linear or branched C 1-20 Alkylene Any one or more methylene groups of the main carbon chain skeleton may be optionally replaced by one or more groups selected from the following: R a 、R b and any combination thereof, each group R a Each independently selected from O, C(O), OC(O), S, S(O), S(O)2, S(O)2N(R a7 )、N(R a7 )S(O)2、C(O)N(R a7 )、N(R a7 )C(O), N(R a7 ) and N(R a7 )C(O)N(R a7 ), where each R a7 Each independently represents H or C 1-3 Alkyl, and when the linear or branched C 1-20 Any two or more methylene groups of the main carbon chain skeleton of the alkylene group may be optionally replaced by two or more groups R a When substituted, each group R a Not directly connected to each other; each group R b are each independently selected from optionally substituted cycloalkylene (eg, optionally substituted C 3-20 cycloalkylene), optionally substituted arylene (e.g., optionally substituted C 5-20 arylene), optionally substituted heterocyclylene (e.g., optionally substituted 4- to 20-membered heterocyclylene), optionally substituted heteroarylene (e.g., optionally substituted 5- to 20-membered heteroarylene), alkynylene (e.g., C 2-6 Alkyne), alkenylene (e.g. C 2-6 and any combination thereof. In some embodiments, R in LIN of the compound of formula (I) w2 Indicates a key. In some embodiments, R in LIN of the compound of formula (I) w2 Represents C(O). In some embodiments, R in LIN of the compound of formula (I) w2 represents C(O)NH or NHC(O). In some embodiments, each ring A in LIN of the compound of formula (I) 1 The same or different and each independently represents a heterocyclylene group (e.g., a 4- to 20-membered heterocyclylene group, such as a 4- to 18-membered, 4- to 15-membered, 4- to 12-membered, 4- to 11-membered, 4- to 10-membered, 4- to 9-membered, 4- to 8-membered, 4- to 7-membered, 4- to 6-membered, 5- to 15-membered, or 5- to 9-membered heterocyclylene group), a cycloalkylene group (e.g., C 3-20 Cycloalkylene), arylene (e.g. C 5-20 Arylene, such as C 6-20 Arylene, C 5-15 Arylene or C 6-15arylene), or heteroarylene (e.g., 5- to 20-membered heteroarylene, e.g., 5- to 15-membered, 5- to 10-membered, 5- to 9-membered, 5- to 8-membered, 5- to 7-membered, or 5- to 6-membered heteroarylene). In some embodiments, a 4- to 20-membered heterocyclylene group is a 4- to 20-membered (e.g., 4- to 15-membered, 4- to 12-membered, 4- to 11-membered, 4- to 10-membered, 4- to 9-membered, 4- to 8-membered, 4- to 7-membered, 4- to 6-membered, 5- to 15-membered, or 5- to 9-membered) monocyclic, bicyclic, tricyclic, or polycyclic saturated or partially unsaturated (i.e., having one or more double bonds, but not fully conjugated) divalent cyclic hydrocarbon group containing one or more (e.g., containing 1 to 5, 1 to 4, 1 to 3, 1 to 2, or 1) heteroatoms independently selected from sulfur, oxygen, and nitrogen. Examples of 4- to 20-membered heterocyclylene groups include, but are not limited to, monocyclic heterocyclylene groups (e.g., 4- to 20-membered monocyclic heterocyclylene groups), bridged heterocyclylene groups (e.g., 5- to 20-membered bridged heterocyclylene groups or 7- to 15-membered bridged heterocyclylene groups), fused heterocyclylene groups, and spiroheterocyclylene groups (e.g., 5- to 20-membered spiroheterocyclylene groups), for example, azetidinylene, oxetanylene, pyrrolidinylene, imidazolidinylene, pyrazolidinylene, tetrahydrofuranylene, tetrahydropyranylene, tetrahydrothiophenylene, tetrahydrothiopyranylene, oxazolidinylene, thiazolidinylene, piperidinylene, piperazinylene, morpholinylene, thiomorpholinylene, azepanylene, azepanylene, oxazolidinylene, thiazolidinylene, piperidinylene, piperazinylene, morpholinylene, thiomorpholinylene, azepanylene, oxazolidinylene, thiazolidinylene, piperidinylene, piperazinylene, morpholin ... In some embodiments, C is substituted with 1- to 2-membered cyclohexyl, 1- to 2-membered cyclohexyl, 1- to 3-membered cyclohexyl, 1- to 4-membered cyclohexyl, 1- to 5-membered cyclohexyl, 1- to 6-membered cyclohexyl, 1- to 2-membered cyclohexyl, 1- to 3-membered cyclohexyl, 1- to 4-membered cyclohexyl, 1- to 3-membered cyclohexyl, 1- to 2-membered cyclohexyl, 1- to 3-membered cyclohexyl, 1- to 4-membered cyclohexyl, 1- to 3-membered cyclohexyl, 1- to 2-membered cyclohexyl, 1- to 3-membered cyclohexyl, 1- to 3-membered cyclohexyl, 1- to 4-membered cyclohexyl, 1- to 3 ... 3-20 Examples of cycloalkylene groups include, but are not limited to, cyclopropylene, cyclobutylene, cyclopentylene, cyclopentenylene, cyclohexylene, cyclohexenylene, cycloheptylene, cyclooctylene, decahydronaphthylene, octahydropentalenylene, octahydro-1H-indenylene, 2,3-dihydro-1H-indenylene, spirocyclylene (e.g., C 5-15In some embodiments, 5- to 20-membered arylene groups include, but are not limited to, phenylene or naphthylene. In some embodiments, 5- to 20-membered heteroarylene groups are 5- to 20-membered (e.g., 5- to 15-membered, 5- to 12-membered, 5- to 9-membered, 5- to 8-membered, 5- to 7-membered, or 5- to 6-membered) heteroarylene groups containing one nitrogen atom and optionally containing a heteroatom selected from nitrogen, oxygen, and sulfur. In some embodiments, examples of 5- to 20-membered heteroarylene groups include, but are not limited to, for example, oxazolylene, isoxazolylene, oxadiazolylene, thienylene, thiazolylene, isothiazolylene, thiadiazolylene, pyrrolylene, imidazolylene, pyrazolylene, triazolylene, pyridinylene, pyrimidinylene, pyridazinylene, pyrazinylene, indolylene, isoindolylene, benzofuranylene, isobenzofuranylene, benzothienylene, indazolylene, benzimidazolylene, benzoxazolylene, benzisoxazolylene, benzothiazolylene, benzisothiazolylene, benzotriazolylene, Benzo[2,1,3]oxadiazole group, benzo[2,1,3]thiadiazolylidene, benzo[1,2,3]thiadiazolylidene, quinolinylene, isoquinolinylene, naphthyridinylene, cinnolinylene, quinazolinylene, quinoxalinylene, phthalazinylene, pyrazolo[1,5-a]pyridinylene, pyrazolo[1,5-a]pyrimidinylene, imidazo[1,2-a]pyridinylene, 1H-pyrrolo[3,2-b]pyridinylene, 1H-pyrrolo[2,3-b]pyridinylene, pyrrolo[2,1-b]thiazolylidene, or imidazo[2,1-b]thiazolylidene. Each ring A 1 Each independently optionally represented by a1 R y1 Group substitution, each R y1 Deuterium, C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), halogenated C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl groups, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), C 1-6 Alkoxy (e.g. C 1-4Alkoxy, for example methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), halo C 1-6 Alkoxy, halogen (such as fluorine, chlorine, bromine or iodine), amino, hydroxy, mercapto, cyano, carboxyl, C 2-6 Alkynyl or C 2-6 a1 represents an integer from 0 to 10, for example an integer of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10. The number of substituents is not subject to any restrictions in principle or automatically limited by the size of the building block. In some embodiments, yl in LIN of the compound of formula (I) represents an integer of 0, 1, 2 or 3. In some embodiments, each ring A in LIN of the compound of formula (I) 1 The same or different and each independently represent the following optionally substituted groups: Each ring A 1 independently optionally be a1 R y1 Group substitution, each R y1 Deuterium, C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 alkyl Base or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), halogenated C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl groups, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), C 1-6 Alkoxy (e.g. C 1-4 Alkoxy, for example methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), halo C 1-6 Alkoxy, halogen (such as fluorine, chlorine, bromine or iodine), amino, hydroxy, mercapto, cyano, carboxyl, C 2-6 Alkynyl (e.g. C 2-4 Alkynyl, such as ethynyl, propynyl, or butynyl) or C 2-6Alkenyl (e.g. C 2-4 a1 represents an integer from 0 to 10, for example an integer of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10. The number of substituents is in principle not subject to any restrictions or automatically limited by the size of the building block. In some embodiments, each ring A in LIN of the compound of formula (I) 2 The same or different and each independently represents a heterocyclylene group (e.g., a 4- to 20-membered heterocyclylene group, such as a 4- to 18-membered, 4- to 15-membered, 4- to 12-membered, 4- to 11-membered, 4- to 10-membered, 4- to 9-membered, 4- to 8-membered, 4- to 7-membered, 4- to 6-membered, 5- to 15-membered, or 5- to 9-membered heterocyclylene group), a cycloalkylene group (e.g., C 3-20 Cycloalkylene), arylene (e.g. C 5-20 Arylene, such as C 6-20 Arylene, C 5-15 Arylene or C 6-15arylene), or heteroarylene (e.g., 5- to 20-membered heteroarylene, e.g., 5- to 15-membered, 5- to 10-membered, 5- to 9-membered, 5- to 8-membered, 5- to 7-membered, or 5- to 6-membered heteroarylene). In some embodiments, a 4- to 20-membered heterocyclylene group is a 4- to 20-membered (e.g., 4- to 15-membered, 4- to 12-membered, 4- to 11-membered, 4- to 10-membered, 4- to 9-membered, 4- to 8-membered, 4- to 7-membered, 4- to 6-membered, 5- to 15-membered, or 5- to 9-membered) monocyclic, bicyclic, tricyclic, or polycyclic saturated or partially unsaturated (i.e., having one or more double bonds, but not fully conjugated) divalent cyclic hydrocarbon group containing one or more (e.g., containing 1 to 5, 1 to 4, 1 to 3, 1 to 2, or 1) heteroatoms independently selected from sulfur, oxygen, and nitrogen. Examples of 4- to 20-membered heterocyclylene groups include, but are not limited to, monocyclic heterocyclylene groups (e.g., 4- to 20-membered monocyclic heterocyclylene groups), bridged heterocyclylene groups (e.g., 5- to 20-membered bridged heterocyclylene groups or 7- to 15-membered bridged heterocyclylene groups), fused heterocyclylene groups, and spiroheterocyclylene groups (e.g., 5- to 20-membered spiroheterocyclylene groups), for example, azetidinylene, oxetanylene, pyrrolidinylene, imidazolidinylene, pyrazolidinylene, tetrahydrofuranylene, tetrahydropyranylene, tetrahydrothiophenylene, tetrahydrothiopyranylene, oxazolidinylene, thiazolidinylene, piperidinylene, piperazinylene, morpholinylene, thiomorpholinylene, azepanylene, azepanylene, oxazolidinylene, thiazolidinylene, piperidinylene, piperazinylene, morpholinylene, thiomorpholinylene, azepanylene, oxazolidinylene, thiazolidinylene, piperidinylene, piperazinylene, morpholin ... In some embodiments, C is substituted with 1- to 2-membered cyclohexyl, 1- to 2-membered cyclohexyl, 1- to 3-membered cyclohexyl, 1- to 4-membered cyclohexyl, 1- to 5-membered cyclohexyl, 1- to 6-membered cyclohexyl, 1- to 2-membered cyclohexyl, 1- to 3-membered cyclohexyl, 1- to 4-membered cyclohexyl, 1- to 3-membered cyclohexyl, 1- to 2-membered cyclohexyl, 1- to 3-membered cyclohexyl, 1- to 4-membered cyclohexyl, 1- to 3-membered cyclohexyl, 1- to 2-membered cyclohexyl, 1- to 3-membered cyclohexyl, 1- to 3-membered cyclohexyl, 1- to 4-membered cyclohexyl, 1- to 3 ... 3-20 Examples of cycloalkylene groups include, but are not limited to, cyclopropylene, cyclobutylene, cyclopentylene, cyclopentenylene, cyclohexylene, cyclohexenylene, cycloheptylene, cyclooctylene, decahydronaphthylene, octahydropentalenylene, octahydro-1H-indenylene, 2,3-dihydro-1H-indenylene, spirocyclylene (e.g., C 5-15In some embodiments, 5- to 20-membered arylene groups include, but are not limited to, phenylene or naphthylene. In some embodiments, 5- to 20-membered heteroarylene groups are 5- to 20-membered (e.g., 5- to 15-membered, 5- to 12-membered, 5- to 9-membered, 5- to 8-membered, 5- to 7-membered, or 5- to 6-membered) heteroarylene groups containing one nitrogen atom and optionally containing a heteroatom selected from nitrogen, oxygen, and sulfur. In some embodiments, examples of 5- to 20-membered heteroarylene groups include, but are not limited to, for example, oxazolylene, isoxazolylene, oxadiazolylene, thienylene, thiazolylene, isothiazolylene, thiadiazolylene, pyrrolylene, imidazolylene, pyrazolylene, triazolylene, pyridinylene, pyrimidinylene, pyridazinylene, pyrazinylene, indolylene, isoindolylene, benzofuranylene, isobenzofuranylene, benzothienylene, indazolylene, benzimidazolylene, benzoxazolylene, benzisoxazolylene, benzothiazolylene, benzisothiazolylene, benzotriazolylene, Benzo[2,1,3]oxadiazole group, benzo[2,1,3]thiadiazolylidene, benzo[1,2,3]thiadiazolylidene, quinolinylene, isoquinolinylene, naphthyridinylene, cinnolinylene, quinazolinylene, quinoxalinylene, phthalazinylene, pyrazolo[1,5-a]pyridinylene, pyrazolo[1,5-a]pyrimidinylene, imidazo[1,2-a]pyridinylene, 1H-pyrrolo[3,2-b]pyridinylene, 1H-pyrrolo[2,3-b]pyridinylene, pyrrolo[2,1-b]thiazolylidene, or imidazo[2,1-b]thiazolylidene. Each ring A 2 Each independently optionally represented by a2 R y2 Group substitution, each R y2 Deuterium, C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), halogenated C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl groups, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), C 1-6 Alkoxy (e.g. C 1-4Alkoxy, for example methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), halo C 1-6 Alkoxy, halogen (such as fluorine, chlorine, bromine or iodine), amino, hydroxy, mercapto, cyano, carboxyl, C 2-6 Alkynyl or C 2-6 a2 represents an integer from 0 to 10, for example an integer of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10. The number of substituents is not subject to any restrictions in principle or automatically limited by the size of the building block. In some embodiments, y2 of the compound of formula (I) represents an integer of 0, 1, 2 or 3. In some embodiments, each ring A in LIN of the compound of formula (I) 2 The same or different and each independently represent the following optionally substituted groups: Each ring A 2 independently optionally by a2 R y2 Group substitution, each R y2 Deuterium, C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 alkyl Base or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), halogenated C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl groups, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), C 1-6 Alkoxy (e.g. C 1-4 Alkoxy, for example methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), halo C 1-6 Alkoxy, halogen (such as fluorine, chlorine, bromine or iodine), amino, hydroxy, mercapto, cyano, carboxyl, C 2-6 Alkynyl (e.g. C 2-4 Alkynyl, such as ethynyl, propynyl, or butynyl) or C 2-6 Alkenyl (e.g. C 2-4a2 represents an integer from 0 to 10, for example an integer of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10. The number of substituents is in principle not subject to any restrictions or automatically limited by the size of the building block. In some embodiments, each ring A in LIN of the compound of formula (I) 3 The same or different and each independently represents a heterocyclylene group (e.g., a 4- to 20-membered heterocyclylene group, such as a 4- to 18-membered, 4- to 15-membered, 4- to 12-membered, 4- to 11-membered, 4- to 10-membered, 4- to 9-membered, 4- to 8-membered, 4- to 7-membered, 4- to 6-membered, 5- to 15-membered, or 5- to 9-membered heterocyclylene group), a cycloalkylene group (e.g., C 3-20 Cycloalkylene), arylene (e.g. C 5-20 Arylene, such as C 6-20 Arylene, C 5-15 Arylene or C 6-15arylene), or heteroarylene (e.g., 5- to 20-membered heteroarylene, e.g., 5- to 15-membered, 5- to 10-membered, 5- to 9-membered, 5- to 8-membered, 5- to 7-membered, or 5- to 6-membered heteroarylene). In some embodiments, a 4- to 20-membered heterocyclylene group is a 4- to 20-membered (e.g., 4- to 15-membered, 4- to 12-membered, 4- to 11-membered, 4- to 10-membered, 4- to 9-membered, 4- to 8-membered, 4- to 7-membered, 4- to 6-membered, 5- to 15-membered, or 5- to 9-membered) monocyclic, bicyclic, tricyclic, or polycyclic saturated or partially unsaturated (i.e., having one or more double bonds, but not fully conjugated) divalent cyclic hydrocarbon group containing one or more (e.g., containing 1 to 5, 1 to 4, 1 to 3, 1 to 2, or 1) heteroatoms independently selected from sulfur, oxygen, and nitrogen. Examples of 4- to 20-membered heterocyclylene groups include, but are not limited to, monocyclic heterocyclylene groups (e.g., 4- to 20-membered monocyclic heterocyclylene groups), bridged heterocyclylene groups (e.g., 5- to 20-membered bridged heterocyclylene groups or 7- to 15-membered bridged heterocyclylene groups), fused heterocyclylene groups, and spiroheterocyclylene groups (e.g., 5- to 20-membered spiroheterocyclylene groups), for example, azetidinylene, oxetanylene, pyrrolidinylene, imidazolidinylene, pyrazolidinylene, tetrahydrofuranylene, tetrahydropyranylene, tetrahydrothiophenylene, tetrahydrothiopyranylene, oxazolidinylene, thiazolidinylene, piperidinylene, piperazinylene, morpholinylene, thiomorpholinylene, azepanylene, azepanylene, oxazolidinylene, thiazolidinylene, piperidinylene, piperazinylene, morpholinylene, thiomorpholinylene, azepanylene, oxazolidinylene, thiazolidinylene, piperidinylene, piperazinylene, morpholin ... In some embodiments, C is substituted with 1- to 2-membered cyclohexyl, 1- to 2-membered cyclohexyl, 1- to 3-membered cyclohexyl, 1- to 4-membered cyclohexyl, 1- to 5-membered cyclohexyl, 1- to 6-membered cyclohexyl, 1- to 2-membered cyclohexyl, 1- to 3-membered cyclohexyl, 1- to 4-membered cyclohexyl, 1- to 5 ... 3-20 Examples of cycloalkylene groups include, but are not limited to, cyclopropylene, cyclobutylene, cyclopentylene, cyclopentenylene, cyclohexylene, cyclohexenylene, cycloheptylene, cyclooctylene, decahydronaphthylene, octahydropentalenylene, octahydro-1H-indenylene, 2,3-dihydro-1H-indenylene, spirocyclylene (e.g., C 5-15In some embodiments, 5- to 20-membered arylene groups include, but are not limited to, phenylene or naphthylene. In some embodiments, 5- to 20-membered heteroarylene groups are 5- to 20-membered (e.g., 5- to 15-membered, 5- to 12-membered, 5- to 9-membered, 5- to 8-membered, 5- to 7-membered, or 5- to 6-membered) heteroarylene groups containing one nitrogen atom and optionally containing a heteroatom selected from nitrogen, oxygen, and sulfur. In some embodiments, examples of 5- to 20-membered heteroarylene groups include, but are not limited to, for example, oxazolylene, isoxazolylene, oxadiazolylene, thienylene, thiazolylene, isothiazolylene, thiadiazolylene, pyrrolylene, imidazolylene, pyrazolylene, triazolylene, pyridinylene, pyrimidinylene, pyridazinylene, pyrazinylene, indolylene, isoindolylene, benzofuranylene, isobenzofuranylene, benzothienylene, indazolylene, benzimidazolylene, benzoxazolylene, benzisoxazolylene, benzothiazolylene, benzisothiazolylene, benzotriazolylene, Benzo[2,1,3]oxadiazole group, benzo[2,1,3]thiadiazolylidene, benzo[1,2,3]thiadiazolylidene, quinolinylene, isoquinolinylene, naphthyridinylene, cinnolinylene, quinazolinylene, quinoxalinylene, phthalazinylene, pyrazolo[1,5-a]pyridinylene, pyrazolo[1,5-a]pyrimidinylene, imidazo[1,2-a]pyridinylene, 1H-pyrrolo[3,2-b]pyridinylene, 1H-pyrrolo[2,3-b]pyridinylene, pyrrolo[2,1-b]thiazolylidene, or imidazo[2,1-b]thiazolylidene. Each ring A 3 Each independently optionally represented by a3 R y3 Group substitution, each R y3 Deuterium, C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), halogenated C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl groups, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), C 1-6 Alkoxy (e.g. C 1-4Alkoxy, for example methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), halo C 1-6 Alkoxy, halogen (such as fluorine, chlorine, bromine or iodine), amino, hydroxy, mercapto, cyano, carboxyl, C 2-6 Alkynyl or C 2-6 a3 represents an integer from 0 to 10, for example an integer of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10. The number of substituents is not subject to any restrictions in principle or automatically limited by the size of the building block. In some embodiments, y3 of the compound of formula (I) represents an integer of 0, 1, 2 or 3. In some embodiments, each ring A of the compound of formula (I) 3 The same or different and each independently represent the following optionally substituted groups: Each ring A 3 Independently optionally a3 R y3 Group substitution, each R y3 Deuterium, C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 alkyl Base or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), halogenated C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl groups, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), C 1-6 Alkoxy (e.g. C 1-4 Alkoxy, for example methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), halo C 1-6 Alkoxy, halogen (such as fluorine, chlorine, bromine or iodine), amino, hydroxy, mercapto, cyano, carboxyl, C 2-6 Alkynyl (e.g. C 2-4 Alkynyl, such as ethynyl, propynyl, or butynyl) or C 2-6 Alkenyl (e.g. C 2-4a3 represents an integer from 0 to 10, for example an integer of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10. The number of substituents is in principle not subject to any restrictions or automatically limited by the size of the building block. In some embodiments, the general formula of LIN of the compound of formula (I) is Non-limiting examples include, but are not limited to, the following structures: wherein the above groups are optionally selected from deuterium, C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 Alkyl groups such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), halogenated C 1-6 Alkyl (e.g. halo-C 1- 4 alkyl groups, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), C 1-6 Alkoxy (e.g. C 1-4 Alkoxy, for example methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), halo C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, carboxyl, C 2-6 Alkynyl or C 2-6 In this article, unless otherwise specified, any end of the above general formula can be connected to R w1 , and the other end is connected to R w2 . In some embodiments, R in the general formula of LIN of the compound of formula (I) w1 Indicates a key. In some embodiments, R in the general formula of LIN of the compound of formula (I) w1 represents an optionally substituted straight or branched C 1-20 Alkylene, wherein the linear or branched C 1-20Any one or more (e.g., 1-15, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3 or 1-2, or 1) methylene groups of the main carbon chain backbone of the alkylene group may be optionally replaced by one or more (e.g., 1-15, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3 or 1-2, or 1) groups selected from the group consisting of: R a 、R b and any combination thereof, each group R a independently selected from O, C(O), OC(O), S, S(O), S(O)2, S(O)2N(R a7 )、N(R a7 )S(O)2、C(O)N(R a7 )、N(R a7 )C(O), N(R a7 ) and N(R a7 )C(O)N(R a7 ), where each R a7 Each independently represents H or C 1-3 Alkyl, and when the linear or branched C 1-20 The two or more methylene groups of the main carbon chain skeleton of the alkylene group are replaced by two or more groups R a When substituted, each group R a are not directly connected to each other; and each group R b are independently selected from optionally substituted cycloalkylene (eg, optionally substituted C 3-20 cycloalkylene), optionally substituted arylene (e.g., optionally substituted C 5-20 arylene), optionally substituted heterocyclylene (e.g., optionally substituted 4- to 20-membered heterocyclylene), optionally substituted heteroarylene (e.g., optionally substituted 5- to 20-membered heteroarylene), alkynylene (e.g., C 2-6 Alkyne), alkenylene (e.g. C 2-6 and any combination thereof, wherein the cycloalkylene, the arylene, the heterocyclylene and the heteroarylene are each independently optionally selected from deuterium, hydroxyl, amino, thiol, nitro, halogen, cyano, oxo, C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), halogenated C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl groups, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), C 1-6 Alkoxy (eg C1-4 alkoxy, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), halo 1-6 Alkoxy (e.g., halo-C 1-4 Alkoxy, for example F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-), C 3-6 Cycloalkyl, halogenated C 3-6 Cycloalkyl, deuterated C 3-6 cycloalkyl, 4- to 10-membered heterocyclic group and any combination thereof, and wherein the linear or branched C 1-20 One or more hydrogen atoms of the alkylene group may be selected from deuterium, hydroxyl, amino, thiol, nitro, halogen, cyano, deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), halogenated C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl groups, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), C 1-6 Alkoxy (e.g. C 1-4 Alkoxy, for example methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), halo C 1-6 Alkoxy (e.g., halo-C 1-4 Alkoxy, for example F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-), C 3-6 Cycloalkyl, halogenated C3-6 Cycloalkyl, deuterated C 3-6 The substituents are substituted by cycloalkyl, 4- to 10-membered heterocyclyl, and any combination thereof. In some embodiments, R in the general formula of LIN of the compound of formula (I) w1 Represents the following general formula: -C 1-15 Alkylene-; -(C(R a8 )(R a9 )) n4 -(R a (C(R a10 )(R a11 )) n5 ) m3 -; -(C(R a8 )(R a9 )) n4 -(R a (C(R a10 )(R a11 )) n5 ) m3 -(R a (C(R a12 )(R a13 )) n6 ) m4 -; -(C(R a8 )(R a9 )) n4 -(R a (C(R a10 )(R a11 )) n5 ) m3 -(R a (C(R a12 )(R a13 )) n6 ) m4 -(R a (C(R a14 )(R a15 )) n7 ) m5 -; -(C(R a8 )(R a9 )) n4 -((C(R a10 )(R a11 )) n5 R a ) m3 -; -(C(R a8 )(R a9)) n4 -((C(R a10 )(R a11 )) n5 R a ) m3 -((C(R a12 )(R a13 )) n6 R a ) m4 -; -(C(R a8 )(R a9 )) n4 -((C(R a10 )(R a11 )) n5 R a ) m3 -((C(R a12 )(R a13 )) n6 R a ) m4 -((C(R a14 )(R a15 )) n7 R a ) m5 -; -(C(R a8 )(R a9 )) n4 -(R b (C(R a10 )(R a11 )) n5 ) m3 -; -(C(R a8 )(R a9 )) n4 -(R b (C(R a10 )(R a11 )) n5 ) m3 -(R b (C(R a12 )(R a13 )) n6 ) m4 -; -(C(R a8 )(R a9 )) n4 -(R b (C(R a10 )(R a11 )) n5 ) m3 -(R b (C(Ra12 )(R a13 )) n6 ) m4 -(R b (C(R a14 )(R a15 )) n7 ) m5 -; -(C(R a8 )(R a9 )) n4 -((C(R a10 )(R a11 )) n5 R b ) m3 -; -(C(R a8 )(R a9 )) n4 -((C(R a10 )(R a11 )) n5 R b ) m3 -((C(R a12 )(R a13 )) n6 R b ) m4 -; -(C(R a8 )(R a9 )) n4 -((C(R a10 )(R a11 )) n5 R b ) m3 -((C(R a12 )(R a13 )) n6 R b ) m4 -((C(R a14 )(R a15 )) n7 R b ) m5 -; -(C(R a8 )(R a9 )) n4 -(R a -R b -(C(R a10 )(R a11 )) n5 ) m3 -; -(C(R a8 )(R a9)) n4 -(R a (C(R a10 )(R a11 )) n5 ) m3 -(R b (C(R a12 )(R a13 )) n6 ) m4 -; -(C(R a8 )(R a9 )) n4 -(R b -R a -(C(R a10 )(R a11 )) a5 ) m3 -; -(C(R a8 )(R a9 )) n4 -(R b (C(R a10 )(R a11 )) n5 ) m3 -(R a (C(R a12 )(R a13 )) n6 ) m4 -; -(C(R a8 )(R a9 )) n4 -((C(R a10 )(R a11 )) n5 -R a -R b ) m3 -; -(C(R a8 )(R a9 )) n4 -((C(R a10 )(R a11 )) n5 R a ) m3 -((C(R a12 )(R a13 )) n6 R b ) m4 -; -(C(R a8 )(R a9 )) n4 -((C(Ra10 )(R a11 )) n5 -R b -R a ) m3 -;or -(C(R a8 )(R a9 )) n4 -((C(R a10 )(R a11 )) n5 R b ) m3 -((C(R a12 )(R a13 )) n6 R a ) m4 -; Among them, each group R a independently selected from O, C(O), OC(O), S, S(O), S(O)2, S(O)2N(R a7 )、N(R a7 )S(O)2、 C(O)N(R a7 )、N(R a7 )C(O), N(R a7 ) and N(R a7 )C(O)N(R a7 ), where each R a7 Each independently represents H or C 1-3 Alkyl; each group R b are independently selected from optionally substituted cycloalkylene (eg, optionally substituted C 3-20 cycloalkylene), optionally substituted arylene (e.g., optionally substituted C 5-20 arylene), optionally substituted heterocyclylene (e.g., optionally substituted 4- to 20-membered heterocyclylene), optionally substituted heteroarylene (e.g., 5- to 20-membered heteroarylene), alkynylene (e.g., C 2-6 Alkyne), alkenylene (e.g. C 2-6 and any combination thereof, wherein the cycloalkylene, the arylene, the heterocyclylene and the heteroarylene are each independently optionally selected from deuterium, hydroxyl, amino, thiol, nitro, halogen, cyano, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 3-6 Cycloalkyl, halogenated C 3-6 Cycloalkyl, deuterated C 3-6substituted by cycloalkyl, 4- to 10-membered heterocyclic group, and any combination thereof; R a8 、R a9 、R a10 、R a11、 R a12 、R a13 、R a14 and R a15 Each independently represents H, deuterium, hydroxyl, amino, thiol, nitro, Halogen, cyano, oxo, halo C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 3-6 Cycloalkyl, halogenated C 3-6 Cycloalkyl, deuterated C 3-6 Cycloalkyl, 4- to 10-membered heterocyclyl, and any combination thereof; and n4, n5, n6, n7, m3, m4, m5 are each independently selected from the integers 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10; and The C 1-15 Any one or more hydrogen atoms of the main carbon chain of the alkylene group may be optionally replaced by a substituent selected from the group consisting of deuterium, hydroxyl, amino alkyl, thiol, nitro, halogen, cyano, halo C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 3-6 Cycloalkyl, halogenated C 3-6 Cycloalkyl, deuterated C 3-6 In this document, unless otherwise specified, any end of the above general formulae may be connected to the R a6 , and the other end is connected to ring A 1 The number of carbon atoms in the above general formulas, i.e., the sum of n4+n5*m3, the sum of n4+n5*m3+n6*m4, and the sum of n4+n5*m3+n6*m4+n7*m5, are each independently an integer less than or equal to 20. In some embodiments, R in the general formula of LIN of the compound of formula (I) w1 Indicates -C 1-15 Alkylene-, wherein the C 1-15 Any one or more hydrogen atoms of the main carbon chain of the alkylene group may be optionally replaced by a substituent selected from the group consisting of deuterium, hydroxyl, amino, thiol, nitro, halogen, cyano, halogenated C 1-6 Alkyl, deuterated C1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 3-6 Cycloalkyl, halogenated C 3-6 Cycloalkyl, deuterated C 3-6 cycloalkyl, 4- to 10-membered heterocyclic group, and any combination thereof. In some embodiments, R in the general formula of LIN of the compound of formula (I) w1 Represents the following groups: -CH2-, -(CH2)2-, -(CH2)3-, -(CH2)4-, -(CH2)5-, -(CH2)6-, -(CH2)7-, -(CH2)8-, -(CH2)9-, -(CH2) 10 -、 -(CH2) 11 -、-(CH2) 12 -、-(CH2) 13 -、-(CH2) 14 -or-(CH2) 15 -; wherein any one or more hydrogen atoms of the group are optionally replaced by a substituent selected from the group consisting of deuterium, hydroxyl, amino, thiol, nitro, halogen, C, cyano, halogenated 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 3-6 Cycloalkyl, halogenated C 3-6 Cycloalkyl, deuterated C 3-6 cycloalkyl, 4- to 10-membered heterocyclic group, and any combination thereof. In some embodiments, R in the general formula of LIN of the compound of formula (I) w1 Represents the following structure: -(C(R a8 )(R a9 )) n4 -(O(C(R a10 )(R a11 )) n5 ) m3 -; -(C(R a8 )(R a9 )) n4 -(O(C(R a10 )(R a11 )) n5 ) m3 -(O(C(R a12 )(R a13 ))n6 ) m4 -; -(C(R a8 )(R a9 )) n4 -(O(C(R a10 )(R a11 )) n5 ) m3 -(O(C(R a12 )(R a13 )) n6 ) m4 -(O(C(R a14 )(R a15 )) n7 ) m5 -; -(C(R a8 )(R a9 )) n4 -((C(R a10 )(R a11 )) n5 O) m3 -; -(C(R a8 )(R a9 )) n4 -((C(R a10 )(R a11 )) n5 O) m3 -((C(R a12 )(R a13 )) n6 O) m4 -; -(C(R a8 )(R a9 )) n4 -((C(R a10 )(R a11 )) n5 O) m3 -((C(R a12 )(R a13 )) n6 O) m4 -((C(R a14 )(R a15 )) n7 O) m5 -; -(C(R a8 )(R a9 )) n4 -(N(R a7 )(C(R a10 )(R a11 )) n5 )m3 -; -(C(R a8 )(R a9 )) n4 -(N(R a7 )(C(R a10 )(R a11 )) n5 ) m3 -(N(R a7 )(C(R a12 )(R a13 )) n6 ) m4 -; -(C(R a8 )(R a9 )) n4 -(N(R a7 )(C(R a10 )(R a11 )) n5 ) m3 -(N(R a7 )(C(R a12 )(R a13 )) n6 ) m4 -(N(R a7 )(C(R a14 )(R a15 )) n7 ) m5 -; -(C(R a8 )(R a9 )) n4 -((C(R a10 )(R a11 )) n5 N(R a7 )) m3 -; -(C(R a8 )(R a9 )) n4 -((C(R a10 )(R a11 )) n5 N(R a7 )) m3 -((C(R a12 )(R a13 )) n6 N(R a7 )) m4 -; -(C(R a8 )(R a9 )) n4 -((C(R a10 )(Ra 11)) n5 N(R a7 )) m3 -((C(R a12 )(R a13 )) n6 N(R a7 )) m4 -((C(R a14 )(R a15 )) n7 N(R a7 )) m5 -; -(C(R a8 )(R a9 )) n4 -(C(O)N(R a7 )-(C(R a10 )(R a11 )) n5 ) m3 -; -(C(R a8 )(R a9 )) n4 -(C(O)N(R a7 )-(C(R a10 )(R a11 )) n5 ) m3 -(C(O)N(R a7 )-(C(R a12 )(R a13 )) n6 ) m4 -; -(C(R a8 )(R a9 )) n4 -(C(O)N(R a7 )-(C(R a10 )(R a11 )) n5 ) m3 -(C(O)N(R a7 )-(C(R a12 )(R a13 )) n6 ) m4 -(C(O)N(R a7 )- (C(R a14 )(R a15 )) n7 ) m5 -; -(C(R a8 )(R a9 ))n4 -((C(R a10 )(R a11 )) n5 -C(O)N(R a7 )) m3 -; -(C(R a8 )(R a9 )) n4 -((C(R a10 )(R a11 )) n5 -C(O)N(R a7 )) m3 -((C(R a12 )(R a13 )) n6 -C(O)N(R a7 )) m4 -; -(C(R a8 )(R a9 )) n4 -((C(R a10 )(R a11 )) n5 -C(O)N(R a7 )) m3 -((C(R a12 )(R a13 )) n6 -C(O)N(R a7 )) m4 -((C(R a14 )(R a15 )) n7 - C(O)N(R a7 )) m5 -; -(C(R a8 )(R a9 )) n4 -(C(O)N(R a7 )-(C(R a10 )(R a11 )) n5 ) m3 -(O-(C(R a12 )(R a13 )) n6 ) m4 -; -(C(R a8 )(R a9 )) n4 -C(O)N(R a7 )-(C(R a10 )(Ra11 )) n5 -(O(C(R a12 )(R a13 )) n6 ) m3 -; -(C(R a8 )(R a9 )) n4 -((C(R a10 )(R a11 )) n5 -C(O)N(R a7 )) m3 -((C(R a12 )(R a13 )) n6 O) m4 -; -(C(R a8 )(R a9 )) n4 -(C(R a10 )(R a11 )) n5 -C(O)N(R a7 )-((C(R a12 )(R a13 )) n6 O) m3 -; -(C(R a8 )(R a9 )) n4 -(N(R a7 )C(O)-(C(R a10 )(R a11 )) n5 ) m3 -; -(C(R a8 )(R a9 )) n4 -(N(R a7 )C(O)-(C(R a10 )(R a11 )) n5 ) m3 -(O-(C(R a12 )(R a13 ))) n6 ) m4 -; -(C(R a8 )(R a9 )) n4 -(N(R a7 )C(O)-(C(R a10 )(R a11 ))n5 ) m3 -(O-(C(R a12 )(R a13 )) n6 ) m4 -(O-(C(R a14 )(R a15 )) n7 ) m5 -; -(C(R a8 )(R a9 )) n4 -N(R a7 )C(O)-(C(R a10 )(R a11 )) n5 -(O(C(R a12 )(R a13 )) n6 ) m3 -; -(C(R a8 )(R a9 )) n4 -N(R a7 )C(O)N(R a7 )-(C(R a10 )(R a11 )) n5 -; -(C(R a8 )(R a9 )) n4 -((C(R a10 )(R a11 )) n5 -N(R a7 )C(O)) m3 -; -(C(R a8 )(R a9 )) n4 -((C(R a10 )(R a11 )) n5 -N(R a7 )C(O)) m3 -((C(R a12 )(R a13 ))) n6 -O) m4 -; -(C(R a8 )(R a9 )) n4 -((C(R a10 )(R a11 )) n5 -N(Ra7 )C(O)) m3 -((C(R a12 )(R a13 )) n6 O) m4 -((C(R a14 )(R a15 )) n7 O) m5 -; -(C(R a8 )(R a9 )) n4 -(C(R a10 )(R a11 )) n5 -N(R a7 )C(O)-((C(R a12 )(R a13 )) n6 O) m3 -; -(C(R a8 )(R a9 )) n4 -(arylene-(C(R a10 )(R a11 )) n5 ) m3 -; -(C(R a8 )(R a9 )) n4 -(arylene-(C(R a10 )(R a11 )) n5 ) m3 -arylene-(C(R a12 )(R a13 )) n6 -; -(C(R a8 )(R a9 )) n4 -((C(R a10 )(R a11 )) n5 -arylene) m3 -; -(C(R a8 )(R a9 )) n4 -((C(R a10 )(R a11 )) n5 -arylene) m3 -(C(R a12 )(R a13 )) n6 -arylene-; -(C(R a8 )(R a9 )) n4 -(Heterocyclylene-(C(R a10 )(R a11 )) n5 ) m3 -; -(C(R a8 )(R a9 )) n4 -(Heterocyclylene-(C(R a10 )(R a11 )) n5 ) m3 -(Heterocyclylene-(C(R a12 )(R a13 )) n6 ) m4 -; -(C(R a8 )(R a9 )) n4 -((C(R a10 )(R a11 )) n5 -heterocyclylene) m3 -; -(C(R a8 )(R a9 )) n4 -((C(R a10 )(R a11 )) n5 -heterocyclylene) m3 -((C(R a12 )(R a13 )) n6 -heterocyclylene) m4 -; -(C(R a8 )(R a9 )) n4 -(heteroarylene-(C(R a10 )(R a11 )) n5 ) m3 -; -(C(R a8 )(R a9 )) n4 -(heteroarylene-(C(R a10 )(R a11 )) n5 ) m3 -(heteroarylene-(C(R a12 )(R a13 )) n6 ) m4-; -(C(R a8 )(R a9 )) n4 -((C(R a10 )(R a11 )) n5 -heteroarylene) m3 -; -(C(R a8 )(R a9 )) n4 -((C(R a10 )(R a11 )) n5 -heteroarylene) m3 -((C(R a12 )(R a13 )) n6 -heteroarylene) m4 -; -(C(R a8 )(R a9 )) n4 -(cycloalkylene-(C(R a10 )(R a11 )) n5 ) m3 -; -(C(R a8 )(R a9 )) n4 -(cycloalkylene-(C(R a10 )(R a11 )) n5 ) m3 -(cycloalkylene-(C(R a12 )(R a13 )) n6 ) m4 -; -(C(R a8 )(R a9 )) n4 -((C(R a10 )(R a11 )) n5 -cycloalkylene) m3 -;or -(C(R a8 )(R a9 )) m4 -((C(R a10 )(R a11 )) n5 -cycloalkylene) m3 -((C(R a12 )(R a13 )) n6 -cycloalkylene)m4 -; Among them, each R a7 independently represents H or C 1-3 alkyl; The cycloalkylene group (eg C 3-20 Cycloalkylene), the arylene group (such as C 5-20 arylene), the heterocyclic group (such as 4- The heteroarylene group (e.g., a 5- to 20-membered heteroarylene group) and the heteroarylene group (e.g., a 5- to 20-membered heteroarylene group) are each independently selected from deuterium, hydroxyl, amino, thiol, nitro, halogen, cyano, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 3-6 Cycloalkyl, halogenated C 3-6 Cycloalkyl, deuterated C 3-6 substituted by cycloalkyl, 4- to 10-membered heterocyclic group, and any combination thereof; R a8 、R a9 、R a10 、R a11、 R a12 、R a13 、R a14 and R a15 Each independently represents H, deuterium, hydroxyl, amino, thiol, nitro, Halogen, cyano, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 3-6 Cycloalkyl, halogenated C 3-6 Cycloalkyl, deuterated C 3-6 Cycloalkyl, 4- to 10-membered heterocyclyl, and any combination thereof; and n4, n5, n6, n7, m3, m4, m5 are independently selected from integers 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10. The total number of carbon atoms in the alkylene group of the general formula, i.e., the sum of n4+n5*m3, the sum of n4+n5*m3+n6*m4, and the sum of n4+n5*m3+n6*m4+n7*m5, are each independently an integer less than or equal to 20. In some embodiments, the general formula of LIN of the compound of formula (I) is w1 Examples of cycloalkylene in the general structure include but are not limited to C 3-20 Cycloalkylene, C 3-15 Cycloalkylene and C3-11 Cycloalkylene, for example, cyclopropylene, cyclobutylene, cyclopentylene, cyclopentenylene, cyclohexylene, cyclohexenylene, cycloheptylene, cyclooctylene, decahydronaphthylene, octahydropentalenylene, octahydro-1H-indenylene, 2,3-dihydro-1H-indenylene, spirocyclylene (for example, C 5-15 The cycloalkylene group is optionally selected from deuterium, hydroxyl, amino, thiol, nitro, halogen, cyano, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 3-6 Cycloalkyl, halogenated C 3-6 Cycloalkyl, deuterated C 3-6 The substituents are substituted by cycloalkyl, 4- to 10-membered heterocyclic group, and any combination thereof. In some embodiments, the general formula of LIN of the compound of formula (I) is w1 Examples of arylene groups in the general structure include, but are not limited to, C 5-20 Arylene, C 6-20 Arylene, C 5-15 Arylene and C 6-15 Arylene, such as phenylene or naphthylene. Arylene is optionally selected from deuterium, hydroxyl, amino, mercapto, nitro, halogen, cyano, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 3-6 Cycloalkyl, halogenated C 3-6 Cycloalkyl, deuterated C 3-6 The substituents are substituted by cycloalkyl, 4- to 10-membered heterocyclic group, and any combination thereof. In some embodiments, the general formula of LIN of the compound of formula (I) is w1Examples of heterocyclylene groups in the general structure of include, but are not limited to, 4- to 20-membered, 4- to 15-membered, 4- to 12-membered, 4- to 11-membered, 4- to 10-membered, 4- to 9-membered, 4- to 8-membered, 4- to 7-membered, 4- to 6-membered, 5- to 15-membered, and 5- to 9-membered heterocyclylene groups, such as azetidinylene, oxetanylene, pyrrolidinylene, imidazolidinylene, pyrazolidinylene, tetrahydrofuranylene, tetrahydropyranylene, tetrahydrothiophenylene, tetrahydrothiopyranylene, oxazolidinylene, thiazolidinylene, piperidinylene, piperazinylene, morpholinylene, thiomorpholinylene, azetidinylene The heterocyclyl group may be selected from the group consisting of cycloheptyl, cycloheptanyl, dioxanyl, cycloheptanyl, cycloheptanyl, diazacyclooctanyl, 6-azabicyclo[3.1.1]heptanyl, 2,5-diazabicyclo[2.2.1]heptanyl, 3,6-diazabicyclo[3.1.1]heptanyl, 3-azabicyclo[3.2.1]octanyl, 3,8-diazabicyclo[3.2.1]octanyl, 3,8-diazabicyclo[3.2.1]octanyl, 2,5-diazabicyclo[2.2.2]octanyl and 5 to 20 membered azaspirocyclyl. The heterocyclyl group may be selected from the group consisting of deuterium, hydroxy, amino, sulfhydryl, nitro, halogen, cyano, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 3-6 Cycloalkyl, halogenated C 3-6 Cycloalkyl, deuterated C 3-6 The substituents are substituted by cycloalkyl, 4- to 10-membered heterocyclic group, and any combination thereof. In some embodiments, the general formula of LIN of the compound of formula (I) is w1Examples of heteroarylene groups in the general structure include, but are not limited to, 5- to 20-membered heteroarylene groups, 5- to 15-membered, 5- to 10-membered, 5- to 9-membered, 5- to 8-membered, 5- to 7-membered, and 5- to 6-membered heteroarylene groups, such as oxazolylene, isoxazolylene, oxadiazolylene, thienylene, thiazolylene, isothiazolylene, thiadiazolylene, pyrrolylene, imidazolylene, pyrazolylene, triazolylene, pyridinylene, pyrimidinylene, pyridazinylene, pyrazinylene, indolylene, isoindolylene, benzofuranylene, isobenzofuranylene, benzothienylene, indazolylene, benzimidazolylene, benzoxazolylene, benzisoxazolylene

[0014] The present invention also includes but is not limited to: a benzothiazolylene group, a benzoisothiazolylene group, a benzotriazole group, a benzo[2,1,3]oxadiazole group, a benzo[2,1,3]thiadiazolylene group, a benzo[1,2,3]thiadiazolylene group, a quinolinyl group, an isoquinolinyl group, a naphthyridinyl group, a cinnolinyl group, a quinazolinyl group, a quinoxalinyl group, a phthalazinyl group, a pyrazolo[1,5-a]pyridinyl group, a pyrazolo[1,5-a]pyrimidinyl group, an imidazo[1,2-a]pyridinyl group, a 1H-pyrrolo[3,2-b]pyridinyl group, a 1H-pyrrolo[2,3-b]pyridinyl group, a pyrrolo[2,1-b]thiazolylene group, or an imidazo[2,1-b]thiazolylene group. Heteroarylene is optionally selected from deuterium, hydroxy, amino, thiol, nitro, halogen, cyano, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 3-6 Cycloalkyl, halogenated C 3-6 Cycloalkyl, deuterated C 3-6 The substituents are substituted by cycloalkyl, 4- to 10-membered heterocyclic group, and any combination thereof. In some embodiments, the general formula of LIN of the compound of formula (I) is w1 Examples include, but are not limited to, the following groups: -O-CH2-, -O-(CH2)2-, -O-(CH2)3-, -O-(CH2)4-, -O-(CH2)5-, -O-(CH2)6-, -O-(CH2)7-, -O-(CH2)8-, - O-(CH2)9-、-O-(CH2)10-、-(CH2)1-O-、-(CH2)2-O-、-(CH2)3-O-、-(CH2)4-O-、-(CH2)5-O-、-(CH2)6-O-、-(CH2)7-O-、-(CH2)8-O-、-(CH2)9-O-、-( CH2)10-O-、-CH2-O-CH2-、-CH2-O-(CH2)2-、-(CH2)1-O-(CH2)3-、-(CH2)1-O-(CH2)4-、-(CH2)1-O-(CH2)5-、-(CH2)1-O-(CH2)6-、-(CH2)1-O-(CH2) 7-、-(CH2)1-O-(CH2)8-、-(CH2)1-O-(CH2)9-、-(CH2)1-O-(CH2)10-、-(CH2)2-O-(CH2)1-、-(CH2)2-O-(CH2)2-、-(CH2)2-O-(CH2)3-、-(CH2)2-O-(C H2)4-、-(CH2)2-O-(CH2)5-、-(CH2)2-O-(CH2)6-、-(CH2)2-O-(CH2)7-、-( CH2)2-O-(CH2)8-、-(CH2)2-O-(CH2)9-、-(CH2)2-O-(CH2)10-、-(CH2)3-O -(CH2)1-、-(CH2)3-O-(CH2)2-、-(CH2)3-O-(CH2)3-、-(CH2)3-O-(CH2)4- 、-(CH2)3-O-(CH2)5-、-(CH2)3-O-(CH2)6-、-(CH2)3-O-(CH2)7-、-(CH2)4 -O-(CH2)1-、-(CH2)4-O-(CH2)2-、-(CH2)4-O-(CH2)3-、-(CH2)4-O-(CH2)4-、-(CH2)4-O-(CH2)5-、-(CH2)4-O-(CH2)6-、-(CH2)5-O-(CH2)1-、-(CH2 )5-O-(CH2)2-、-(CH2)5-O-(CH2)3-、-(CH2)5-O-(CH2)4-、-(CH2)5-O-(CH2)5-、-(CH2)6-O-(CH2)1-、-(CH2)6-O-(CH2)2-、-(CH2)6-O-(CH2)3-、-(C H2)6-O-(CH2)4-、-(CH2)7-O-(CH2)1-、-(CH2)7-O-(CH2)2-、-(CH2)7-O-(CH2)3-、-(CH2)8-O-(CH2)1-、-(CH2)8-O-(CH2)2-、-CH(CH3)-O-(CH2)1-、-CH(CH3)-O-(CH2)2-、-CH(CH3)-O-(CH2)3-、-CH(CH3)-O-(CH2)4-、-CH(CH3)-O-(CH2)5-、-CH(CH3)-O-(CH2)6-、-CH(CH3)-O-(CH2)7-、-CH(CH3)-O-(CH2)8-、-CH(CH3)-O-(CH2)9-、-CH(CH3)-O-(CH2)10-、-(O(CH2)2)2-、-(O(CH2)2)3-、-(O(CH2)2)4-、-(O(CH2)2)5-、-(O(CH2)2)6-、-(O(C H2)2)7-、-CH2-(O(CH2)2)2-、-CH2-(O(CH2)2)3-、-CH2-(O(CH2)2)4-、- CH2-(O(CH2)2)5-、-CH2-(O(CH2)2)6-、-CH2-(O(CH2)2)7-、-CH2-(O(CH2) )2)1-OCH2-、-CH2-(O(CH2)2)2-OCH2-、-CH2-(O(CH2)2)3-OCH2-、-CH2-( O(CH2)2)4-OCH2-、-CH2-(O(CH2)2)5-OCH2-、-(CH2)2-(O(CH2)2)2-、-(C H2)2-(O(CH2)2)3-、-(CH2)2-(O(CH2)2)4-、-(CH2)2-(O(CH2)2)5-、-(C H2)2-(O(CH2)2)6-、-(CH2)3-(O(CH2)2)2-、-(CH2)3-(O(CH2)2)3-、-(CH 2)3-(O(CH2)2)4-、-(CH2)3-(O(CH2)2)5-、-(CH2)4-(O(CH2)2)2-、-(CH2 )4-(O(CH2)2)3-、-(CH2)4-(O(CH2)2)4-、-(CH2)4-(O(CH2)2)5-、-CH2-( O(CH2)3)2-、-CH2-(O(CH2)3)3-、-CH2-(O(CH2)3)4-、-(CH2)2-(O(CH2)3)2-、-(CH2)2-(O(CH2)3)3-、-(CH2)2-(O(CH2)3)4-、-(CH2)3-(O(CH2)3)2-、-(CH2)3-(O(CH2)3)3-、-(CH2)3-(O(CH2)3)4-、-CH2-O-(CH2)2-O-(CH2)3-、-(CH2)2-(O(CH2)2)2-(O(CH2)3)2-、-(CH2)3-O-(CH2)2-O-(CH2)3-、-(CH2)3-(O(CH2)2)2-(O(CH2)3)2-、-CH2-O-(CH2)3-O-(CH2)2-、-CH2-(O(CH2)3)2-(O(CH2)2)2-、-(CH2)2-O-(CH2)3-O-(CH2)2-、-(CH2)2-(O(CH2)3)2-(O(CH2)2)2-、-(CH2)3-O-(CH2)3-O-(CH2)2-、-(CH2)3-(O(CH2)3)2-(O(CH2)2)2-、-CH2-O-(CH2)2-O-CH2-、-(CH2)2-O-(CH2)2-O-CH2-、-(CH2)2-(O(CH2)2)2-O-(CH2)3-、-(CH2)2-(O(CH2)2)3-O-(CH2)3-、-(CH2)2-(O(CH2)2)4-O-(CH2)3-、-(CH2)5-(O(CH2)2)2-O-(CH2)5-、-(CH2)5-(O(CH2)2)2-O-(CH2)6-、-(CH2)1-N(R、 a7 )-(CH2)1-、-(CH2)1-N(R a7 )-(CH2)2-、-(CH2)1-N(R a7 )-(CH2)3-、-(CH2)1-N(R a7 )-(CH2)4-、-(CH2)1-N(R a7 )-(CH2)5-、-(CH2)1-N(R a7 )-(CH2)6-、-(CH2)1-N(R a7 )-(CH2)7-、-(CH2)1-N(R a7 )-(CH2)8-、-(CH2)1-N(R a7 )-(CH2)9-、-(CH2)1-N(R a7 )-(CH2) 10 -、-N(R a7 )-(CH2)1-、-N(R a7 )-(CH2)2-、-N(R a7 )-(CH2)3-、-N(R a7 )-(CH2)4-、-N(R a7 )-(CH2)5-、-N(R a7 )-(CH2)6-、-N(R a7 )-(CH2)7-、-N(Ra7 )-(CH2)8-、-N(R a7 )-(CH2)9-、-N(R a7 )-(CH2) 10 -、-(CH2)2-N(R a7 )-(CH2)1-、-(CH2)2-N(R a7 )-(CH2)2-、-(CH2)2-N(R a7 )-(CH2)3-、-(CH2)2-N(R a7 )-(CH2)4-、-(CH2)2-N(R a7 )-(CH2)5-、-(CH2)2-N(R a7 )-(CH2)6-、-(CH2)2-N(R a7 )-(CH2)7-、-(CH2)2-N(R a7 )-(CH2)8-、-(CH2)2-N(R a7 )-(CH2)9-、-(CH2)2-N(R a7 )-(CH2) 10 -、-(CH2)3-N(R a7 )-(CH2)1-、-(CH2)3-N(R a7 )-(CH2)2-、-(CH2)3-N(R a7 )-(CH2)3-、-(CH2)4-N(R a7 )-(CH2)1-、-(CH2)4-N(R a7 )-(CH2)2-、-(CH2)4-N(R a7 )-(CH2)3-、-(CH2)4-N(R a7 )-(CH2)4-、-(CH2)5-N(R a7 )-(CH2)1-、-(CH2)5-N(R a7 )-(CH2)2-、-(CH2)5-N(R a7 )-(CH2)3-、-(CH2)5-N(R a7 )-(CH2)4-、-(CH2)5-N(R a7 )-(CH2)5-、-(CH2)6-N(R a7 )-(CH2)1-、-(CH2)6-N(R a7 )-(CH2)2-、-(CH2)6-N(R a7 )-(CH2)3-、-(CH2)7-N(R a7 )-(CH2)1-、-(CH2)7-N(Ra7 )-(CH2)2-、-(CH2)7-N(R a7 )-(CH2)3-、-(CH2)8-N(R a7 )-(CH2)1-、-(CH2)8-N(R a7 )-(CH2)2-、-(CH2)8-N(R a7 )-(CH2)3-、-CH(CH3)-N(R a7 )-(CH2)1-、-CH(CH3)-N(R a7 )-(CH2)2-、-CH(CH3)-N(R a7 )-(CH2)3-、-CH(CH3)-N(R a7 )-(CH2)4-、-CH(CH3)-N(R a7 )-(CH2)5-、-CH(CH3)-N(R a7 )-(CH2)6-、-CH(CH3)-N(R a7 )-(CH2)7-、-CH(CH3)-N(R a7 )-(CH2)8-、-CH(CH3)-N(R a7 )-(CH2)9-、-CH(CH3)-N(R a7)-(CH2)10-, -C(O)NHCH2-, -C(O)NH(CH2)2-, -C(O)NH(CH2)3-, -C(O)NH(CH2)4-, -C(O)NH(CH2)5-, -CH2C(O)NHCH2-, -(CH2)2C(O)NH(CH2)2-, -(CH2) 2C(O)NH(CH2)3-, -(CH2)2C(O)NH(CH2)4-, -(CH2)2C(O)NH(CH2)5-, -(CH2)3C(O)NH(CH2)3-, -(CH2)3C(O)NH(CH2)4-, -(CH2)4C(O)NH(CH2)4-, -(CH2 )5C(O)NH(CH2)5-, -(CH2)6C(O)NH(CH2)7-, -(CH2)6C(O)NH(CH2)6-, -(CH2)7C(O)NH(CH2)7-, -(CH2)2C(O)NH(CH2)2-O-(CH2)2-, -NHC(O)CH2-, -NHC (O)(CH2)2-, -NHC(O)(CH2)3-, -NHC(O)(CH2)4-, -NHC(O)(CH2)5-, -CH2NHC(O)CH2-, -(CH2)2NHC(O)(CH2)2-, -(CH2)2NHC(O)(CH2)3-, -(CH2)2NHC(O )(CH2)4-, -(CH2)2NHC(O)(CH2)5-, -(CH2)3NHC(O)(CH2)3-, -(CH2)3NHC(O)(CH2)4-, -(CH2)4NHC(O)(CH2)4-, -(CH2)5NHC(O)(CH2)5-, -(CH2)6NHC( O)(CH2)7-, -(CH2)6NHC(O)(CH2)6-, -(CH2)7NHC(O)(CH2)7-, -(CH2)4NHC(O)(CH2)8-, -(CH2)2NHC(O)(CH2)2-O-(CH2)2-, -(CH2)4NHC(O)CH2-, -phenylene -CH2-, -phenylene-(CH2)2-, -phenylene-(CH2)3-, -phenylene-(CH2)4-, -phenylene-(CH2)5-, -phenylene-(CH2)6-, -phenylene-(CH2)7-, -phenylene-(CH2)8-, -CH2-phenylene-CH2-, -CH2-phenylene-(CH2)2-, -CH2-phenylene-(CH2)3-, -CH2-phenylene-(CH2)4-, -CH2-phenylene-(CH2)5-, -CH2-phenylene-(CH2)6-, -CH2-phenylene-(CH2)7-, -CH2-phenylene-(CH2)8-, -(CH2)2-phenylene-(CH2)1-,-(CH2)2-phenylene-(CH2)2-, -(CH2)2-phenylene-(CH2)3-, -(CH2)2-phenylene-(CH2)4-, -(CH2)2-phenylene-(CH2)5-, -(CH2)2-phenylene-(CH2)6-, -(CH2)2-phenylene-(CH2)7-, -(CH2)2-phenylene-(CH2)8-, -(CH2)3-phenylene-CH2-, -(CH2)3-phenylene-(CH2)2-, -(CH2)3-phenylene-(CH2)3-, -(CH2)3-phenylene-(CH2)4-, -(CH2)3-phenylene-(CH2)5-, -(CH2)3-phenylene -(CH2)6-, -(CH2)3-phenylene-(CH2)7-, -(CH2)3-phenylene-(CH2)8-, -(CH2)4-phenylene-CH2-, -(CH2)4-phenylene-(CH2)2-, -(CH2)4-phenylene-(CH2)3-, -(CH2)4-phenylene-(CH2)4-, -(CH2)4-phenylene-(CH2)5-, -(CH2)4-phenylene-(CH2)6-, -(CH2)4-phenylene-(CH2)7-, -(CH2)4-phenylene-(CH2)8-, -(CH2)5-phenylene-(CH2)1-, -(CH2)5-phenylene-(CH2)2-, - (CH2)5-phenylene-(CH2)3-, -(CH2)5-phenylene-(CH2)4-, -(CH2)5-phenylene-(CH2)5-, -(CH2)5-phenylene-(CH2)6-, -(CH2)5-phenylene-(CH2)7-, -(CH2)5-phenylene-(CH2)8-, -(CH2)6-phenylene-(CH2)1-, -(CH2)6-phenylene-(CH2)2-, -(CH2)6-phenylene-(CH2)3-, -(CH2)6-phenylene-(CH2)4-, -(CH2)6-phenylene-(CH2)5-, -(CH2)6-phenylene-(CH2)6-, -(CH2)6-phenylene-(CH2) Phenyl-(CH2)7-, -(CH2)6-phenylene-(CH2)8-, -(CH2)7-phenylene-(CH2)1-, -(CH2)7-phenylene-(CH2)2-, -(CH2)7-phenylene-(CH2)3-, -(CH2)7-phenylene-(CH2)4-, -(CH2)7-phenylene-(CH2)8-, -(CH2)8-phenylene-CH2-, -(CH2)8-phenylene-(CH2)2-, -(CH2)8-phenylene-(CH2)3-, -(CH2)8-phenylene-(CH2)4-, -(CH2)8-phenylene-(CH2)5-, -(CH2)8-phenylene-(CH2)6-,-(CH2)8-phenylene-(CH2)7-、-N(R、 a7 )-CH2-phenylene-CH2-、-N(R a7 )-CH2-phenylene-(CH2)2-, -N(R a7 )-CH2-phenylene-(CH2)3-、-N(R a7 )-CH2-phenylene-(CH2)4-、-N(R a7 )-CH2-phenylene-(CH2)5-、-N(R a7 )-CH2-phenylene-(CH2)6-、-N(R a7 )-CH2-phenylene-(CH2)7-、-N(R a7 )-CH2-phenylene-(CH2)8-, -CH2-N(R a7 )-CH2-phenylene-CH2-, -CH2-N(R a7 )-CH2-phenylene-(CH2)2-, -CH2-N(R a7 )-CH2-phenylene-(CH2)3-, -CH2-N(R a7 )-CH2-phenylene-(CH2)4-, -CH2-N(R a7 )-CH2-phenylene-(CH2)5-, -CH2-N(R a7 )-CH2-phenylene-(CH2)6-, -CH2-N(R a7 )-CH2-phenylene-(CH2)7-, -CH2-N(R a7 )-CH2-phenylene-(CH2)8-, -CH2-N(R a7 )-(CH2)2-phenylene-CH2-, -CH2-N(R a7 )-(CH2)2-phenylene-(CH2)2-, -CH2-N(R a7 )-(CH2)2-phenylene-(CH2)3-, -CH2-N(R a7 )-(CH2)2-phenylene-(CH2)4-, -CH2-N(R a7 )-(CH2)2-phenylene-(CH2)5-, -CH2-N(R a7 )-(CH2)2-phenylene-(CH2)6-, -CH2-N(R a7 )-(CH2)2-phenylene-(CH2)7-, -CH2-N(R a7 )-(CH2)2-phenylene-(CH2)8-, -(CH2)2-N(R a7 )-CH2-phenylene-CH2-, -(CH2)2-N(R a7)-CH2-phenylene-(CH2)2-, -(CH2)2-N(R a7 )-CH2-phenylene-(CH2)3-, -(CH2)2-N(R a7 )-CH2-phenylene-(CH2)4-, -(CH2)2-N(R a7 )-CH2-phenylene-(CH2)5-, -(CH2)2-N(R a7 )-CH2-phenylene-(CH2)6-, -(CH2)2-N(R a7 )-CH2-phenylene-(CH2)7-, -(CH2)2-N(R a7 )-CH2-phenylene-(CH2)8-, -(CH2)3-N(R a7 )-CH2-phenylene-CH2-, -(CH2)3-N(R a7 )-CH2-phenylene-(CH2)2-, -(CH2)3-N(R a7 )-CH2-phenylene-(CH2)3-, -(CH2)3-N(R a7 )-CH2-phenylene-(CH2)8-, -(CH2)4-N(R a7 )-CH2-phenylene-CH2-, -(CH2)4-N(R a7 )-CH2-phenylene-(CH2)2-, -(CH2)4-N(R a7 )-CH2-phenylene-(CH2)3-、-(CH2)4-N(R a7 )-CH2-phenylene-(CH2)8-, -(CH2)5-N(R a7 )-CH2-phenylene-(CH2)3-, -(CH2)5-N(R a7 )-CH2-phenylene-(CH2)8-, -(CH2)6-N(R a7 )-CH2-phenylene-(CH2)3-、-(CH2)6-N(R a7 )-CH2-phenylene-(CH2)8-, -(CH2)7-N(R a7 )-CH2-phenylene-(CH2)3-, -(CH2)8-N(R a7 )-CH2-phenylene-CH2-, -(CH2)8-N(R a7 )-CH2-phenylene-(CH2)2-, -(CH2)8-N(R a7 )-CH2-phenylene-(CH2)3-, -(CH2)8-N(R a7 )-CH2-phenylene-(CH2)4-、-(CH2)8-N(R a7)-CH2-phenylene-(CH2)5-, -(CH2)8-N(R a7)-CH2-phenylene-(CH2)6-, -piperidinylene-CH2-, -piperidinylene-(CH2)2-, -piperidinylene-(CH2)3-, -piperidinylene-(CH2)4-, -piperidinylene-(CH2)5-, -piperidinylene-(CH2)6-, -piperidinylene-(CH2)7-, -piperidinylene-(CH2)8-, -CH2-piperidinylene-CH2-, -CH2-piperidinylene-(CH2)2-, -CH2-piperidinylene-(CH2)3-, -CH2-piperidinylene-(CH2)4-, -CH2-piperidinylene-(CH2)5-, -CH2-piperidinylene-(CH2)6-, -CH2-piperidinylene-(CH2)7- , -(CH2)2-piperidinylene-(CH2)8-, -(CH2)2-piperidinylene-(CH2)1-, -(CH2)2-piperidinylene-(CH2)2-, -(CH2)2-piperidinylene-(CH2)3-, -(CH2)2-piperidinylene-(CH2)4-, -(CH2)2-piperidinylene-(CH2)5-, -(CH2)2-piperidinylene-(CH2)6-, -(CH2)2-piperidinylene-(CH2)7-, -(CH2)2-piperidinylene-(CH2)8-, -(CH2)3-piperidinylene-CH2-, -(CH2)3-piperidinylene-(CH2)2-, -(CH2)3-piperidinylene-(CH2)3-, -( -(CH2)3-piperidinylene-(CH2)4-, -(CH2)3-piperidinylene-(CH2)5-, -(CH2)3-piperidinylene-(CH2)6-, -(CH2)3-piperidinylene-(CH2)7-, -(CH2)3-piperidinylene-(CH2)8-, -(CH2)4-piperidinylene-CH2-, -(CH2)4-piperidinylene-(CH2)2-, -(CH2)4-piperidinylene-(CH2)3-, -(CH2)4-piperidinylene-(CH2)4-, -(CH2)4-piperidinylene-(CH2)5-, -(CH2)4-piperidinylene-(CH2)6-, -(CH2)4-piperidinylene-(CH2)7-, -(CH2)3-piperidinylene-(CH2)8-, -(CH2)4-piperidinylene-CH2-, -(CH2)4-piperidinylene-(CH2)2-, -(CH2)4-piperidinylene-(CH2)3-, -(CH2)4-piperidinylene-(CH2)4-, -(CH2)4-piperidinylene-(CH2)5-, -(CH2)4-piperidinylene-(CH2)6-, -(CH2)4-piperidinylene-(CH2)7-, -(CH2) -(CH2)4-piperidinylene-(CH2)8-, -(CH2)5-piperidinylene-(CH2)1-, -(CH2)5-piperidinylene-(CH2)2-, -(CH2)5-piperidinylene-(CH2)3-, -(CH2)5-piperidinylene-(CH2)4-, -(CH2)5-piperidinylene-(CH2)5-, -(CH2)5-piperidinylene-(CH2)6-, -(CH2)5-piperidinylene-(CH2)7-, -(CH2)5-piperidinylene-(CH2)8-, -(CH2)6-piperidinylene-(CH2)1-, -(CH2)6-piperidinylene-(CH2)2-, -(CH2)6-piperidinylene-(CH2)3-,-(CH2)6-piperidinylene-(CH2)4-, -(CH2)6-piperidinylene-(CH2)5-, -(CH2)6-piperidinylene-(CH2)6-, -(CH2)6-piperidinylene-(CH2)7-, -(CH2)6-piperidinylene-(CH2)8-, -(CH2)7-piperidinylene-(CH2)1-, -(CH2)7-piperidinylene-(CH2)2-, -(CH2)7-piperidinylene-(CH2)3-, -(CH2)7-piperidinylene -(CH2)4-, -(CH2)7-piperidinylene-(CH2)8-, -(CH2)8-piperidinylene-CH2-, -(CH2)8-piperidinylene-(CH2)2-, -(CH2)8-piperidinylene-(CH2)3-, -(CH2)8-piperidinylene-(CH2)4-, -(CH2)8-piperidinylene-(CH2)5-, -(CH2)8-piperidinylene-(CH2)6-, -(CH2)8-piperidinylene-(CH2)7-, -N(R, a7 )-CH2-piperidinyl-CH2-、-N(R a7 )-CH2-piperidinyl-(CH2)2-、-N(R a7 )-CH2-piperidinyl-(CH2)3-、-N(R a7 )-CH2-piperidinyl-(CH2)4-、-N(R a7 )-CH2-piperidinyl-(CH2)5-、-N(R a7 )-CH2-piperidinyl-(CH2)6-、-N(R a7 )-CH2-piperidinyl-(CH2)7-、-N(R a7 )-CH2-piperidinyl-(CH2)8-, -CH2-N(R a7 )-CH2-piperidinyl-CH2-, -CH2-N(R a7 )-CH2-piperidinyl-(CH2)2-, -CH2-N(R a7 )-CH2-piperidinyl-(CH2)3-, -CH2-N(R a7 )-CH2-piperidinyl-(CH2)4-, -CH2-N(R a7 )-CH2-piperidinyl-(CH2)5-, -CH2-N(R a7 )-CH2-piperidinyl-(CH2)6-, -CH2-N(R a7 )-CH2-piperidinyl-(CH2)7-, -CH2-N(R a7 )-CH2-piperidinyl-(CH2)8-, -CH2-N(R a7)-(CH2)2-piperidinyl-CH2-, -CH2-N(R a7 )-(CH2)2-piperidinyl-(CH2)2-, -CH2-N(R a7 )-(CH2)2-piperidinyl-(CH2)3-, -CH2-N(R a7 )-(CH2)2-piperidinyl-(CH2)4-, -CH2-N(R a7 )-(CH2)2-piperidinyl-(CH2)5-, -CH2-N(R a7 )-(CH2)2-piperidinyl-(CH2)6-, -CH2-N(R a7 )-(CH2)2-piperidinyl-(CH2)7-, -CH2-N(R a7 )-(CH2)2-piperidinyl-(CH2)8-, -(CH2)2-N(R a7 )-CH2-piperidinyl-CH2-, -(CH2)2-N(R a7 )-CH2-piperidinyl-(CH2)2-, -(CH2)2-N(R a7 )-CH2-piperidinyl-(CH2)3-, -(CH2)2-N(R a7 )-CH2-piperidinyl-(CH2)4-, -(CH2)2-N(R a7 )-CH2-piperidinyl-(CH2)5-, -(CH2)2-N(R a7 )-CH2-piperidinyl-(CH2)6-, -(CH2)2-N(R a7 )-CH2-piperidinyl-(CH2)7-, -(CH2)2-N(R a7 )-CH2-piperidinyl-(CH2)8-, -(CH2)3-N(R a7 )-CH2-piperidinyl-CH2-, -(CH2)3-N(R a7 )-CH2-piperidinyl-(CH2)2-, -(CH2)3-N(R a7 )-CH2-piperidinyl-(CH2)3-, -(CH2)3-N(R a7 )-CH2-piperidinyl-(CH2)8-, -(CH2)4-N(R a7 )-CH2-piperidinyl-CH2-, -(CH2)4-N(R a7 )-CH2-piperidinyl-(CH2)2-, -(CH2)4-N(R a7 )-CH2-piperidinyl-(CH2)3-, -(CH2)4-N(R a7)-CH2-piperidinyl-(CH2)8-, -(CH2)5-N(R a7 )-CH2-piperidinyl-(CH2)3-, -(CH2)5-N(R a7 )-CH2-piperidinyl-(CH2)8-, -(CH2)6-N(R a7 )-CH2-piperidinyl-(CH2)3-, -(CH2)6-N(R a7 )-CH2-piperidinyl-(CH2)8-, -(CH2)7-N(R a7 )-CH2-piperidinyl-(CH2)3-, -(CH2)8-N(R a7 )-CH2-piperidinyl-CH2-, -(CH2)8-N(R a7 )-CH2-piperidinyl-(CH2)2-, -(CH2)8-N(R a7 )-CH2-piperidinyl-(CH2)3-, -(CH2)8-N(R a7 )-CH2-piperidinyl-(CH2)4-、-(CH2)8-N(R a7 )-CH2-piperidinyl-(CH2)5-, -(CH2)8-N(R a7)-CH2-piperidinylene-(CH2)6-, -piperazinylene-CH2-, -piperazinylene-(CH2)2-, -piperazinylene-(CH2)3-, -piperazinylene-(CH2)4-, -piperazinylene-(CH2)5-, -piperazinylene-(CH2)6-, -piperazinylene-(CH2)7-, -piperazinylene-(CH2)8-, -CH2-piperazinylene-CH2-, -CH2-piperazinylene-(CH2)2-, -CH2-piperazinylene-(CH2)3-, -CH2-piperazinylene-(CH2)4-, -CH2-piperazinylene-(CH2)5-, -CH2-piperazinylene-(CH2)6-, -CH2-piperazinylene-(CH2)7-, -piperazinylene-(CH2)8-, -CH2-piperazinylene-CH2-, -CH2-piperazinylene-(CH2)2-, -CH2-piperazinylene-(CH2)3-, -CH2-piperazinylene-(CH2)4-, -CH2-piperazinylene-(CH2)5-, -CH2-piperazinylene-(CH2)6-, -CH2-piperazinylene-(CH2)7 -, -CH2-piperazinylene-(CH2)8-, -(CH2)2-piperazinylene-(CH2)1-, -(CH2)2-piperazinylene-(CH2)2-, -(CH2)2-piperazinylene-(CH2)3-, -(CH2)2-piperazinylene-(CH2)4-, -(CH2)2-piperazinylene-(CH2)5-, -(CH2)2-piperazinylene-(CH2)6-, -(CH2)2-piperazinylene-(CH2)7-, -(CH2)2-piperazinylene-(CH2)8-, -(CH2)3-piperazinylene-CH2-, -(CH2)3-piperazinylene-(CH2)2-, -(CH2)3-piperazinylene-(CH2)3-, -( -(CH2)3-piperazinylene-(CH2)4-, -(CH2)3-piperazinylene-(CH2)5-, -(CH2)3-piperazinylene-(CH2)6-, -(CH2)3-piperazinylene-(CH2)7-, -(CH2)3-piperazinylene-(CH2)8-, -(CH2)4-piperazinylene-CH2-, -(CH2)4-piperazinylene-(CH2)2-, -(CH2)4-piperazinylene-(CH2)3-, -(CH2)4-piperazinylene-(CH2)4-, -(CH2)4-piperazinylene-(CH2)5-, -(CH2)4-piperazinylene-(CH2)6-, -(CH2)4-piperazinylene-(CH2)7-, -(CH2)3-piperazinylene-(CH2)8-, -(CH2)4-piperazinylene-CH2-, -(CH2)4-piperazinylene-(CH2)2-, -(CH2)4-piperazinylene-(CH2)3-, -(CH2)4-piperazinylene-(CH2)4-, -(CH2)4-piperazinylene-(CH2)5-, -(CH2)4-piperazinylene-(CH2)6-, -(CH2)4-piperazinylene-(CH2)7-, -(CH2) -(CH2)4-piperazinylene-(CH2)8-, -(CH2)5-piperazinylene-(CH2)1-, -(CH2)5-piperazinylene-(CH2)2-, -(CH2)5-piperazinylene-(CH2)3-, -(CH2)5-piperazinylene-(CH2)4-, -(CH2)5-piperazinylene-(CH2)5-, -(CH2)5-piperazinylene-(CH2)6-, -(CH2)5-piperazinylene-(CH2)7-, -(CH2)5-piperazinylene-(CH2)8-, -(CH2)6-piperazinylene-(CH2)1-, -(CH2)6-piperazinylene-(CH2)2-, -(CH2)6-piperazinylene-(CH2)3-,-(CH2)6-piperazinylene-(CH2)4-, -(CH2)6-piperazinylene-(CH2)5-, -(CH2)6-piperazinylene-(CH2)6-, -(CH2)6-piperazinylene-(CH2)7-, -(CH2)6-piperazinylene-(CH2)8-, -(CH2)7-piperazinylene-(CH2)1-, -(CH2)7-piperazinylene-(CH2)2-, -(CH2)7-piperazinylene -(CH2)3-, -(CH2)7-piperazinylene-(CH2)4-, -(CH2)8-piperazinylene-CH2-, -(CH2)8-piperazinylene-(CH2)2-, -(CH2)8-piperazinylene-(CH2)3-, -(CH2)8-piperazinylene-(CH2)4-, -(CH2)8-piperazinylene-(CH2)5-, or -(CH2)8-piperazinylene-(CH2)6-; Among them, each R a7 independently represents H or C 1-3 alkyl; The phenylene, the piperazinyl and the piperidinyl are each independently selected from deuterium, hydroxyl, amino, thiol, nitro, halogen cyano, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 3-6 Cycloalkyl, halogenated C 3-6 Cycloalkyl, deuterated C 3-6 In this article, unless otherwise specified, any end of the above groups can be connected to the R a6 , and the other end is connected to ring A 1 For example, the O in the group -O-CH2- can be connected to the R a6 , and CH2 can connect A of the compound of formula (I) 1 ,vice versa. In some embodiments, when the general formula of LIN of the compound of formula (I) is w2 and R w1 When all of y1, y2 and y3 represent an integer of 0, LIN represents a bond, i.e., LIN does not exist, R of the compound of formula (I) a6 Directly connect to PBM's R c group. In some embodiments, examples of LIN of the compound of formula (I) include, but are not limited to, the following groups: C(O)、C(O)NH、NHC(O)、-CH2-、-(CH2)2-、-(CH2)3-、-(CH2)4-、-(CH2)5-、-(CH2)6-、-(CH2)7-、- (CH2)8-、-(CH2)9-、-(CH2)10-、-(CH2)11-、-(CH2) 12 -、-(CH2) 13 -、-(CH2) 14 -、-(CH2) 15 -;-O-CH2-、-O-(CH2)2-、-O-(CH2)3-、-O-(CH2)4-、-O-(CH2)5-、-O-(CH2)6-、-O-(CH2)7-、-O-(CH2)8-、-O-(CH2)9-、-O-(CH2) 10-、-(CH2)1-O-、-(CH2)2-O-、-(CH2)3-O-、-(CH2)4-O-、-(CH2)5-O-、-(CH2)6-O-、-(CH2)7-O-、-(CH2)8-O-、-(CH2)9-O-、-(CH2)10-O-、-CH2-O-CH2- 、-CH2-O-(CH2)2-、-(CH2)1-O-(CH2)3-、-(CH2)1-O-(CH2)4-、-(CH2)1-O-(CH2)5-、-(CH2)1-O-(CH2)6-、-(CH2)1-O-(CH2)7-、-(CH2)1-O-(CH2)8-、 -(CH2)2-O-(CH2)1-、-(CH2)2-O-(CH2)2-、-(CH2)2-O-(CH2)3-、-(CH2)2-O-(CH2)4-、-(CH2)2-O-(CH2)5-、-(CH2)2-O-(CH2)6-、-(CH2)2-O-(CH2)7-、-(CH2)2-O-(CH2)8-、-(CH2)3-O-(CH2)1-、-(CH2)3-O-(CH2)2-、-(CH2)3-O-(CH2)3-、-(CH2)3-O-(CH2)4-、-(CH2)3-O-(CH2)5-、-(CH2)3-O-(CH2 )6-、-(CH2)3-O-(CH2)7-、-(CH2)4-O-(CH2)1-、-(CH2)4-O-(CH2)2-、-(CH2)4-O-(CH2)3-、-(CH2)4-O-(CH2)4-、-(CH2)4-O-(CH2)5-、-(CH2)4-O-(C H2)6-、-(CH2)5-O-(CH2)1-、-(CH2)5-O-(CH2)2-、-(CH2)5-O-(CH2)3-、-( CH2)5-O-(CH2)4-、-(CH2)5-O-(CH2)5-、-(CH2)6-O-(CH2)1-、-(CH2)6-O- (CH2)2-、-(CH2)6-O-(CH2)3-、-(CH2)6-O-(CH2)4-、-(CH2)7-O-(CH2)1-、-(CH2)7-O-(CH2)2-、-(CH2)7-O-(CH2)3-、-(CH2)8-O-(CH2)1-、-(CH2)8-O-(CH2)2-、-CH(CH3)-O-(CH2)1-、-CH(CH3)-O-(CH2)2-、-CH(CH3)-O-(CH2)3-、-CH(CH3)-O-(CH2)4-、-CH(CH3)-O-(CH2)5-、-CH(CH3)-O-(CH2)6-、-CH(CH3)-O-(CH2)7-、-CH(CH3)-O-(CH2)8-、-(O(CH2)2)2-、-(O(CH2)2)3-、-(O(CH2)2)4-、-(O(CH2)2)5-、-(O(CH2)2)6-、-CH2-(O(CH2)2)2-、-CH2-(O(CH2)2)3-、-CH2-(O(CH2)2)4-、-CH2-(O(CH2)2)5-、-CH2-(O(CH2)2)6-、-CH2-(O(CH2)2)1-OCH2-、-CH2-(O(CH2)2)2-OCH2-、-CH2-(O( CH2)2)3-OCH2-、-CH2-(O(CH2)2)4-OCH2-、-CH2-(O(CH2)2)5-OCH2-、-C H2-(O(CH2)2)6-OCH2-、-(CH2)2-(O(CH2)2)2-、-(CH2)2-(O(CH2)2)3-、 -(CH2)2-(O(CH2)2)4-、-(CH2)2-(O(CH2)2)5-、-(CH2)2-(O(CH2)2)6-、 -(CH2)3-(O(CH2)2)2-、-(CH2)3-(O(CH2)2)3-、-(CH2)3-(O(CH2)2)4-、 -(CH2)3-(O(CH2)2)5-、-(CH2)4-(O(CH2)2)2-、-(CH2)4-(O(CH2)2)3-、-(CH2)4-(O(CH2)2)4-、-(CH2)4-(O(CH2)2)5-、-CH2-(O(CH2)3)2-、-CH2-(O(CH2)3)3-、-CH2-(O(CH2)3)4-、-(CH2)2-(O(CH2)3)2-、-(CH2)2-(O(CH2)3)3-、-(CH2)2-(O(CH2)3)4-、-(CH2)3-(O(CH2)3)2-、-(CH2)3-( O(CH2)3)3-、-CH2-O-(CH2)2-O-(CH2)3-、-CH2-(O(CH2)2)2-(O(CH2)3)2-、(CH2)2-O-(CH2)2-O-(CH2)3-、-(CH2)2-(O(CH2)2)2-(O(CH2)3)2-、-(CH2)3-O-(CH2)2-O-(CH2)3-、-(CH2)3-(O(CH2)2)2-(O(CH2)3)2-、-CH2-O-(CH2)3-O-(CH2)2-、-CH2-(O(CH2)3)2-(O(CH2)2)2-、(CH2)1-N(R、 a7 )-(CH2)1-、-(CH2)1-N(Ra7 )-(CH2)2-、-(CH2)1-N(R a7 )-(CH2)3-、-(CH2)1-N(R a7 )-(CH2)4-、-(CH2)1-N(R a7 )-(CH2)5-、-(CH2)1-N(R a7 )-(CH2)6-、-N(R a7 )-(CH2)1-、-N(R a7 )-(CH2)2-、-N(R a7 )-(CH2)3-、-N(R a7 )-(CH2)4-、-N(R a7 )-(CH2)5-、-N(R a7 )-(CH2)6-、-(CH2)2-N(R a7 )-(CH2)1-、-(CH2)2-N(R a7 )-(CH2)2-、-(CH2)2-N(R a7 )-(CH2)3-、-(CH2)2-N(R a7 )-(CH2)4-、-(CH2)2-N(R a7 )-(CH2)5-、-(CH2)2-N(R a7 )-(CH2)6-、-(CH2)3-N(R a7 )-(CH2)1-、-(CH2)3-N(R a7 )-(CH2)2-、-(CH2)3-N(R a7 )-(CH2)3-、-(CH2)4-N(R a7 )-(CH2)1-、-(CH2)4-N(R a7 )-(CH2)2-、-(CH2)4-N(R a7 )-(CH2)3-、-(CH2)4-N(R a7 )-(CH2)4-、-(CH2)5-N(R a7 )-(CH2)1-、-(CH2)5-N(R a7 )-(CH2)2-、-(CH2)5-N(R a7 )-(CH2)3-、-(CH2)5-N(R a7 )-(CH2)4-、-(CH2)5-N(R a7 )-(CH2)5-、-(CH2)6-N(R a7 )-(CH2)1-、-(CH2)6-N(R a7)-(CH2)2-、-(CH2)6-N(R a7 )-(CH2)3-、-(CH2)7-N(R a7 )-(CH2)1-、-(CH2)7-N(R a7 )-(CH2)2-、-(CH2)7-N(R a7 )-(CH2)3-、-(CH2)8-N(R a7 )-(CH2)1-、-(CH2)8-N(R a7 )-(CH2)2-、-(CH2)8-N(R a7 )-(CH2)3-、-CH(CH3)-N(R a7 )-(CH2)1-、-CH(CH3)-N(R a7 )-(CH2)2-、-CH(CH3)-N(R a7 )-(CH2)3-、-CH(CH3)-N(R a7 )-(CH2)4-、-CH(CH3)-N(R a7 )-(CH2)5-、-CH(CH3)-N(R a7)-(CH2)6-, -C(O)NHCH2-, -C(O)NH(CH2)2-, -C(O)NH(CH2)3-, -C(O)NH(CH2)4-, -C(O)NH(CH2)5-, -CH2C(O)NHCH2-, -(CH2)2C(O)NH(CH2)2-, -(CH2 )2C(O)NH(CH2)3-, -(CH2)2C(O)NH(CH2)4-, -(CH2)2C(O)NH(CH2)5-, -(CH2)3C(O)NH(CH2)3-, -(CH2)3C(O)NH(CH2)4-, -(CH2)4C(O)NH(CH2)4-, -(C H2)5C(O)NH(CH2)5-, -(CH2)2C(O)NH(CH2)2-O-(CH2)2-, -NHC(O)CH2-, -NHC(O)(CH2)2-, -NHC(O)(CH2)3-, -NHC(O)(CH2)4-, -NHC(O)(CH2)5-, -CH2 NHC(O)CH2-, -(CH2)2NHC(O)(CH2)2-, -(CH2)2NHC(O)(CH2)3-, -(CH2)2NHC(O)(CH2)4-, -(CH2)2NHC(O)(CH2)5-, -(CH2)3NHC(O)(CH2)3-, -(CH2)3N HC(O)(CH2)4-, -(CH2)4NHC(O)(CH2)4-, -(CH2)5NHC(O)(CH2)5-, -(CH2)2NHC(O)(CH2)2-O-(CH2)2-, -(CH2)4NHC(O)CH2-, -CH2-phenylene-CH2-, -CH2-phenylene-(CH2)2-, -CH2-phenylene-(CH2)3-, -CH2-phenylene-(CH2)4-, -CH2-phenylene-(CH2)5-, -CH2-phenylene-(CH2)6-, -(CH2)2-phenylene-(CH2)1-, -(CH2)2-phenylene-(CH2)2-, -(CH2) 2-phenylene-(CH2)3-, -(CH2)2-phenylene-(CH2)4-, -(CH2)2-phenylene-(CH2)5-, -(CH2)3-phenylene-CH2-, -(CH2)3-phenylene-(CH2)2-, -(CH2)3-phenylene-(CH2)3-, -(CH2)3-phenylene-(CH2)4-, -(CH2)3-phenylene-(CH2)5-, -(CH2)4-phenylene-CH2-, -(CH2)4-phenylene-(CH2)2-, -(CH2)4-phenylene-(CH2)3-, -(CH2)4-phenylene-(CH2)4-, -(CH2)4-phenylene-(CH2)5-,-CH2-piperidinylene-CH2-, -CH2-piperidinylene-(CH2)2-, -CH2-piperidinylene-(CH2)3-, -CH2-piperidinylene-(CH2)4-, -CH2-piperidinylene-(CH2)5-, -CH2-piperidinylene-(CH2)6-, -(CH2)2-piperidinylene-(CH2)1-, -(CH2)2-piperidinylene-(CH2)2-, -(CH2)2-piperidinylene-(CH2)3-, -(CH2)2-piperidinylene-(CH2)4-, -(CH2)2-piperidinylene-( -(CH2)5-, -(CH2)3-piperidinylene-CH2-, -(CH2)3-piperidinylene-(CH2)2-, -(CH2)3-piperidinylene-(CH2)3-, -(CH2)3-piperidinylene-(CH2)4-, -(CH2)3-piperidinylene-(CH2)5-, -CH2-piperazinylene-CH2-, -CH2-piperazinylene-(CH2)2-, -CH2-piperazinylene-(CH2)3-, -CH2-piperazinylene-(CH2)4-, -CH2-piperazinylene-(CH2)5-, -(CH2)2 -piperazinylene-(CH2)1-, -(CH2)2-piperazinylene-(CH2)2-, -(CH2)2-piperazinylene-(CH2)3-, -(CH2)2-piperazinylene-(CH2)4-, -(CH2)2-piperazinylene-(CH2)5-, -(CH2)3-piperazinylene-CH2-, -(CH2)3-piperazinylene-(CH2)2-, -(CH2)3-piperazinylene-(CH2)3-, -(CH2)3-piperazinylene-(CH2)4-, -(CH2)3-piperazinylene-(CH2)5-, -(C H2)4-piperazinylene-CH2-, -(CH2)4-piperazinylene-(CH2)2-, -(CH2)4-piperazinylene-(CH2)3-, -(CH2)4-piperazinylene-(CH2)4-, -(CH2)4-piperazinylene-(CH2)5-, -(CH2)8-piperazinylene-CH2-, -(CH2)8-piperazinylene-(CH2)2-, -(CH2)8-piperazinylene-(CH2)3-, -(CH2)8-piperazinylene-(CH2)4-, or -(CH2)8-piperazinylene-(CH2)5-; wherein the above groups are optionally selected from deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogen, amino hydroxyl, thiol, cyano, carboxyl, C 2-6 Alkynyl or C 2-6In this article, unless otherwise specified, any end of the above groups can be connected to the R a6 , and the other end is connected to the R c group. In some embodiments, examples of LIN of the compound of formula (I) include, but are not limited to, the following groups: wherein the above groups are optionally selected from deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogen, amino hydroxyl, thiol, cyano, carboxyl, C 2-6 Alkynyl or C 2-6 In this article, unless otherwise specified, any end of the above groups can be connected to the R a6 , and the other end is connected to the R c group. In some embodiments, the compound of formula (I) is also represented by the following structure of formula (I-1), formula (I-2), formula (I-3), formula (I-4), formula (I-5), formula (I-6), formula (I-7), or formula (I-8): Among them, Z, R a1 、R a2 、R a3 、R a4 、(R a5 ) m 、R a6 ,LIN,R c 、(R 1a ) p1a 、R 1b 、(R 1c ) p1b 、R 1d , Ring A, R 2a 、R 2b 、 (R 2c ) p2a 、(R 2d ) p2b 、(R 3a ) p3a 、R 3b 、X1、X2、X3、X4、R 4a 、R4b 、(R 4c ) p4a 、(R 4d ) p4b , Ring B, R 5a 、R 5b 、(R 6a ) p6a 、(R 6b ) p6b 、R x1 , Ring C, Ring D, Ring E, Ring F, R 8a 、R 8b 、(R 8c ) p8a and (R 8d ) p8b As defined above for the compounds of formula (I) and its various subembodiments. In some embodiments, provided are specific compounds of Formula (I) and their salts (including pharmaceutically acceptable salts, such as their hydrochlorides), prodrugs, solvates, isotopically enriched analogs, polymorphs, stereoisomers (including enantiomers and diastereomers), or mixtures of stereoisomers of the following Table 1: Table 1 Compounds of the present disclosure Compound of formula (II) The present disclosure provides a compound of formula (II) or its salt (including pharmaceutically acceptable salt), stereoisomer (including enantiomer), solvate, isotopically enriched analog, prodrug or polymorph: in Z represents C(O) or CH2; R a1 、R a2 、R a3 and R a4 are the same or different and each independently represent hydrogen, deuterium, halogen (such as fluorine, chlorine, bromine or iodine), C 1-6 alkyl Base (such as C 1-5 Alkyl, C 1-4 Alkyl or C 1-3alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halo-C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 Alkoxy (e.g. C 1-4 Alkoxy, for example methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), halo C 1-6 Alkoxy (e.g., halo-C 1-4 Alkoxy, such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-) or deuterated C 1-6 alkoxy; (R a5 ) m represents that the isoindoline ring connected thereto is optionally replaced by m R a5 Replace, each R a5 The same or different and each independently represents deuterium, Halogen (e.g., fluorine, chlorine, bromine or iodine), hydroxy, mercapto, nitro, amino, cyano, C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halo-C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C1-6 Alkoxy (e.g. C 1-4 Alkoxy, for example methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), halo C 1-6 Alkoxy (e.g., halo-C 1-4 Alkoxy, such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-) or deuterated C 1-6 alkoxy; m represents an integer 0, 1, 2 or 3; R E express: Among them, ring Y 1 represents a heterocyclic group containing at least 2 nitrogen atoms, (R d1 ) n1 Represents ring Y 1 Optionally n1 R d1 Group Generation, each R d1 Each independently represents deuterium, halogen, hydroxyl, mercapto, nitro, amino, cyano, oxo, C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halo-C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 Alkoxy (e.g. C 1-4 Alkoxy, for example methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy) or halogenated C 1-6 Alkoxy (e.g., halo-C 1-4an alkoxy group such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-), and n1 represents an integer from 0 to 20; and R1 represents N(R w ), where R w Represents hydrogen or C 1-3 Alkyl, and R E1 represents hydrogen; or R1 represents a bond, and R E1 represents NH2; or R E express: Among them, ring Y 3 represents a heterocyclic group containing one nitrogen atom, (R d3 ) n3 Represents ring Y 3 Optionally n3 R d3 Group substitution, Each Rd3 independently represents deuterium, halogen, hydroxyl, mercapto, nitro, amino, cyano, oxo, C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halo-C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 Alkoxy (e.g. C 1-4 Alkoxy, for example methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy) or halogenated C 1-6 Alkoxy (e.g., halo-C 1-4an alkoxy group such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-), and n3 represents an integer from 0 to 20; and where R s1 express Symbol **** indicates the ring Y 3 The connection point of R E2 represents NH2; Provided that the following compounds are not included: 3-(1-oxo-5-(piperazin-1-ylamino)isoindolin-2-yl)piperidine-2,6-dione. The compounds of formula (II) provided herein, or their salts (including pharmaceutically acceptable salts), stereoisomers (including enantiomers), solvates, isotopically enriched analogs, prodrugs, or polymorphs, have CRBN binding affinity, facilitate recruitment of substrate proteins, can act as molecular glues to bind to CRBN E3 ubiquitin ligases, and can also be applied to bifunctional protein-degrading small molecule drugs. The compounds of formula (II) disclosed herein have anti-tumor activity or excellent pharmacokinetic properties. In some embodiments, Z of the compound of formula (II) represents C(O). In some embodiments, Z of the compound of formula (II) represents CH2. In some embodiments, R of the compound of formula (II) a1 、R a2 、R a3 and R a4 are the same or different and each independently represent hydrogen, deuterium, halogen (such as fluorine, chlorine, bromine or iodine), C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), halogenated C 1-6 Alkyl (e.g. halo-C 1-4Alkyl groups, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), C 1-6 Alkoxy (e.g. C 1-4 Alkoxy, for example methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), halo C 1-6 Alkoxy (e.g., halo-C 1.4 Alkoxy, such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-) or deuterated C 1-6 Alkoxy. In some embodiments, R of the compound of formula (II) a1 、R a2 、R a3 and R a4 Represents hydrogen. In some embodiments, m of the compound of formula (II) represents the integer 0. In some embodiments, m of the compound of formula (II) represents an integer of 1, 2, or 3. In some embodiments, each R of the compound of formula (II) a5 The same or different and each independently represent a halogen (eg, fluorine, chlorine, bromine or iodine). In some embodiments, R of the compound of formula (II) E express: Among them, ring Y 1 represents a heterocyclic group containing at least 2 nitrogen atoms, (R d1 ) n1 Represents ring Y 1 Optionally n1 R d1 Group substitution, each R d1 Each independently represents deuterium, halogen, hydroxyl, mercapto, nitro, amino, cyano, oxo, C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halo-C 1-6 Alkyl (e.g. halo-C 1-4Alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 Alkoxy (e.g. C 1-4 Alkoxy, for example methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy) or halogenated C 1-6 Alkoxy (e.g., halo-C 1-4 an alkoxy group such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-), and n1 represents an integer from 0 to 20; and (i) R1 represents N(R w ), where R w Represents hydrogen or C 1-3 Alkyl, and R E1 represents hydrogen; or (ii) R1 represents a bond, and R E1 Indicates NH2. In some embodiments, R of the compound of formula (II) E Ring Y in 1

[0065] represents a 4- to 20-membered heterocyclylene group containing at least 2 nitrogen atoms. Examples of 4- to 20-membered heterocyclylene groups containing at least 2 nitrogen atoms include, but are not limited to, 4- to 20-membered heterocyclylene groups containing 2-4 nitrogen atoms. Representative examples include: diazetidinylene, imidazolidinylene, pyrazolidinylene, piperazinylene, 1,2,3,4-tetrahydropyrazinylene, hexahydropyrimidinylene, hexahydropyridazinylene, diazaheptanylene, diazaoctanylene, diazabicyclo[3.1.1]heptaneylene, diazabicyclo[2.2.1]heptaneylene, diazabicyclo[3.2.1]octanylene, diazabicyclo[2.2.2] octanylidene, diazaspiro[2.3]hexaneylidene, diazaspiro[3.3]heptaneylidene, diazaspiro[2.4]heptaneylidene, diazaspiro[3.4]octanylidene, diazaspiro[3.5]nonaneylidene, diazaspiro[4.4]nonaneylidene, diazaspiro[4.5]decaneylidene, diazaspiro[5.5]undecaneylidene, octahydropyrrolo[3,4-c]pyrroleylidene or decahydronaphthyridinylidene, or Among them, ring Y 1 Optionally n1 R d1 Group substitution, each R d1 are independently deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano Group, oxo group, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy or C 1-6 alkoxy; and n1 represents an integer from 0 to 20. In some embodiments, R of the compound of formula (II) E Ring Y in 1 Optionally n1 R d1 Group substitution, each R d1 are each independently deuterium, halogen (such as fluorine, chlorine, bromine or iodine), hydroxyl, mercapto, nitro, amino, cyano, oxo, C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halo-C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 Alkoxy (e.g. C 1-4 Alkoxy, for example methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy) or halogenated C 1-6 Alkoxy (e.g., halo-C 1-4alkoxy, for example F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-), and n1 represents an integer from 0 to 20, for example an integer of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 20. The number of substituents is in principle not subject to any restrictions or automatically limited by the size of the building block. In some embodiments, R of the compound of formula (II) E R1 in represents N(R w ), where R w Represents hydrogen or C 1-3 alkyl (e.g., methyl, ethyl, or propyl), and R E1 Represents hydrogen. In some embodiments, when R of the compound of formula (II) E R1 in represents N(R w ), where R w Represents hydrogen or C 1-3 Alkyl (such as methyl, ethyl or propyl), R E1 It may represent a protecting group for an amino group, for example, tert-butyloxycarbonyl (boc) and the like. In some embodiments, R of the compound of formula (II) E R1 in represents a bond, and R E1 In some embodiments, R E1 The NH2 represented may further have a protecting group, such as tert-butyloxycarbonyl (boc) and the like. In some embodiments, R of the compound of formula (II) E express: Among them, ring Y 3 represents a heterocyclic group containing one nitrogen atom (e.g., a 4- to 20-membered heterocyclic group containing one nitrogen atom), (R d3 ) n3 express Ring Y 3 Optionally n3 R d3 Group substitution, each R d3 Each independently represents deuterium, halogen (such as fluorine, chlorine, bromine or iodine), hydroxyl, mercapto, nitro, amino, cyano, oxo, C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), deuterated C1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), halogenated C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl groups, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), C 1-6 Alkoxy (e.g. C 1-4 Alkoxy, for example methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy) or halogenated C 1-6 Alkoxy (e.g., halo-C 1-4 an alkoxy group such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-), and n3 represents an integer from 0 to 20; and where R s1 express Symbol **** indicates the ring Y 3 connection points; and R E2 Indicates NH2. In some embodiments, R of the compound of formula (II) E Ring Y in 3represents a 4- to 20-membered heterocyclylene group containing one nitrogen atom (e.g., a 4- to 15-membered, 4- to 12-membered, 4- to 11-membered, 4- to 10-membered, 4- to 9-membered, 4- to 8-membered, 4- to 7-membered, 4- to 6-membered, 5- to 15-membered, or 5- to 9-membered heterocyclylene group). A 4- to 20-membered heterocyclylene group containing one nitrogen atom is a 4- to 20-membered (e.g., a 4- to 15-membered, 4- to 12-membered, 4- to 11-membered, 4- to 10-membered, 4- to 9-membered, 4- to 8-membered, 4- to 7-membered, 4- to 6-membered, 5- to 15-membered, or 5- to 9-membered) heterocyclylene group containing one nitrogen atom and optionally containing a heteroatom selected from oxygen and sulfur. Examples of 4- to 20-membered heterocyclylene groups containing one nitrogen atom include, but are not limited to, azetidinylene, pyrrolidinylene, piperidinylene, tetrahydropyridinylene, azepanylene, azaoctanylene, azabicyclo[3.1.1]alkaneylene, azabicyclo[2.2.1]heptaneylene, azabicyclo[3.2.1]octanylene, azabicyclo[2.2.2] ... azaspiro[2.3]hexanediyl, azaspiro[3.3]heptandiyl, azaspiro[2.4]heptandiyl, azaspiro[3.4]octandiyl, azaspiro[3.5]nonanediyl, azaspiro[4.4]nonanediyl, azaspiro[4.5]decanediyl, azaspiro[5.5]undecanediyl, octahydrocyclopenta[c]pyrrolidyl or octahydropyrrolo[3,4-c]pyrrolidyl, or The ring Y 3 Optionally n3 R d3 Group substitution, each R d3 are independently deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano Group, oxo group, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy or C 1-6 alkoxy; and n3 represents an integer from 0 to 20. In some embodiments, R of the compound of formula (II) E R in s1 Indicates S, and R E2 Indicates NH2. In some embodiments, R of the compound of formula (II) E R in s1 Represents ****-CH2-S-, or ****-CH2CH2-S-, the symbol **** indicates the ring Y 3 The connection point, and R E2 Indicates NH2. In some embodiments, in the compound of formula (II), when Z represents CH2, m represents the integer 0, R1 represents N(R w ), where R w represents hydrogen, and ring Y 1 When it represents piperazinyl, ring Y 1 By n1 R d1 Group substitution, each R d1 Each independently represents deuterium, halogen, hydroxyl, mercapto, nitro, amino, cyano, oxo, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy or C 1-6 alkoxy, and n1 represents an integer of 1-20. In some embodiments, the compound of formula (II) is also the following formula (II-1), formula (II-2), formula (II-3), or formula (II-4): in Z represents C(O) or CH2; R a1 、R a2 、R a3 and R a4 are the same or different and each independently represent hydrogen, deuterium, halogen (such as fluorine, chlorine, bromine or iodine), C 1-6 alkyl Base (such as C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halo-C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 Alkoxy (e.g. C 1-4 Alkoxy, for example methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), halo C 1-6 Alkoxy (e.g., halo-C 1-4Alkoxy, such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-) or deuterated C 1-6 alkoxy; (R a5 ) m represents that the isoindoline ring connected thereto is optionally replaced by m R a5 Replace, each R a5 The same or different and each independently represents deuterium, Halogen (e.g., fluorine, chlorine, bromine or iodine), hydroxy, mercapto, nitro, amino, cyano, C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halo-C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 Alkoxy (e.g. C 1-4 Alkoxy, for example methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), halo C 1-6 Alkoxy (e.g., halo-C 1-4 Alkoxy, such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-) or deuterated C 1-6 alkoxy; m represents an integer 0, 1, 2 or 3; R E express: Among them, ring Y 1 represents a heterocyclic group containing at least 2 nitrogen atoms, (R d1 )n1 Represents ring Y 1 Optionally n1 R d1 Group substitution, each R d1 Each independently represents deuterium, halogen, hydroxyl, mercapto, nitro, amino, cyano, oxo, C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halo-C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl groups, such as CD3, CD3CD2-, CD3CD2CD 2- etc.), C 1-6 Alkoxy (e.g. C 1-4 Alkoxy, for example methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy) or halogenated C 1-6 Alkoxy (e.g., halo-C 1-4 an alkoxy group, for example F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-), and n1 represents an integer from 0 to 20 (for example an integer of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 20. The number of substituents is in principle not subject to any restrictions or automatically limited by the size of the building block); and R1 represents N(R w ), where R w Represents hydrogen or C 1-3 Alkyl, and R E1 represents hydrogen; or R1 represents a bond, and R E1 represents NH2; or R E express: Among them, ring Y 3 represents a heterocyclic group containing one nitrogen atom, (Rd3 ) n3 Represents ring Y 3 Optionally n3 R d3 Group substitution, each R d3 Each independently represents deuterium, halogen, hydroxyl, mercapto, nitro, amino, cyano, oxo, C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halo-C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl groups, such as CD3, CD3CD 2- 、CD3CD2CD 2- etc.), C 1-6 Alkoxy (e.g. C 1-4 Alkoxy, for example methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy) or halogenated C 1-6 Alkoxy (e.g., halo-C 1-4 an alkoxy group, for example F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-), and n3 represents an integer from 0 to 20 (for example an integer of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 20. The number of substituents is in principle not subject to any restrictions or automatically limited by the size of the building block); and where R s1 express Symbol **** indicates the ring Y 3 connection points; and R E2 represents NH2; Provided that the following compounds are not included: 3-(1-oxo-5-(piperazin-1-ylamino)isoindolin-2-yl)piperidine-2,6-dione. In some embodiments, provided are specific compounds of Formula (II) and their salts (including pharmaceutically acceptable salts, such as their hydrochlorides), prodrugs, solvates, isotopically enriched analogs, polymorphs, stereoisomers (including enantiomers and diastereomers), or mixtures of stereoisomers of the following Table 2: Table 2 Compounds of the present disclosure II. Other forms of the compound (including salts, enantiomers, stereoisomers, solvates, isotopically enriched analogs, prodrug or polymorph) The compounds of the present disclosure have the structure of any one of Formula (I), (I-1), (I-2), (I-3), (I-4), (I-5), (I-6), (I-7), (I-8), (II), (II-1), (II-2), (II-3), or (II-4). Unless otherwise indicated, when referring to the compounds of the present disclosure, it refers to compounds including any one of Formula (I), (I-1), (I-2), (I-3), (I-4), (I-5), (I-6), (I-7), (I-8), (II), (II-1), (II-2), (II-3), or (II-4), as well as specific compounds falling within the scope of these general formulas. It should be recognized that the compounds of the present disclosure (including compounds of Formula (I)-7, (I-1), (I-2), (I-3), (I-4), (I-5), (I-6), (I-7), (I-8), (II)-1), (II-2), (II-3), or (II-4)) may have stereo configurations and, therefore, may exist in more than one stereoisomer form. The present disclosure also relates to optically enriched compounds having stereo configurations, such as about greater than 90% ee, such as about 95% ee or 97% ee, or greater than 99% ee, and mixtures thereof, including racemic mixtures. As used herein, "optically enriched" means that the mixture of enantiomers is composed of a significantly greater proportion of one enantiomer and can be described by enantiomeric excess (ee%). Purification of isomers and separation of isomeric mixtures can be achieved by standard techniques known in the art (e.g., column chromatography, preparative TLC, preparative HPLC, asymmetric synthesis (e.g., by using chiral intermediates) and / or chiral resolution, etc.). In some embodiments, polymorphic forms of the compounds of the present disclosure (including compounds of Formula (I)-(1), (I-2), (I-3), (I-4), (I-5), (I-6), (I-7), (I-8), (II), (II-1), (II-2), (II-3), or (II-4)) or salts of the compounds of the present disclosure are also provided. The salts of the compounds of the present disclosure may be pharmaceutically acceptable salts, including but not limited to hydrohalides (including hydrochlorides, hydrobromides), sulfates, maleates, sulfonates, citrates / citrates, lactates, lactobionates, L-tartrates, fumarates, L-malates, L-lactates, α-ketoglutarate, hippurates, D-glucuronates, D-gluconates, α-D-glucoheptonates, glycolates, mucates, L-ascorbic acid, orotates, picrates, glycinates, alanates, arginates, cinnamates, laurates, pamoates, sebacates, benzenesulfonates, methanesulfonates, ethanesulfonates, edisylate, formates, acetates, 2,2-dichloroacetates, pivalates, propionates, pentanoates, thiazolinates, thiazolinates, pyrimidines ... The compounds of the present invention may be present in the form of unsolvated or solvated pharmaceutically acceptable solvents such as water, ethanol, etc. The compounds of the present invention may be present in the form of unsolvated or solvated pharmaceutically acceptable solvents such as water, ethanol, etc. In some embodiments, the compounds of the present disclosure can be prepared as prodrugs or prodrugs. Prodrugs can be converted into parent drugs in the body and exert their effects. In some embodiments, isotope-labeled compounds of the present disclosure are also provided. Examples of isotopes include deuterium (D or 2 H). III. Pharmaceutical Compositions / Formulations In some embodiments, the present disclosure provides a pharmaceutical composition comprising as an active ingredient a compound of the present disclosure (a compound of formula (I) or a compound of formula (II)) or a pharmaceutically acceptable salt, solvate, isotopically enriched analog, polymorph, prodrug, stereoisomer (including enantiomers), or mixture of stereoisomers thereof, and at least one pharmaceutically acceptable carrier. In some embodiments, pharmaceutically acceptable carriers include, but are not limited to, fillers, stabilizers, dispersants, suspending agents, diluents, excipients, thickeners, colorants, solvents, or encapsulating materials. A carrier must be "acceptable" if it is compatible with the other ingredients of the formulation (including the compounds useful in the present disclosure) and is not harmful to the patient. Some examples of materials that are pharmaceutically acceptable carriers include: sugars, such as lactose, glucose, and sucrose; starches, such as corn starch and potato starch; cellulose and its derivatives, such as sodium carboxymethylcellulose, ethylcellulose, and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients, such as cocoa butter and suppository waxes; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and soybean oil; glycols, such as propylene glycol; polyols, such as glycerol, sorbitol, mannitol, and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffers, such as magnesium hydroxide and aluminum hydroxide; phosphate buffered saline surfactants; polyoxyethylene, polyvinyl pyrrolidone, polyacrylamide, poloxamer; and other nontoxic compatible substances used in pharmaceutical formulations. The pharmaceutical composition of the present disclosure further includes at least one second therapeutic agent, such as an anticancer agent. The second therapeutic agent can be combined with the compound of formula (I) described herein to treat the disease or condition described herein. The second therapeutic agent includes, but is not limited to, a chemotherapeutic agent, an immunotherapeutic agent, a gene therapy agent, and the like. The pharmaceutical composition of the present disclosure comprising the compound of the present disclosure (compound of formula (I) or compound of formula (II)) or a pharmaceutically acceptable salt thereof as an active ingredient can be prepared into a suitable dosage form according to a suitable administration route (including but not limited to nasal administration, inhalation administration, topical administration, oral administration, oral mucosal administration, rectal administration, pleural cavity administration, peritoneal administration, vaginal administration, intramuscular administration, subcutaneous administration, transdermal administration, epidural administration, intrathecal administration and intravenous administration), such as spray preparations, patches, tablets (e.g., conventional tablets, dispersible tablets, orally disintegrating tablets), capsules (e.g., soft capsules, hard capsules, enteric-coated capsules), dragees, lozenges, powders, granules, powder injections, suppositories, or liquid preparations (e.g., suspensions (e.g., aqueous or oily suspensions), solutions, emulsions or syrups), or conventional injection forms such as injectable solutions (e.g., sterile injection solutions prepared according to methods known in the art using water, Ringer's solution or isotonic sodium chloride solution as a carrier or solvent) or lyophilized compositions. Those skilled in the art can also prepare the compounds of the present disclosure (compounds of formula (I) or (II)) into conventional, dispersible, chewable, orally rapidly disintegrating or rapidly dissolving preparations, or sustained-release capsules or controlled-release capsules as needed. The compound of the present disclosure (compound of formula (I) or compound of formula (II)) as the active ingredient is contained in a pharmaceutically acceptable carrier or diluent in an amount sufficient to deliver to the subject a therapeutically effective amount for the indication to be treated without causing serious toxic effects in the treated subject. The dosage of the active compound for all diseases or conditions mentioned herein is, for example, from about 5 ng / kg subject weight / day to 500 mg / kg subject weight / day, from about 10 ng / kg subject weight / day to 300 mg / kg subject weight / day, for example, from 0.1 to 100 mg / kg subject weight / day, or from 0.5 to about 25 mg / kg subject weight / day. The compounds of the present invention (compounds of formula (I) or compounds of formula (II)) or pharmaceutically acceptable salts thereof can be conveniently administered in any suitable dosage form, and the specifications of suitable dosage forms include but are not limited to less than 1 mg, 1 mg to 3000 mg, 5 mg to 1000 mg, for example, 5 to 500 mg, 25 to 250 mg of active ingredient per unit dosage form. IV.Kits / Packaging Products The compound of the present disclosure (compound of formula (I) or compound of formula (II)), or its pharmaceutically acceptable salt, solvate, isotopically enriched analog, polymorph, prodrug, stereoisomer (including enantiomer), or mixture of stereoisomers, is used as a medicament. The medicament of the present disclosure or the pharmaceutical composition of the present disclosure may be present in a medicine box / packaged product. The medicine box / packaged product may include packaging or container. The packaging or container includes, but is not limited to, ampoules, blister packs, pharmaceutical plastic bottles, vials, pharmaceutical glass bottles, containers, syringes, laminated flexible packaging, co-extruded film infusion containers, test tubes, and dispensing devices, etc. The medicine box / packaged product may include product instructions for use. V. Methods and Uses The compounds of formula (I) described in the present disclosure, or pharmaceutically acceptable salts, solvates, isotopically enriched analogs, polymorphs, prodrugs, stereoisomers (including enantiomers), or mixtures of stereoisomers thereof, can be used as pharmaceutical agents. In particular, the compound of formula (I) described in the present disclosure, or a pharmaceutically acceptable salt, solvate, isotopically enriched analog, polymorph, prodrug, stereoisomer (including enantiomer), or mixture of stereoisomers thereof can be used to prepare a medicament for treating and / or preventing a disease or condition selected from the following: tumors, infectious diseases, autoinflammatory diseases, inflammatory diseases, autoimmune diseases, neurological diseases, respiratory diseases, hemorrhagic shock, transplant rejection, multiple organ dysfunction syndrome (MODS), sarcoidosis, adult respiratory distress syndrome, cardiovascular disease, Richter syndrome (RS), acute liver failure, diabetes, Kennedy disease, seborrheic alopecia, hirsutism, skin diseases, functional uterine bleeding, anemia, aplastic anemia in children, endometriosis, polycystic ovary syndrome and thyroid disease. In some embodiments, the disease or condition includes, but is not limited to, myeloma, including multiple myeloma, plasma cell myeloma, smoldering myeloma, smoldering multiple myeloma; myelofibrosis; bone marrow disease; myelodysplastic syndrome (MDS); previously treated myelodysplastic syndrome; transplant-related cancer; neutropenia; leukemia, including acute myeloid leukemia (AML), chronic myeloid leukemia (CML), chronic myeloid leukemia, acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), B-cell chronic lymphocytic leukemia, anemia associated with leukemia, acute B-cell leukemia, T-cell leukemia, acute T-lymphocytic leukemia, lymphoma cell leukemia, monocytic leukemia, myelomonocytic leukemia; lymphoma, including diffuse large B-cell lymphoma, non-Hodgkin's lymphoma, Hodgkin's lymphoma Tumor, anaplastic lymphoma, anaplastic large cell lymphoma, immunoblastic T-cell lymphoma, CD20-positive lymphoma, mantle cell lymphoma, follicular lymphoma (FL), Burkitt's lymphoma, marginal zone lymphoma (MZL), primary lymphoma, B-cell lymphoma, relapsed B-cell non-Hodgkin's lymphoma, relapsed diffuse large B-cell lymphoma, relapsed mediastinal large B-cell lymphoma, primary mediastinal large B-cell lymphoma thyroid cancer; melanoma; lung cancer, including lung adenocarcinoma, lung squamous cell carcinoma, non-small cell lung cancer, and small cell lung cancer; inflammatory myofibroblastic tumor; colorectal cancer; intestinal cancer; glioma; astrocytoblastoma; and neuroglioma.Peripheral neuroepithelial tumors; ovarian cancer; bronchogenic cancer; prostate cancer; breast cancer, including triple-negative breast cancer, incidental breast cancer, ductal carcinoma, and patients with Cowden disease; pancreatic cancer; central nervous system cancer; neuroblastoma; extramedullary plasmacytoma; plasmacytoma; gastric cancer; gastrointestinal stromal tumors; esophageal cancer; colorectal adenocarcinoma; esophageal squamous cell carcinoma; liver cancer; renal cell carcinoma; bladder cancer; endometrial cancer; uterine cancer; head and neck cancer; brain cancer; oral cancer; sarcomas, including rhabdomyosarcoma, various adipose tumors, Ewing sarcoma / primitive neuroectodermal tumors (Ewing / PNETs), and leiomyosarcoma; urothelial carcinoma; basal cell carcinoma; oral squamous cell carcinoma; bile duct cancer; bone cancer; cervical cancer; skin cancer; Richter syndrome (Richter syndrome) sepsis syndrome; autoimmune diseases, including rheumatoid arthritis, autoimmune encephalomyelitis, ankylosing spondylitis, psoriasis, psoriatic arthritis, systemic lupus erythematosus, multiple sclerosis, recurrent oral ulcers, Kawasaki disease, polymyositis / dermatomyositis, Sjögren's syndrome, atopic dermatitis, hidradenitis suppurativa, gout, type 1 diabetes, urticaria, inflammatory bowel disease (including Crohn's disease and ulcerative colitis); keratoconjunctivitis sicca; autoinflammatory diseases, including gout; inflammatory diseases, including pneumonia, osteoarthritis, synovitis, systemic inflammatory response syndrome, airway inflammation, bronchitis; cerebral malaria; infectious diseases, including viral pneumonia, AIDS (AIDS S), COVID-19 novel coronavirus infection, Gram-negative bacterial infection, Gram-positive bacterial infection, tuberculosis, etc.; septic shock; bacterial meningitis; chronic obstructive pulmonary disease; asthma; hemorrhagic shock; organ (including kidney, heart, lung) or tissue transplant rejection; diabetes; sarcoidosis; adult respiratory distress syndrome; multiple organ failure caused by cachexia and septic shock; acute liver failure; functional uterine bleeding; anemia; pediatric aplastic anemia; endometriosis; polycystic ovary syndrome; thyroid disease; cardiovascular disease (such as coronary heart disease, congestive heart failure, myocardial infarction, atherosclerosis); skin diseases (such as acne); Kennedy disease; seborrheic alopecia; and hirsutism. The method for preventing and / or treating a disease or condition in a subject comprises administering to the subject a therapeutically effective amount of a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as described herein comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient, wherein the disease or condition includes but is not limited to tumors, infectious diseases, autoinflammatory diseases, inflammatory diseases, autoimmune diseases, neurological diseases, respiratory diseases, hemorrhagic shock, transplant rejection, multiple organ dysfunction syndrome (MODS), sarcoidosis, adult respiratory distress syndrome, cardiovascular disease, Richter syndrome (RS), acute liver failure, diabetes, Kennedy disease, seborrheic alopecia, hirsutism, skin diseases, functional uterine bleeding, anemia, pediatric aplastic anemia, endometriosis, polycystic ovary syndrome and thyroid disease. In some embodiments, the disease or condition includes, but is not limited to: myeloma, including multiple myeloma, plasma cell myeloma, smoldering myeloma, smoldering multiple myeloma; myelofibrosis; bone marrow disease; myelodysplastic syndrome (MDS); previously treated myelodysplastic syndrome; transplant-related cancer; neutropenia; leukemia, including acute myeloid leukemia (AML), chronic myeloid leukemia (CML), chronic myeloid leukemia, acute lymphoblastic leukemia (AML), chronic myeloid leukemia (CML), chronic myeloid leukemia, acute lymphoblastic leukemia ( ALL), chronic lymphocytic leukemia (CLL), B-cell chronic lymphocytic leukemia, anemia associated with leukemia, acute B-cell leukemia, T-cell leukemia, acute T-cell leukemia, lymphoma cell leukemia, monocytic leukemia, myelomonocytic leukemia; lymphoma, including diffuse large B-cell lymphoma, non-Hodgkin's lymphoma, Hodgkin's lymphoma, anaplastic lymphoma, anaplastic large cell lymphoma, immunoblastic T-cell lymphoma, CD20 positive lymphoma, mantle cell lymphoma, follicular lymphoma (FL), Burkitt's lymphoma, marginal zone lymphoma (MZL), primary lymphoma, B-cell lymphoma, relapsed B-cell non-Hodgkin's lymphoma, relapsed diffuse large B-cell lymphoma, relapsed mediastinal large B-cell lymphoma, primary mediastinal large B-cell lymphoma, relapsed transformed non-Hodgkin's lymphoma, refractory B-cell non-Hodgkin's lymphoma, refractory diffuse large B-cell lymphoma, refractory primary mediastinal large B-cell lymphoma refractory transformed non-Hodgkin lymphoma; thyroid cancer; melanoma; lung cancer, including adenocarcinoma, squamous cell carcinoma, non-small cell lung cancer, and small cell lung cancer; inflammatory myofibroblastic tumor; colorectal cancer; intestinal cancer; glioma; astrocytoblastoma; glioma; peripheral neuroepithelial tumor; ovarian cancer; bronchogenic carcinoma; prostate cancer; breast cancer, including triple-negative breast cancer, incidental breast cancer, ductal carcinoma, and patients with Cowden disease; pancreatic cancer; central nervous system cancers; neuroblastoma;Extramedullary plasmacytoma; plasmacytoma; gastric cancer; gastrointestinal stromal tumor; esophageal cancer; colorectal adenocarcinoma; esophageal squamous cell carcinoma; liver cancer; renal cell carcinoma; bladder cancer; endometrial cancer; uterine cancer; head and neck cancer; brain cancer; oral cancer; sarcomas, including rhabdomyosarcoma, various adipose tumors, Ewing sarcoma / primitive neuroectodermal tumors (Ewing / PNETs), and leiomyosarcoma; urothelial carcinoma; basal cell carcinoma; oral squamous cell carcinoma; bile duct cancer; bone cancer; cervical cancer; skin cancer; Richter syndrome sepsis syndrome; autoimmune diseases, including rheumatoid arthritis, autoimmune encephalomyelitis, ankylosing spondylitis, psoriasis, psoriatic arthritis, systemic lupus erythematosus, multiple sclerosis, recurrent oral ulcers, Kawasaki disease, polymyositis / dermatomyositis, Sjögren's syndrome, atopic dermatitis, hidradenitis suppurativa, gout, type 1 diabetes, urticaria, inflammatory bowel disease (including Crohn's disease and ulcerative colitis); keratoconjunctivitis sicca; autoinflammatory diseases, including gout; inflammatory diseases, including pneumonia, osteoarthritis, synovitis, systemic inflammatory response syndrome, airway inflammation, bronchitis; cerebral malaria; infectious diseases, including viral pneumonia, AIDS (AIDS S), COVID-19 novel coronavirus infection, Gram-negative bacterial infection, Gram-positive bacterial infection, tuberculosis, etc.; septic shock; bacterial meningitis; chronic obstructive pulmonary disease; asthma; hemorrhagic shock; organ (including kidney, heart, lung) or tissue transplant rejection; diabetes; sarcoidosis; adult respiratory distress syndrome; multiple organ failure caused by cachexia and septic shock; acute liver failure; functional uterine bleeding; anemia; pediatric aplastic anemia; endometriosis; polycystic ovary syndrome; thyroid disease; cardiovascular disease (such as coronary heart disease, congestive heart failure, myocardial infarction, atherosclerosis); skin diseases (such as acne); Kennedy disease; seborrheic alopecia; and hirsutism. In the method for preventing and / or treating a disease or condition in a subject, a therapeutically effective amount of a compound of formula (I) described herein, or a pharmaceutical composition comprising a compound of formula (I) as an active ingredient described herein, is administered to the subject by at least one administration route selected from nasal administration, inhalation administration, topical administration, oral administration, oral mucosal administration, rectal administration, pleural cavity administration, peritoneal administration, intramuscular administration, subcutaneous administration, transdermal administration, epidural space administration, intrathecal administration, and intravenous administration. The compound of formula (II) described in the present disclosure, or a pharmaceutically acceptable salt, solvate, isotopically enriched analog, polymorph, prodrug, stereoisomer (including enantiomer), or mixture of stereoisomers thereof is a novel CRBN E3 ubiquitin ligase ligand that can bind to CRBN E3 ligase as a molecular glue. The compound of formula (II) described in the present disclosure, or a pharmaceutically acceptable salt, solvate, isotopically enriched analog, polymorph, prodrug, stereoisomer (including enantiomer), or mixture of stereoisomers thereof can be used to prepare a Cereblon protein (CRBN) binding agent. 3-(1-Oxo-5-(piperazin-1-ylamino)isoindolin-2-yl)piperidine-2,6-dione (GT-04304) or a salt, enantiomer, stereoisomer, solvate, isotopically enriched analog, prodrug or polymorph thereof can bind to CRBN E3 ligase and can therefore also be used to prepare Cereblon protein (CRBN) binders. The compound of formula (II) described in the present disclosure, or its pharmaceutically acceptable salt, solvate, isotopically enriched analog, polymorph, prodrug, stereoisomer (including enantiomer), or mixture of stereoisomers can be used to prepare the compound of formula (I) of the present disclosure. The compound of formula (I) described in the present disclosure can be used to treat and / or prevent diseases or conditions selected from the following: tumors, infectious diseases, autoinflammatory diseases, inflammatory diseases, autoimmune diseases, neurological diseases, respiratory diseases, hemorrhagic shock, transplant rejection, multiple organ dysfunction syndrome (MODS), sarcoidosis, adult respiratory distress syndrome, cardiovascular disease, Richter syndrome (RS), acute liver failure, diabetes, Kennedy disease, seborrheic alopecia, hirsutism, skin diseases, functional uterine bleeding, anemia, aplastic anemia in children, endometriosis, polycystic ovary syndrome and thyroid disease. The compound of formula (II) described in the present disclosure, or its pharmaceutically acceptable salt, solvate, isotopically enriched analog, polymorph, prodrug, stereoisomer (including enantiomer), or mixture of stereoisomers, can also be used as a medicament. In particular, the compound of formula (II) described in the present disclosure, or its pharmaceutically acceptable salt, solvate, isotopically enriched analog, polymorph, prodrug, stereoisomer (including enantiomer), or mixture of stereoisomers, can be used to prepare a medicament for preventing and / or treating diseases or conditions associated with the cereblon protein. Diseases or conditions associated with cereblon proteins include: tumors, cancers, and autoimmune diseases. In some embodiments, the diseases or conditions associated with cereblon proteins include, but are not limited to: myeloma, including multiple myeloma, plasma cell myeloma, smoldering myeloma, smoldering multiple myeloma; myelofibrosis; bone marrow disease; myelodysplastic syndrome (MDS); previously treated myelodysplastic syndrome; transplant-related cancers; neutropenia; leukemia, including acute myeloid leukemia (AML), chronic myeloid leukemia (CML), chronic myeloid leukemia, acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), B-cell chronic lymphocytic leukemia, Anemia associated with leukemia, acute B-cell leukemia, T-cell leukemia, acute T-cell leukemia, lymphoma cell leukemia, monocytic leukemia, myelomonocytic leukemia; lymphomas, including diffuse large B-cell lymphoma, non-Hodgkin's lymphoma, Hodgkin's lymphoma, anaplastic lymphoma, anaplastic large cell lymphoma, immunoblastic T-cell lymphoma, CD20-positive lymphoma, mantle cell lymphoma, follicular lymphoma (FL), Burkitt's lymphoma, marginal zone lymphoma (MZL), primary lymphoma, B-cell lymphoma, relapsed B-cell non-Hodgkin's lymphoma, relapsed diffuse refractory diffuse large B-cell lymphoma; refractory primary mediastinal large B-cell lymphoma; recurrent transformed non-Hodgkin's lymphoma; refractory B-cell non-Hodgkin's lymphoma; refractory diffuse large B-cell lymphoma; refractory primary mediastinal large B-cell lymphoma; refractory transformed non-Hodgkin's lymphoma; thyroid cancer; melanoma; lung cancer, including adenocarcinoma, squamous cell carcinoma, non-small cell lung cancer, and small cell lung cancer; inflammatory myofibroblastic tumor; colorectal cancer; intestinal cancer; glioma; glioblastoma; astrocytoma; ovarian cancer; bronchogenic carcinoma; prostate cancer; breast cancer, including triple-negative breast cancer, incidental breast cancer, ductal carcinoma, and ovarian cancer. Patients with Deng's disease; pa...

Claims

1. A compound of formula (I) or a salt, enantiomer, stereoisomer, solvate, isotopically enriched analog, prodrug or polymorph thereof: PBM-LIN-ULM (I) Wherein PBM represents a targeting moiety capable of binding to a protein, and PBM is covalently linked to ULM via the group LIN; ULM represents a ligand moiety capable of binding to an E3 ubiquitin ligase and represents a structure of the following formula (ULM): in Z represents C(O) or CH2; R a1 、R a2 、R a3 and R a4 The same or different and each independently represents hydrogen, deuterium, halogen, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy or halogenated C 1-6 alkoxy; (R a5 ) m represents that the isoindoline ring connected thereto is optionally replaced by m R a5 Replace, each R a5 The same or different and each independently represents deuterium, halogen, hydroxyl, mercapto, nitro, amino, cyano, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy or halogenated C 1-6 alkoxy; m represents an integer 0, 1, 2 or 3; R a6 express: Among them, ring Y 1 represents a heterocyclic group containing at least 2 nitrogen atoms, (R d1 ) n1 Represents ring Y 1 Optionally n1 R d1 Group substitution, each R d1 Each independently represents deuterium, halogen, hydroxyl, mercapto, nitro, amino, cyano, oxo, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy or C 1-6 alkoxy, and n1 represents an integer of 0-20; and R1 represents N(R w ), where R w Represents hydrogen or C 1-3 alkyl, and R2 represents a bond, or R2 represents CH2, C(O), **-NHC(O)- or **-N(CH3)C(O)-, or R2 represents a structure of the following formula: Among them, ring Y 2 represents a cycloalkylene group or a heterocyclic group containing at least one nitrogen atom, (R d2 ) n2 Represents ring Y 2 Optionally n2 R d2 Group substitution, each R d2 are independently deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano, oxo, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy or C 1-6 alkoxy, and n2 represents an integer of 0-20; or R1 represents a bond, and R2 represents N(R w ), where R w Represents hydrogen or C 1-3 Alkyl, or R2 represents **C(O)N(R w ), where R w Represents hydrogen or C 1-3 Alkyl, or R2 represents **-CH=N-; or R a6 express: where R x represents NH or **-CH=N-; or R a6 express: Among them, ring Y 3 represents a heterocyclic group containing one nitrogen atom, (R d3 ) n3 Represents ring Y 3 Optionally n3 R d3 Group substitution, each R d3 Each independently represents deuterium, halogen, hydroxyl, mercapto, nitro, amino, cyano, oxo, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy or C 1-6 alkoxy, and n3 represents an integer of 0-20; and where R s1 express Symbol **** indicates the ring Y 3 The connection point of R s2 N(R w ) or **C(O)N(R w ), where R w Represents hydrogen or C 1-3 alkyl; The symbols ** in the above formulas indicate the connection point with LIN; and LIN represents a bond or a structure of the following formula: where R w2 Connect PBM, R w1 Connect R a6 ; R w2 represents a bond, C(O), C(O)NH, or NHC(O); Each ring A 1 are the same or different and each independently represent a heterocyclylene group, a cycloalkylene group, an arylene group or a heteroarylene group, y1 represents an integer of 0, 1, 2 or 3, (R y1 ) a1 Represents each ring A 1 independently optionally be a1 R y1 Group substitution, each R y1 Deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, carboxyl, C 2-6 Alkynyl or C 2-6 alkenyl, and a1 represents an integer of 0-10; Each ring A 2 are the same or different and each independently represent a heterocyclylene group, a cycloalkylene group, an arylene group or a heteroarylene group, y2 represents an integer of 0, 1, 2 or 3, (R y2 ) a2 Represents each ring A 2 Each independently optionally represented by a2 R y2 Group substitution, each R y2 Deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, carboxyl, C 2-6 Alkynyl or C 2-6 alkenyl, and a2 represents an integer of 0-10; Each ring A 3 are the same or different and each independently represent a heterocyclylene group, a cycloalkylene group, an arylene group or a heteroarylene group, y3 represents an integer of 0, 1, 2 or 3, (R y3 ) a3 Represents each ring A 3 Independently optionally a3 R y3 Group substitution, each R y3 Deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, carboxyl, C 2-6 Alkynyl or C 2-6 alkenyl, and a3 represents an integer of 0-10; R w1 represents a bond, or represents an optionally substituted straight or branched C 1-20 Alkylene, wherein the linear or branched C 1-20 Any one or more methylene groups of the main carbon chain skeleton of the alkylene group may be optionally replaced by one or more groups selected from the following: a 、R b and any combination thereof, each group R a Each independently selected from O, C(O), OC(O), S, S(O), S(O)2, S(O)2N(R a7 )、N(R a7 )S(O)2、C(O)N(R a7 )、N(R a7 )C(O), N(R a7 ) and N(R a7 )C(O)N(R a7 ), where each R a7 Each independently represents H or C 1-3 Alkyl, and when the linear or branched C 1-20 Any two or more methylene groups of the main carbon chain skeleton of the alkylene group are replaced by two or more groups R a When substituted, each group R a Not directly connected to each other; each group R b Each is independently selected from optionally substituted cycloalkylene, optionally substituted arylene, optionally substituted heterocyclylene, optionally substituted heteroarylene, alkynylene, alkenylene, and any combination thereof.

2. A compound of formula (I) or a salt, enantiomer, stereoisomer, solvate, isotopically enriched analog, prodrug or polymorph thereof according to claim 1, wherein the PBM represents a small molecule ligand that binds to the following proteins: epidermal growth factor receptor (EGFR), cyclin-dependent kinase 4 / 6 (CDK4 / 6), breakpoint cluster region (BCR)-Abelson leukemia virus (ABL) (BCR-ABL) tyrosine kinase, androgen receptor (AR), or interleukin-1 receptor-associated kinase 1 / 2 / 3 / 4 (IRAK1 / 2 / 3 / 4).

3. The compound of formula (I) or a salt, enantiomer, stereoisomer, solvate, isotopically enriched analog, prodrug or polymorph thereof according to claim 1, wherein the PBM comprises a structure selected from the following formula: in (R 1a ) p1a Indicates that the benzene ring to which it is connected can be optionally replaced by p1a R 1a Replace, each R 1a The same or different and each independently represents deuterium, halogen, hydroxyl, NH2, NO2, cyano, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy or halogenated C 1-6 alkoxy; p1a represents an integer 0, 1, 2, 3, 4, or 5; R 1b represents a bond or optionally selected from C 1-3 Alkyl, deuterated C 1-3 Alkyl, halogenated C 1-3 Alkyl and halogen substituted C 1-2 alkylene; (R 1c ) p1b The quinazoline ring in formula (PBM-1) is optionally replaced by p1b R 1c Replace, each R 1c The same or different and each independently represents deuterium, halogen, NO2, cyano, halogenated C 1-6 Alkyl, C 1-10 Alkyl, deuterated C 1-10 Alkyl, C 1-10 Alkoxy, halogenated C 1-10 Alkoxy, -O-optionally substituted heterocyclyl, or -NHC(O)R 1e , where R 1e Indicates C 1-10 Alkyl, deuterated C 1-10 Alkyl or C 2-10 Alkenyl, such as R 1c Represents methyl, methoxy, For example p1b represents an integer 1, 2, or 3; R 1d Represents hydrogen, deuterium or C 1-3 alkyl; R in formula (PBM-2) 2a represents -NHC(O)- or -C(O)NH-; R 2b Indicates -NH-, -N(C 1-6 alkyl)- or ethynylene; Ring A in formula (PBM-2) represents a 5- to 20-membered monocyclic or bicyclic or polycyclic heteroaryl group containing 1 to 4 heteroatoms selected from N, O and S, (R 2c ) p2a Indicates that the ring A is optionally replaced by p2a R 2c Replace, and each R 2c The same or different and each independently represent an optionally substituted 5- to 15-membered heteroaryl, deuterium, halogen, hydroxyl, cyano, amino, NO2, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy or halogenated C 1-6 alkoxy; p2a represents an integer 0, 1, 2, or 3; Each (R 2d ) p2b Each independently represents that the benzene ring connected thereto is each independently optionally replaced by p2b R 2d Replace, each R 2d The same or different and each independently represents deuterium, halogen, hydroxyl, cyano, amino, NO2, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Alkyl, deuterated C 1-6 Alkyl or halogenated C 1-6 alkyl; Each p2b is the same or different and independently represents an integer of 0, 1, 2, 3 or 4; (R 3a ) p3a Indicates that the benzene ring connected to it is p3a R 3a Replace, each R 3a The same or different and each independently represents deuterium, halogen, hydroxyl, cyano, amino, NO2, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Alkyl, deuterated C 1-6 Alkyl or halogenated C 1-6 alkyl; p3a represents an integer 1, 2, 3, 4, or 5; R 3b Halogen, C 1-6 Alkyl, deuterated C 1-6 Alkyl or halogenated C 1-6 alkyl; X1 in the formula (PBM-4) represents CR 4e or fragment The symbol # represents the connection point of N adjacent to X1, the symbol ## represents the connection point with X2, and each R 4e Each independently represents deuterium, hydrogen, halogen, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, -C(O)-C 1-6 Alkyl, -C(O)-deuterated C 1-6 Alkyl or -C(O)NR 4f R 4g , where R 4f 、R 4g are the same or different and each independently represent hydrogen, C 1-6 Alkyl or deuterated C 1-6 Alkyl, and R 4f 、R 4g Not simultaneously hydrogen; X2 in formula (PBM-4) represents N or CR4 h , where R 4h Represents hydrogen, deuterium, halogen, C 1-6 Alkyl, deuterated C 1-6 Alkyl or halogenated C 1-6 alkyl; X3 and X4 each independently represent CH or N; R 4a represents a bond or an optionally substituted heteroarylene (e.g., a halogen- or deuterium-substituted heteroarylene); R 4b Represents hydrogen, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, or optionally substituted C 3-12 Cycloalkyl; (R 4c ) p4a The pyridine ring connected thereto is optionally replaced by p4a R 4c Replace, each R 4c The same or different and each independently represents deuterium, halogen, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy or halogenated C 1-6 Alkoxy, p4a represents an integer of 0, 1, 2 or 3; (R 4d ) p4b represents a nitrogen-containing bicyclic heteroaromatic ring connected thereto which is optionally replaced by p4b R 4d Replace, each R 4d The same or different and each independently represents deuterium, halogen, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy or halogenated C 1-6 Alkoxy, p4b represents an integer of 0 or 1; Ring B in formula (PBM-5) represents a 5- to 20-membered monocyclic or bicyclic or polycyclic heteroarylene group containing 1 to 4 heteroatoms selected from N, O and S; R 5b represents an optionally substituted 5- to 15-membered heteroaryl, an optionally substituted 5- to 15-membered heterocyclyl, deuterium, halogen, hydroxyl, cyano, amino, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy or halogenated C 1-6 alkoxy; R 5a Represents hydrogen, halogen, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy or halogenated C 1-6 alkoxy; R in formula (PBM-6) x1 Indicates a bond or C(O), or R x1 Represents -C(O)NH-R x2 -C(O)-***, where the symbol *** represents the c The connection point, and R x2 represents an optionally substituted C 3-15 Cycloalkyl; (R 6a ) p6a Indicates that the 1H-pyrrolo[2,3-b]pyridine ring connected thereto is optionally replaced by p6a R 6a Replace, and each R 6a Each independently represents a cyano group, a halogen group, a hydroxyl group, an amino group, a nitro group, a C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy or halogenated C 1- 6 alkoxy, and p6a represents an integer of 0, 1, 2, 3, 4 or 5; (R 6b ) p6b Indicates that the pyridine ring connected thereto is optionally replaced by p6b R 6b Replace, and each R 6b Each independently represents cyano, halogen, hydroxyl, nitro, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy or halogenated C 1-6 Alkoxy or NR 6c R 6d , where R 6c 、R 6d are the same or different and each independently represent hydrogen, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, optionally substituted C 3-15 cycloalkyl or an optionally substituted 4- to 15-membered heterocyclyl, and p6b represents an integer of 0, 1, 2 or 3; Ring C in formula (PBM-7) represents C 6-10 Aryl or 5- to 20-membered heteroaryl (e.g., a 5- to 20-membered heteroaryl group comprising 1 or 2 5- to 7-membered rings and 1-4 heteroatoms selected from N, O, and S), wherein the ring C is optionally substituted by one or more R 7a Replace, and each R 7a The same or different and each independently is deuterium, halogen, hydroxyl, cyano, amino, nitro, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkenyl, or C 2-6 Alkynyl; Ring D in formula (PBM-7) represents C 3-15 Cycloalkyl or 4- to 20-membered heterocyclyl (e.g., 4- to 20-membered heterocyclyl containing 1 to 4 heteroatoms selected from N, O, and S), wherein the ring D is optionally substituted by one or more R 7b Replace, and each R 7b The same or different and each independently is deuterium, halogen, hydroxyl, cyano, amino, nitro, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy or halogenated C 1-6 alkoxy; Ring E in formula (PBM-7) represents a 5- to 20-membered heteroaryl group (e.g., a 5- to 20-membered monocyclic or bicyclic heteroaryl group containing 1 to 4 heteroatoms selected from N, O, and S), and the ring E is optionally substituted by one or more R 7c Replace, and each R 7c The same or different and each independently is deuterium, halogen, hydroxyl, cyano, amino, nitro, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy or halogenated C 1-6 alkoxy; R in formula (PBM-8) 8a Indicates N or CH; R 8b represents NHC(O), C(O)NH, NHS(O)2 or S(O)2NH; (R 8c ) p8a Indicates R-containing 8a The six-membered ring is p8a R 8c Replace, each R 8c The same or different and each independently represents halogen, hydroxyl, mercapto, cyano, amino, nitro, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy or halogenated C 1-6 alkoxy, and p8a represents an integer of 0, 1, 2, 3 or 4; Ring F represents a 5- to 15-membered heteroarylene group, (R 8d ) p8b Indicates that the ring F connected to it is optionally replaced by p8b R 8d Replace, each R 8d The same or different and each independently represents halogen, hydroxyl, mercapto, cyano, amino, nitro, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, hydroxy substituted C 1-6 Alkyl, amino substituted C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy or optionally substituted C 3-15 cycloalkyl, and p8b represents an integer of 0, 1, 2 or 3; and R in each general formula c Each independently represents a bond, -O-, -N(R d )-, -NHC(O)-*, -C(O)NH-*, -N(R d )-R f -N(R e )-*、-R f -C(O)NH-*、-R f -NHC(O)-*、-R f -C(O)O-*、-R f -OC(O)-*, -C(O)O-*, -OC(O)-*, -R f -、-R f -N(R d )-*、-OR f -N(R d )-*、 Among them, each ring W 1 are the same or different and each independently represent a nitrogen-containing heterocyclylene group, a cycloalkylene group, an arylene group or a heteroarylene group, t1 represents an integer of 0, 1 or 2, (R c1 ) m1 Indicates each ring W 1 Each independently optionally represented by m1 R c1 Group substitution, each R c1 Deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, carboxyl, C 2-6 Alkynyl, C 2-6 Alkenyl, optionally deuterated C 3-6 Cycloalkyl or R c4 -R c3 -, where R c3 is an optional substituted C 1-6 Alkylene or optionally substituted C 2-6 Alkenylene, R c4 Represents halogen, R c5 R c6 N-, hydroxyl, carboxyl, ethynyl or vinyl, where R c5 and R c6 The same or different and each independently represents hydrogen or C 1-3 alkyl, and m1 represents an integer of 0-20; Each ring W 2 are the same or different and each independently represent a nitrogen-containing heterocyclylene group, a cycloalkylene group, an arylene group or a heteroarylene group, t2 represents an integer of 0 or 1, (R c2 ) m2 Indicates each ring W 2 Each independently optionally represented by m2 R c2 Group substitution, each R c2 Deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, carboxyl, C 2-6 Alkynyl, C 2-6 Alkenyl, optionally deuterated C 3-6 Cycloalkyl or R c8 -R c7 -, where R c7 is an optional substituted C 1-6 Alkylene or optionally substituted C 2-6 Alkenylene, R c8 Represents halogen, R c9 R c10 N-, hydroxyl, carboxyl, ethynyl or vinyl, where R c9 and R c10 The same or different and each independently represents hydrogen or C 1-3 alkyl, and m2 represents an integer of 0-20; and R d and R e Each independently represents hydrogen or C 1-6 Alkyl, R f and R g Each independently represents an optionally substituted C 1-6 Alkylene or optionally substituted C 2-6 alkenylene, and the symbol * indicates the point of attachment to LIN.

4. The compound of formula (I) or a salt, enantiomer, stereoisomer, solvate, isotopically enriched analog, prodrug or polymorph thereof according to claim 3, wherein the PBM represents a structure of the following formula: where R c As defined in claim 3.

5. The compound of formula (I) or its salt, enantiomer, stereoisomer, solvate, isotopically enriched analog, prodrug or polymorph as claimed in claim 3, wherein The R c Each independently represents a bond, -O-, -NHC(O)-*, -C(O)NH-*, -C(O)O-*, -OC(O)-*, or -NH-, or R c Each independently represents the structure of the following formula: -N(R d )-、-N(R d )-R f -N(R e )-*、-R f -C(O)NH-*、-R f -NHC(O)-*、-R f -C(O)O-*、-R f -OC(O)-*、-R f -、-R f -N(R d )-*、-O-R f -N(R d )-*、 Among them, each ring W 1 are the same or different and each independently represent a 4- to 20-membered nitrogen-containing heterocyclic group, C 3-20 Cycloalkylene, C 5-20 arylene, or 5- to 20-membered heteroarylene, t1 represents an integer of 0, 1 or 2, (R c1 ) m1 Indicates each ring W 1 Each independently optionally represented by m1 R c1 Group substitution, each R c1 Deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, carboxyl, C 2-6 Alkynyl, C 2-6 Alkenyl, optionally deuterated C 3-6 Cycloalkyl, or R c4 -R c3 -, where R c3 is an optional substituted C 1-6 Alkylene or optionally substituted C 2-6 Alkenylene, R c4 Represents halogen, R c5 R c6 N-, hydroxy, carboxyl, ethynyl, or vinyl, where R c5 and R c6 The same or different and each independently represents hydrogen or C 1-3 alkyl, and m1 represents an integer of 0-20; Each ring W 2 are the same or different and each independently represent a 4- to 20-membered nitrogen-containing heterocyclic group, C 3-20 Cycloalkylene, C 5-20 arylene, or 5- to 20-membered heteroarylene, t2 represents an integer of 0 or 1, (R c2 ) m2 Indicates each ring W 2 Each independently optionally represented by m2 R c2 Group substitution, each R c2 Deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, carboxyl, C 2-6 Alkynyl, C 2-6 Alkenyl, optionally deuterated C 3-6 Cycloalkyl, or R c8 -R c7 -, where R c7 is an optional substituted C 1-6 Alkylene or optionally substituted C 2-6 Alkenylene, R c8 Represents halogen, R c9 R c10 N-, hydroxy, carboxyl, ethynyl, or vinyl, where R c9 and R c10 The same or different and each independently represents hydrogen or C 1-3 alkyl, and m2 represents an integer of 0-20; and R d and R e Each independently represents hydrogen or C 1-6 Alkyl, R f and R g Each independently represents an optionally substituted C 1-6 Alkylene or optionally substituted C 2-6 alkenylene; The C 1-6 Alkylene and C 2-6 Each alkenylene group is independently optionally substituted with one or more radicals selected from deuterium, halogen, hydroxyl, mercapto, cyano, amino, nitro, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy or halogenated C 1-6 Substitution of the alkoxy group by a substituent; and The symbol * indicates the connection point to LIN.

6. A compound of formula (I) or a salt, enantiomer, stereoisomer, solvate, isotopically enriched analog, prodrug or polymorph thereof as claimed in any one of claims 3 to 5, wherein Each ring W 1 are the same or different and each independently represent a 4- to 15-membered nitrogen-containing heterocyclic group, C 3-15 Cycloalkylene, 6- to 15-membered arylene, or 5- to 15-membered heteroarylene, for example piperidinylene, piperazinylene, morpholinylene, azetidinylene, pyrrolidinylene, imidazolidinylene, pyrazolidinylene, oxazolidinylene, thiazolidinylene, thiomorpholinylene, azepanylene, diazepanylene, azaocinylene, diazaocinylene, azabicyclo[3.1.1]heptanylene, azabicyclo[2.2.1]heptanylene, azabicyclo[3.2.1]octanylene, azabicyclo[2.2.2]octanylene, diazabicyclo[3.1.1]heptanylene, diazabicyclo[2.2.1]heptanylene, diazabicyclo[ 3.2.1]octanylidene, diazabicyclo[2.2.2]octanylidene, 3-azaspiro[5.5]undecylidene, 8-azaspiro[4.5]decylidene, 2-oxo-8-azaspiro[4.5]decylidene, 3-methyl-2-oxo-8-azaspiro[4.5]decylidene, cyclopropylene, cyclobutylene, cyclopentylidene, cyclopentenylidene, cyclohexylidene, cyclohexenylidene, cycloheptylene, cyclooctylene, decahydronaphthylene, octahydropentalenylidene, octahydro-1H-indenylidene, 2,3-dihydro-1H-indenylidene, spirocyclylene, adamantylidene alkyl, noradamantylene, norbornylene, phenylene, naphthylene, furylene, oxazolylene, isoxazolylene, oxadiazolylene, thienylene, thiazolylene, isothiazolylene, thiadiazolylene, pyrrolylene, imidazolylene, pyrazolylene, triazolylene, pyridylene, pyrimidylene, pyridazinylene, pyrazinylene, indolylene, isoindolylene, benzofuranylene, isobenzofuranylene, benzothienylene, indazolylene, benzimidazolylene, benzoxazolylene, benzisoxazolylene, benzothiazolylene, benzisothiazolylene, benzotriazolylene, benzo [2,1,3]oxadiazole-based group, benzo[2,1,3]thiadiazolylidene, benzo[1,2,3]thiadiazolylidene, quinolinylene, isoquinolinylene, naphthyridinylene, cinnolinylene, quinazolinylene, quinoxalinylene, phthalazinylene, pyrazolo[1,5-a]pyridinylene, pyrazolo[1,5-a]pyrimidinylene, imidazo[1,2-a]pyridinylene, 1H-pyrrolo[3,2-b]pyridinylene, 1H-pyrrolo[2,3-b]pyridinylene, pyrrolo[2,1-b]thiazolylidene, or imidazo[2,1-b]thiazolylidene, or Among them, each ring W 1 Each independently optionally represented by m1 R c1 Group substitution, each R c1 Deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, carboxyl, C 2-6 Alkynyl, C 2-6 Alkenyl, optionally deuterated C 3-6 Cycloalkyl, or R c4 -R c3 -, where R c3 is an optional substituted C 1-6 Alkylene or optionally substituted C 2-6 Alkenylene, R c4 Represents halogen, R c5 R c6 N-, hydroxyl, carboxyl, ethynyl or vinyl, where R c5 and R c6 The same or different and each independently represents hydrogen or C 1-3 Alkyl, and the C 1-6 The alkylene group and the C 2-6 Each alkenylene group is independently optionally substituted with one or more radicals selected from deuterium, halogen, hydroxyl, mercapto, cyano, amino, nitro, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy or halogenated C 1-6 The alkoxy group is substituted by a substituent, and m1 represents an integer of 0-20; and / or Each ring W 2 are the same or different and each independently represent a 4- to 15-membered nitrogen-containing heterocyclic group, C 3-15 Cycloalkylene, 6- to 15-membered arylene, or 5- to 15-membered heteroarylene, for example, piperidinylene, piperazinylene, morpholinylene, azetidinylene, pyrrolidinylene, imidazolidinylene, pyrazolidinylene, oxazolidinylene, thiazolidinylene, thiomorpholinylene, azepanylene, diazepanylene, azaocinylene, diazaocinylene, azabicyclo[3.1.1]heptanylene, azabicyclo[2.2.1]heptanylene, azabicyclo[3.2.1]octanylene, azabicyclo[2.2.2]octanylene, diazabicyclo[3.1.1]heptanylene, diazabicyclo[2.2.1]heptanylene, diazabicyclo[ 3.2.1]octanylidene, diazabicyclo[2.2.2]octanylidene, 3-azaspiro[5.5]undecylidene, 8-azaspiro[4.5]decylidene, 2-oxo-8-azaspiro[4.5]decylidene, 3-methyl-2-oxo-8-azaspiro[4.5]decylidene, cyclopropylene, cyclobutylene, cyclopentylidene, cyclopentenylidene, cyclohexylidene, cyclohexenylidene, cycloheptylene, cyclooctylene, decahydronaphthylene, octahydropentalenylidene, octahydro-1H-indenylidene, 2,3-dihydro-1H-indenylidene, spirocyclylene, adamantylidene alkyl, noradamantylene, norbornylene, phenylene, naphthylene, furylene, oxazolylene, isoxazolylene, oxadiazolylene, thienylene, thiazolylene, isothiazolylene, thiadiazolylene, pyrrolylene, imidazolylene, pyrazolylene, triazolylene, pyridylene, pyrimidylene, pyridazinylene, pyrazinylene, indolylene, isoindolylene, benzofuranylene, isobenzofuranylene, benzothienylene, indazolylene, benzimidazolylene, benzoxazolylene, benzisoxazolylene, benzothiazolylene, benzisothiazolylene, benzotriazolylene, benzo [2,1,3]oxadiazole-based group, benzo[2,1,3]thiadiazolylidene, benzo[1,2,3]thiadiazolylidene, quinolinylene, isoquinolinylene, naphthyridinylene, cinnolinylene, quinazolinylene, quinoxalinylene, phthalazinylene, pyrazolo[1,5-a]pyridinylene, pyrazolo[1,5-a]pyrimidinylene, imidazo[1,2-a]pyridinylene, 1H-pyrrolo[3,2-b]pyridinylene, 1H-pyrrolo[2,3-b]pyridinylene, pyrrolo[2,1-b]thiazolylidene, or imidazo[2,1-b]thiazolylidene, or Among them, each ring W 2 Each independently optionally represented by m2 R c2 Group substitution, each R c2 Deuterium, C 1-6 Alkyl, deuterated C 1- 6-alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, carboxyl, C 2-6 Alkynyl, C 2-6 Alkenyl, optionally deuterated C 3-6 Cycloalkyl, or R c8 -R c7 -, where R c7 is an optional substituted C 1-6 Alkylene or optionally substituted C 2-6 Alkenylene, R c8 Represents halogen, R c9 R c10 N-, hydroxy, carboxyl, ethynyl, or vinyl, where R c9 and R c10 The same or different and each independently represents hydrogen or C 1-3 Alkyl, and the C 1-6 The alkylene group and the C 2-6 Each alkenylene group is independently optionally substituted with one or more deuterium, halogen, hydroxyl, mercapto, cyano, amino, nitro, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy or halogenated C 1-6 The substituent of the alkoxy group is substituted, and m2 represents an integer of 0-20.

7. A compound of formula (I) or a salt, enantiomer, stereoisomer, solvate, isotopically enriched analog, prodrug or polymorph thereof as claimed in any one of claims 3 to 5, wherein in R c In the general formulas of Represents the following groups: wherein said groups are each independently optionally further substituted with one or more selected from deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, carboxyl, C 2-6 Alkynyl, C 2-6 Alkenyl, optionally deuterated C 3-6 Cycloalkyl, R c12 -R c11 , or any combination thereof, wherein R c11 is an optional substituted C 1- 6 alkylene or optionally substituted C 2-6 Alkenylene, R c12 Represents halogen, R c13 R c14 N-, hydroxy, carboxyl, ethynyl, or vinyl, where R c13 and R c14 The same or different and each independently represents hydrogen or C 1-3 Alkyl, the C 1-6 Alkylene and C 2-6 Each alkenylene group is independently optionally substituted with one or more radicals selected from deuterium, halogen, hydroxyl, mercapto, cyano, amino, nitro, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy or halogenated C 1-6 The substituents of the alkoxy group are substituted.

8. A compound of formula (I) or a salt, enantiomer, stereoisomer, solvate, isotopically enriched analog, prodrug or polymorph thereof as claimed in any one of claims 3 to 5, wherein R c Represents the following groups: a key, -O-, -NHC(O)-*, -C(O)NH-*, -C(O)O-*, -OC(O)-*, -CH2C(O)O-*, -CH2OC(O)-*, -NH-, -N(CH3)-, -NH-CH2-*, -N(CH3)-CH2-*, -N(CH3)-(CH2)2-N(CH3)-*, -N(CH3)-(CH2)3-N(CH3)-*, -NH-(CH2)2-N(CH3)-*, -N(CH3)-(CH2)3-NH-*, -CH2-NHC(O)-*, -CH2-C(O)NH-*, -CH2-NH-*, -O-(CH2)2-N(CH3)-*, -O-(CH2)2-NH-*, or -CH2-N(CH3)-*, or wherein said groups are each independently optionally further substituted with one or more selected from deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, C 2-6 Alkynyl, C 2-6 Alkenyl, optionally deuterated C 3-6 Cycloalkyl, R c12 -R c11 -, or any combination thereof, wherein R c11 is an optional substituted C 1-6 Alkylene or optionally substituted C 2-6 Alkenylene, R c12 Represents halogen, R c13 R c14 N-, hydroxy, carboxyl, ethynyl, or vinyl, where R c13 and R c14 The same or different and each independently represents hydrogen or C 1-3 Alkyl, the C 1-6 Alkylene and C 2-6 Each alkenylene group is independently optionally substituted with one or more radicals selected from deuterium, halogen, hydroxyl, mercapto, cyano, amino, nitro, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy or halogenated C 1-6 Substituents of the alkoxy group are substituted; and the symbol * indicates the point of attachment to LIN.

9. A compound of formula (I) or a salt, enantiomer, stereoisomer, solvate, isotopically enriched analog, prodrug or polymorph thereof as described in any one of claims 1 to 5, wherein the PBM represents the structure of the following formula (PBM-1-1-1), formula (PBM-1-1-2), formula (PBM-2-1-1), formula (PBM-3-1-1), formula (PBM-4-1-1), formula (PBM-4-2-1), formula (PBM-5-2-1), formula (PBM-5-4-1), formula (PBM-6-4-1), formula (PBM-7-1-1), formula (PBM-7-4-1), formula (PBM-8-12-1), formula (PBM-8-12-2) or formula (PBM-8-13-1):

10. A compound of formula (I) or a salt, enantiomer, stereoisomer, solvate, isotopically enriched analog, prodrug or polymorph thereof according to any one of claims 1 to 9, wherein the ULM represents the structure of the following Formula (ULM-1-1), Formula (ULM-1-2), Formula (ULM-1-3) or Formula (ULM-1-4): Among them, Z, R a1 、R a2 、R a3 、R a4 、(R a5 ) m and R a6 As defined in claim 1.

11. A compound of formula (I) or a salt, enantiomer, stereoisomer, solvate, isotopically enriched analog, prodrug or polymorph thereof according to any one of claims 1 to 9, wherein the ULM represents the structure of the following Formula (ULM-2-1), Formula (ULM-2-2), Formula (ULM-2-3) or Formula (ULM-2-4): Among them, Z, (R a5 ) m and R a6 As defined in claim 1.

12. A compound of formula (I) or a salt, enantiomer, stereoisomer, solvate, isotopically enriched analog, prodrug or polymorph thereof as claimed in any one of claims 1 to 11, wherein The ring Y 1 represents a 4- to 20-membered heterocyclylene group containing at least 2 nitrogen atoms, (R d1 ) n1 Represents ring Y 1 Optionally n1 R d1 Group substitution, each R d1 are independently deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano, oxo, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy or C 1-6 alkoxy, and n1 represents an integer of 0-20; or The ring Y 2 Indicates C 3-20 Cycloalkylene or a 4- to 20-membered heterocyclylene containing at least one nitrogen atom, (R d2 ) n2 Represents ring Y 2 Optionally n2 R d2 Group substitution, each R d2 are independently deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano, oxo, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy or C 1-6 alkoxy, and n2 represents an integer of 0-20; or The ring Y 3 represents a 4- to 20-membered heterocyclic group containing one nitrogen atom, (R d3 ) n3 Represents ring Y 3 Optionally n3 R d3 Group substitution, each R d3 Each independently represents deuterium, halogen, hydroxyl, mercapto, nitro, amino, cyano, oxo, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy or C 1-6 alkoxy, and n3 represents an integer of 0-20.

13. A compound of formula (I) or a salt, enantiomer, stereoisomer, solvate, isotopically enriched analog, prodrug or polymorph thereof as claimed in any one of claims 1 to 12, wherein (i) the ring Y 1 represents a 4- to 20-membered heterocyclic group containing 2-4 nitrogen atoms; for example, the ring Y 1 express: diazetidinylidene, imidazolidinylidene, pyrazolidinylidene, piperazinylidene, 1,2,3,4-tetrahydropyrazinylidene, hexahydropyrimidinylidene, hexahydropyridazinylidene, diazaheptanylidene, diazaoctanylidene, diazabicyclo[3.1.1]heptanylidene, diazabicyclo[2.2.1]heptanylidene, diazabicyclo[3.2.1]octanylidene, diazabicyclo[2.2.2]octanylidene , diazaspiro[2.3]hexanediyl, diazaspiro[3.3]heptanylidene, diazaspiro[2.4]heptanylidene, diazaspiro[3.4]octanylidene, diazaspiro[3.5]nonanediyl, diazaspiro[4.4]nonanediyl, diazaspiro[4.5]decanediyl, diazaspiro[5.5]undecanediyl, octahydropyrrolo[3,4-c]pyrrolediyl or decahydronaphthyridinylidene, or The ring Y 1 Optionally n1 R d1 Group substitution, each R d1 are independently deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano, oxo, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy or C 1-6 alkoxy; n1 represents an integer from 0 to 20; or (ii) the ring Y 2 Indicates C 3-20 Cycloalkylene or 4- to 20-membered heterocyclic group containing 1-4 nitrogen atoms; for example, the ring Y 2 express: Cyclopropylene, cyclobutylene, cyclopentylene, cyclopentenylene, cyclohexylene, cyclohexenylene, cycloheptylene, cyclooctylene, decahydronaphthylene, octahydropentalenylene, octahydro-1H-indenylene, 2,3-dihydro-1H-indenylene, C 5-15 Spirocyclylene, C 5-15 bridged cyclic groups (e.g., adamantylene, noradamantylene, norbornylene), azetidinylene, diazetidinylene, pyrrolidinylene, imidazolidinylene, pyrazolidinylene, piperidinylene, tetrahydropyridinylene, piperazinylene, 1,2,3,4-tetrahydropyrazinylene, hexahydropyrimidinylene, hexahydropyridazinylene, azepanylene, diazepanylene, azocinylene, diazabicyclo[3.1.1]heptanediyl, azabicyclo[2.2.1]heptanediyl, azabicyclo[3.2.1]octandiyl, azabicyclo[2.2.2]octandiyl, diazabicyclo[3.1.1]heptanediyl, diazabicyclo[2.2.1]heptanediyl, diazabicyclo[3.2.1]octandiyl, diazabicyclo[2.

2. 2] octanyl group, azaspiro[2.3]hexanyl group, azaspiro[3.3]heptanyl group, azaspiro[2.4]heptanyl group, azaspiro[3.4]octanyl group, azaspiro[3.5]nonanyl group, azaspiro[4.4]nonanyl group, azaspiro[4.5]decanyl group, azaspiro[5.5]undecanyl group, diazaspiro[2.3]hexanyl group, diazaspiro[3 .3]heptanediylene, diazaspiro[2.4]heptanediylene, diazaspiro[3.4]octanylidene, diazaspiro[3.5]nonanediylene, diazaspiro[4.4]nonanediylene, diazaspiro[4.5]decanediylene, diazaspiro[5.5]undecanediylene, octahydrocyclopenta[c]pyrrolylene, octahydropyrrolo[3,4-c]pyrrolylene or decahydronaphthyridinylidene, or The ring Y 2 Optionally n2 R d2 Group substitution, each R d2 are independently deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano, oxo, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy or C 1-6 alkoxy; and n2 represents an integer from 0 to 20; or (iii) the ring Y 3 represents a 4- to 20-membered heterocyclic group containing 1 nitrogen atom; for example, the ring Y 3 express: an azetidinylene, a pyrrolidinylene, a piperidinylene, a tetrahydropyridinylene, an azepanylene, an azacyclooctanylene, an azabicyclo[3.1.1]alkylene, an azabicyclo[2.2.1]heptanylene, an azabicyclo[3.2.1]octanylene, an azabicyclo[2.2.2]octanylene, an azaspiro[2.3]hexanylene, an azaspiro[3.3]heptanylene, an azaspiro[2.4]heptanylene, an azaspiro[3.4]octanylene, an azaspiro[3.5]nonanylene, an azaspiro[4.4]nonanylene, an azaspiro[4.5]decanylene, an azaspiro[5.5]undecanylene, an octahydrocyclopenta[c]pyrrolylene, or an octahydropyrrolo[3,4-c]pyrrolylene, or The ring Y 3 Optionally n3 R d3 Group substitution, each R d3 are independently deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano, oxo, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy or C 1-6 alkoxy; and n3 represents an integer from 0 to 20.

14. A compound of formula (I) or a salt, enantiomer, stereoisomer, solvate, isotopically enriched analog, prodrug or polymorph thereof as claimed in any one of claims 1 to 13, wherein (i) Each ring A 1 are the same or different and each independently represent a 4- to 20-membered heterocyclylene group, C 3-20 Cycloalkylene, C 5-20 Arylene, or 5- to 20-membered heteroarylene, for example, each ring A 1 Each independently represents: Azetidinyl, diazetidinyl, oxetanyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, oxazolidinyl, thiazolidinyl, piperidinyl, tetrahydropyridinyl, piperazinyl, 1,2,3,4-tetrahydropyrazinyl, hexahydropyrimidinyl, hexahydropyridazinyl, morpholinyl, thio ... Azabicyclo[3.1.1]heptanylene, azabicyclo[3.1.1]heptanylene, azabicyclo[2.2.1]heptanylene, azabicyclo[3.2.1]octanylene, azabicyclo[3.2.1]hep ... octanylidene), azabicyclo[2.2.2]octanylidene, diazabicyclo[3.1.1]heptaneylidene (e.g., 3,6-diazabicyclo[3.1.1]heptaneylidene), diazabicyclo[2.2.1]heptaneylidene (e.g., 2,5-diazabicyclo[2.2.1]heptaneylidene), diazabicyclo[3.2.1]octanylidene (e.g., 3,8-diazabicyclo[3.2.1]octanylidene), alkylidene), diazabicyclo[2.2.2]octanidene (e.g., 2,5-diazabicyclo[2.2.2]octanidene), 5- to 20-membered azaspirocyclyl, cyclopropylene, cyclobutylidene, cyclopentylidene, cyclopentenylidene, cyclohexylidene, cyclohexenylidene, cycloheptylidene, cyclooctylidene, decahydronaphthylidene, octahydropentalenylidene, octahydro-1H-indenylidene, 2,3-dihydro-1H-indenylidene, C 5-15 spirocyclylene, adamantylene, noradamantylene, norbornylene, phenylene, naphthylene, furylene, oxazolylene, isoxazolylene, oxadiazolylene, thienylene, thiazolylene, isothiazolylene, thiadiazolylene, pyrrolylene, imidazolylene, pyrazolylene, triazolylene, pyridylene, pyrimidylene, pyridazinylene, pyrazinylene, indolylene, isoindolylene, benzofuranylene, isobenzofuranylene, benzothienylene, indazolylene, benzimidazolylene, benzoxazolylene, benzisoxazolylene, benzothiazolylene, benzisothiazolylene, benzotriazolylene 1H-pyrrolo[3,2-b]pyridinyl, 1H-pyrrolo[2,3-b]pyridinyl, 1H-pyrrolo[2,3-b]pyridinyl, 1H-pyrrolo[2,1-b]thiazolylene, 1H-pyrrolo[2,1-b]thiazolylene, 1H-pyrrolo[3,2-b]pyridinyl, 1H-pyrrolo[2,3-b]pyridinyl, 1H-pyrrolo[2,1-b]thiazolylene ...1-b]thiazolylene, 1H-pyrrolo[2,1-b]thiazolylene, 1H-pyrrolo[2,1-b]thiazolylene, 1H-pyrrolo[2,1-b]thiazolylene, 1H-pyrrolo[3,2-b]pyridinyl, 1H-pyrrolo[2,3-b]pyridinyl, 1H-pyrrolo[2,1-b]thiazolylene, 1H-pyrrolo[2,1-b]thiazolylene, 1H-pyrrolo[2,1-b]thiazolylene, 1H-pyrrolo[2,1-b]thiazolylene, 1H-pyrrolo[2,1-b]thiazolylene, 1 y1 represents an integer 0, 1, 2 or 3, (R y1 ) a1 Represents each ring A 1 Each independently optionally represented by a1 R y1 Group substitution, each R y1 Deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, carboxyl, C 2-6 Alkynyl or C 2-6 alkenyl, and a1 represents an integer of 0-10; and / or (ii) Each ring A 2 are the same or different and each independently represent a 4- to 20-membered heterocyclylene group, C 3-20 Cycloalkylene, C 5-20 Arylene, or 5- to 20-membered heteroarylene, for example, each ring A 2 Each independently represents: Azetidinyl, diazetidinyl, oxetanyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, oxazolidinyl, thiazolidinyl, piperidinyl, tetrahydropyridinyl, piperazinyl, 1,2,3,4-tetrahydropyrazinyl, hexahydropyrimidinyl, hexahydropyridazinyl, morpholinyl, thio ... Azabicyclo[3.1.1]heptanylene, azabicyclo[3.1.1]heptanylene, azabicyclo[2.2.1]heptanylene, azabicyclo[3.2.1]octanylene, azabicyclo[3.2.1]hep ... octanylidene), azabicyclo[2.2.2]octanylidene, diazabicyclo[3.1.1]heptaneylidene (e.g., 3,6-diazabicyclo[3.1.1]heptaneylidene), diazabicyclo[2.2.1]heptaneylidene (e.g., 2,5-diazabicyclo[2.2.1]heptaneylidene), diazabicyclo[3.2.1]octanylidene (e.g., 3,8-diazabicyclo[3.2.1]octanylidene), alkylidene), diazabicyclo[2.2.2]octanidene (e.g., 2,5-diazabicyclo[2.2.2]octanidene), 5- to 20-membered azaspirocyclyl, cyclopropylene, cyclobutylidene, cyclopentylidene, cyclopentenylidene, cyclohexylidene, cyclohexenylidene, cycloheptylidene, cyclooctylidene, decahydronaphthylidene, octahydropentalenylidene, octahydro-1H-indenylidene, 2,3-dihydro-1H-indenylidene, C 5-15 spirocyclylene, adamantylene, noradamantylene, norbornylene, phenylene, naphthylene, furylene, oxazolylene, isoxazolylene, oxadiazolylene, thienylene, thiazolylene, isothiazolylene, thiadiazolylene, pyrrolylene, imidazolylene, pyrazolylene, triazolylene, pyridylene, pyrimidylene, pyridazinylene, pyrazinylene, indolylene, isoindolylene, benzofuranylene, isobenzofuranylene, benzothienylene, indazolylene, benzimidazolylene, benzoxazolylene, benzisoxazolylene, benzothiazolylene, benzisothiazolylene, benzotriazolylene 1H-pyrrolo[3,2-b]pyridinyl, 1H-pyrrolo[2,3-b]pyridinyl, 1H-pyrrolo[2,3-b]pyridinyl, 1H-pyrrolo[2,3-b]pyridinyl, 1H-pyrrolo[2,1-b]thiazolylene, 1H-pyrrolo[2,1-b]thiazolylene, 1H-pyrrolo[3,2-b]pyridinyl, 1H-pyrrolo[2,3-b]pyridinyl, 1H-pyrrolo[2,1-b]thiazolylene ...3,2-b]pyridinyl, 1H-pyrrolo[2,3-b]pyridinyl, 1H-pyrrolo[2,3-b]pyridinyl, 1H-pyrrolo[2,1-b]thiazolylene, 1H-pyrrolo[2,1-b]thiazolylene, 1H-pyrrolo[2,1-b]thiazolylene, 1H-pyrrolo[2,1-b]thiazolylene, 1H-pyrrolo[2,1-b]thiazolylene, 1H- y2 represents an integer of 0, 1, 2 or 3, (R y2 ) a2 Represents each ring A 2 Each independently optionally represented by a2 R y2 Group substitution, each R y2 Deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, carboxyl, C 2-6 Alkynyl or C 2-6 alkenyl, and a2 represents an integer of 0-10; and / or (iii) Ring A 3 are the same or different and each independently represent a 4- to 20-membered heterocyclylene group, C 3-20 Cycloalkylene, C 5-20 Arylene, or 5- to 20-membered heteroarylene, for example, each ring A 3 Each independently represents: Azetidinyl, diazetidinyl, oxetanyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, oxazolidinyl, thiazolidinyl, piperidinyl, tetrahydropyridinyl, piperazinyl, 1,2,3,4-tetrahydropyrazinyl, hexahydropyrimidinyl, hexahydropyridazinyl, morpholinyl, thio ... Azabicyclo[3.1.1]heptanylene, azabicyclo[3.1.1]heptanylene, azabicyclo[2.2.1]heptanylene, azabicyclo[3.2.1]octanylene, azabicyclo[3.2.1]hep ... octanylidene), azabicyclo[2.2.2]octanylidene, diazabicyclo[3.1.1]heptaneylidene (e.g., 3,6-diazabicyclo[3.1.1]heptaneylidene), diazabicyclo[2.2.1]heptaneylidene (e.g., 2,5-diazabicyclo[2.2.1]heptaneylidene), diazabicyclo[3.2.1]octanylidene (e.g., 3,8-diazabicyclo[3.2.1]octanylidene), alkylidene), diazabicyclo[2.2.2]octanidene (e.g., 2,5-diazabicyclo[2.2.2]octanidene), 5- to 20-membered azaspirocyclyl, cyclopropylene, cyclobutylidene, cyclopentylidene, cyclopentenylidene, cyclohexylidene, cyclohexenylidene, cycloheptylidene, cyclooctylidene, decahydronaphthylidene, octahydropentalenylidene, octahydro-1H-indenylidene, 2,3-dihydro-1H-indenylidene, C 5-15 spirocyclylene, adamantylene, noradamantylene, norbornylene, phenylene, naphthylene, furylene, oxazolylene, isoxazolylene, oxadiazolylene, thienylene, thiazolylene, isothiazolylene, thiadiazolylene, pyrrolylene, imidazolylene, pyrazolylene, triazolylene, pyridylene, pyrimidylene, pyridazinylene, pyrazinylene, indolylene, isoindolylene, benzofuranylene, isobenzofuranylene, benzothienylene, indazolylene, benzimidazolylene, benzoxazolylene, benzisoxazolylene, benzothiazolylene, benzisothiazolylene, benzotriazolylene 1H-pyrrolo[3,2-b]pyridinyl, 1H-pyrrolo[2,3-b]pyridinyl, 1H-pyrrolo[2,3-b]pyridinyl, 1H-pyrrolo[2,3-b]pyridinyl, 1H-pyrrolo[2,1-b]thiazolylene, 1H-pyrrolo[2,1-b]thiazolylene, 1H-pyrrolo[3,2-b]pyridinyl, 1H-pyrrolo[2,3-b]pyridinyl, 1H-pyrrolo[2,1-b]thiazolylene ...3,2-b]pyridinyl, 1H-pyrrolo[2,3-b]pyridinyl, 1H-pyrrolo[2,3-b]pyridinyl, 1H-pyrrolo[2,1-b]thiazolylene, 1H-pyrrolo[2,1-b]thiazolylene, 1H-pyrrolo[2,1-b]thiazolylene, 1H-pyrrolo[2,1-b]thiazolylene, 1H-pyrrolo[2,1-b]thiazolylene, 1H- y3 represents an integer of 0, 1, 2 or 3, (R y3 ) a3 Represents each ring A 3 Each independently optionally represented by a3 R y3 Group substitution, each R y3 Deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, carboxyl, C 2-6 Alkynyl or C 2-6 alkenyl, and a3 represents an integer of 0-10; and / or (iv)R w1 represents a bond, or represents an optionally substituted straight or branched C 1-20 Alkylene, wherein the linear or branched C 1-20 Any one or more methylene groups of the main carbon chain skeleton of the alkylene group may be optionally replaced by one or more groups selected from the following: a 、R b and any combination thereof, each group R a Each independently selected from O, C(O), OC(O), S, S(O), S(O)2, S(O)2N(R a7 )、N(R a7 )S(O)2、C(O)N(R a7 )、N(R a7 )C(O), N(R a7 ) and N(R a7 )C(O)N(R a7 ), where each R a7 Each independently represents H or C 1-3 Alkyl, and when the linear or branched C 1-20 Any two or more methylene groups of the main carbon chain skeleton of the alkylene group are replaced by two or more groups R a When substituted, each group R a Not directly connected to each other; each group R b are each independently selected from optionally substituted cycloalkylene (eg, optionally substituted C 3-20 cycloalkylene), optionally substituted arylene (e.g., optionally substituted C 5-20 arylene), optionally substituted heterocyclylene (e.g., optionally substituted 4- to 20-membered heterocyclylene), optionally substituted heteroarylene (e.g., optionally substituted 5- to 20-membered heteroarylene), alkynylene (e.g., C 2-6 Alkyne), alkenylene (e.g. C 2-6 and any combination thereof, wherein the cycloalkylene, the arylene, the heterocyclylene and the heteroarylene are each independently optionally selected from deuterium, hydroxyl, amino, thiol, nitro, halogen, cyano, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 3-6 Cycloalkyl, halogenated C 3-6 Cycloalkyl, deuterated C 3-6 cycloalkyl, 4- to 10-membered heterocyclic group and any combination thereof, and wherein the linear or branched C 1-20 One or more hydrogen atoms of the alkylene group may be selected from deuterium, hydroxyl, amino, mercapto, nitro, halogen, cyano, haloC 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 3-6 Cycloalkyl, halogenated C 3-6 Cycloalkyl, deuterated C 3-6 The substituents are substituted by cycloalkyl, 4- to 10-membered heterocyclyl, and any combination thereof.

15. A compound of formula (I) as claimed in any one of claims 1 to 14, or a salt, enantiomer, stereoisomer, solvate, isotopically enriched analogue, prodrug or polymorph thereof, wherein the part in the general formula of LIN is express: wherein the above groups are optionally selected from deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, carboxyl, C 2-6 Alkynyl or C 2-6 Substitution of the alkenyl group by a substituent; and / or R w1 represents a key, or R w1 express: -C 1-15 Alkylene-; -(C(R a8 )(R a9 )) n4 -(R a (C(R a10 )(R a11 )) n5 ) m3 -; -(C(R a8 )(R a9 )) n4 -(R a (C(R a10 )(R a11 )) n5 ) m3 -(R a (C(R a12 )(R a13 )) n6 ) m4 -; -(C(R a8 )(R a9 )) n4 -(R a (C(R a10 )(R a11 )) n5 ) m3 -(R a (C(R a12 )(R a13 )) n6 ) m4 -(R a (C(R a14 )(R a15 )) n7 ) m5 -; -(C(R a8 )(R a9 )) n4 -((C(R a10 )(R a11 )) n5 R a ) m3 -; -(C(R a8 )(R a9 )) n4 -((C(R a10 )(R a11 )) n5 R a ) m3 -((C(R a12 )(R a13 )) n6 R a ) m4 -; -(C(R a8 )(R a9 )) n4 -((C(R a10 )(R a11 )) n5 R a ) m3 -((C(R a12 )(R a13 )) n6 R a ) m4 -((C(R a14 )(R a15 )) n7 R a ) m5 -; -(C(R a8 )(R a9 )) n4 -(R b (C(R a10 )(R a11 )) n5 ) m3 -; -(C(R a8 )(R a9 )) n4 -(R b (C(R a10 )(R a11 )) n5 ) m3 -(R b (C(R a12 )(R a13 )) n6 ) m4 -; -(C(R a8 )(R a9 )) n4 -(R b (C(R a10 )(R a11 )) n5 ) m3 -(R b (C(R a12 )(R a13 )) n6 ) m4 -(R b (C(R a14 )(R a15 )) n7 ) m5 -; -(C(R a8 )(R a9 )) n4 -((C(R a10 )(R a11 )) n5 R b ) m3 -; -(C(R a8 )(R a9 )) n4 -((C(R a10 )(R a11 )) n5 R b ) m3 -((C(R a12 )(R a13 )) n6 R b ) m4 -; -(C(R a8 )(R a9 )) n4 -((C(R a10 )(R a11 )) n5 R b ) m3 -((C(R a12 )(R a13 )) n6 R b ) m4 -((C(R a14 )(R a15 )) n7 R b ) m5 -; -(C(R a8 )(R a9 )) n4 -(R a -R b -(C(R a10 )(R a11 )) n5 ) m3 -; -(C(R a8 )(R a9 )) n4 -(R a (C(R a10 )(R a11 )) n5 ) n3 -(R b (C(R a12 )(R a13 )) n6 ) m4 -; -(C(R a8 )(R a9 )) n4 -(R b -R a -(C(R a10 )(R a11 )) n5 ) m3 -; -(C(R a8 )(R a9 )) n4 -(R b (C(R a10 )(R a11 )) n5 ) m3 -(R a (C(R a12 )(R a13 )) n6 ) m4 -; -(C(R a8 )(R a9 )) n4 -((C(R a10 )(R a11 )) n5 -R a -R b ) m3 -; -(C(R a8 )(R a9 )) n4 -((C(R a10 )(R a11 )) n5 R a ) m3 -((C(R a12 )(R a13 )) n6 R b ) m4 -; -(C(R a8 )(R a9 )) n4 -((C(R a10 )(R a11 )) n5 -R b -R a ) m3 -;or -(C(R a8 )(R a9 )) n4 -((C(R a10 )(R a11 )) n5 R b ) m3 -((C(R a12 )(R a13 )) n6 R a ) m4 -; in, Each group R a independently selected from O, C(O), OC(O), S, S(O), S(O)2, S(O)2N(R a7 )、N(R a7 )S(O)2、C(O)N(R a7 )、N(R a7 )C(O), N(R a7 ) and N(R a7 )C(O)N(R a7 ), where each R a7 Each independently represents H or C 1-3 Alkyl; each group R b are independently selected from optionally substituted cycloalkylene (eg, optionally substituted C 3-20 cycloalkylene), optionally substituted arylene (e.g., optionally substituted C 5-20 arylene), optionally substituted heterocyclylene (e.g., optionally substituted 4- to 20-membered heterocyclylene), optionally substituted heteroarylene (e.g., 5- to 20-membered heteroarylene), alkynylene (e.g., C 2-6 Alkyne), alkenylene (e.g. C 2-6 and any combination thereof, wherein the cycloalkylene, the arylene, the heterocyclylene and the heteroarylene are each independently optionally selected from deuterium, hydroxyl, amino, thiol, nitro, halogen, cyano, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 3-6 Cycloalkyl, halogenated C 3-6 Cycloalkyl, deuterated C 3-6 substituted by cycloalkyl, 4- to 10-membered heterocyclic group, and any combination thereof; R a8 、R a9 、R a10 、R a11 、R a12 、R a13 、R a14 and R a15 Each independently represents H, deuterium, hydroxyl, amino, mercapto, nitro, halogen, cyano, oxo, halo 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 3-6 Cycloalkyl, halogenated C 3-6 Cycloalkyl, deuterated C 3-6 Cycloalkyl, 4- to 10-membered heterocyclyl, and any combination thereof; and n4, n5, n6, n7, m3, m4, m5 are each independently selected from the integers 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10; and The C 1-15 Any one or more hydrogen atoms of the main carbon chain of the alkylene group may be optionally replaced by a substituent selected from the group consisting of deuterium, hydroxyl, amino, thiol, nitro, halogen, cyano, oxo, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 3-6 Cycloalkyl, halogenated C 3-6 Cycloalkyl, deuterated C 3-6 cycloalkyl, 4- to 10-membered heterocyclic group, and any combination thereof.

16. A compound of formula (I) according to any one of claims 1 to 15, or a salt, enantiomer, stereoisomer, solvate, isotopically enriched analog, prodrug or polymorph thereof, wherein R w1 Represents the following structure: -(C(R a8 )(R a9 )) n4 -(O(C(R a10 )(R a11 )) n5 ) m3 -; -(C(R a8 )(R a9 )) n4 -(O(C(R a10 )(R a11 )) n5 ) m3 -(O(C(R a12 )(R a13 )) n6 ) m4 -; -(C(R a8 )(R a9 )) n4 -(O(C(R a10 )(R a11 )) n5 ) m3 -(O(C(R a12 )(R a13 )) n6 ) m4 -(O(C(R a14 )(R a15 )) n7 ) m5 -; -(C(R a8 )(R a9 )) n4 -((C(R a10 )(R a11 )) n5 O) m3 -; -(C(R a8 )(R a9 )) n4 -((C(R a10 )(R a11 )) n5 0) m3 -((C(R a12 )(R a13 )) n6 O) m4 -; -(C(R a8 )(R a9 )) n4 -((C(R a10 )(R a11 )) n5 O) m3 -((C(R a12 )(R a13 )) n6 O) m4 -((C(R a14 )(R a15 )) n7 O) m5 -; -(C(R a8 )(R a9 )) n4 -(N(R a7 )(C(R a10 )(R a11 )) n5 ) m3 -; -(C(R a8 )(R a9 )) n4 -(N(R a7 )(C(R a10 )(R a11 )) n5 ) m3 -(N(R a7 )(C(R a12 )(R a13 )) n6 ) m4 -; -(C(R a8 )(R a9 )) n4 -(N(R a7 )(C(R a10 )(R a11 )) n5 ) m3 -(N(R a7 )(C(R a12 )(R a13 )) n6 ) m4 -(N(R a7 )(C(R a14 )(R a15 )) n7 ) m5 -; -(C(R a8 )(R a9 )) n4 -((C(R a10 )(R a11 )) n5 N(R a7 )) m3 -; -(C(R a8 )(R a9 )) n4 -((C(R a10 )(R a11 )) n5 N(R a7 )) m3 -((C(R a12 )(R a13 )) n6 N(R a7 )) m4 -; -(C(R a8 )(R a9 )) n4 -((C(R a10 )(R a 11)) n5 N(R a7 )) m3 -((C(R a12 )(R a13 )) n6 N(R a7 )) m4 -((C(R a14 )(R a15 )) n7 N(R a7 )) m5 -; -(C(R a8 )(R a9 )) n4 -(C(O)N(R a7 )-(C(R a10 )(R a11 )) n5 ) m3 -; -(C(R a8 )(R a9 )) n4 -(C(O)N(R a7 )-(C(R a10 )(R a11 )) n5 ) m3 -(C(O)N(R a7 )-(C(R a12 )(R a13 )) n6 ) m4 -; -(C(R a8 )(R a9 )) n4 -(C(O)N(R a7 )-(C(R a10 )(R a11 )) n5 ) m3 -(C(O)N(R a7 )-(C(R a12 )(R a13 )) n6 ) m4 -(C(O)N(R a7 )-(C(R a14 )(R a15 )) n7 ) m5 -; -(C(R a8 )(R a9 )) n4 -((C(R a10 )(R a11 )) n5 -C(O)N(R a7 )) m3 -; -(C(R a8 )(R a9 )) n4 -((C(R a10 )(R a11 )) n5 -C(O)N(R a7 )) m3 -((C(R a12 )(R a13 )) n6 -C(O)N(R a7 )) m4 -; -(C(R a8 )(R a9 )) n4 -((C(R a10 )(R a11 )) n5 -C(O)N(R a7 )) m3 -((C(R a12 )(R a13 )) n6 -C(O)N(R a7 )) m4 -((C(R a14 )(R a15 )) n7 -C(O)N(R a7 )) m5 -; -(C(R a8 )(R a9 )) n4 -(C(O)N(R a7 )-(C(R a10 )(R a11 )) n5 ) m3 -(O-(C(R a12 )(R a13 )) n6 ) m4 -; -(C(R a8 )(R a9 )) n4 -C(O)N(R a7 )-(C(R a10 )(R a11 )) n5 -(O(C(R a12 )(R a13 )) n6 ) m3 -; -(C(R a8 )(R a9 )) n4 -((C(R a10 )(R a11 )) n5 -C(O)N(R a7 )) m3 -((C(R a12 )(R a13 )) n6 O) m4 -; -(C(R a8 )(R a9 )) n4 -(C(R a10 )(R a11 )) n5 -C(O)N(R a7 )-((C(R a12 )(R a13 )) n6 O) m3 -; -(C(R a8 )(R a9 )) n4 -(N(R a7 )C(O)-(C(R a10 )(R a11 )) n5 ) m3 -; -(C(R a8 )(R a9 )) n4 -(N(R a7 )C(O)-(C(R a10 )(R a11 )) n5 ) m3 -(O-(C(R a12 )(R a13 ))) n6 ) m4 -; -(C(R a8 )(R a9 )) n4 -(N(R a7 )C(O)-(C(R a10 )(R a11 )) n5 ) m3 -(O-(C(R a12 )(R a13 )) n6 ) m4 -(O-(C(R a14 )(R a15 )) n7 ) m5 -; -(C(R a8 )(R a9 )) n4 -N(R a7 )C(O)-(C(R a10 )(R a11 )) n5 -(O(C(R a12 )(R a13 )) n6 ) m3 -; -(C(R a8 )(R a9 )) n4 -N(R a7 )C(O)N(R a7 )-(C(R a10 )(R a11 )) n5 -; -(C(R a8 )(R a9 )) n4 -((C(R a10 )(R a11 )) n5 -N(R a7 )C(O)) m3 -; -(C(R a8 )(R a9 )) n4 -((C(R a10 )(R a11 )) n5 -N(R a7 )C(O)) m3 -((C(R a12 )(R a13 ))) n6 -O) m4 -; -(C(R a8 )(R a9 )) n4 -((C(R a10 )(R a11 )) n5 -N(R a7 )C(O)) m3 -((C(R a12 )(R a13 )) n6 O) m4 -((C(R a14 )(R a15 )) n7 O) m5 -; -(C(R a8 )(R a9 )) n4 -(C(R a10 )(R a11 )) n5 -N(R a7 )C(O)-((C(R a12 )(R a13 )) n6 O) m3 -; -(C(R a8 )(R a9 )) n4 -(arylene-(C(R a10 )(R a11 )) n5 ) m3 -; -(C(R a8 )(R a9 )) n4 -(arylene-(C(R a10 )(R a11 )) n5 ) m3 -arylene-(C(R a12 )(R a13 )) n6 -; -(C(R a8 )(R a9 )) n4 -((C(R a10 )(R a11 )) n5 -arylene) m3 -; -(C(R a8 )(R a9 )) n4 -((C(R a10 )(R a11 )) n5 -arylene) m3 -(C(R a12 )(R a13 )) n6 -arylene-; -(C(R a8 )(R a9 )) n4 -(Heterocyclylene-(C(R a10 )(R a11 )) n5 ) m3 -; -(C(R a8 )(R a9 )) n4 -(Heterocyclylene-(C(R a10 )(R a11 )) n5 ) m3 -(Heterocyclylene-(C(R a12 )(R a13 )) n6 ) m4 -; -(C(R a8 )(R a9 )) n4 -((C(R a10 )(R a11 )) n5 -heterocyclylene) m3 -; -(C(R a8 )(R a9 )) n4 -((C(R a10 )(R a11 )) n5 -heterocyclylene) m3 -((C(R a12 )(R a13 )) n6 -heterocyclylene) m4 -; -(C(R a8 )(R a9 )) n4 -(heteroarylene-(C(R a10 )(R a11 )) n5 ) m3 -; -(C(R a8 )(R a9 )) n4 -(heteroarylene-(C(R a10 )(R a11 )) n5 ) m3 -(heteroarylene-(C(R a12 )(R a13 )) n6 ) m4 -; -(C(R a8 )(R a9 )) n4 -((C(R a10 )(R a11 )) n5 -heteroarylene) m3 -; -(C(R a8 )(R a9 )) n4 -((C(R a10 )(R a11 )) n5 -heteroarylene) m3 -((C(R a12 )(R a13 )) n6 -heteroarylene) m4 -; -(C(R a8 )(R a9 )) n4 -(cycloalkylene-(C(R a10 )(R a11 )) n5 ) m3 -; -(C(R a8 )(R a9 )) n4 -(cycloalkylene-(C(R a10 )(R a11 )) n5 ) m3 -(cycloalkylene-(C(R a12 )(R a13 )) n6 ) m4 -; -(C(R a8 )(R a9 )) n4 -((C(R a10 )(R a11 )) n5 -cycloalkylene) m3 -;or -(C(R a8 )(R a9 )) n4 -((C(R a10 )(R a11 )) n5 -cycloalkylene) m3 -((C(R a12 )(R a13 )) n6 -cycloalkylene) m4 -; Among them, each R a7 independently represents H or C 1-3 alkyl; The cycloalkylene group (eg C 3-20 Cycloalkylene), the arylene group (such as C 5-20 arylene), the heterocyclylene (e.g., 4- to 20-membered heterocyclylene) and the heteroarylene (e.g., 5- to 20-membered heteroarylene) are each independently optionally selected from deuterium, hydroxyl, amino, thiol, nitro, halogen, cyano, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 3-6 Cycloalkyl, halogenated C 3-6 Cycloalkyl, deuterated C 3-6 substituted by cycloalkyl, 4- to 10-membered heterocyclic group, and any combination thereof; R a8 、R a9 、R a10 、R a11 、R a12 、R a13 、R a14 and R a15 Each independently represents H, deuterium, hydroxyl, amino, mercapto, nitro, halogen, cyano, halo C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 3-6 Cycloalkyl, halogenated C 3-6 Cycloalkyl, deuterated C 3-6 Cycloalkyl, 4- to 10-membered heterocyclyl, and any combination thereof; and n4, n5, n6, n7, m3, m4, m5 are each independently selected from the integers 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.

17. A compound of formula (I) or a salt, enantiomer, stereoisomer, solvate, isotopically enriched analog, prodrug or polymorph thereof as claimed in any one of claims 1 to 16, wherein R w1 express: -CH2-、-(CH2)2-、-(CH2)3-、-(CH2)4-、-(CH2)5-、-(CH2)6-、-(CH2)7-、-(CH2)8-、-(CH2)9-、-(CH2) 10 -、-(CH2) 11 -、-(CH2) 12 -、-(CH2) 13 -、-(CH2) 14 -、-(CH2) 15 -;-O-CH2-、-O-(CH2)2-、-O-(CH2)3-、-O-(CH2)4-、-O-(CH2)5-、-O-(CH2)6-、-O-(CH2)7-、-O-(CH2)8-、-O-(CH2)9-、-O-(CH2) 10 -、-(CH2)1-O-、-(CH2)2-O-、-(CH2)3-O-、-(CH2)4-O-、-(CH2)5-O-、-(CH2)6-O-、-(CH2)7-O-、-(CH2)8-O-、-(CH2)9-O-、-(CH2) 10 -O-、-CH2-O-CH2-、-CH2-O-(CH2)2-、-(CH2)1-O-(CH2)3-、-(CH2)1-O-(CH2)4-、-(CH2)1-O-(CH2)5-、-(CH2)1-O-(CH2)6-、-(CH2)1-O-(CH2)7-、-(CH2)1-O-(CH2)8-、-(CH2)1-O-(CH2)9-、-(CH2)1-O-(CH2) 10 -、-(CH2)2-O-(CH2)1-、-(CH2)2-O-(CH2)2-、-(CH2)2-O-(CH2)3-、-(CH2)2-O-(CH2)4-、-(CH2)2-O-(CH2)5-、-(CH2)2-O-(CH2)6-、-(CH2)2-O-(CH2)7-、-(CH2)2-O-(CH2)8-、-(CH2)2-O-(CH2)9-、-(CH2)2-O-(CH2) 10 -、-(CH2)3-O-(CH2)1-、-(CH2)3-O-(CH2)2-、-(CH2)3-O-(CH2)3-、-(CH2)3-O-(CH2)4-、-(CH2)3-O-(CH2)5-、-(CH2)3-O-(CH2)6-、-(CH2)3-O-(CH2)7-、-(CH2)4-O-(CH2)1-、-(CH2)4-O-(CH2)2-、-(CH 2)4-O-(CH2)3-、-(CH2)4-O-(CH2)4-、-(CH2)4-O-(CH2)5-、-(CH2)4-O-(CH2)6-、-(CH2)5-O-(CH2)1-、-(CH2)5-O-(CH2)2-、-(CH2)5-O-(CH2)3-、-(CH2)5-O-(CH2)4-、-(CH2)5-O-(CH2)5-、-(CH2)6-O-( CH2)1-、-(CH2)6-O-(CH2)2-、-(CH2)6-O-(CH2)3-、-(CH2)6-O-(CH2)4-、-(CH2)7-O-(CH2)1-、-(CH2)7-O-(CH2)2-、-(CH2)7-O-(CH2)3-、-(CH2)8-O-(CH2)1-、-(CH2)8-O-(CH2)2-、-CH(CH3)-O-(CH2)1- 、-CH(CH3)-O-(CH2)2-、-CH(CH3)-O-(CH2)3-、-CH(CH3)-O-(CH2)4-、-CH(CH3)-O-(CH2)5-、-CH(CH3)-O-(CH2)6-、-CH(CH3)-O-(CH2)7-、-CH(CH3)-O-(CH2)8-、-CH(CH3)-O-(CH2)9-、-CH(CH3)-O-(CH2) 10 -、-(O(CH2)2)2-、-(O(CH2)2)3-、-(O(CH2)2)4-、-(O(CH2)2)5-、-(O(CH2)2)6-、-(O(CH2)2)7-、-CH2-(O(CH2)2)2-、-CH2-(O(CH2)2)3-、-CH2-(O(CH2 )2)4-、-CH2-(O(CH2)2)5-、-CH2-(O(CH2)2)6-、-CH2-(O(CH2)2)7-、-CH2- (O(CH2)2)1-OCH2-、-CH2-(O(CH2)2)2-OCH2-、-CH2-(O(CH2)2)3-OCH2-、-C H2-(O(CH2)2)4-OCH2-、-CH2-(O(CH2)2)5-OCH2-、-(CH2)2-(O(CH2)2)2-、 -(CH2)2-(O(CH2)2)3-、-(CH2)2-(O(CH2)2)4-、-(CH2)2-(O(CH2)2)5-、-(C H2)2-(O(CH2)2)6-、-(CH2)3-(O(CH2)2)2-、-(CH2)3-(O(CH2)2)3-、-(CH2 )3-(O(CH2)2)4-、-(CH2)3-(O(CH2)2)5-、-(CH2)4-(O(CH2)2)2-、-(CH2)4- (O(CH2)2)3-、-(CH2)4-(O(CH2)2)4-、-(CH2)4-(O(CH2)2)5-、-CH2-(O(CH2)3)2-、-CH2-(O(CH2)3)3-、-CH2-(O(CH2)3)4-、-(CH2)2-(O(CH2)3)2-、-( CH2)2-(O(CH2)3)3-、-(CH2)2-(O(CH2)3)4-、-(CH2)3-(O(CH2)3)2-、-(CH2)3-(O(CH2)3)3-、-(CH2)3-(O(CH2)3)4-、-CH2-O-(CH2)2-O-(CH2)3-、-CH2-(O(CH2)2)2-(O(CH2)3)2-、(CH2)2-O-(CH2)2-O-(CH2)3-、-(CH2)2-(O(CH2)2)2-(O(CH2)3)2-、-(CH2)3-O-(CH2)2-O-(CH2)3-、-(CH2)3-(O(CH2)2 )2-(O(CH2)3)2-、-CH2-O-(CH2)3-O-(CH2)2-、-CH2-(O(CH2)3)2-(O(CH2)2)2-、-(CH2)2-O-(CH2)3-O-(CH2)2-、-(CH2)2-(O(CH2)3)2-(O(CH2)2)2-、-(CH2)3-O-(CH2)3-O-(CH2)2-、-(CH2)3-(O(CH2)3)2-(O(CH2)2)2-、-CH2-O-(CH2)2-O-CH2-、-(CH2)2-O-(CH2)2-O-CH2-、-(CH2)2-(O(CH2)2)2-O-(CH2)3-、-(CH2)2-(O(CH2)2)3-O-(CH2)3-、-(CH2)2-(O(CH2)2)4-O-(CH2)3-、-(CH2)5-(O(CH2)2)2-O-(CH2)5-、-(CH2)5-(O(CH2)2)2-O-(CH2)6-、-(CH2)1-N(R、 a7 )-(CH2)1-、-(CH2)1-N(R a7 )-(CH2)2-、-(CH2)1-N(R a7 )-(CH2)3-、-(CH2)1-N(R a7 )-(CH2)4-、-(CH2)1-N(R a7 )-(CH2)5-、-(CH2)1-N(R a7 )-(CH2)6-、-(CH2)1-N(R a7 )-(CH2)7-、-(CH2)1-N(R a7 )-(CH2)8-、-(CH2)1-N(R a7 )-(CH2)9-、-(CH2)1-N(R a7 )-(CH2) 10 -、-N(R a7 )-(CH2)1-、-N(R a7 )-(CH2)2-、-N(R a7 )-(CH2)3-、-N(R a7 )-(CH2)4-、-N(R a7 )-(CH2)5-、-N(R a7 )-(CH2)6-、-N(R a7 )-(CH2)7-、-N(R a7 )-(CH2)8-、-N(R a7 )-(CH2)9-、-N(R a7 )-(CH2) 10 -、-(CH2)2-N(R a7 )-(CH2)1-、-(CH2)2-N(R a7 )-(CH2)2-、-(CH2)2-N(R a7 )-(CH2)3-、-(CH2)2-N(R a7 )-(CH2)4-、-(CH2)2-N(R a7 )-(CH2)5-、-(CH2)2-N(R a7 )-(CH2)6-、-(CH2)2-N(R a7 )-(CH2)7-、-(CH2)2-N(R a7 )-(CH2)8-、-(CH2)2-N(R a7 )-(CH2)9-、-(CH2)2-N(R a7 )-(CH2) 10 -、-(CH2)3-N(R a7 )-(CH2)1-、-(CH2)3-N(R a7 )-(CH2)2-、-(CH2)3-N(R a7 )-(CH2)3-、-(CH2)4-N(R a7 )-(CH2)1-、-(CH2)4-N(R a7 )-(CH2)2-、-(CH2)4-N(R a7 )-(CH2)3-、-(CH2)4-N(R a7 )-(CH2)4-、-(CH2)5-N(R a7 )-(CH2)1-、-(CH2)5-N(R a7 )-(CH2)2-、-(CH2)5-N(R a7 )-(CH2)3-、-(CH2)5-N(R a7 )-(CH2)4-、-(CH2)5-N(R a7 )-(CH2)5-、-(CH2)6-N(R a7 )-(CH2)1-、-(CH2)6-N(R a7 )-(CH2)2-、-(CH2)6-N(R a7 )-(CH2)3-、-(CH2)7-N(R a7 )-(CH2)1-、-(CH2)7-N(R a7 )-(CH2)2-、-(CH2)7-N(R a7 )-(CH2)3-、-(CH2)8-N(R a7 )-(CH2)1-、-(CH2)8-N(R a7 )-(CH2)2-、-(CH2)8-N(R a7 )-(CH2)3-、-CH(CH3)-N(R a7 )-(CH2)1-、-CH(CH3)-N(R a7 )-(CH2)2-、-CH(CH3)-N(R a7 )-(CH2)3-、-CH(CH3)-N(R a7 )-(CH2)4-、-CH(CH3)-N(R a7 )-(CH2)5-、-CH(CH3)-N(R a7 )-(CH2)6-、-CH(CH3)-N(R a7 )-(CH2)7-、-CH(CH3)-N(R a7 )-(CH2)8-、-CH(CH3)-N(R a7 )-(CH2)9-、-CH(CH3)-N(R a7 )-(CH2) 10 -, -C(O)NHCH2-, -C(O)NH(CH2)2-, -C(O)NH(CH2)3-, -C(O)NH(CH2)4-, -C(O)NH(CH2)5-, -CH2C(O)NHCH2-, -(CH2)2C(O)NH(CH2)2-, -(CH2)2C(O)NH (CH2)3-, -(CH2)2C(O)NH(CH2)4-, -(CH2)2C(O)NH(CH2)5-, -(CH2)3C(O)NH(CH2)3-, -(CH2)3C(O)NH(CH2)4-, -(CH2)4C(O)NH(CH2)4-, -(CH2)5C(O) NH(CH2)5-, -(CH2)6C(O)NH(CH2)7-, -(CH2)6C(O)NH(CH2)6-, -(CH2)7C(O)NH(CH2)7-, -(CH2)2C(O)NH(CH2)2-O-(CH2)2-, -NHC(O)CH2-, -NHC(O)(C H2)2-, -NHC(O)(CH2)3-, -NHC(O)(CH2)4-, -NHC(O)(CH2)5-, -CH2NHC(O)CH2-, -(CH2)2NHC(O)(CH2)2-, -(CH2)2NHC(O)(CH2)3-, -(CH2)2NHC(O)(CH 2)4-, -(CH2)2NHC(O)(CH2)5-, -(CH2)3NHC(O)(CH2)3-, -(CH2)3NHC(O)(CH2)4-, -(CH2)4NHC(O)(CH2)4-, -(CH2)5NHC(O)(CH2)5-, -(CH2)6NHC(O)( CH2)7-, -(CH2)6NHC(O)(CH2)6-, -(CH2)7NHC(O)(CH2)7-, -(CH2)4NHC(O)(CH2)8-, -(CH2)2NHC(O)(CH2)2-O-(CH2)2-, -(CH2)4NHC(O)CH2-, -phenylene-C H2-, -phenylene-(CH2)2-, -phenylene-(CH2)3-, -phenylene-(CH2)4-, -phenylene-(CH2)5-, -phenylene-(CH2)6-, -phenylene-(CH2)7-, -phenylene-(CH2)8-, -CH2-phenylene-CH2-, -CH2-phenylene-(CH2)2-, -CH2-phenylene-(CH2)3-, -CH2-phenylene-(CH2)4-, -CH2-phenylene-(CH2)5-, -CH2-phenylene-(CH2)6-, -CH2-phenylene-(CH2)7-, -CH2-phenylene-(CH2)8-, -(CH2)2-phenylene-(CH2)1-,-(CH2)2-phenylene-(CH2)2-, -(CH2)2-phenylene-(CH2)3-, -(CH2)2-phenylene-(CH2)4-, -(CH2)2-phenylene-(CH2)5-, -(CH2)2-phenylene-(CH2)6-, -(CH2)2-phenylene-(CH2)7-, -(CH2)2-phenylene-(CH2)8-, -(CH2)3-phenylene-CH2-, -(CH2)3-phenylene-(CH2)2-, -(CH2)3-phenylene-(CH2)3-, -(CH2)3-phenylene-(CH2)4-, -(CH2)3-phenylene-(CH2)5-, -(CH2)3-phenylene -(CH2)6-, -(CH2)3-phenylene-(CH2)7-, -(CH2)3-phenylene-(CH2)8-, -(CH2)4-phenylene-CH2-, -(CH2)4-phenylene-(CH2)2-, -(CH2)4-phenylene-(CH2)3-, -(CH2)4-phenylene-(CH2)4-, -(CH2)4-phenylene-(CH2)5-, -(CH2)4-phenylene-(CH2)6-, -(CH2)4-phenylene-(CH2)7-, -(CH2)4-phenylene-(CH2)8-, -(CH2)5-phenylene-(CH2)1-, -(CH2)5-phenylene-(CH2)2-, - (CH2)5-phenylene-(CH2)3-, -(CH2)5-phenylene-(CH2)4-, -(CH2)5-phenylene-(CH2)5-, -(CH2)5-phenylene-(CH2)6-, -(CH2)5-phenylene-(CH2)7-, -(CH2)5-phenylene-(CH2)8-, -(CH2)6-phenylene-(CH2)1-, -(CH2)6-phenylene-(CH2)2-, -(CH2)6-phenylene-(CH2)3-, -(CH2)6-phenylene-(CH2)4-, -(CH2)6-phenylene-(CH2)5-, -(CH2)6-phenylene-(CH2)6-, -(CH2)6-phenylene-(CH2) Phenyl-(CH2)7-, -(CH2)6-phenylene-(CH2)8-, -(CH2)7-phenylene-(CH2)1-, -(CH2)7-phenylene-(CH2)2-, -(CH2)7-phenylene-(CH2)3-, -(CH2)7-phenylene-(CH2)4-, -(CH2)7-phenylene-(CH2)8-, -(CH2)8-phenylene-CH2-, -(CH2)8-phenylene-(CH2)2-, -(CH2)8-phenylene-(CH2)3-, -(CH2)8-phenylene-(CH2)4-, -(CH2)8-phenylene-(CH2)5-, -(CH2)8-phenylene-(CH2)6-,-(CH2)8-phenylene-(CH2)7-、-N(R、 a7 )-CH2-phenylene-CH2-、-N(R a7 )-CH2-phenylene-(CH2)2-, -N(R a7 )-CH2-phenylene-(CH2)3-、-N(R a7 )-CH2-phenylene-(CH2)4-、-N(R a7 )-CH2-phenylene-(CH2)5-、-N(R a7 )-CH2-phenylene-(CH2)6-、-N(R a7 )-CH2-phenylene-(CH2)7-、-N(R a7 )-CH2-phenylene-(CH2)8-, -CH2-N(R a7 )-CH2-phenylene-CH2-, -CH2-N(R a7 )-CH2-phenylene-(CH2)2-, -CH2-N(R a7 )-CH2-phenylene-(CH2)3-, -CH2-N(R a7 )-CH2-phenylene-(CH2)4-, -CH2-N(R a7 )-CH2-phenylene-(CH2)5-, -CH2-N(R a7 )-CH2-phenylene-(CH2)6-, -CH2-N(R a7 )-CH2-phenylene-(CH2)7-, -CH2-N(R a7 )-CH2-phenylene-(CH2)8-, -CH2-N(R a7 )-(CH2)2-phenylene-CH2-, -CH2-N(R a7 )-(CH2)2-phenylene-(CH2)2-, -CH2-N(R a7 )-(CH2)2-phenylene-(CH2)3-, -CH2-N(R a7 )-(CH2)2-phenylene-(CH2)4-, -CH2-N(R a7 )-(CH2)2-phenylene-(CH2)5-, -CH2-N(R a7 )-(CH2)2-phenylene-(CH2)6-, -CH2-N(R a7 )-(CH2)2-phenylene-(CH2)7-, -CH2-N(R a7 )-(CH2)2-phenylene-(CH2)8-, -(CH2)2-N(R a7 )-CH2-phenylene-CH2-, -(CH2)2-N(R a7 )-CH2-phenylene-(CH2)2-, -(CH2)2-N(R a7 )-CH2-phenylene-(CH2)3-, -(CH2)2-N(R a7 )-CH2-phenylene-(CH2)4-, -(CH2)2-N(R a7 )-CH2-phenylene-(CH2)5-, -(CH2)2-N(R a7 )-CH2-phenylene-(CH2)6-, -(CH2)2-N(R a7 )-CH2-phenylene-(CH2)7-, -(CH2)2-N(R a7 )-CH2-phenylene-(CH2)8-, -(CH2)3-N(R a7 )-CH2-phenylene-CH2-, -(CH2)3-N(R a7 )-CH2-phenylene-(CH2)2-, -(CH2)3-N(R a7 )-CH2-phenylene-(CH2)3-, -(CH2)3-N(R a7 )-CH2-phenylene-(CH2)8-, -(CH2)4-N(R a7 )-CH2-phenylene-CH2-, -(CH2)4-N(R a7 )-CH2-phenylene-(CH2)2-, -(CH2)4-N(R a7 )-CH2-phenylene-(CH2)3-、-(CH2)4-N(R a7 )-CH2-phenylene-(CH2)8-, -(CH2)5-N(R a7 )-CH2-phenylene-(CH2)3-, -(CH2)5-N(R a7 )-CH2-phenylene-(CH2)8-, -(CH2)6-N(R a7 )-CH2-phenylene-(CH2)3-、-(CH2)6-N(R a7 )-CH2-phenylene-(CH2)8-, -(CH2)7-N(R a7 )-CH2-phenylene-(CH2)3-, -(CH2)8-N(R a7 )-CH2-phenylene-CH2-, -(CH2)8-N(R a7 )-CH2-phenylene-(CH2)2-, -(CH2)8-N(R a7 )-CH2-phenylene-(CH2)3-, -(CH2)8-N(R a7 )-CH2-phenylene-(CH2)4-、-(CH2)8-N(R a7 )-CH2-phenylene-(CH2)5-, -(CH2)8-N(R a7 )-CH2-phenylene-(CH2)6-, -piperidinylene-CH2-, -piperidinylene-(CH2)2-, -piperidinylene-(CH2)3-, -piperidinylene-(CH2)4-, -piperidinylene-(CH2)5-, -piperidinylene-(CH2)6-, -piperidinylene-(CH2)7-, -piperidinylene-(CH2)8-, -CH2-piperidinylene-CH2-, -CH2-piperidinylene-(CH2)2-, -CH2-piperidinylene-(CH2)3-, -CH2-piperidinylene-(CH2)4-, -CH2-piperidinylene-(CH2)5-, -CH2-piperidinylene-(CH2)6-, -CH2-piperidinylene-(CH2)7- , -(CH2)2-piperidinylene-(CH2)8-, -(CH2)2-piperidinylene-(CH2)1-, -(CH2)2-piperidinylene-(CH2)2-, -(CH2)2-piperidinylene-(CH2)3-, -(CH2)2-piperidinylene-(CH2)4-, -(CH2)2-piperidinylene-(CH2)5-, -(CH2)2-piperidinylene-(CH2)6-, -(CH2)2-piperidinylene-(CH2)7-, -(CH2)2-piperidinylene-(CH2)8-, -(CH2)3-piperidinylene-CH2-, -(CH2)3-piperidinylene-(CH2)2-, -(CH2)3-piperidinylene-(CH2)3-, -( -(CH2)3-piperidinylene-(CH2)4-, -(CH2)3-piperidinylene-(CH2)5-, -(CH2)3-piperidinylene-(CH2)6-, -(CH2)3-piperidinylene-(CH2)7-, -(CH2)3-piperidinylene-(CH2)8-, -(CH2)4-piperidinylene-CH2-, -(CH2)4-piperidinylene-(CH2)2-, -(CH2)4-piperidinylene-(CH2)3-, -(CH2)4-piperidinylene-(CH2)4-, -(CH2)4-piperidinylene-(CH2)5-, -(CH2)4-piperidinylene-(CH2)6-, -(CH2)4-piperidinylene-(CH2)7-, -(CH2)3-piperidinylene-(CH2)8-, -(CH2)4-piperidinylene-CH2-, -(CH2)4-piperidinylene-(CH2)2-, -(CH2)4-piperidinylene-(CH2)3-, -(CH2)4-piperidinylene-(CH2)4-, -(CH2)4-piperidinylene-(CH2)5-, -(CH2)4-piperidinylene-(CH2)6-, -(CH2)4-piperidinylene-(CH2)7-, -(CH2) -(CH2)4-piperidinylene-(CH2)8-, -(CH2)5-piperidinylene-(CH2)1-, -(CH2)5-piperidinylene-(CH2)2-, -(CH2)5-piperidinylene-(CH2)3-, -(CH2)5-piperidinylene-(CH2)4-, -(CH2)5-piperidinylene-(CH2)5-, -(CH2)5-piperidinylene-(CH2)6-, -(CH2)5-piperidinylene-(CH2)7-, -(CH2)5-piperidinylene-(CH2)8-, -(CH2)6-piperidinylene-(CH2)1-, -(CH2)6-piperidinylene-(CH2)2-, -(CH2)6-piperidinylene-(CH2)3-,-(CH2)6-piperidinylene-(CH2)4-, -(CH2)6-piperidinylene-(CH2)5-, -(CH2)6-piperidinylene-(CH2)6-, -(CH2)6-piperidinylene-(CH2)7-, -(CH2)6-piperidinylene-(CH2)8-, -(CH2)7-piperidinylene-(CH2)1-, -(CH2)7-piperidinylene-(CH2)2-, -(CH2)7-piperidinylene-(CH2)3-, -(CH2)7-piperidinylene -(CH2)4-, -(CH2)7-piperidinylene-(CH2)8-, -(CH2)8-piperidinylene-CH2-, -(CH2)8-piperidinylene-(CH2)2-, -(CH2)8-piperidinylene-(CH2)3-, -(CH2)8-piperidinylene-(CH2)4-, -(CH2)8-piperidinylene-(CH2)5-, -(CH2)8-piperidinylene-(CH2)6-, -(CH2)8-piperidinylene-(CH2)7-, -N(R, a7 )-CH2-piperidinyl-CH2-、-N(R a7 )-CH2-piperidinyl-(CH2)2-、-N(R a7 )-CH2-piperidinyl-(CH2)3-、-N(R a7 )-CH2-piperidinyl-(CH2)4-、-N(R a7 )-CH2-piperidinyl-(CH2)5-、-N(R a7 )-CH2-piperidinyl-(CH2)6-、-N(R a7 )-CH2-piperidinyl-(CH2)7-、-N(R a7 )-CH2-piperidinyl-(CH2)8-, -CH2-N(R a7 )-CH2-piperidinyl-CH2-, -CH2-N(R a7 )-CH2-piperidinyl-(CH2)2-, -CH2-N(R a7 )-CH2-piperidinyl-(CH2)3-, -CH2-N(R a7 )-CH2-piperidinyl-(CH2)4-, -CH2-N(R a7 )-CH2-piperidinyl-(CH2)5-, -CH2-N(R a7 )-CH2-piperidinyl-(CH2)6-, -CH2-N(R a7 )-CH2-piperidinyl-(CH2)7-, -CH2-N(R a7 )-CH2-piperidinyl-(CH2)8-, -CH2-N(R a7 )-(CH2)2-piperidinyl-CH2-, -CH2-N(R a7 )-(CH2)2-piperidinyl-(CH2)2-, -CH2-N(R a7 )-(CH2)2-piperidinyl-(CH2)3-, -CH2-N(R a7 )-(CH2)2-piperidinyl-(CH2)4-, -CH2-N(R a7 )-(CH2)2-piperidinyl-(CH2)5-, -CH2-N(R a7 )-(CH2)2-piperidinyl-(CH2)6-, -CH2-N(R a7 )-(CH2)2-piperidinyl-(CH2)7-, -CH2-N(R a7 )-(CH2)2-piperidinyl-(CH2)8-, -(CH2)2-N(R a7 )-CH2-piperidinyl-CH2-, -(CH2)2-N(R a7 )-CH2-piperidinyl-(CH2)2-, -(CH2)2-N(R a7 )-CH2-piperidinyl-(CH2)3-, -(CH2)2-N(R a7 )-CH2-piperidinyl-(CH2)4-, -(CH2)2-N(R a7 )-CH2-piperidinyl-(CH2)5-, -(CH2)2-N(R a7 )-CH2-piperidinyl-(CH2)6-, -(CH2)2-N(R a7 )-CH2-piperidinyl-(CH2)7-, -(CH2)2-N(R a7 )-CH2-piperidinyl-(CH2)8-, -(CH2)3-N(R a7 )-CH2-piperidinyl-CH2-, -(CH2)3-N(R a7 )-CH2-piperidinyl-(CH2)2-, -(CH2)3-N(R a7 )-CH2-piperidinyl-(CH2)3-, -(CH2)3-N(R a7 )-CH2-piperidinyl-(CH2)8-, -(CH2)4-N(R a7 )-CH2-piperidinyl-CH2-, -(CH2)4-N(R a7 )-CH2-piperidinyl-(CH2)2-, -(CH2)4-N(R a7 )-CH2-piperidinyl-(CH2)3-, -(CH2)4-N(R a7 )-CH2-piperidinyl-(CH2)8-, -(CH2)5-N(R a7 )-CH2-piperidinyl-(CH2)3-, -(CH2)5-N(R a7 )-CH2-piperidinyl-(CH2)8-, -(CH2)6-N(R a7 )-CH2-piperidinyl-(CH2)3-, -(CH2)6-N(R a7 )-CH2-piperidinyl-(CH2)8-, -(CH2)7-N(R a7 )-CH2-piperidinyl-(CH2)3-, -(CH2)8-N(R a7 )-CH2-piperidinyl-CH2-, -(CH2)8-N(R a7 )-CH2-piperidinyl-(CH2)2-, -(CH2)8-N(R a7 )-CH2-piperidinyl-(CH2)3-, -(CH2)8-N(R a7 )-CH2-piperidinyl-(CH2)4-、-(CH2)8-N(R a7 )-CH2-piperidinyl-(CH2)5-, -(CH2)8-N(R a7 )-CH2-piperidinylene-(CH2)6-, -piperazinylene-CH2-, -piperazinylene-(CH2)2-, -piperazinylene-(CH2)3-, -piperazinylene-(CH2)4-, -piperazinylene-(CH2)5-, -piperazinylene-(CH2)6-, -piperazinylene-(CH2)7-, -piperazinylene-(CH2)8-, -CH2-piperazinylene-CH2-, -CH2-piperazinylene-(CH2)2-, -CH2-piperazinylene-(CH2)3-, -CH2-piperazinylene-(CH2)4-, -CH2-piperazinylene-(CH2)5-, -CH2-piperazinylene-(CH2)6-, -CH2-piperazinylene-(CH2)7-, -piperazinylene-(CH2)8-, -CH2-piperazinylene-CH2-, -CH2-piperazinylene-(CH2)2-, -CH2-piperazinylene-(CH2)3-, -CH2-piperazinylene-(CH2)4-, -CH2-piperazinylene-(CH2)5-, -CH2-piperazinylene-(CH2)6-, -CH2-piperazinylene-(CH2)7 -, -CH2-piperazinylene-(CH2)8-, -(CH2)2-piperazinylene-(CH2)1-, -(CH2)2-piperazinylene-(CH2)2-, -(CH2)2-piperazinylene-(CH2)3-, -(CH2)2-piperazinylene-(CH2)4-, -(CH2)2-piperazinylene-(CH2)5-, -(CH2)2-piperazinylene-(CH2)6-, -(CH2)2-piperazinylene-(CH2)7-, -(CH2)2-piperazinylene-(CH2)8-, -(CH2)3-piperazinylene-CH2-, -(CH2)3-piperazinylene-(CH2)2-, -(CH2)3-piperazinylene-(CH2)3-, -( -(CH2)3-piperazinylene-(CH2)4-, -(CH2)3-piperazinylene-(CH2)5-, -(CH2)3-piperazinylene-(CH2)6-, -(CH2)3-piperazinylene-(CH2)7-, -(CH2)3-piperazinylene-(CH2)8-, -(CH2)4-piperazinylene-CH2-, -(CH2)4-piperazinylene-(CH2)2-, -(CH2)4-piperazinylene-(CH2)3-, -(CH2)4-piperazinylene-(CH2)4-, -(CH2)4-piperazinylene-(CH2)5-, -(CH2)4-piperazinylene-(CH2)6-, -(CH2)4-piperazinylene-(CH2)7-, -(CH2)3-piperazinylene-(CH2)8-, -(CH2)4-piperazinylene-CH2-, -(CH2)4-piperazinylene-(CH2)2-, -(CH2)4-piperazinylene-(CH2)3-, -(CH2)4-piperazinylene-(CH2)4-, -(CH2)4-piperazinylene-(CH2)5-, -(CH2)4-piperazinylene-(CH2)6-, -(CH2)4-piperazinylene-(CH2)7-, -(CH2) -(CH2)4-piperazinylene-(CH2)8-, -(CH2)5-piperazinylene-(CH2)1-, -(CH2)5-piperazinylene-(CH2)2-, -(CH2)5-piperazinylene-(CH2)3-, -(CH2)5-piperazinylene-(CH2)4-, -(CH2)5-piperazinylene-(CH2)5-, -(CH2)5-piperazinylene-(CH2)6-, -(CH2)5-piperazinylene-(CH2)7-, -(CH2)5-piperazinylene-(CH2)8-, -(CH2)6-piperazinylene-(CH2)1-, -(CH2)6-piperazinylene-(CH2)2-, -(CH2)6-piperazinylene-(CH2)3-,-(CH2)6-piperazinylene-(CH2)4-, -(CH2)6-piperazinylene-(CH2)5-, -(CH2)6-piperazinylene-(CH2)6-, -(CH2)6-piperazinylene-(CH2)7-, -(CH2)6-piperazinylene-(CH2)8-, -(CH2)7-piperazinylene-(CH2)1-, -(CH2)7-piperazinylene-(CH2)2-, -(CH2)7-piperazinylene -(CH2)3-, -(CH2)7-piperazinylene-(CH2)4-, -(CH2)8-piperazinylene-CH2-, -(CH2)8-piperazinylene-(CH2)2-, -(CH2)8-piperazinylene-(CH2)3-, -(CH2)8-piperazinylene-(CH2)4-, -(CH2)8-piperazinylene-(CH2)5-, or -(CH2)8-piperazinylene-(CH2)6-; Among them, each R a7 independently represents H or C 1-3 alkyl; The phenylene, the piperazinyl and the piperidinyl are each independently selected from deuterium, hydroxyl, amino, thiol, nitro, halogen, cyano, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 3-6 Cycloalkyl, halogenated C 3-6 Cycloalkyl, deuterated C 3-6 The substituents are substituted by cycloalkyl, 4- to 10-membered heterocyclic group, and any combination thereof.

18. A compound of formula (I) or a salt, enantiomer, stereoisomer, solvate, isotopically enriched analog, prodrug or polymorph thereof as claimed in any one of claims 1 to 17, wherein LIN represents: a bond, C(O), C(O)NH, NHC(O), -CH2-, -(CH2)2-, -(CH2)3-, -(CH2)4-, -(CH2)5-, -(CH2)6-, -(CH2)7-, -(CH2)8-, -(CH2)9-, -(CH2) 10 -, -(CH2) 11 -, -(CH2) 12 -, -(CH2) 13 -, -(CH2) 14 -, -(CH2) 15 -; -O-CH2-, -O-(CH2)2-, -O-(CH2)3-, -O-(CH2)4-, -O-(CH2)5-, -O-(CH2)6-, -O-(CH2)7-, -O-(CH2)8-, -O-(CH2)9-, -O-(CH2) 10 -, -(CH2)1-O-, -(CH2)2-O-, -(CH2)3-O-, -(CH2)4-O-, -(CH2)5-O-, -(CH2)6-O-, -(CH2)7-O-, -(CH2)8-O-, -(CH2)9-O-, -(CH2) 10 -O-、-CH2-O-CH2-、-CH2-O-(CH2)2-、-(CH2)1-O-(CH2)3-、-(CH2)1-O-(CH2)4-、-(CH2)1-O-(CH2)5-、-(CH2)1-O-(CH2)6-、-(CH2)1-O-(CH2)7-、-( CH2)1-O-(CH2)8-、-(CH2)2-O-(CH2)1-、-(CH2)2-O-(CH2)2-、-(CH2)2-O-(CH2)3-、-(CH2)2-O-(CH2)4-、-(CH2)2-O-(CH2)5-、-(CH2)2-O-(CH2)6-、-(CH2)2-O-(CH2)7-、-(CH2)2-O-(CH2)8-、-(CH2)3-O-(CH2)1-、-(CH2)3-O-(CH2)2-、-(CH2)3-O-(CH2)3-、-(CH2)3-O-(CH2)4-、-(CH2)3-O-(CH2 )5-、-(CH2)3-O-(CH2)6-、-(CH2)3-O-(CH2)7-、-(CH2)4-O-(CH2)1-、-(CH2)4-O-(CH2)2-、-(CH2)4-O-(CH2)3-、-(CH2)4-O-(CH2)4-、-(CH2)4-O-(C H2)5-、-(CH2)4-O-(CH2)6-、-(CH2)5-O-(CH2)1-、-(CH2)5-O-(CH2)2-、- (CH2)5-O-(CH2)3-、-(CH2)5-O-(CH2)4-、-(CH2)5-O-(CH2)5-、-(CH2)6-O -(CH2)1-、-(CH2)6-O-(CH2)2-、-(CH2)6-O-(CH2)3-、-(CH2)6-O-(CH2)4-、-(CH2)7-O-(CH2)1-、-(CH2)7-O-(CH2)2-、-(CH2)7-O-(CH2)3-、-(CH2)8-O-(CH2)1-、-(CH2)8-O-(CH2)2-、-CH(CH3)-O-(CH2)1-、-CH(CH3)-O-(CH2)2-、-CH(CH3)-O-(CH2)3-、-CH(CH3)-O-(CH2)4-、-CH(CH3)-O-(CH2)5 -、-CH(CH3)-O-(CH2)6-、-CH(CH3)-O-(CH2)7-、-CH(CH3)-O-(CH2)8-、-(O(CH2)2)2-、-(O(CH2)2)3-、-(O(CH2)2)4-、-(O(CH2)2)5-、-(O(CH2)2)6-、-CH2-(O(CH2)2)2-、-CH2-(O(CH2)2)3-、-CH2-(O(CH2)2)4-、-CH2-(O(CH2)2)5-、-CH2-(O(CH2)2)6-、-CH2-(O(CH2)2)1-OCH2-、 -CH2-(O(CH2)2)2-OCH2-、-CH2-(O(CH2)2)3-OCH2-、-CH2-(O(CH2)2)4-OCH2-、-CH2-(O(CH2)2)5-OCH2-、-CH2-(O(CH2)2)6-OCH 2-、-(CH2)2-(O(CH2)2)2-、-(CH2)2-(O(CH2)2)3-、-(CH2)2-(O(CH2)2)4-、-(CH2)2-(O(CH2)2)5-、-(CH2)2-(O(CH2)2)6-、-(CH2)3-(O(CH2)2)2-、-(CH2)3-(O(CH2)2)3-、-(CH2)3-(O(CH2)2)4-、-(CH2)3-(O(CH2)2)5-、-(CH2)4-(O(CH2)2)2-、-(CH2)4-(O(C H2)2)3-、-(CH2)4-(O(CH2)2)4-、-(CH2)4-(O(CH2)2)5-、-CH2-(O(CH2)3)2-、-CH2-(O(CH2)3)3-、-CH2-(O(CH2)3)4-、-(CH2)2- (O(CH2)3)2-、-(CH2)2-(O(CH2)3)3-、-(CH2)2-(O(CH2)3)4-、-(CH2)3-(O(CH2)3)2-、-(CH2)3-(O(CH2)3)3-、-CH2-O-(CH2)2-O -(CH2)3-、-CH2-(O(CH2)2)2-(O(CH2)3)2-、(CH2)2-O-(CH2)2-O-(CH2)3-、-(CH2)2-(O(CH2)2)2-(O(CH2)3)2-、-(CH2)3-O-(CH2)2-O-(CH2)3-、-(CH2)3-(O(CH2)2)2-(O(CH2)3)2-、-CH2-O-(CH2)3-O-(CH2)2-、-CH2-(O(CH2)3)2-(O(CH2)2)2-、(CH2)1-N(R、 a7 )-(CH2)1-、-(CH2)1-N(R a7 )-(CH2)2-、-(CH2)1-N(R a7 )-(CH2)3-、-(CH2)1-N(R a7 )-(CH2)4-、-(CH2)1-N(R a7 )-(CH2)5-、-(CH2)1-N(R a7 )-(CH2)6-、-N(R a7 )-(CH2)1-、-N(R a7 )-(CH2)2-、-N(R a7 )-(CH2)3-、-N(R a7 )-(CH2)4-、-N(R a7 )-(CH2)5-、-N(R a7 )-(CH2)6-、-(CH2)2-N(R a7 )-(CH2)1-、-(CH2)2-N(R a7 )-(CH2)2-、-(CH2)2-N(R a7 )-(CH2)3-、-(CH2)2-N(R a7 )-(CH2)4-、-(CH2)2-N(R a7 )-(CH2)5-、-(CH2)2-N(R a7 )-(CH2)6-、-(CH2)3-N(R a7 )-(CH2)1-、-(CH2)3-N(R a7 )-(CH2)2-、-(CH2)3-N(R a7 )-(CH2)3-、-(CH2)4-N(R a7 )-(CH2)1-、-(CH2)4-N(R a7 )-(CH2)2-、-(CH2)4-N(R a7 )-(CH2)3-、-(CH2)4-N(R a7 )-(CH2)4-、-(CH2)5-N(R a7 )-(CH2)1-、-(CH2)5-N(R a7 )-(CH2)2-、-(CH2)5-N(R a7 )-(CH2)3-、-(CH2)5-N(R a7 )-(CH2)4-、-(CH2)5-N(R a7 )-(CH2)5-、-(CH2)6-N(R a7 )-(CH2)1-、-(CH2)6-N(R a7 )-(CH2)2-、-(CH2)6-N(R a7 )-(CH2)3-、-(CH2)7-N(R a7 )-(CH2)1-、-(CH2)7-N(R a7 )-(CH2)2-、-(CH2)7-N(R a7 )-(CH2)3-、-(CH2)8-N(R a7 )-(CH2)1-、-(CH2)8-N(R a7 )-(CH2)2-、-(CH2)8-N(R a7 )-(CH2)3-、-CH(CH3)-N(R a7 )-(CH2)1-、-CH(CH3)-N(R a7 )-(CH2)2-、-CH(CH3)-N(R a7 )-(CH2)3-、-CH(CH3)-N(R a7 )-(CH2)4-、-CH(CH3)-N(R a7 )-(CH2)5-、-CH(CH3)-N(R a7 )-(CH2)6-, -C(O)NHCH2-, -C(O)NH(CH2)2-, -C(O)NH(CH2)3-, -C(O)NH(CH2)4-, -C(O)NH(CH2)5-, -CH2C(O)NHCH2-, -(CH2)2C(O)NH(CH2)2-, -(CH2 )2C(O)NH(CH2)3-, -(CH2)2C(O)NH(CH2)4-, -(CH2)2C(O)NH(CH2)5-, -(CH2)3C(O)NH(CH2)3-, -(CH2)3C(O)NH(CH2)4-, -(CH2)4C(O)NH(CH2)4-, -(C H2)5C(O)NH(CH2)5-, -(CH2)2C(O)NH(CH2)2-O-(CH2)2-, -NHC(O)CH2-, -NHC(O)(CH2)2-, -NHC(O)(CH2)3-, -NHC(O)(CH2)4-, -NHC(O)(CH2)5-, -CH2 NHC(O)CH2-, -(CH2)2NHC(O)(CH2)2-, -(CH2)2NHC(O)(CH2)3-, -(CH2)2NHC(O)(CH2)4-, -(CH2)2NHC(O)(CH2)5-, -(CH2)3NHC(O)(CH2)3-, -(CH2)3N HC(O)(CH2)4-, -(CH2)4NHC(O)(CH2)4-, -(CH2)5NHC(O)(CH2)5-, -(CH2)2NHC(O)(CH2)2-O-(CH2)2-, -(CH2)4NHC(O)CH2-, -CH2-phenylene-CH2-, -CH2-phenylene-(CH2)2-, -CH2-phenylene-(CH2)3-, -CH2-phenylene-(CH2)4-, -CH2-phenylene-(CH2)5-, -CH2-phenylene-(CH2)6-, -(CH2)2-phenylene-(CH2)1-, -(CH2)2-phenylene-(CH2)2-, -(CH2) 2-phenylene-(CH2)3-, -(CH2)2-phenylene-(CH2)4-, -(CH2)2-phenylene-(CH2)5-, -(CH2)3-phenylene-CH2-, -(CH2)3-phenylene-(CH2)2-, -(CH2)3-phenylene-(CH2)3-, -(CH2)3-phenylene-(CH2)4-, -(CH2)3-phenylene-(CH2)5-, -(CH2)4-phenylene-CH2-, -(CH2)4-phenylene-(CH2)2-, -(CH2)4-phenylene-(CH2)3-, -(CH2)4-phenylene-(CH2)4-, -(CH2)4-phenylene-(CH2)5-,-CH2-piperidinylene-CH2-, -CH2-piperidinylene-(CH2)2-, -CH2-piperidinylene-(CH2)3-, -CH2-piperidinylene-(CH2)4-, -CH2-piperidinylene-(CH2)5-, -CH2-piperidinylene-(CH2)6-, -(CH2)2-piperidinylene-(CH2)1-, -(CH2)2-piperidinylene-(CH2)2-, -(CH2)2-piperidinylene-(CH2)3-, -(CH2)2-piperidinylene-(CH2)4-, -(CH2)2-piperidinylene-( -(CH2)5-, -(CH2)3-piperidinylene-CH2-, -(CH2)3-piperidinylene-(CH2)2-, -(CH2)3-piperidinylene-(CH2)3-, -(CH2)3-piperidinylene-(CH2)4-, -(CH2)3-piperidinylene-(CH2)5-, -CH2-piperazinylene-CH2-, -CH2-piperazinylene-(CH2)2-, -CH2-piperazinylene-(CH2)3-, -CH2-piperazinylene-(CH2)4-, -CH2-piperazinylene-(CH2)5-, -(CH2)2 -piperazinylene-(CH2)1-, -(CH2)2-piperazinylene-(CH2)2-, -(CH2)2-piperazinylene-(CH2)3-, -(CH2)2-piperazinylene-(CH2)4-, -(CH2)2-piperazinylene-(CH2)5-, -(CH2)3-piperazinylene-CH2-, -(CH2)3-piperazinylene-(CH2)2-, -(CH2)3-piperazinylene-(CH2)3-, -(CH2)3-piperazinylene-(CH2)4-, -(CH2)3-piperazinylene-(CH2)5-, -(C H2)4-piperazinylene-CH2-, -(CH2)4-piperazinylene-(CH2)2-, -(CH2)4-piperazinylene-(CH2)3-, -(CH2)4-piperazinylene-(CH2)4-, -(CH2)4-piperazinylene-(CH2)5-, -(CH2)8-piperazinylene-CH2-, -(CH2)8-piperazinylene-(CH2)2-, -(CH2)8-piperazinylene-(CH2)3-, -(CH2)8-piperazinylene-(CH2)4-, or -(CH2)8-piperazinylene-(CH2)5-; or, LIN means: wherein the above groups are optionally selected from deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, carboxyl, C 2-6 Alkynyl or C 2-6 The substituents of the alkenyl group are substituted.

19. A compound of formula (I) or a salt, enantiomer, stereoisomer, solvate, isotopically enriched analog, prodrug or polymorph thereof according to any one of claims 1 to 18, which is also represented by the structure of the following formula (I-1), formula (I-2), formula (I-3), formula (I-4), formula (I-5), formula (I-6), formula (I-7) or formula (I-8): Among them, Z, R a1 、R a2 、R a3 、R a4 、(R a5 ) m 、R a6 ,LIN,R c 、(R 1a ) p1a 、R 1b 、(R 1c ) p1b 、R 1d , Ring A, R 2a 、R 2b 、(R 2c ) p2a 、(R 2d ) p2b 、(R 3a ) p3a 、R 3b 、X1、X2、X3、X4、R 4a 、R 4b 、(R 4c ) p4a 、(R 4d ) p4b , Ring B, R 5a 、R 5b 、(R 6a ) p6a 、(R 6b ) p6b 、R x1 , Ring C, Ring D, Ring E, R 8a 、R 8b 、(R 8c ) p8a and (R 8d ) p8b As defined in claim 3.

20. A compound of formula (I) according to claim 1 or a salt, enantiomer, stereoisomer, solvate, isotopically enriched analog, prodrug or polymorph thereof, selected from the compounds in Table 1.

21. A compound of formula (I) or a salt, enantiomer, stereoisomer, solvate, or polymorph thereof as claimed in any one of claims 1 to 20, which is a hydrohalide salt (including hydrochloride, hydrobromide), sulfate, maleate, sulfonate, citrate / citrate, lactate, lactobionate, L-tartrate, fumarate, L-malate, L-lactate, α-ketoglutarate, hippurate, D-glucuronate, D-gluconate, α-D-glucoheptonate, glycolate, mucate, L-ascorbate, orotate, picrate, glycinate, alanine, arginine, cinnamate, laurate, pamoate, sebacate, benzenesulfonate, methanesulfonate, ethanesulfonate, edisylate, formate, acetate, 2,2- dichloroacetate, pivalate, propionate, valerate, palmitate, triphenylacetate, 2-ethyl-succinate, iodate, nicotinate, L-pyroglutamate, L-proline, ferulate, 2-hydroxyethanesulfonate, nitrate, gentisate, cholate, salicylate, terephthalate, glutarate, adipate, stearate, oleate, undecenoate, camphorate, camphorsulfonate, dodecylsulfonate, phosphate, thiocyanate, dihydrogenphosphate, pyrophosphate, metaphosphate, oxalate, carbonate, malonate, benzoate, mandelate, succinate, pyruvate, p-chlorobenzenesulfonate, 1,5-naphthalenedisulfonate, 3-hydroxy-2-naphthoate, 1-hydroxy-2-naphthoate, 2-naphthalenesulfonate, trifluoroacetate, glycolate, or p-toluenesulfonate.

22. A compound of formula (II) or a salt, enantiomer, stereoisomer, solvate, isotopically enriched analog, prodrug or polymorph thereof: in Z represents C(O) or CH2; R a1 、R a2 、R a3 and R a4 The same or different and each independently represents hydrogen, deuterium, halogen, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy or halogenated C 1-6 alkoxy; (R a5 ) m represents that the isoindoline ring connected thereto is optionally replaced by m R a5 Replace, each R a5 The same or different and each independently represents deuterium, halogen, hydroxyl, mercapto, nitro, amino, cyano, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy or halogenated C 1-6 alkoxy; m represents an integer 0, 1, 2 or 3; R E express: Among them, ring Y 1 represents a heterocyclic group containing at least 2 nitrogen atoms, (R d1 ) n1 Represents ring Y 1 Optionally n1 R d1 Group substitution, each R d1 Each independently represents deuterium, halogen, hydroxyl, mercapto, nitro, amino, cyano, oxo, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy or C 1-6 alkoxy, and n1 represents an integer of 0-20; and R1 represents N(R w ), where R w Represents hydrogen or C 1-3 Alkyl, and R E1 represents hydrogen; or R1 represents a bond, and R E1 represents NH2; or R E express: Among them, ring Y 3 represents a heterocyclic group containing one nitrogen atom, (R d3 ) n3 Represents ring Y 3 Optionally n3 R d3 Group substitution, each R d3 Each independently represents deuterium, halogen, hydroxyl, mercapto, nitro, amino, cyano, oxo, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy or C 1-6 alkoxy, and n3 represents an integer of 0-20; and where R s1 express Symbol **** indicates the ring Y 3 The connection point of R E2 represents NH2; Provided that the following compounds are not included: 3-(1-oxo-5-(piperazin-1-ylamino)isoindolin-2-yl)piperidine-2,6-dione.

23. A compound of formula (II) or a salt, enantiomer, stereoisomer, solvate, isotopically enriched analog, prodrug or polymorph thereof according to claim 22, which is also a compound of formula (II-1), formula (II-2), formula (II-3) or formula (II-4): Among them, Z, R a1 、R a2 、R a3 、R a4 、(R a5 ) m and R E As defined in claim 21.

24. A compound of formula (II) or a salt, enantiomer, stereoisomer, solvate, isotopically enriched analog, prodrug or polymorph thereof as claimed in claim 22 or 23, wherein (i) When Z represents CH2, m represents an integer of 0, R w represents hydrogen, and ring Y 1 When it represents piperazinyl, ring Y 1 By n1 R d1 Group substitution, each R d1 Each independently represents deuterium, halogen, hydroxyl, mercapto, nitro, amino, cyano, oxo, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy or C 1-6 alkoxy, and n1 represents an integer of 1 to 20; or (ii) the ring Y 1 represents a 4- to 20-membered heterocyclylene group containing at least 2 nitrogen atoms, (R d1 ) n1 Represents ring Y 1 Optionally n1 R d1 Group substitution, each R d1 Each independently represents deuterium, halogen, hydroxyl, mercapto, nitro, amino, cyano, oxo, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy or C 1-6 alkoxy, and n1 represents an integer of 0-20; or (iii) the ring Y 3 represents a 4- to 20-membered heterocyclic group containing one nitrogen atom, (R d3 ) n3 Represents ring Y 3 Optionally n3 R d3 Group substitution, each R d3 Each independently represents deuterium, halogen, hydroxyl, mercapto, nitro, amino, cyano, oxo, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy or C 1-6 alkoxy, and n3 represents an integer of 0-20.

25. The compound of formula (II) as described in any one of claims 22 to 24, or a salt, enantiomer, stereoisomer, solvate, isotopically enriched analog, prodrug or polymorph thereof, wherein the ring Y 1 represents a 4- to 20-membered heterocyclic group containing 2-4 nitrogen atoms, for example, the ring Y 1 express: Diazetidinylidene, imidazolidinylidene, pyrazolidinylidene, piperazinylidene, 1,2,3,4-tetrahydropyrazinylidene, hexahydropyrimidinylidene, hexahydropyridazinylidene, diazaheptanylidene, diazaoctanylidene, diazabicyclo[3.1.1]heptanylidene, diazabicyclo[2.2.1]heptanylidene, diazabicyclo[3.2.1]octanylidene, diazabicyclo[2.2.2]octanylidene , diazaspiro[2.3]hexanediyl, diazaspiro[3.3]heptanylidene, diazaspiro[2.4]heptanylidene, diazaspiro[3.4]octanylidene, diazaspiro[3.5]nonanediyl, diazaspiro[4.4]nonanediyl, diazaspiro[4.5]decanediyl, diazaspiro[5.5]undecanediyl, octahydropyrrolo[3,4-c]pyrrolediyl or decahydronaphthyridinylidene, or The ring Y 1 Optionally n1 R d1 Group substitution, each R d1 Each independently represents deuterium, halogen, hydroxyl, mercapto, nitro, amino, cyano, oxo, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy or C 1-6 alkoxy, and n1 represents an integer of 0-20.

26. A compound of formula (II) according to claim 22, or a salt, enantiomer, stereoisomer, solvate, isotopically enriched analog, prodrug or polymorph thereof, selected from the compounds in Table 2.

27. A compound of formula (II) or a salt, enantiomer, stereoisomer, solvate, or polymorph thereof as described in any one of claims 22 to 26, which is a hydrohalide salt (including hydrochloride, hydrobromide), sulfate, maleate, sulfonate, citrate / citrate, lactate, lactobionate, L-tartrate, fumarate, L-malate, L-lactate, α-ketoglutarate, hippurate, D-glucuronate, D-gluconate, α-D-glucoheptonate, glycolate, mucate, L-ascorbate, orotate, picrate, glycinate, alanine, arginine, cinnamate, laurate, pamoate, sebacate, benzenesulfonate, methanesulfonate, ethanesulfonate, edisylate, formate, acetate, 2, 2-dichloroacetate, pivalate, propionate, valerate, palmitate, triphenylacetate, 2-ethyl-succinate, iodate, nicotinate, L-pyroglutamate, L-proline, ferulate, 2-hydroxyethanesulfonate, nitrate, gentisate, cholate, salicylate, terephthalate, glutarate, adipate, stearate, oleate, undecenoate, camphorate, camphorsulfonate, dodecylsulfonate, phosphate, thiocyanate, dihydrogenphosphate, pyrophosphate, metaphosphate, oxalate, carbonate, malonate, benzoate, mandelate, succinate, pyruvate, p-chlorobenzenesulfonate, 1,5-naphthalenedisulfonate, 3-hydroxy-2-naphthoate, 1-hydroxy-2-naphthoate, 2-naphthalenesulfonate, trifluoroacetate, glycolate, or p-toluenesulfonate.

28. A pharmaceutical composition comprising: A compound of formula (I) according to any one of claims 1 to 21, or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate, isotopically enriched analog, prodrug or polymorph thereof, and at least one pharmaceutically acceptable carrier; or A compound of formula (II) according to any one of claims 22 to 27, or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate, isotopically enriched analog, prodrug or polymorph thereof, and at least one pharmaceutically acceptable carrier; and optionally includes at least one additional therapeutic agent, such as an anti-cancer agent.

29. A kit or test kit comprising: A compound of formula (I) or a pharmaceutically acceptable salt thereof as claimed in any one of claims 1 to 21; or A compound of formula (II) or a pharmaceutically acceptable salt thereof as claimed in any one of claims 22 to 27; or The pharmaceutical composition of claim 28.

30. A compound of formula (I) or a salt, enantiomer, stereoisomer, solvate, isotopically enriched analog, prodrug or polymorph as described in any one of claims 1 to 21 for use in treating and / or preventing a disease or condition selected from the group consisting of tumors, infectious diseases, autoinflammatory diseases, inflammatory diseases, autoimmune diseases, neurological diseases, respiratory diseases, hemorrhagic shock, transplant rejection, multiple organ dysfunction syndrome (MODS), sarcoidosis, adult respiratory distress syndrome, cardiovascular disease, Richter syndrome (RS), acute liver failure, diabetes, Kennedy disease, seborrheic alopecia, hirsutism, skin diseases, dysfunctional uterine bleeding, anemia, aplastic anemia in children, endometriosis, polycystic ovary syndrome and thyroid disease.

31. A compound of formula (I) or a salt, enantiomer, stereoisomer, solvate, isotopically enriched analog, prodrug or polymorph thereof according to claim 30, wherein the disease or condition is selected from the group consisting of: myeloma, including multiple myeloma, plasma cell myeloma, smoldering myeloma, smoldering multiple myeloma; myelofibrosis; bone marrow disease; myelodysplastic syndrome (MDS); previously treated myelodysplastic syndrome; transplant-related cancer; neutropenia; leukemia, including acute myeloid leukemia (AML), chronic myeloid leukemia (CML), chronic myeloid leukemia, acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), B-cell chronic lymphocytic leukemia, anemia associated with leukemia, acute B lymphocytic leukemia, T lymphocytic leukemia, acute T lymphocytic leukemia, lymphoma cell leukemia, monocytic leukemia, myelomonocytic leukemia; lymphoma Tumors, including diffuse large B-cell lymphoma, non-Hodgkin's lymphoma, Hodgkin's lymphoma, anaplastic lymphoma, anaplastic large cell lymphoma, immunoblastic T-cell lymphoma, CD20-positive lymphoma, mantle cell lymphoma, follicular lymphoma (FL), Burkitt's lymphoma, marginal zone lymphoma (MZL), primary lymphoma, B-cell lymphoma, relapsed B-cell non-Hodgkin's lymphoma, relapsed diffuse large B-cell lymphoma, relapsed mediastinal large B-cell Lymphoma, primary mediastinal large B-cell lymphoma, relapsed transformed non-Hodgkin's lymphoma, refractory B-cell non-Hodgkin's lymphoma, refractory diffuse large B-cell lymphoma, refractory primary mediastinal large B-cell lymphoma, refractory transformed non-Hodgkin's lymphoma; thyroid cancer; melanoma; lung cancer, including lung adenocarcinoma, lung squamous cell carcinoma, non-small cell lung cancer, and small cell lung cancer; inflammatory myofibroblastic tumor; colorectal cancer; intestinal cancer; brain glioma; astrocytoblastoma; glioma; Peripheral neuroepithelial tumors; ovarian cancer; bronchogenic cancer; prostate cancer; breast cancer, including triple-negative breast cancer, incidental breast cancer, ductal carcinoma, and patients with Cowden disease; pancreatic cancer; central nervous system cancers; neuroblastoma; extramedullary plasmacytoma; plasmacytoma; gastric cancer; gastrointestinal stromal tumors; esophageal cancer; colorectal adenocarcinoma; esophageal squamous cell carcinoma; liver cancer; renal cell carcinoma; bladder cancer; endometrial cancer; uterine cancer; head and neck cancer; brain cancer; oral cancer; sarcomas, including rhabdomyosarcoma, various adipose-derived tumors, Ewing sarcoma / primitive neuroectodermal tumors (Ewing / PNETs), and leiomyosarcoma; urothelial carcinoma; basal cell carcinoma; oral squamous cell carcinoma; and bile duct cancer. Bone cancer; cervical cancer; skin cancer; Richter syndrome (RS); sepsis syndrome; autoimmune diseases, including rheumatoid arthritis, autoimmune encephalomyelitis, ankylosing spondylitis, psoriasis, psoriatic arthritis, systemic lupus erythematosus, multiple sclerosis, recurrent oral ulcers, Kawasaki disease, polymyositis / dermatomyositis, Sjögren's syndrome, atopic dermatitis, hidradenitis suppurativa, gout, type 1 diabetes, urticaria, inflammatory bowel disease (including Crohn's disease and ulcerative colitis); keratoconjunctivitis sicca; autoinflammatory diseases, including gout; inflammatory diseases, including pneumonia, osteoarthritis, synovitis, systemic inflammatory response syndrome, airway inflammation, bronchitis; cerebral malaria; infectious diseases, including viral pneumonia, AIDS (AIDS), S), COVID-19 novel coronavirus infection, Gram-negative bacterial infection, Gram-positive bacterial infection, tuberculosis, etc.; septic shock; bacterial meningitis; chronic obstructive pulmonary disease; asthma; hemorrhagic shock; organ (including kidney, heart, lung) or tissue transplant rejection; diabetes; sarcoidosis; adult respiratory distress syndrome; multiple organ failure due to cachexia and septic shock; acute liver failure; functional uterine bleeding; anemia; aplastic anemia in children; endometriosis; polycystic ovary syndrome; thyroid disease; cardiovascular disease (such as coronary heart disease, congestive heart failure, myocardial infarction, atherosclerosis); skin diseases (such as acne); Kennedy disease; seborrheic alopecia; and hirsutism.

32. A compound of formula (II) or a salt, enantiomer, stereoisomer, solvate, isotopically enriched analogue, prodrug or polymorph thereof as claimed in any one of claims 22 to 27 for use in the treatment and / or prevention of a disease or condition associated with the cereblon protein.

33. The compound of formula (II) or a salt, enantiomer, stereoisomer, solvate, isotopically enriched analog, prodrug or polymorph thereof according to claim 32, wherein the disease or disorder associated with cereblon protein is selected from the group consisting of: tumors, cancers and autoimmune diseases, such as myeloma, including multiple myeloma, plasma cell myeloma, smoldering myeloma, smoldering multiple myeloma; myelofibrosis; bone marrow disease; myelodysplastic syndrome (MDS); Previously treated myelodysplastic syndrome; transplant-related cancers; neutropenia; leukemias, including acute myeloid leukemia (AML), chronic myeloid leukemia (CML), chronic myeloid leukemia, acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), B-cell chronic lymphocytic leukemia, anemia associated with leukemia, acute B-cell lymphocytic leukemia, T-cell lymphocytic leukemia, acute T-cell lymphocytic leukemia, lymphoma cell leukemia, monocytic leukemia Lymphomas, including diffuse large B-cell lymphoma, non-Hodgkin's lymphoma, Hodgkin's lymphoma, anaplastic lymphoma, anaplastic large cell lymphoma, immunoblastic T-cell lymphoma, CD20-positive lymphoma, mantle cell lymphoma, follicular lymphoma (FL), Burkitt's lymphoma, marginal zone lymphoma (MZL), primary lymphoma, B-cell lymphoma, relapsed B-cell non-Hodgkin's lymphoma, relapsed diffuse large B-cell lymphoma, relapsed Recurrent mediastinal large B-cell lymphoma, primary mediastinal large B-cell lymphoma, relapsed transformed non-Hodgkin's lymphoma, refractory B-cell non-Hodgkin's lymphoma, refractory diffuse large B-cell lymphoma, refractory primary mediastinal large B-cell lymphoma, refractory transformed non-Hodgkin's lymphoma; thyroid cancer; melanoma; lung cancer, including adenocarcinoma, squamous cell carcinoma, non-small cell lung cancer, and small cell lung cancer; inflammatory myofibroblastic tumor; colorectal cancer; intestinal cancer; glioma; astrocytoblastoma; glioma; Peripheral neuroepithelial tumors; ovarian cancer; bronchogenic cancer; prostate cancer; breast cancer, including triple-negative breast cancer, incidental breast cancer, ductal carcinoma, and patients with Cowden disease; pancreatic cancer; central nervous system cancers; neuroblastoma; extramedullary plasmacytoma; plasmacytoma; gastric cancer; gastrointestinal stromal tumors; esophageal cancer; colorectal adenocarcinoma; esophageal squamous cell carcinoma; liver cancer; renal cell carcinoma; bladder cancer; endometrial cancer; uterine cancer; head and neck cancer; brain cancer; oral cancer; sarcomas, including rhabdomyosarcoma, various adipose-derived tumors, Ewing sarcoma / primitive neuroectodermal tumors (Ewing / PNETs), and leiomyosarcoma; urothelial carcinoma; basal cell carcinoma; oral squamous cell carcinoma; and bile duct cancer. bone cancer; cervical cancer; skin cancer; Richter syndrome (RS); and autoimmune diseases, including rheumatoid arthritis, autoimmune encephalomyelitis, ankylosing spondylitis, psoriasis, psoriatic arthritis, systemic lupus erythematosus, multiple sclerosis, recurrent oral ulcers, Kawasaki disease, polymyositis / dermatomyositis, Sjögren's syndrome, atopic dermatitis, hidradenitis suppurativa, gout, type 1 diabetes, urticaria, and inflammatory bowel disease (including Crohn's disease and ulcerative colitis).

34. A compound of formula (I) or a salt, enantiomer, stereoisomer, solvate, isotopically enriched analog, prodrug or polymorph as claimed in any one of claims 1 to 21 for the preparation of a medicament for treating and / or preventing a disease or condition selected from the group consisting of: tumors, infectious diseases, autoinflammatory diseases, inflammatory diseases, autoimmune diseases, neurological diseases, respiratory diseases, hemorrhagic shock, transplant rejection, multiple organ dysfunction syndrome (MODS), sarcoidosis, adult respiratory distress syndrome, cardiovascular disease, Richter syndrome (RS), acute liver failure, diabetes, Kennedy disease, seborrheic alopecia, hirsutism, skin diseases, dysfunctional uterine bleeding, anemia, aplastic anemia in children, endometriosis, polycystic ovary syndrome and thyroid disease.

35. A method for treating or preventing a disease or condition in a subject, comprising administering to the subject a therapeutically effective amount of a compound of formula (I) or a salt, enantiomer, stereoisomer, solvate, isotopically enriched analog, prodrug or polymorph thereof as described in any one of claims 1 to 21, wherein the disease or condition is selected from the group consisting of: tumors, infectious diseases, autoinflammatory diseases, inflammatory diseases, autoimmune diseases, neurological diseases, respiratory diseases, hemorrhagic shock, transplant rejection, multiple organ dysfunction syndrome (MODS), sarcoidosis, adult respiratory distress syndrome, cardiovascular disease, Richter syndrome (RS), acute liver failure, diabetes, Kennedy disease, seborrheic alopecia, hirsutism, skin diseases, dysfunctional uterine bleeding, anemia, aplastic anemia in children, endometriosis, polycystic ovary syndrome and thyroid disease.

36. The use of claim 34 or the method of claim 35, wherein the disease or condition is selected from the group consisting of: myeloma, including multiple myeloma, plasma cell myeloma, smoldering myeloma, smoldering multiple myeloma; myelofibrosis; bone marrow disease; myelodysplastic syndrome (MDS); previously treated myelodysplastic syndrome; transplant-related cancer; neutropenia; leukemia, including acute myeloid leukemia (AML), chronic myeloid leukemia (CML), chronic myeloid leukemia, acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), B-cell chronic lymphocytic leukemia, anemia associated with leukemia, acute B-cell leukemia, T-cell leukemia, acute T-lymphocytic leukemia, lymphoma cell leukemia, monocytic leukemia, myelomonocytic leukemia; lymphoma, including diffuse large B-cell lymphoma , non-Hodgkin lymphoma, Hodgkin lymphoma, anaplastic lymphoma, anaplastic large cell lymphoma, immunoblastic T-cell lymphoma, CD20-positive lymphoma, mantle cell lymphoma, follicular lymphoma (FL), Burkitt's lymphoma, marginal zone lymphoma (MZL), primary lymphoma, B-cell lymphoma, relapsed B-cell non-Hodgkin lymphoma, relapsed diffuse large B-cell lymphoma, relapsed mediastinal large B-cell lymphoma, primary Mediastinal large B-cell lymphoma, relapsed transformed non-Hodgkin's lymphoma, refractory B-cell non-Hodgkin's lymphoma, refractory diffuse large B-cell lymphoma, refractory primary mediastinal large B-cell lymphoma, refractory transformed non-Hodgkin's lymphoma; thyroid cancer; melanoma; lung cancer, including lung adenocarcinoma, lung squamous cell carcinoma, non-small cell lung cancer, and small cell lung cancer; inflammatory myofibroblastic tumor; colorectal cancer; intestinal cancer; brain glioma; astrocytoblastoma; glioma; Peripheral neuroepithelial tumors; ovarian cancer; bronchogenic cancer; prostate cancer; breast cancer, including triple-negative breast cancer, incidental breast cancer, ductal carcinoma, and patients with Cowden disease; pancreatic cancer; central nervous system cancers; neuroblastoma; extramedullary plasmacytoma; plasmacytoma; gastric cancer; gastrointestinal stromal tumors; esophageal cancer; colorectal adenocarcinoma; esophageal squamous cell carcinoma; liver cancer; renal cell carcinoma; bladder cancer; endometrial cancer; uterine cancer; head and neck cancer; brain cancer; oral cancer; sarcomas, including rhabdomyosarcoma, various adipose-derived tumors, Ewing sarcoma / primitive neuroectodermal tumors (Ewing / PNETs), and leiomyosarcoma; urothelial carcinoma; basal cell carcinoma; oral squamous cell carcinoma; and bile duct cancer. Bone cancer; cervical cancer; skin cancer; Richter syndrome (RS); sepsis syndrome; autoimmune diseases, including rheumatoid arthritis, autoimmune encephalomyelitis, ankylosing spondylitis, psoriasis, psoriatic arthritis, systemic lupus erythematosus, multiple sclerosis, recurrent oral ulcers, Kawasaki disease, polymyositis / dermatomyositis, Sjögren's syndrome, atopic dermatitis, hidradenitis suppurativa, gout, type 1 diabetes, urticaria, inflammatory bowel disease (including Crohn's disease and ulcerative colitis); keratoconjunctivitis sicca; autoinflammatory diseases, including gout; inflammatory diseases, including pneumonia, osteoarthritis, synovitis, systemic inflammatory response syndrome, airway inflammation, bronchitis; cerebral malaria; infectious diseases, including viral pneumonia, AIDS (AIDS), S), COVID-19 novel coronavirus infection, Gram-negative bacterial infection, Gram-positive bacterial infection, tuberculosis, etc.; septic shock; bacterial meningitis; chronic obstructive pulmonary disease; asthma; hemorrhagic shock; organ (including kidney, heart, lung) or tissue transplant rejection; diabetes; sarcoidosis; adult respiratory distress syndrome; multiple organ failure due to cachexia and septic shock; acute liver failure; functional uterine bleeding; anemia; aplastic anemia in children; endometriosis; polycystic ovary syndrome; thyroid disease; cardiovascular disease (such as coronary heart disease, congestive heart failure, myocardial infarction, atherosclerosis); skin diseases (such as acne); Kennedy disease; seborrheic alopecia; and hirsutism.

37. Use of a compound of formula (II) or a salt, enantiomer, stereoisomer, solvate, isotopically enriched analog, prodrug or polymorph thereof as described in any one of claims 22 to 27, or 3-(1-oxo-5-(piperazin-1-ylamino)isoindolin-2-yl)piperidine-2,6-dione or a salt, enantiomer, stereoisomer, solvate, isotopically enriched analog, prodrug or polymorph thereof, for the preparation of a medicament for treating and / or preventing a disease or condition associated with the cereblon protein.

38. A method of treating or preventing a disease or condition associated with cereblon protein in a subject, comprising administering to the subject a therapeutically effective amount of a compound of formula (II) as described in any one of claims 22 to 27, or a salt, enantiomer, stereoisomer, solvate, isotopically enriched analog, prodrug or polymorph thereof, or 3-(1-oxo-5-(piperazin-1-ylamino)isoindolin-2-yl)piperidine-2,6-dione, or a salt, enantiomer, stereoisomer, solvate, isotopically enriched analog, prodrug or polymorph thereof.

39. The use of claim 37 or the method of claim 38, wherein the disease or disorder associated with the cereblon protein is selected from the group consisting of tumors, cancers and autoimmune diseases.

40. The use of claim 37 or the method of claim 38, wherein the disease or condition associated with the cereblon protein is selected from the group consisting of: myeloma, including multiple myeloma, plasma cell myeloma, smoldering myeloma, smoldering multiple myeloma; myelofibrosis; bone marrow disease; myelodysplastic syndrome (MDS); previously treated myelodysplastic syndrome; transplant-related cancer; neutropenia; leukemia, including acute myeloid leukemia (AML), chronic myeloid leukemia (CML), chronic myeloid leukemia, acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), B-cell chronic lymphocytic leukemia, anemia associated with leukemia, acute B-lymphocytic leukemia, T-lymphocytic leukemia, acute T-lymphocytic leukemia, lymphoma cell leukemia, monocytic leukemia, myelomonocytic leukemia; lymphoma, including diffuse large B-cell lymphoma, non-Hodgkin's lymphoma, Hodgkin's lymphoma, anaplastic lymphoma, anaplastic large cell lymphoma, immunoblastic T-cell lymphoma, CD20-positive lymphoma, mantle cell lymphoma, follicular lymphoma (FL), Burkitt's lymphoma, marginal zone lymphoma (MZL), primary lymphoma, B-cell lymphoma, relapsed B-cell non-Hodgkin's lymphoma, relapsed diffuse large B-cell lymphoma, relapsed mediastinal large B-cell lymphoma, Primary mediastinal large B-cell lymphoma, relapsed transformed non-Hodgkin's lymphoma, refractory B-cell non-Hodgkin's lymphoma, refractory diffuse large B-cell lymphoma, refractory primary mediastinal large B-cell lymphoma, refractory transformed non-Hodgkin's lymphoma; thyroid cancer; melanoma; lung cancer, including lung adenocarcinoma, lung squamous cell carcinoma, non-small cell lung cancer, and small cell lung cancer; inflammatory myofibroblastic tumor; colorectal cancer; intestinal cancer; brain glioma; astrocytoblastoma; glioma; Peripheral neuroepithelial tumors; ovarian cancer; bronchogenic cancer; prostate cancer; breast cancer, including triple-negative breast cancer, incidental breast cancer, ductal carcinoma, and patients with Cowden disease; pancreatic cancer; central nervous system cancers; neuroblastoma; extramedullary plasmacytoma; plasmacytoma; gastric cancer; gastrointestinal stromal tumors; esophageal cancer; colorectal adenocarcinoma; esophageal squamous cell carcinoma; liver cancer; renal cell carcinoma; bladder cancer; endometrial cancer; uterine cancer; head and neck cancer; brain cancer; oral cancer; sarcomas, including rhabdomyosarcoma, various adipose-derived tumors, Ewing sarcoma / primitive neuroectodermal tumors (Ewing / PNETs), and leiomyosarcoma; urothelial carcinoma; basal cell carcinoma; oral squamous cell carcinoma; and bile duct cancer. bone cancer; cervical cancer; skin cancer; Richter syndrome (RS); and autoimmune diseases, including rheumatoid arthritis, autoimmune encephalomyelitis, ankylosing spondylitis, psoriasis, psoriatic arthritis, systemic lupus erythematosus, multiple sclerosis, recurrent oral ulcers, Kawasaki disease, polymyositis / dermatomyositis, Sjögren's syndrome, atopic dermatitis, hidradenitis suppurativa, gout, type 1 diabetes, urticaria, and inflammatory bowel disease (including Crohn's disease and ulcerative colitis).

41. Use of a compound of formula (II) or a salt, enantiomer, stereoisomer, solvate, isotopically enriched analog, prodrug or polymorph thereof as described in any one of claims 22 to 27, or 3-(1-oxo-5-(piperazin-1-ylamino)isoindolin-2-yl)piperidine-2,6-dione or a salt, enantiomer, stereoisomer, solvate, isotopically enriched analog, prodrug or polymorph thereof for the preparation of a Cereblon protein (CRBN) binder.

42. Use of a compound of formula (II) or a salt, enantiomer, stereoisomer, solvate, isotopically enriched analog, prodrug or polymorph thereof as described in any one of claims 22 to 27, or 3-(1-oxo-5-(piperazin-1-ylamino)isoindolin-2-yl)piperidine-2,6-dione or a salt, enantiomer, stereoisomer, solvate, isotopically enriched analog, prodrug or polymorph thereof, for preparing a compound of formula (I) or a salt, enantiomer, stereoisomer, solvate, isotopically enriched analog, prodrug or polymorph thereof as described in claim 1.

43. A method for preparing a compound of formula (I) as claimed in claim 1, comprising using a compound of formula (M1) and a compound of formula (M2) as starting materials to prepare a compound of formula (I): Among them, PBM, R a1 、R a2 、R a3 、R a4 、(R a5 ) m , Z, R w2 , Ring A 1 , Ring A 2 , Ring A 3 ,y1,y2,y3,(R y1 ) a1 、(R y2 ) a2 and (R y3 ) a3 As defined in claim 1; and R w3 represents a bond, or represents an optionally substituted straight or branched C 1-19 Alkylene, wherein the linear or branched C 1-19 Any one or more methylene groups of the main carbon chain skeleton of the alkylene group may be optionally replaced by one or more groups selected from the following: a 、R b and any combination thereof, each group R a Each independently selected from O, C(O), OC(O), S, S(O), S(O)2, S(O)2N(R a7 )、N(R a7 )S(O)2、C(O)N(R a7 )、N(R a7 )C(O), N(R a7 ) and N(R a7 )C(O)N(R a7 ), where each R a7 Each independently represents H or C 1-3 Alkyl, and when the linear or branched C 1-19 Any two or more methylene groups of the main carbon chain skeleton of the alkylene group are replaced by two or more groups R a When substituted, each group R a Not directly connected to each other; each group R b Each independently selected from optionally substituted cycloalkylene, optionally substituted arylene, optionally substituted heterocyclylene, optionally substituted heteroarylene, alkynylene, alkenylene and any combination thereof; and wherein the linear or branched C 1-19 One or more hydrogen atoms of the alkylene group may be selected from deuterium, hydroxyl, amino, mercapto, nitro, halogen, cyano, haloC 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 3-6 Cycloalkyl, halogenated C 3-6 Cycloalkyl, deuterated C 3-6 cycloalkyl, 4- to 10-membered heterocyclyl, and any combination thereof; and R w4 Indicates CHO, COOH or Among them, ring Y 2 and (R d2 ) n2 As defined in claim 1; Where (1) when R w4 When it represents CHO or COOH, (a1)R L1 N(R w ), R L2 and R L3 Together with the N atoms to which they are attached, they form or (a2)R L1 and R L2 Formed together And R L3 Indicates H or C 1-3 alkyl; or (a3)R L1 Indicates NH, R L2 Indicates a key, R L3 means H; or (a4)R L1 express The symbol **** indicates that L2 The connection point, R L2 express The symbol ### indicates the connection point with N, and the ring Y 3 and (R d3 ) n3 As defined in claim 1, and R L3 Indicates H or C 1-3 alkyl; or Where (2) when R w4 express When R L1 N(R w ), R L2 and R L3 Together with the N atoms to which they are attached, they form as well as Among them, the above R w 、Ring Y 1 and (R d1 ) n1 As defined in claim 1.

44. The method of claim 43, wherein (1) When R w4 When CHO is represented, the compound of formula (M1) and the compound of formula (M2) undergo reductive amination reaction to prepare the compound of formula (I), wherein The structure represented by the following general formula is represented accordingly: (2) When R w4 When the compound of formula (M1) and the compound of formula (M2) undergo amide condensation reaction to prepare the compound of formula (I), wherein the compound of formula (I) The structure represented by the following general formula is represented accordingly: or (3) When R w4 express When the compound of formula (M1) reacts with the compound of formula (M2) to form urea, the compound of formula (I) is prepared, wherein The structure represented by the following general formula is represented accordingly:

45. A method for preparing a compound of formula (II) as claimed in claim 22, comprising using a compound of formula (M3) and a compound of formula (M4) as starting materials to prepare a compound of formula (II): where R a1 、R a2 、R a3 、R a4 、(R a5 ) m , Z, Ring Y 1 、R w and (R d1 ) n1 As defined in claim 22; Y represents F or Br; W1 represents H, and W2 represents an amino protecting group; or W1 represents an amino protecting group, and W2 represents H; and R E express: Among them, ring Y 1 represents a heterocyclic group containing at least 2 nitrogen atoms, (R d1 ) n1 Represents ring Y 1 Optionally n1 R d1 Group substitution, each R d1 Each independently represents deuterium, halogen, hydroxyl, mercapto, nitro, amino, cyano, oxo, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy or C 1-6 alkoxy, and n1 represents an integer of 0-20; and R1 represents N(R w ), where R w Represents hydrogen or C 1-3 Alkyl, and R E1 represents hydrogen; or R1 represents a bond, and R E1 Indicates NH2.

Images